{"af737e6bba2de57279e22698e2057be35136980e": [["INTRODUCTIONSince severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (1) (2) (3) (4) was first discovered, the need to develop a sensitive, simple assay to detect its antigens and antibodies has become increasingly pressing.INTRODUCTIONSARS-CoV can be detected by real-time PCR during the early phase of infection (5, 6) .", [["acute respiratory syndrome", "DISEASE", 25, 51], ["coronavirus", "DISEASE", 63, 74], ["infection", "DISEASE", 321, 330], ["1) (2) (3)", "SIMPLE_CHEMICAL", 87, 97], ["INTRODUCTIONSARS-CoV", "GENE_OR_GENE_PRODUCT", 241, 261], ["antigens", "PROTEIN", 184, 192], ["antibodies", "PROTEIN", 197, 207], ["INTRODUCTIONSince severe acute respiratory syndrome-associated coronavirus (SARS-CoV", "SPECIES", 0, 84], ["severe acute respiratory syndrome", "PROBLEM", 18, 51], ["associated coronavirus", "PROBLEM", 52, 74], ["a sensitive, simple assay", "PROBLEM", 144, 169], ["antibodies", "PROBLEM", 197, 207], ["infection", "PROBLEM", 321, 330], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory syndrome", "OBSERVATION", 31, 51], ["coronavirus", "OBSERVATION_MODIFIER", 63, 74], ["infection", "OBSERVATION", 321, 330]]], ["This technique allows for a highly sensitive determination using nasopharyngeal aspirates (NSPs) of SARS patients, with a sensitivity and specificity of 79% and 98%, respectively (6) .", [["nasopharyngeal aspirates", "ANATOMY", 65, 89], ["SARS", "DISEASE", 100, 104], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 65, 89], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["nasopharyngeal aspirates", "TEST", 65, 89], ["a sensitivity", "TEST", 120, 133], ["specificity", "TEST", 138, 149], ["nasopharyngeal", "ANATOMY", 65, 79], ["aspirates", "OBSERVATION", 80, 89]]], ["Likewise, a method employing an enzyme-linked immunosorbent assay (ELISA) has also achieved sensitive detection using the blood of SARS patients (7) .", [["blood", "ANATOMY", 122, 127], ["SARS", "DISEASE", 131, 135], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["a method", "TEST", 10, 18], ["an enzyme", "TEST", 29, 38], ["immunosorbent assay", "TEST", 46, 65]]], ["The detection of antibodies against SARS-CoV by ELISA and Western blotting (WB) in patient serum has also been reported (2, 8, 9) .INTRODUCTIONA simple device based on the rapid enzyme immunoassay (EIA) format for detecting SARS-CoV antigens that could be used for point-of-care testing near a patient care site (10) has yet to be developed.", [["serum", "ANATOMY", 91, 96], ["SARS-CoV", "ORGANISM", 36, 44], ["patient", "ORGANISM", 83, 90], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["SARS-CoV antigens", "GENE_OR_GENE_PRODUCT", 224, 241], ["patient", "ORGANISM", 294, 301], ["antibodies", "PROTEIN", 17, 27], ["SARS-CoV antigens", "PROTEIN", 224, 241], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 294, 301], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 224, 232], ["The detection", "TEST", 0, 13], ["antibodies", "TEST", 17, 27], ["SARS", "PROBLEM", 36, 40], ["ELISA", "TEST", 48, 53], ["Western blotting (WB) in patient serum", "TEST", 58, 96], ["INTRODUCTIONA simple device", "TREATMENT", 131, 158], ["the rapid enzyme immunoassay", "TEST", 168, 196], ["SARS-CoV antigens", "PROBLEM", 224, 241]]], ["Recently, an immunochromatographic test using colloidal gold particles serving as detectors, and recombinant N-Ag of SARS-CoV as a source of antigen for capturing the antibodies was described for measuring antibodies to SARS-CoV (11, 12) .", [["N-Ag", "CHEMICAL", 109, 113], ["SARS", "DISEASE", 220, 224], ["Ag", "CHEMICAL", 111, 113], ["N-Ag", "GENE_OR_GENE_PRODUCT", 109, 113], ["SARS-CoV", "ORGANISM", 117, 125], ["SARS-CoV", "ORGANISM", 220, 228], ["recombinant N-Ag", "PROTEIN", 97, 113], ["CoV", "PROTEIN", 122, 125], ["antibodies", "PROTEIN", 167, 177], ["antibodies", "PROTEIN", 206, 216], ["SARS-CoV", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 220, 228], ["an immunochromatographic test", "TEST", 10, 39], ["colloidal gold particles", "TREATMENT", 46, 70], ["SARS", "PROBLEM", 117, 121], ["the antibodies", "TEST", 163, 177], ["CoV", "TEST", 225, 228]]], ["It should be noted, however, that immunochromatographic test methods using gold particles as detectors are likely to be less sensitive for the detection of antigens than EIA or ELISA, which can amplify signal intensity by enzyme catalyzing of the substrate.", [["gold particles", "SIMPLE_CHEMICAL", 75, 89], ["antigens", "PROTEIN", 156, 164], ["immunochromatographic test methods", "TEST", 34, 68], ["EIA", "TEST", 170, 173], ["ELISA", "TEST", 177, 182]]], ["Thus, a rapid immunochromatographic test (RICT) method based on EIA appears promising for analyte detection with a high sensitivity (10) .INTRODUCTIONThe principle behind the RICT assay method (10) is as follows: When a sample is applied onto the sample application pad of the RICT device (as described in Fig. 1) , an immune complex is formed between N-Ag of the applied sample and the anti-N-Ag antibody conjugated with ALP in the pad.", [["sample", "ANATOMY", 372, 378], ["N-Ag", "CHEMICAL", 352, 356], ["anti-N-Ag", "CHEMICAL", 387, 396], ["N-Ag", "CHEMICAL", 352, 356], ["Ag", "CHEMICAL", 394, 396], ["anti-N-Ag", "GENE_OR_GENE_PRODUCT", 387, 396], ["ALP", "GENE_OR_GENE_PRODUCT", 422, 425], ["pad", "TISSUE", 433, 436], ["immune complex", "PROTEIN", 319, 333], ["N-Ag", "PROTEIN", 352, 356], ["anti-N", "PROTEIN", 387, 393], ["Ag antibody", "PROTEIN", 394, 405], ["ALP", "PROTEIN", 422, 425], ["a rapid immunochromatographic test", "TEST", 6, 40], ["EIA", "TEST", 64, 67], ["analyte detection", "TEST", 90, 107], ["the RICT assay method", "TEST", 171, 192], ["the sample application pad", "TREATMENT", 243, 269], ["the RICT device", "TREATMENT", 273, 288], ["an immune complex", "PROBLEM", 316, 333], ["the anti-N-Ag antibody", "TREATMENT", 383, 405], ["ALP in the pad", "TREATMENT", 422, 436], ["pad", "ANATOMY", 433, 436]]], ["The immune complex elutes toward the detection zone by lateral flow along the membrane due to capillary force and diffusion by rupturing the developing reservoir in the bottom of the device.", [["membrane", "ANATOMY", 78, 86], ["capillary", "ANATOMY", 94, 103], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["capillary", "TISSUE", 94, 103], ["immune complex", "PROTEIN", 4, 18], ["the detection zone", "TEST", 33, 51], ["lateral flow", "TEST", 55, 67], ["capillary force and diffusion", "PROBLEM", 94, 123], ["lateral", "OBSERVATION_MODIFIER", 55, 62], ["flow", "OBSERVATION", 63, 67], ["capillary force", "OBSERVATION", 94, 109], ["rupturing", "OBSERVATION", 127, 136], ["developing", "OBSERVATION_MODIFIER", 141, 151], ["reservoir", "OBSERVATION_MODIFIER", 152, 161], ["bottom", "OBSERVATION_MODIFIER", 169, 175], ["device", "OBSERVATION", 183, 189]]], ["Thereafter, N-Ag of the immune complex can react with anti-N-Ag antibodies immobilized at the detection zone.", [["N-Ag", "CHEMICAL", 12, 16], ["anti-N-Ag", "CHEMICAL", 54, 63], ["Ag", "CHEMICAL", 14, 16], ["Ag", "CHEMICAL", 61, 63], ["N-Ag", "SIMPLE_CHEMICAL", 12, 16], ["anti-N-Ag antibodies", "GENE_OR_GENE_PRODUCT", 54, 74], ["N-Ag", "PROTEIN", 12, 16], ["immune complex", "PROTEIN", 24, 38], ["anti-N", "PROTEIN", 54, 60], ["Ag antibodies", "PROTEIN", 61, 74], ["anti-N-Ag antibodies", "TREATMENT", 54, 74]]], ["ALP in the complex then catalyzes the dephosphorylation of 5-bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP), resulting in a color development that can be visualized at the detection zone and judged as positive.INTRODUCTIONWe expressed recombinant N-Ag of SARS-CoV (Urbani strain) based on its genomic sequences.", [["5-bromo-4-chloro-3-indolyl phosphate disodium salt", "CHEMICAL", 59, 109], ["BCIP", "CHEMICAL", 111, 115], ["N-Ag", "CHEMICAL", 256, 260], ["5-bromo-4-chloro-3-indolyl phosphate disodium salt", "CHEMICAL", 59, 109], ["BCIP", "CHEMICAL", 111, 115], ["Ag", "CHEMICAL", 258, 260], ["ALP", "GENE_OR_GENE_PRODUCT", 0, 3], ["5-bromo-4-chloro-3-indolyl phosphate disodium salt", "SIMPLE_CHEMICAL", 59, 109], ["BCIP", "SIMPLE_CHEMICAL", 111, 115], ["N-Ag", "GENE_OR_GENE_PRODUCT", 256, 260], ["SARS-CoV", "ORGANISM", 264, 272], ["Urbani strain", "ORGANISM", 274, 287], ["ALP", "PROTEIN", 0, 3], ["recombinant N-Ag", "PROTEIN", 244, 260], ["genomic sequences", "DNA", 302, 319], ["SARS-CoV", "SPECIES", 264, 272], ["ALP", "TEST", 0, 3], ["the dephosphorylation", "TEST", 34, 55], ["bromo", "TEST", 61, 66], ["chloro", "TREATMENT", 69, 75], ["indolyl phosphate disodium salt (BCIP)", "TREATMENT", 78, 116], ["the detection zone", "TEST", 177, 195], ["SARS", "PROBLEM", 264, 268], ["CoV (Urbani strain)", "TREATMENT", 269, 288]]], ["We then developed a novel RICT based on EIA for measuring N-Ag of SARS-CoV, using the monoclonal antibody (MoAb) produced by immunizing the recombinant N-Ag to mice.Preparation of MoAbsMoAbs rSN150, rSN122, rSN29, rSN21-2, and rSN18 (but not SN5-25) against recombinant N-Ag were prepared in mouse ascites according to a conventional procedure (13, 14) and then purified from the ascites by affinity chromatography on protein A agarose (MAPS-II kit; Bio-Rad, Hercules, CA).", [["ascites", "ANATOMY", 298, 305], ["ascites", "ANATOMY", 380, 387], ["N-Ag", "CHEMICAL", 58, 62], ["N-Ag", "CHEMICAL", 152, 156], ["N-Ag", "CHEMICAL", 270, 274], ["ascites", "DISEASE", 298, 305], ["ascites", "DISEASE", 380, 387], ["Ag", "CHEMICAL", 60, 62], ["Ag", "CHEMICAL", 154, 156], ["Ag", "CHEMICAL", 272, 274], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["MoAb", "GENE_OR_GENE_PRODUCT", 107, 111], ["N-Ag", "GENE_OR_GENE_PRODUCT", 152, 156], ["mice", "ORGANISM", 160, 164], ["MoAbs", "GENE_OR_GENE_PRODUCT", 180, 185], ["rSN122", "SIMPLE_CHEMICAL", 199, 205], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 214, 221], ["rSN18", "SIMPLE_CHEMICAL", 227, 232], ["SN5-25", "ORGANISM", 242, 248], ["N-Ag", "GENE_OR_GENE_PRODUCT", 270, 274], ["mouse", "ORGANISM", 292, 297], ["N-Ag", "PROTEIN", 58, 62], ["monoclonal antibody", "PROTEIN", 86, 105], ["MoAb", "PROTEIN", 107, 111], ["recombinant N", "PROTEIN", 140, 153], ["Ag", "PROTEIN", 154, 156], ["MoAbsMoAbs", "PROTEIN", 180, 190], ["rSN150", "PROTEIN", 191, 197], ["rSN122", "PROTEIN", 199, 205], ["rSN29", "PROTEIN", 207, 212], ["rSN21", "PROTEIN", 214, 219], ["rSN18", "PROTEIN", 227, 232], ["SN5", "PROTEIN", 242, 245], ["recombinant N-Ag", "PROTEIN", 258, 274], ["Rad", "PROTEIN", 454, 457], ["mice", "SPECIES", 160, 164], ["mouse", "SPECIES", 292, 297], ["SARS-CoV", "SPECIES", 66, 74], ["mice", "SPECIES", 160, 164], ["mouse", "SPECIES", 292, 297], ["a novel RICT", "PROBLEM", 18, 30], ["EIA", "TEST", 40, 43], ["SARS", "PROBLEM", 66, 70], ["CoV", "PROBLEM", 71, 74], ["the monoclonal antibody (MoAb", "TREATMENT", 82, 111], ["MoAbsMoAbs", "TEST", 180, 190], ["rSN21", "TEST", 214, 219], ["SN5", "TEST", 242, 245], ["recombinant N-Ag", "PROBLEM", 258, 274], ["mouse ascites", "PROBLEM", 292, 305], ["a conventional procedure", "TREATMENT", 319, 343], ["the ascites", "PROBLEM", 376, 387], ["affinity chromatography", "TEST", 391, 414], ["protein A agarose", "TEST", 418, 435], ["MAPS", "TEST", 437, 441], ["II kit", "TEST", 442, 448], ["Bio", "TEST", 450, 453], ["ascites", "OBSERVATION", 298, 305], ["ascites", "OBSERVATION", 380, 387], ["Rad", "ANATOMY", 454, 457]]], ["For the preparation of SN5-25, the synthetic peptide of GQTVTKKSAAEASKKPR (amino acid sequence: 244-260 of N-Ag), termed SN-5 peptide, was used as the immunizing agent instead of recombinant N-Ag.", [["SN5-25", "CHEMICAL", 23, 29], ["GQTVTKKSAAEASKKPR", "CHEMICAL", 56, 73], ["amino acid", "CHEMICAL", 75, 85], ["244-260 of N-Ag", "CHEMICAL", 96, 111], ["SN-5 peptide", "CHEMICAL", 121, 133], ["SN5-25", "CHEMICAL", 23, 29], ["amino acid", "CHEMICAL", 75, 85], ["N-Ag", "CHEMICAL", 107, 111], ["SN5-25", "SIMPLE_CHEMICAL", 23, 29], ["GQTVTKKSAAEASKKPR", "SIMPLE_CHEMICAL", 56, 73], ["amino acid", "AMINO_ACID", 75, 85], ["SN-5 peptide", "SIMPLE_CHEMICAL", 121, 133], ["Ag", "PROTEIN", 109, 111], ["SN5", "TEST", 23, 26], ["amino acid sequence", "TEST", 75, 94], ["SN-5 peptide", "TREATMENT", 121, 133], ["the immunizing agent", "TREATMENT", 147, 167]]], ["Polyclonal antibodies used to capture alkaline phosphate (ALP) in the RICT assay were prepared from rabbit serum after immunization with ALP.", [["serum", "ANATOMY", 107, 112], ["phosphate", "CHEMICAL", 47, 56], ["phosphate", "CHEMICAL", 47, 56], ["alkaline phosphate", "SIMPLE_CHEMICAL", 38, 56], ["ALP", "GENE_OR_GENE_PRODUCT", 58, 61], ["rabbit", "ORGANISM", 100, 106], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["ALP", "GENE_OR_GENE_PRODUCT", 137, 140], ["Polyclonal antibodies", "PROTEIN", 0, 21], ["alkaline phosphate", "PROTEIN", 38, 56], ["ALP", "PROTEIN", 58, 61], ["ALP", "PROTEIN", 137, 140], ["rabbit", "SPECIES", 100, 106], ["rabbit", "SPECIES", 100, 106], ["Polyclonal antibodies", "TEST", 0, 21], ["alkaline phosphate", "TEST", 38, 56], ["ALP", "TEST", 58, 61], ["the RICT assay", "TEST", 66, 80], ["immunization", "TREATMENT", 119, 131], ["ALP", "TEST", 137, 140]]], ["They were immobilized at the R position on the membrane of the RICT device.Preparation of MoAbsMost of the chemicals used are listed below; all other chemicals used were of reagent-grade quality.", [["membrane", "ANATOMY", 47, 55], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["MoAbs", "GENE_OR_GENE_PRODUCT", 90, 95], ["MoAbs", "PROTEIN", 90, 95], ["the RICT device", "TREATMENT", 59, 74], ["MoAbs", "TREATMENT", 90, 95]]], ["The molecular weight marker kit was purchased from Invitrogen (bench mark prestained protein ladder; Invitrogen Japan, K.K, Tokyo, Japan).Preparation of Recombinant N-AgWe constructed cDNA fragments based on genome sequences corresponding to a N-Ag of SARS-CoV virus (Urbani strain), as obtained from GenBank (access no. AY278741).", [["N-Ag", "CHEMICAL", 244, 248], ["AY278741", "CHEMICAL", 321, 329], ["Ag", "CHEMICAL", 246, 248], ["AY278741", "CHEMICAL", 321, 329], ["SARS-CoV virus", "ORGANISM", 252, 266], ["Urbani strain", "ORGANISM", 268, 281], ["AY278741", "SIMPLE_CHEMICAL", 321, 329], ["Recombinant N-AgWe constructed cDNA fragments", "DNA", 153, 198], ["SARS-CoV virus", "SPECIES", 252, 266], ["SARS-CoV virus", "SPECIES", 252, 266], ["The molecular weight marker kit", "TEST", 0, 31], ["Recombinant N-AgWe constructed cDNA fragments", "PROBLEM", 153, 198], ["genome sequences", "TEST", 208, 224], ["a N", "TEST", 242, 245], ["SARS", "PROBLEM", 252, 256], ["CoV virus (Urbani strain", "PROBLEM", 257, 281]]], ["Thirty-two different primers with a length of 50-54 bases were synthesized based on the sequence of consecutive regions of the entire 1,269-bp sequence (i.e., 1-50, 45-80, ----, 281-330, 321-370, ---, 601-649, 621-670, ---, 901-950, 940-990, --, and 1219-1269) .", [["50-54 bases", "DNA", 46, 57], ["1,269-bp sequence", "DNA", 134, 151], ["a length", "TEST", 34, 42]]], ["Each of the primer sequences overlapped the neighboring primer sequence by 10-12 bases, and the entire N-Ag sequence was covered.", [["N-Ag", "CHEMICAL", 103, 107], ["N", "CHEMICAL", 103, 104], ["Ag", "CHEMICAL", 105, 107], ["primer sequences", "DNA", 12, 28], ["neighboring primer sequence", "DNA", 44, 71], ["N-Ag sequence", "DNA", 103, 116], ["the primer sequences", "TEST", 8, 28], ["the neighboring primer sequence", "TEST", 40, 71], ["the entire N-Ag sequence", "TREATMENT", 92, 116]]], ["The primers were synthesized by Sigma Genosis Japan (Ishikari, Hokkaido, Japan).Preparation of Recombinant N-AgTwo large cDNA fragments (bp 1-649 and 621-1269), both containing the NheI restriction site at position 634 of the N-Ag, were prepared stepwise using 16 primers spanning bases 1-649 and 621-1269, respectively, by PCR amplification (model 381A DNA synthesizer; Applied Biosystems, Foster City, CA).", [["N-Ag", "CHEMICAL", 226, 230], ["Ag", "CHEMICAL", 228, 230], ["NheI", "GENE_OR_GENE_PRODUCT", 181, 185], ["N-Ag", "GENE_OR_GENE_PRODUCT", 226, 230], ["Recombinant N-AgTwo large cDNA fragments", "DNA", 95, 135], ["bp 1-649 and 621-1269", "DNA", 137, 158], ["NheI restriction site", "DNA", 181, 202], ["position 634", "DNA", 206, 218], ["N-Ag", "DNA", 226, 230], ["large cDNA fragments", "PROBLEM", 115, 135], ["bp", "TEST", 137, 139], ["the N-Ag", "TEST", 222, 230], ["primers spanning bases", "TEST", 264, 286], ["PCR amplification", "TEST", 324, 341], ["DNA synthesizer", "TREATMENT", 354, 369], ["large", "OBSERVATION_MODIFIER", 115, 120], ["cDNA fragments", "OBSERVATION", 121, 135]]], ["For example, the polynucleotide spanning bases 1-649 was synthesized as follows: A solution containing primers spanning bases 281-330 and 321-370 was mixed and PCR amplification was carried out in the presence of Pfu DNA polymerase as described previously (15) .", [["bases 1-649", "CHEMICAL", 41, 52], ["bases 281-330 and 321-370", "CHEMICAL", 120, 145], ["Pfu", "GENE_OR_GENE_PRODUCT", 213, 216], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["Pfu DNA polymerase", "PROTEIN", 213, 231], ["the polynucleotide spanning bases", "TEST", 13, 46], ["A solution", "TREATMENT", 81, 91], ["primers spanning bases", "TEST", 103, 125], ["PCR amplification", "TEST", 160, 177], ["Pfu DNA polymerase", "PROBLEM", 213, 231], ["bases", "ANATOMY_MODIFIER", 41, 46]]], ["This resulted in the formation of an oligonucleotide spanning bases 281-370.", [["bases 281-370", "CHEMICAL", 62, 75], ["an oligonucleotide spanning bases", "TEST", 34, 67]]], ["The same method using additional neighboring primers at the both ends of the oligomer spanning bases 281-370 was carried out using consecutive primers, which eventually resulted in a cDNA fragment spanning bases 1-649 of N-Ag.Preparation of Recombinant N-AgFinally, a full-length DNA polynucleotide containing EcoRI and BamHI sites was obtained from the two large DNA fragments (1-649 and 621-1269) by clearing and ligation at the site of 634 and was applied to construct a plasmid PCR using primers 5 0 -CCGCCGG AATTCATGTCTGATAATGGACCC-3 0 and 3 0 -GTT TGCGGATCCTTATGCCTGAGTTGAATC-5 0 .Preparation of Recombinant N-AgThe obtained recombinant N-Ag DNA was purified using a PCR purification kit following the manufacturer's instructions (Qiagen, Hilden, Germany), and inserted into EcoRI and BamHI sites of the expression vectors of pW6A (15) , resulting in a plasmid named pWSN.", [["plasmid", "ANATOMY", 859, 866], ["bases 281-370", "CHEMICAL", 95, 108], ["bases 1-649 of N-Ag", "CHEMICAL", 206, 225], ["N-Ag", "CHEMICAL", 614, 618], ["N-Ag", "CHEMICAL", 643, 647], ["Ag", "CHEMICAL", 223, 225], ["5 0 -CCGCCGG", "CHEMICAL", 500, 512], ["Ag", "CHEMICAL", 616, 618], ["Ag", "CHEMICAL", 645, 647], ["N-Ag", "GENE_OR_GENE_PRODUCT", 221, 225], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["EcoRI", "GENE_OR_GENE_PRODUCT", 310, 315], ["BamHI", "GENE_OR_GENE_PRODUCT", 320, 325], ["DNA", "CELLULAR_COMPONENT", 364, 367], ["N-Ag", "SIMPLE_CHEMICAL", 614, 618], ["N-Ag", "GENE_OR_GENE_PRODUCT", 643, 647], ["DNA", "CELLULAR_COMPONENT", 648, 651], ["EcoRI", "GENE_OR_GENE_PRODUCT", 781, 786], ["BamHI", "GENE_OR_GENE_PRODUCT", 791, 796], ["pW6A (15)", "GENE_OR_GENE_PRODUCT", 832, 841], ["pWSN", "GENE_OR_GENE_PRODUCT", 873, 877], ["oligomer spanning bases 281-370", "DNA", 77, 108], ["cDNA fragment", "DNA", 183, 196], ["N-Ag", "PROTEIN", 221, 225], ["Recombinant N-AgFinally", "DNA", 241, 264], ["full-length DNA polynucleotide", "DNA", 268, 298], ["EcoRI and BamHI sites", "DNA", 310, 331], ["DNA fragments", "DNA", 364, 377], ["1-649 and 621-1269", "DNA", 379, 397], ["plasmid PCR", "DNA", 474, 485], ["Recombinant N-Ag", "PROTEIN", 602, 618], ["recombinant N-Ag DNA", "DNA", 631, 651], ["EcoRI and BamHI sites", "DNA", 781, 802], ["expression vectors", "DNA", 810, 828], ["pW6A (15)", "DNA", 832, 841], ["plasmid", "DNA", 859, 866], ["pWSN", "DNA", 873, 877], ["The same method", "TREATMENT", 0, 15], ["additional neighboring primers", "TREATMENT", 22, 52], ["the oligomer spanning bases", "TEST", 73, 100], ["consecutive primers", "TREATMENT", 131, 150], ["a cDNA fragment spanning bases", "PROBLEM", 181, 211], ["N-Ag", "TEST", 221, 225], ["a full-length DNA polynucleotide", "TREATMENT", 266, 298], ["EcoRI and BamHI sites", "TREATMENT", 310, 331], ["the two large DNA fragments", "PROBLEM", 350, 377], ["ligation", "TREATMENT", 415, 423], ["a plasmid PCR using primers", "TREATMENT", 472, 499], ["AATTCATGTCTGATAATGGACCC", "TEST", 513, 536], ["TGCGGATCCTTATGCCTGAGTTGAATC", "TEST", 554, 581], ["recombinant N-Ag DNA", "TREATMENT", 631, 651], ["a PCR purification", "TREATMENT", 671, 689], ["EcoRI and BamHI sites", "TREATMENT", 781, 802], ["cDNA fragment", "OBSERVATION", 183, 196], ["two", "OBSERVATION_MODIFIER", 354, 357], ["large", "OBSERVATION_MODIFIER", 358, 363], ["DNA fragments", "OBSERVATION", 364, 377], ["ligation", "OBSERVATION", 415, 423]]], ["Escherichia coli (BL21 (DE3) strain) was transformed with the pWSN vector as described elsewhere (15, 16) .", [["Escherichia coli", "ORGANISM", 0, 16], ["BL21", "GENE_OR_GENE_PRODUCT", 18, 22], ["DE3", "GENE_OR_GENE_PRODUCT", 24, 27], ["pWSN vector", "DNA", 62, 73], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "SPECIES", 0, 16], ["BL21", "SPECIES", 18, 22], ["Escherichia coli", "PROBLEM", 0, 16]]], ["Growth and harvesting of the transformed E. coli cells, and the subsequent treatment to obtain the lysate of the cells were performed essentially as described previously (15) .", [["cells", "ANATOMY", 49, 54], ["lysate", "ANATOMY", 99, 105], ["cells", "ANATOMY", 113, 118], ["E. coli cells", "CELL", 41, 54], ["cells", "CELL", 113, 118], ["transformed E. coli cells", "CELL_LINE", 29, 54], ["E. coli", "SPECIES", 41, 48], ["E. coli", "SPECIES", 41, 48], ["the transformed E. coli cells", "TREATMENT", 25, 54], ["the subsequent treatment", "TREATMENT", 60, 84], ["the lysate of the cells", "TREATMENT", 95, 118], ["harvesting", "OBSERVATION_MODIFIER", 11, 21], ["coli cells", "OBSERVATION", 44, 54]]], ["The recombinant N-Ag protein from the lysate suspension was also purified as described previously (15) .", [["lysate", "ANATOMY", 38, 44], ["N-Ag", "CHEMICAL", 16, 20], ["Ag", "CHEMICAL", 18, 20], ["N-Ag", "GENE_OR_GENE_PRODUCT", 16, 20], ["lysate", "ORGANISM_SUBSTANCE", 38, 44], ["recombinant N-Ag protein", "PROTEIN", 4, 28], ["The recombinant N-Ag protein", "TREATMENT", 0, 28], ["the lysate suspension", "TREATMENT", 34, 55], ["lysate suspension", "OBSERVATION", 38, 55]]], ["The concentration of purified recombinant N-Ag was determined using a BCA protein assay reagent (Pierce Biotechnology, Inc., Rockford, IL).Preparation of SARS-CoV AntigenSARS-CoV (Urbani strain) was provided by Dr. Koichi Morita of Nagasaki University and prepared at the Biosafety Level 3 Laboratory of the Graduate School of Veterinary Medicine, Hokkaido University.", [["N-Ag", "CHEMICAL", 42, 46], ["SARS", "DISEASE", 154, 158], ["N-Ag", "CHEMICAL", 42, 46], ["N-Ag", "GENE_OR_GENE_PRODUCT", 42, 46], ["IL", "GENE_OR_GENE_PRODUCT", 135, 137], ["SARS-CoV AntigenSARS-CoV", "ORGANISM", 154, 178], ["Urbani", "ORGANISM", 180, 186], ["purified recombinant N-Ag", "PROTEIN", 21, 46], ["SARS-CoV AntigenSARS-CoV", "SPECIES", 154, 178], ["purified recombinant N-Ag", "TREATMENT", 21, 46], ["a BCA protein assay reagent", "TREATMENT", 68, 95], ["SARS", "TEST", 154, 158], ["CoV AntigenSARS", "TEST", 159, 174], ["CoV (Urbani strain", "TREATMENT", 175, 193]]], ["The preparation and treatment of the live viruses were carried out in accordance with the guidelines proposed by Hokkaido University.", [["The preparation", "TREATMENT", 0, 15], ["treatment", "TREATMENT", 20, 29], ["the live viruses", "PROBLEM", 33, 49]]], ["Briefly, Vero E6 cells were grown to confluence in minimum essential medium containing 10% fetal bovine serum at 371C.", [["Vero E6 cells", "ANATOMY", 9, 22], ["fetal bovine serum", "ANATOMY", 91, 109], ["Vero E6 cells", "CELL", 9, 22], ["bovine", "ORGANISM", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["Vero E6 cells", "CELL_LINE", 9, 22], ["bovine", "SPECIES", 97, 103], ["Vero E6", "SPECIES", 9, 16], ["bovine", "SPECIES", 97, 103], ["Vero E6 cells", "TREATMENT", 9, 22], ["fetal bovine serum", "TEST", 91, 109], ["E6 cells", "OBSERVATION", 14, 22], ["medium", "OBSERVATION_MODIFIER", 69, 75]]], ["The cells were infected with SARS-CoV at 10 7 TCID 50 /mL and then cultured for 42 hr at 371C.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["The culture was centrifuged at 41C and 2,000 rpm for 15 min, and the supernatant was collected.", [["supernatant", "ANATOMY", 69, 80], ["The culture", "TEST", 0, 11]]], ["The supernatant solution was heated at 561C for 90 min and thereafter kept at \u00c0801 until further use.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant solution", "TREATMENT", 0, 24]]], ["Supernatant from cultured Vero E6 cells that were not infected with SARS-CoV were also prepared as controls.WB AnalysisThe proteins that were expressed in E. coli and then purified were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), as described previously (15) .", [["Supernatant", "ANATOMY", 0, 11], ["Vero E6 cells", "ANATOMY", 26, 39], ["sodium dodecyl sulfatepolyacrylamide", "CHEMICAL", 198, 234], ["sodium dodecyl sulfatepolyacrylamide", "CHEMICAL", 198, 234], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["Vero E6 cells", "CELL", 26, 39], ["SARS-CoV", "ORGANISM", 68, 76], ["E. coli", "ORGANISM", 155, 162], ["sodium dodecyl sulfatepolyacrylamide", "SIMPLE_CHEMICAL", 198, 234], ["cultured Vero E6 cells", "CELL_LINE", 17, 39], ["E. coli", "SPECIES", 155, 162], ["Vero E6", "SPECIES", 26, 33], ["SARS-CoV", "SPECIES", 68, 76], ["E. coli", "SPECIES", 155, 162], ["Supernatant from cultured Vero E6 cells", "PROBLEM", 0, 39], ["SARS", "PROBLEM", 68, 72], ["WB Analysis", "TEST", 108, 119], ["The proteins", "TEST", 119, 131], ["E. coli", "PROBLEM", 155, 162], ["sodium dodecyl sulfatepolyacrylamide", "TREATMENT", 198, 234], ["gel electrophoresis", "TEST", 235, 254], ["E6 cells", "OBSERVATION", 31, 39], ["not", "UNCERTAINTY", 50, 53], ["infected", "OBSERVATION_MODIFIER", 54, 62], ["E. coli", "OBSERVATION", 155, 162]]], ["For WB, the electrophoretic transfer of proteins such as recombinant N-Ag and native N-Ag from gels to nitrocellulose paper (pore size=0.45 mm; Schleicher and Schnell, Germany) was performed essentially as described previously (15) .", [["WB", "ANATOMY", 4, 6], ["pore", "ANATOMY", 125, 129], ["N-Ag", "CHEMICAL", 69, 73], ["N-Ag", "CHEMICAL", 85, 89], ["Ag", "CHEMICAL", 71, 73], ["N-Ag", "CHEMICAL", 85, 89], ["nitrocellulose", "CHEMICAL", 103, 117], ["N-Ag", "SIMPLE_CHEMICAL", 69, 73], ["N-Ag", "SIMPLE_CHEMICAL", 85, 89], ["recombinant N-Ag", "PROTEIN", 57, 73], ["native N", "PROTEIN", 78, 86], ["Ag", "PROTEIN", 87, 89], ["WB", "TEST", 4, 6], ["the electrophoretic transfer of proteins", "TREATMENT", 8, 48], ["recombinant N-Ag", "TREATMENT", 57, 73], ["native N-Ag from gels", "TREATMENT", 78, 99]]], ["In brief, the nitrocellulose paper, following incubation with either MoAbs or mouse anti-SN-5 peptide serum and subsequently with the anti-mouse antibody conjugated with peroxidase (POD; Dako Cytomation, Co. Ltd., Kyoto, Japan), was washed with phosphate-buffered saline (PBS) buffer containing 0.05% Tween 20.", [["serum", "ANATOMY", 102, 107], ["anti-SN-5 peptide", "CHEMICAL", 84, 101], ["phosphate", "CHEMICAL", 245, 254], ["nitrocellulose", "CHEMICAL", 14, 28], ["phosphate", "CHEMICAL", 245, 254], ["Tween 20", "CHEMICAL", 301, 309], ["MoAbs", "GENE_OR_GENE_PRODUCT", 69, 74], ["mouse", "ORGANISM", 78, 83], ["anti-SN-5", "GENE_OR_GENE_PRODUCT", 84, 93], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["peroxidase", "GENE_OR_GENE_PRODUCT", 170, 180], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 245, 270], ["MoAbs", "PROTEIN", 69, 74], ["anti-mouse antibody", "PROTEIN", 134, 153], ["peroxidase", "PROTEIN", 170, 180], ["POD", "PROTEIN", 182, 185], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["the nitrocellulose paper", "TREATMENT", 10, 34], ["either MoAbs", "TREATMENT", 62, 74], ["mouse anti-SN-5 peptide serum", "TEST", 78, 107], ["the anti-mouse antibody", "TEST", 130, 153], ["phosphate-buffered saline (PBS) buffer", "TREATMENT", 245, 283]]], ["A solution of 4-chloronaphthol was applied to the paper, and an intense color of catalized 4-chloronaphthol with POD was detected (15) .", [["4-chloronaphthol", "CHEMICAL", 14, 30], ["4-chloronaphthol", "CHEMICAL", 91, 107], ["4-chloronaphthol", "CHEMICAL", 14, 30], ["4-chloronaphthol", "CHEMICAL", 91, 107], ["4-chloronaphthol", "SIMPLE_CHEMICAL", 14, 30], ["4-chloronaphthol", "SIMPLE_CHEMICAL", 91, 107], ["POD", "SIMPLE_CHEMICAL", 113, 116], ["POD", "PROTEIN", 113, 116], ["A solution of 4-chloronaphthol", "TREATMENT", 0, 30]]], ["The native N-Ag used for WB analysis was prepared as follows: The precipitate, which was obtained by ultracentrifugation of supernatant from the cultured Vero E6 cells with SARS-CoV, was given 3% SDS in 5 mM Tris buffer pH 7.4, boiled for 5 min, and applied on SDS-PAGE.", [["supernatant", "ANATOMY", 124, 135], ["cells", "ANATOMY", 162, 167], ["N-Ag", "CHEMICAL", 11, 15], ["N-Ag", "CHEMICAL", 11, 15], ["Tris", "CHEMICAL", 208, 212], ["Vero E6 cells", "CELL", 154, 167], ["SARS-CoV", "ORGANISM", 173, 181], ["native N-Ag", "PROTEIN", 4, 15], ["cultured Vero E6 cells", "CELL_LINE", 145, 167], ["Vero E6", "SPECIES", 154, 161], ["SARS-CoV", "SPECIES", 173, 181], ["WB analysis", "TEST", 25, 36], ["SARS", "PROBLEM", 173, 177], ["3% SDS", "TREATMENT", 193, 199], ["Tris buffer pH", "TEST", 208, 222]]], ["Mouse anti-SN-5 peptide serum for Fig. 2 or mouse MoAbs against SARS-CoV for Fig. 4 were used as the primary antibody, and rabbit anti-mouse antibodies conjugated with POD were used as the secondary antibody.ELISA ProcedureTo evaluate the immunoreactivity of MoAbs by ELISA, the wells of a plastic microplate (Falcon 3912, micro test III flexible assay plate; Becton Dickinson, San Jose, CA) were coated with 1 mg/mL of recombinant N-Ag in 10 mM PBS (pH 7.4) for 24 hr at 41C.", [["serum", "ANATOMY", 24, 29], ["anti-SN-5 peptide", "CHEMICAL", 6, 23], ["N-Ag", "CHEMICAL", 432, 436], ["Ag", "CHEMICAL", 434, 436], ["Mouse", "ORGANISM", 0, 5], ["anti-SN-5", "GENE_OR_GENE_PRODUCT", 6, 15], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["mouse", "ORGANISM", 44, 49], ["MoAbs", "GENE_OR_GENE_PRODUCT", 50, 55], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["rabbit", "ORGANISM", 123, 129], ["POD", "SIMPLE_CHEMICAL", 168, 171], ["MoAbs", "GENE_OR_GENE_PRODUCT", 259, 264], ["N-Ag", "SIMPLE_CHEMICAL", 432, 436], ["mouse MoAbs", "PROTEIN", 44, 55], ["primary antibody", "PROTEIN", 101, 117], ["rabbit anti-mouse antibodies", "PROTEIN", 123, 151], ["POD", "PROTEIN", 168, 171], ["secondary antibody", "PROTEIN", 189, 207], ["MoAbs", "PROTEIN", 259, 264], ["recombinant N-Ag", "PROTEIN", 420, 436], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 44, 49], ["rabbit", "SPECIES", 123, 129], ["anti-mouse", "SPECIES", 130, 140], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 44, 49], ["SARS-CoV", "SPECIES", 64, 72], ["rabbit", "SPECIES", 123, 129], ["Mouse anti-SN", "TREATMENT", 0, 13], ["SARS", "PROBLEM", 64, 68], ["Fig", "PROBLEM", 77, 80], ["the primary antibody", "TEST", 97, 117], ["rabbit anti-mouse antibodies", "TREATMENT", 123, 151], ["POD", "TREATMENT", 168, 171], ["a plastic microplate (Falcon", "TREATMENT", 288, 316], ["micro test III flexible assay plate", "TREATMENT", 323, 358], ["recombinant N-Ag", "TREATMENT", 420, 436], ["pH", "TEST", 451, 453], ["secondary antibody", "OBSERVATION", 189, 207]]], ["The plate was washed with 10 mM PBS (pH 7.4) containing 0.05% Tween 20.", [["Tween 20", "CHEMICAL", 62, 70], ["The plate", "TREATMENT", 0, 9], ["pH", "TEST", 37, 39], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The ELISA was carried out as described previously (15) .", [["The ELISA", "TEST", 0, 9]]], ["Briefly, 50 mL of solution containing MoAb at eight different concentrations (1, 3, 10, 30, 90, 280, 830, and 2,500 ng/mL) was added into the wells of the plate and incubated for 1 hr at room temperature.", [["MoAb", "SIMPLE_CHEMICAL", 38, 42], ["solution containing MoAb", "TREATMENT", 18, 42]]], ["After washing with the PBS buffer containing Tween 20, goat anti-mouse antibodies conjugated with POD (Dako Cytomation, Co. Ltd., Kyoto, Japan) was added and incubated for 1 hr.", [["Tween 20", "CHEMICAL", 45, 53], ["Tween 20", "SIMPLE_CHEMICAL", 45, 53], ["goat", "ORGANISM", 55, 59], ["POD", "SIMPLE_CHEMICAL", 98, 101], ["goat anti-mouse antibodies", "PROTEIN", 55, 81], ["POD", "PROTEIN", 98, 101], ["goat", "SPECIES", 55, 59], ["anti-mouse", "SPECIES", 60, 70], ["goat", "SPECIES", 55, 59], ["the PBS buffer containing Tween", "TREATMENT", 19, 50], ["goat anti-mouse antibodies", "TREATMENT", 55, 81]]], ["After the wells were washed with PBS buffer, 50 mL of 2,2-azinobis(3-ethyl benzothiazoline-6-sulfonic acid) ammonium salt (ABTS)/H 2 O 2 were added.", [["2,2-azinobis(3-ethyl benzothiazoline-6-sulfonic acid", "CHEMICAL", 54, 106], ["ammonium salt", "CHEMICAL", 108, 121], ["ABTS", "CHEMICAL", 123, 127], ["H", "CHEMICAL", 129, 130], ["2,2-azinobis(3-ethyl benzothiazoline-6-sulfonic acid) ammonium salt", "CHEMICAL", 54, 121], ["ABTS", "CHEMICAL", 123, 127], ["H 2 O 2", "CHEMICAL", 129, 136], ["2,2-azinobis(3-ethyl benzothiazoline-6-sulfonic acid) ammonium salt", "SIMPLE_CHEMICAL", 54, 121], ["ABTS", "SIMPLE_CHEMICAL", 123, 127], ["H 2 O 2", "SIMPLE_CHEMICAL", 129, 136], ["PBS buffer", "TREATMENT", 33, 43], ["azinobis", "TREATMENT", 58, 66], ["ethyl benzothiazoline", "TREATMENT", 69, 90], ["sulfonic acid) ammonium salt (ABTS)", "TREATMENT", 93, 128]]], ["After the plate was incubated for 5 min, absorbance at 405 nm was measured.", [["the plate", "TREATMENT", 6, 15]]], ["The concentrations of MoAb at 50% of the maximum absorbance was used as an index for the apparent affinity of the antibody.ELISA ProcedureFor the competitive ELISA assay of the MoAbs, the wells of a plastic microplate were coated with 1 mg/mL of recombinant N-Ag, and essentially the same ELISA procedure as described above was used except that POD was used as the labeling enzyme and the assay buffer was 10 mM Tris buffer (pH 7.4) containing 0.15 M NaCl and 1% BSA.", [["N-Ag", "CHEMICAL", 258, 262], ["NaCl", "CHEMICAL", 451, 455], ["Ag", "CHEMICAL", 260, 262], ["Tris", "CHEMICAL", 412, 416], ["NaCl", "CHEMICAL", 451, 455], ["MoAb", "GENE_OR_GENE_PRODUCT", 22, 26], ["MoAbs", "GENE_OR_GENE_PRODUCT", 177, 182], ["N-Ag", "SIMPLE_CHEMICAL", 258, 262], ["POD", "SIMPLE_CHEMICAL", 345, 348], ["BSA", "SIMPLE_CHEMICAL", 463, 466], ["MoAb", "PROTEIN", 22, 26], ["MoAbs", "PROTEIN", 177, 182], ["recombinant N-Ag", "PROTEIN", 246, 262], ["POD", "PROTEIN", 345, 348], ["The concentrations of MoAb", "TREATMENT", 0, 26], ["the maximum absorbance", "TEST", 37, 59], ["an index", "TEST", 72, 80], ["ELISA Procedure", "TREATMENT", 123, 138], ["a plastic microplate", "TREATMENT", 197, 217], ["recombinant N-Ag", "TREATMENT", 246, 262], ["the same ELISA procedure", "TREATMENT", 280, 304], ["the labeling enzyme", "TEST", 361, 380], ["the assay buffer", "TREATMENT", 385, 401], ["pH", "TEST", 425, 427], ["0.15 M NaCl", "TREATMENT", 444, 455], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["Briefly, a mixture of 1 mg/mL of MoAb labeled with ALP and 5 mg/mL of free MoAb used as the competitor was added to the wells of a microplate and incubated for 1 hr at room temperature.", [["MoAb", "SIMPLE_CHEMICAL", 33, 37], ["ALP", "GENE_OR_GENE_PRODUCT", 51, 54], ["MoAb", "SIMPLE_CHEMICAL", 75, 79], ["MoAb", "PROTEIN", 33, 37], ["ALP", "PROTEIN", 51, 54], ["MoAb", "PROTEIN", 75, 79], ["MoAb", "TREATMENT", 33, 37], ["ALP", "TREATMENT", 51, 54], ["free MoAb", "TREATMENT", 70, 79], ["the competitor", "TREATMENT", 88, 102], ["a microplate", "TREATMENT", 129, 141]]], ["After the wells were washed, a 4-nitrophenyl-phosphate (PNPP) solution was added and absorbance at 405 nm was measured.ELISA ProcedureFor detection of the recombinant or native N-Ag of SARS-CoV by a two-step sandwich-format ELISA, the wells of a plastic microplate (Nunc-Immunot modules plate; Nunc A/C, Roskilde, Denmark) were coated with MoAbs against recombinant N-Ag or a synthetic peptide in 0.1 M phosphate buffer (pH 7.5) for 24 hr at 41.", [["4-nitrophenyl-phosphate", "CHEMICAL", 31, 54], ["PNPP", "CHEMICAL", 56, 60], ["N-Ag", "CHEMICAL", 177, 181], ["N-Ag", "CHEMICAL", 366, 370], ["phosphate", "CHEMICAL", 403, 412], ["4-nitrophenyl-phosphate", "CHEMICAL", 31, 54], ["PNPP", "CHEMICAL", 56, 60], ["Ag", "CHEMICAL", 179, 181], ["Ag", "CHEMICAL", 368, 370], ["phosphate", "CHEMICAL", 403, 412], ["4-nitrophenyl-phosphate", "SIMPLE_CHEMICAL", 31, 54], ["PNPP", "SIMPLE_CHEMICAL", 56, 60], ["N-Ag", "GENE_OR_GENE_PRODUCT", 177, 181], ["SARS-CoV", "ORGANISM", 185, 193], ["MoAbs", "GENE_OR_GENE_PRODUCT", 340, 345], ["N-Ag", "SIMPLE_CHEMICAL", 366, 370], ["recombinant or native N-Ag", "PROTEIN", 155, 181], ["MoAbs", "PROTEIN", 340, 345], ["recombinant N-Ag", "PROTEIN", 354, 370], ["SARS-CoV", "SPECIES", 185, 193], ["a 4-nitrophenyl-phosphate (PNPP) solution", "TREATMENT", 29, 70], ["ELISA Procedure", "TREATMENT", 119, 134], ["SARS", "PROBLEM", 185, 189], ["format ELISA", "TEST", 217, 229], ["a plastic microplate", "TREATMENT", 244, 264], ["Immunot modules plate", "TREATMENT", 271, 292], ["A/C, Roskilde, Denmark)", "TREATMENT", 299, 322], ["MoAbs", "TREATMENT", 340, 345], ["recombinant N-Ag", "TREATMENT", 354, 370], ["a synthetic peptide", "TREATMENT", 374, 393], ["phosphate buffer", "TREATMENT", 403, 419], ["pH", "TEST", 421, 423]]], ["The coating concentration of the wells was set at 14 mg/mL MoAb.", [["The coating concentration of the wells", "TREATMENT", 0, 38], ["coating", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["The washing and blocking procedures were the same as described previously (15) .", [["The washing", "TREATMENT", 0, 11], ["blocking procedures", "TREATMENT", 16, 35]]], ["The ELISA was carried out in a two-step sandwich format.", [["The ELISA", "TEST", 0, 9]]], ["In brief, MoAbs against N-Ag of SARS-CoV conjugated with ALP were used as the label.", [["N-Ag", "CHEMICAL", 24, 28], ["Ag", "CHEMICAL", 26, 28], ["MoAbs", "GENE_OR_GENE_PRODUCT", 10, 15], ["N-Ag", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["ALP", "GENE_OR_GENE_PRODUCT", 57, 60], ["MoAbs", "PROTEIN", 10, 15], ["N-Ag", "PROTEIN", 24, 28], ["CoV", "PROTEIN", 37, 40], ["ALP", "PROTEIN", 57, 60], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV conjugated with ALP", "TREATMENT", 37, 60]]], ["Then 100 mL of the test sample containing recombinant N-Ag or proteins obtained from supernatant of cultured Vero cells with SARS-CoV were placed in the microplate wells and incubated for 1 hr at ambient temperature.", [["sample", "ANATOMY", 24, 30], ["supernatant", "ANATOMY", 85, 96], ["Vero cells", "ANATOMY", 109, 119], ["N-Ag", "CHEMICAL", 54, 58], ["Ag", "CHEMICAL", 56, 58], ["N-Ag", "GENE_OR_GENE_PRODUCT", 54, 58], ["Vero cells", "CELL", 109, 119], ["SARS-CoV", "ORGANISM", 125, 133], ["recombinant N-Ag", "PROTEIN", 42, 58], ["cultured Vero cells", "CELL_LINE", 100, 119], ["SARS-CoV", "SPECIES", 125, 133], ["the test sample", "TEST", 15, 30], ["SARS", "PROBLEM", 125, 129], ["CoV", "PROBLEM", 130, 133], ["the microplate wells", "TREATMENT", 149, 169]]], ["After the plate was washed with 10 mM Tris buffer (pH 8.0) containing 0.15 M NaCl and 0.05% Triton X-100, 100 mL of MoAbs conjugated with ALP were added and incubated for 1 hr.", [["NaCl", "CHEMICAL", 77, 81], ["Triton X-100", "CHEMICAL", 92, 104], ["Tris", "CHEMICAL", 38, 42], ["NaCl", "CHEMICAL", 77, 81], ["Triton X-100", "SIMPLE_CHEMICAL", 92, 104], ["MoAbs", "SIMPLE_CHEMICAL", 116, 121], ["ALP", "GENE_OR_GENE_PRODUCT", 138, 141], ["MoAbs", "PROTEIN", 116, 121], ["ALP", "PROTEIN", 138, 141], ["the plate", "TREATMENT", 6, 15], ["10 mM Tris buffer", "TREATMENT", 32, 49], ["pH", "TEST", 51, 53], ["0.15 M NaCl", "TREATMENT", 70, 81], ["ALP", "TREATMENT", 138, 141]]], ["After the wells were washed, 100 mL of PNPP solution was added and absorbance at 405 nm was measured.", [["PNPP", "CHEMICAL", 39, 43], ["PNPP", "CHEMICAL", 39, 43], ["PNPP", "SIMPLE_CHEMICAL", 39, 43], ["PNPP solution", "TREATMENT", 39, 52]]], ["The detection limit values were estimated from the standard ELISA curves with a signal-to-noise ratio (SNR) of 2.Preparation of the RICT Device, and the RICT ProcedureThe basic concept of a rapid immunoassay with an all-in-one device based on the immunochromatographic method was previously described (10) .", [["the standard ELISA curves", "TEST", 47, 72], ["a signal", "TEST", 78, 86], ["SNR", "TEST", 103, 106], ["the RICT Device", "TREATMENT", 128, 143], ["the RICT Procedure", "TREATMENT", 149, 167], ["a rapid immunoassay", "TEST", 188, 207], ["the immunochromatographic method", "TEST", 243, 275], ["rapid", "OBSERVATION_MODIFIER", 190, 195]]], ["The device used in this study is schematically depicted in Fig. 1 .", [["The device", "TREATMENT", 0, 10], ["this study", "TEST", 19, 29]]], ["The RICT was designed for a qualitative analysis to detect the nucleocapsid protein of SARS-CoV on the basis of a positive or negative judgment.Preparation of the RICT Device, and the RICT ProcedureThree pads fixed onto sheets of nitrocellulose membrane (0.13 mm, 5 mm, and 50 mm (D \u00c2 W \u00c2 L), respectively) were used for liquid absorption, sample application, and solution development (Millipore Corp., Cork, Ireland).", [["membrane", "ANATOMY", 245, 253], ["SARS", "DISEASE", 87, 91], ["nitrocellulose", "CHEMICAL", 230, 244], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["membrane", "CELLULAR_COMPONENT", 245, 253], ["RICT", "DNA", 4, 8], ["nucleocapsid protein", "PROTEIN", 63, 83], ["SARS-CoV", "SPECIES", 87, 95], ["a qualitative analysis", "TEST", 26, 48], ["the nucleocapsid protein", "TEST", 59, 83], ["SARS", "PROBLEM", 87, 91], ["the RICT Device", "TREATMENT", 159, 174], ["the RICT ProcedureThree pads", "TREATMENT", 180, 208], ["nitrocellulose membrane", "TREATMENT", 230, 253], ["D \u00c2 W \u00c2 L)", "TREATMENT", 281, 291], ["liquid absorption", "TREATMENT", 321, 338], ["sample application", "TREATMENT", 340, 358]]], ["To assemble the assay device, three pads were placed on the entire membrane of the cassette and molded with a plastic cover to make an all-in-one device.Preparation of the RICT Device, and the RICT ProcedureThe pads and membrane sheet were pretreated as follows: Pad 2: A 5-mL solution containing an anti-N-Ag of SARS-CoV antibody conjugated with ALP in 50 mM Bis-Tris buffer (pH 7.2), 0.15 M NaCl, 0.5% BSA, and 1% Triton X-100 was absorbed onto pads of sizes 0.5 mm, 5 mm, and 9 mm (D \u00c2 W \u00c2 L) made of porous matrix.", [["membrane", "ANATOMY", 67, 75], ["membrane sheet", "ANATOMY", 220, 234], ["anti-N-Ag", "CHEMICAL", 300, 309], ["Bis-Tris", "CHEMICAL", 360, 368], ["NaCl", "CHEMICAL", 393, 397], ["BSA", "CHEMICAL", 404, 407], ["Triton X-100", "CHEMICAL", 416, 428], ["Ag", "CHEMICAL", 307, 309], ["Bis-Tris", "CHEMICAL", 360, 368], ["NaCl", "CHEMICAL", 393, 397], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["anti-N-Ag", "SIMPLE_CHEMICAL", 300, 309], ["SARS-CoV", "SIMPLE_CHEMICAL", 313, 321], ["ALP", "SIMPLE_CHEMICAL", 347, 350], ["Bis-Tris buffer", "SIMPLE_CHEMICAL", 360, 375], ["BSA", "SIMPLE_CHEMICAL", 404, 407], ["Triton X-100", "SIMPLE_CHEMICAL", 416, 428], ["matrix", "CELLULAR_COMPONENT", 511, 517], ["anti-N", "PROTEIN", 300, 306], ["Ag", "PROTEIN", 307, 309], ["SARS-CoV antibody", "PROTEIN", 313, 330], ["ALP", "PROTEIN", 347, 350], ["SARS-CoV", "SPECIES", 313, 321], ["the assay device", "TREATMENT", 12, 28], ["three pads", "TREATMENT", 30, 40], ["a plastic cover", "TREATMENT", 108, 123], ["an all-in-one device", "TREATMENT", 132, 152], ["the RICT Device", "TREATMENT", 168, 183], ["the RICT Procedure", "TREATMENT", 189, 207], ["The pads and membrane sheet", "TREATMENT", 207, 234], ["A 5-mL solution", "TREATMENT", 270, 285], ["an anti-N", "TEST", 297, 306], ["SARS", "TEST", 313, 317], ["CoV antibody", "TEST", 318, 330], ["ALP", "TEST", 347, 350], ["Bis", "TEST", 360, 363], ["pH", "TEST", 377, 379], ["NaCl", "TEST", 393, 397], ["BSA", "TEST", 404, 407], ["D \u00c2 W \u00c2 L)", "TREATMENT", 485, 495], ["porous matrix", "PROBLEM", 504, 517], ["porous matrix", "OBSERVATION", 504, 517]]], ["The pads were subsequently dried by air blowing.", [["pads", "ORGANISM_SUBDIVISION", 4, 8], ["The pads", "TREATMENT", 0, 8], ["pads", "OBSERVATION_MODIFIER", 4, 8], ["dried", "OBSERVATION_MODIFIER", 27, 32], ["air blowing", "OBSERVATION", 36, 47]]], ["The addition of Triton X-100 is essential to avoid interference from an immuno and/or enzyme reaction from the sample.", [["Triton X-100", "CHEMICAL", 16, 28], ["Triton X-100", "CHEMICAL", 16, 28], ["Triton X-100", "SIMPLE_CHEMICAL", 16, 28], ["Triton X", "TREATMENT", 16, 24], ["an immuno", "TEST", 69, 78], ["enzyme reaction", "PROBLEM", 86, 101], ["the sample", "TEST", 107, 117]]], ["Pad 3: BCIP (5 mL, used for the ALP substrate) was absorbed onto a pad that was then dried.", [["BCIP", "CHEMICAL", 7, 11], ["BCIP", "SIMPLE_CHEMICAL", 7, 11], ["ALP", "SIMPLE_CHEMICAL", 32, 35], ["ALP", "PROTEIN", 32, 35], ["Pad", "TEST", 0, 3], ["BCIP", "TEST", 7, 11], ["the ALP substrate", "TREATMENT", 28, 45], ["a pad", "TREATMENT", 65, 70], ["pad", "ANATOMY", 67, 70]]], ["The anti-ALP antibody and anti-N-Ag of SARS-CoV antibody were immobilized at the R and T positions on the membrane sheet in the detection zone.", [["membrane sheet", "ANATOMY", 106, 120], ["anti-N-Ag", "CHEMICAL", 26, 35], ["Ag", "CHEMICAL", 33, 35], ["anti-ALP antibody", "GENE_OR_GENE_PRODUCT", 4, 21], ["anti-N-Ag", "GENE_OR_GENE_PRODUCT", 26, 35], ["CoV", "ORGANISM", 44, 47], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["anti-ALP antibody", "PROTEIN", 4, 21], ["anti-N", "PROTEIN", 26, 32], ["Ag", "PROTEIN", 33, 35], ["SARS-CoV antibody", "PROTEIN", 39, 56], ["SARS-CoV", "SPECIES", 39, 47], ["The anti-ALP antibody", "TEST", 0, 21], ["anti-N", "TEST", 26, 32], ["SARS", "TEST", 39, 43], ["CoV antibody", "TEST", 44, 56]]], ["R and T indicated the reference and test lines, respectively.", [["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["test lines", "TEST", 36, 46]]], ["Then 300 mL of 0.1 M diethanol amine buffer (pH 9.8) containing 1 mM MgCl 2 (used as the developing solution) was added to the reservoir, which was then sealed with an aluminum film.Preparation of the RICT Device, and the RICT ProcedureThe assay procedure for RICT was performed as follows: A 25 mL sample containing either recombinant N-Ag or native SARS-CoV antigens was dropped onto the sample application pad, and the developing solution reservoir was then ruptured by pressing it with a finger.", [["sample", "ANATOMY", 390, 396], ["finger", "ANATOMY", 492, 498], ["diethanol amine", "CHEMICAL", 21, 36], ["MgCl 2", "CHEMICAL", 69, 75], ["aluminum", "CHEMICAL", 168, 176], ["N-Ag", "CHEMICAL", 336, 340], ["diethanol amine", "CHEMICAL", 21, 36], ["MgCl 2", "CHEMICAL", 69, 75], ["aluminum", "CHEMICAL", 168, 176], ["Ag", "CHEMICAL", 338, 340], ["diethanol amine", "SIMPLE_CHEMICAL", 21, 36], ["MgCl 2", "SIMPLE_CHEMICAL", 69, 75], ["N-Ag", "GENE_OR_GENE_PRODUCT", 336, 340], ["SARS-CoV antigens", "GENE_OR_GENE_PRODUCT", 351, 368], ["finger", "ORGANISM_SUBDIVISION", 492, 498], ["recombinant N-Ag", "PROTEIN", 324, 340], ["native SARS-CoV antigens", "PROTEIN", 344, 368], ["SARS-CoV", "SPECIES", 351, 359], ["0.1 M diethanol amine buffer (pH", "TREATMENT", 15, 47], ["1 mM MgCl", "TREATMENT", 64, 73], ["an aluminum film", "TEST", 165, 181], ["the RICT Device", "TREATMENT", 197, 212], ["the RICT Procedure", "TREATMENT", 218, 236], ["The assay procedure", "TREATMENT", 236, 255], ["RICT", "TREATMENT", 260, 264], ["A 25 mL sample", "TEST", 291, 305], ["native SARS", "PROBLEM", 344, 355], ["CoV antigens", "PROBLEM", 356, 368], ["the sample application pad", "TREATMENT", 386, 412], ["the developing solution reservoir", "TREATMENT", 418, 451], ["SARS", "OBSERVATION", 351, 355], ["ruptured", "OBSERVATION", 461, 469], ["finger", "ANATOMY", 492, 498]]], ["The device was incubated at room temperature.", [["The device", "TREATMENT", 0, 10]]], ["At 15 min after sample application, a blue line observed by the naked eye at the T position was judged as positive.", [["sample", "ANATOMY", 16, 22], ["eye", "ANATOMY", 70, 73], ["eye", "ORGAN", 70, 73], ["sample application", "TREATMENT", 16, 34], ["a blue line", "TREATMENT", 36, 47], ["blue line", "OBSERVATION", 38, 47], ["eye", "ANATOMY", 70, 73], ["positive", "OBSERVATION", 106, 114]]], ["When no band was observed after 15 min, the result was judged as negative.", [["negative", "OBSERVATION", 65, 73]]], ["In addition to the line at the T position, a blue line appeared at the R position and was used as an index of the validation of test performance.Preparation of SARS-CoVMost of the viral samples for the assay in this study were prepared from the supernatant of Vero E6 cells inoculated with SARS-CoV from patients.", [["samples", "ANATOMY", 186, 193], ["supernatant", "ANATOMY", 245, 256], ["cells", "ANATOMY", 268, 273], ["Vero E6 cells", "CELL", 260, 273], ["SARS-CoV", "ORGANISM", 290, 298], ["patients", "ORGANISM", 304, 312], ["Vero E6 cells", "CELL_LINE", 260, 273], ["patients", "SPECIES", 304, 312], ["Vero E6", "SPECIES", 260, 267], ["SARS-CoV", "SPECIES", 290, 298], ["a blue line", "TREATMENT", 43, 54], ["the validation of test performance", "TEST", 110, 144], ["SARS", "PROBLEM", 160, 164], ["the viral samples", "TEST", 176, 193], ["the assay", "TEST", 198, 207], ["this study", "TEST", 211, 221], ["Vero E6 cells", "TREATMENT", 260, 273], ["line", "OBSERVATION", 19, 23], ["blue line", "OBSERVATION", 45, 54]]], ["The original viral suspension contained 7.95 \u00c2 10 6 TCID 50 /mL of SARS-CoV and was diluted according to test requirements with 0.1 M Tris buffer (pH8.0) containing 0.15 M NaCl, 3% BSA, and, unless otherwise stated, 0.1% Nonidet P-40 (NP-40).", [["NaCl", "CHEMICAL", 172, 176], ["BSA", "CHEMICAL", 181, 184], ["Nonidet P-40", "CHEMICAL", 221, 233], ["NP-40", "CHEMICAL", 235, 240], ["Tris", "CHEMICAL", 134, 138], ["NaCl", "CHEMICAL", 172, 176], ["Nonidet P-40", "CHEMICAL", 221, 233], ["BSA", "SIMPLE_CHEMICAL", 181, 184], ["Nonidet P-40", "SIMPLE_CHEMICAL", 221, 233], ["NP-40", "SIMPLE_CHEMICAL", 235, 240], ["SARS-CoV", "SPECIES", 67, 75], ["The original viral suspension", "TEST", 0, 29], ["SARS", "TEST", 67, 71], ["CoV", "TEST", 72, 75], ["0.1 M Tris buffer", "TREATMENT", 128, 145], ["0.15 M NaCl", "TREATMENT", 165, 176], ["NP", "TEST", 235, 237], ["viral suspension", "OBSERVATION", 13, 29]]], ["This buffer was also used for dilution of serum and NSP, when necessary.", [["serum", "ANATOMY", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["NSP", "GENE_OR_GENE_PRODUCT", 52, 55], ["This buffer", "TREATMENT", 0, 11], ["dilution of serum and NSP", "TREATMENT", 30, 55]]], ["To prevent SARS-CoV infection during the assay procedure, we added NP-40 to the sample buffer to inactivate the SARS-CoV.Samples to Determine Analytical SensitivityA 25 mL sample was used for each RICT assay.", [["Samples", "ANATOMY", 121, 128], ["SARS-CoV infection", "DISEASE", 11, 29], ["NP-40", "CHEMICAL", 67, 72], ["SARS", "DISEASE", 112, 116], ["SARS-CoV", "ORGANISM", 11, 19], ["SARS-CoV", "ORGANISM", 112, 120], ["SARS-CoV", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 112, 120], ["SARS", "PROBLEM", 11, 15], ["CoV infection", "PROBLEM", 16, 29], ["the assay procedure", "TREATMENT", 37, 56], ["NP", "TREATMENT", 67, 69], ["the sample buffer", "TREATMENT", 76, 93], ["Samples", "TEST", 121, 128], ["Analytical SensitivityA", "TREATMENT", 142, 165], ["each RICT assay", "TEST", 192, 207], ["SARS", "OBSERVATION", 11, 15], ["CoV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 20, 29]]], ["The measurement of analytical sensitivity of the RICT assay with native SARS-CoV was carried out using samples prepared by serial 10-fold dilutions of viral cultures containing 7.95 \u00c2 10 6 TCID 50 /mL of SARS-CoV for all MoAb pair systems, and 1.59 \u00c2 10 5 TCID 50 /mL for the rSN122 and rSN21-2 pair systems.", [["samples", "ANATOMY", 103, 110], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["rSN21", "PROTEIN", 287, 292], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 204, 212], ["analytical sensitivity", "TEST", 19, 41], ["the RICT assay", "TEST", 45, 59], ["native SARS-CoV", "PROBLEM", 65, 80], ["samples", "TEST", 103, 110], ["viral cultures", "TEST", 151, 165], ["SARS", "TEST", 204, 208], ["CoV", "TEST", 209, 212], ["all MoAb pair systems", "TEST", 217, 238], ["the rSN122", "TEST", 272, 282], ["rSN21", "TEST", 287, 292]]], ["To obtain a more precise limit of detection, further testing was performed with nine dilutions (1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, and 9-fold dilutions of the positive sample solution with which antigen level was 7.95 \u00c2 10 2 TCID 50 /mL for rSN122/rSN21-2 and rSN122/rSN29 pair system, and 7.95 \u00c2 10 4 TCID 50 /mL for rSN150/rSN122 and rSN18/ rSN122 pair system).Samples to Determine Analytical SensitivityFor the measurement of analytical sensitivity with recombinant N-Ag, we used samples of a serial 2-fold dilution of the solution containing recombinant N-Ag at 2 ng/mL.", [["samples", "ANATOMY", 482, 489], ["N-Ag", "CHEMICAL", 468, 472], ["N-Ag", "CHEMICAL", 557, 561], ["Ag", "CHEMICAL", 470, 472], ["Ag", "CHEMICAL", 559, 561], ["rSN122", "ORGANISM", 259, 265], ["N-Ag", "GENE_OR_GENE_PRODUCT", 468, 472], ["N-Ag", "GENE_OR_GENE_PRODUCT", 557, 561], ["rSN122", "PROTEIN", 259, 265], ["rSN150", "PROTEIN", 317, 323], ["SN122", "PROTEIN", 325, 330], ["rSN18", "PROTEIN", 335, 340], ["rSN122", "PROTEIN", 342, 348], ["recombinant N-Ag", "PROTEIN", 456, 472], ["recombinant N-Ag", "PROTEIN", 545, 561], ["further testing", "TEST", 45, 60], ["nine dilutions", "TEST", 80, 94], ["the positive sample solution", "TREATMENT", 154, 182], ["antigen level", "TEST", 194, 207], ["SN21", "TEST", 248, 252], ["pair system", "TEST", 272, 283], ["Samples", "TEST", 362, 369], ["Analytical Sensitivity", "TEST", 383, 405], ["a serial 2-fold dilution of the solution", "TREATMENT", 493, 533], ["recombinant N-Ag", "TREATMENT", 545, 561]]], ["The highest respective dilutions of the SARS-CoV preparation (TCID 50 /mL) and recombinant N-Ag that resulted in a positive judgment were defined as the limits of analytical sensitivity in the present study.Samples to Determine Specificity and ReproducibilityFor the RICT specificity and reproducibility analyses, all tests were performed using the rSN122/rSN21-2 pair system.", [["SARS", "DISEASE", 40, 44], ["N-Ag", "CHEMICAL", 91, 95], ["Ag", "CHEMICAL", 93, 95], ["N-Ag", "GENE_OR_GENE_PRODUCT", 91, 95], ["recombinant N-Ag", "PROTEIN", 79, 95], ["rSN122", "DNA", 349, 355], ["rSN21", "DNA", 356, 361], ["SARS-CoV", "SPECIES", 40, 48], ["the SARS-CoV preparation", "TREATMENT", 36, 60], ["a positive judgment", "PROBLEM", 113, 132], ["the present study", "TEST", 189, 206], ["Samples", "TEST", 207, 214], ["Specificity", "TEST", 228, 239], ["Reproducibility", "TEST", 244, 259], ["the RICT specificity", "TEST", 263, 283], ["reproducibility analyses", "TEST", 288, 312], ["all tests", "TEST", 314, 323], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["For the RICT specificity analysis, 150 different human sera (50 normal human sera, 50 sera from pregnant women, and 50 from rheumatoid arthritis patients), as well as 50 human NSPs (including those from 14 patients infected with the influenza virus) were tested.", [["sera", "ANATOMY", 55, 59], ["sera", "ANATOMY", 77, 81], ["sera", "ANATOMY", 86, 90], ["NSPs", "ANATOMY", 176, 180], ["rheumatoid arthritis", "DISEASE", 124, 144], ["influenza virus", "DISEASE", 233, 248], ["human", "ORGANISM", 49, 54], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["human", "ORGANISM", 71, 76], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["women", "ORGANISM", 105, 110], ["patients", "ORGANISM", 145, 153], ["human", "ORGANISM", 170, 175], ["NSPs", "CANCER", 176, 180], ["patients", "ORGANISM", 206, 214], ["influenza virus", "ORGANISM", 233, 248], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 71, 76], ["women", "SPECIES", 105, 110], ["patients", "SPECIES", 145, 153], ["human", "SPECIES", 170, 175], ["patients", "SPECIES", 206, 214], ["influenza virus", "SPECIES", 233, 248], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 170, 175], ["the RICT specificity analysis", "TEST", 4, 33], ["different human sera", "TEST", 39, 59], ["human sera", "TEST", 71, 81], ["rheumatoid arthritis", "PROBLEM", 124, 144], ["the influenza virus", "PROBLEM", 229, 248]]], ["To collect the NSPs we inserted tubing into the subject's nostril parallel to the palate and aspirated the nasopharyngeal secretions, dispensed in 1 mL of sterile saline (pH 7.0).", [["nostril", "ANATOMY", 58, 65], ["palate", "ANATOMY", 82, 88], ["nasopharyngeal secretions", "ANATOMY", 107, 132], ["nostril", "ORGAN", 58, 65], ["palate", "ORGAN", 82, 88], ["nasopharyngeal secretions", "ORGANISM_SUBSTANCE", 107, 132], ["saline", "SIMPLE_CHEMICAL", 163, 169], ["NSPs", "DNA", 15, 19], ["the NSPs", "TREATMENT", 11, 19], ["tubing", "TREATMENT", 32, 38], ["the nasopharyngeal secretions", "PROBLEM", 103, 132], ["sterile saline", "TREATMENT", 155, 169], ["pH", "TEST", 171, 173], ["nostril", "ANATOMY", 58, 65], ["palate", "ANATOMY", 82, 88], ["aspirated", "OBSERVATION", 93, 102], ["nasopharyngeal", "ANATOMY", 107, 121], ["secretions", "OBSERVATION", 122, 132]]], ["The specimens were kept in sterile vials until they were used in the experiments.Samples for Other AnalysesTo prepare positive serum and respiratory aspirates to mimic the patient samples, we added 10 mL of the SARS-CoV suspension at 7.95 \u00c2 10 6 TCID 50 /mL to 1 mL of human serum or NSP.", [["specimens", "ANATOMY", 4, 13], ["serum", "ANATOMY", 127, 132], ["respiratory aspirates", "ANATOMY", 137, 158], ["samples", "ANATOMY", 180, 187], ["serum", "ANATOMY", 275, 280], ["SARS", "DISEASE", 211, 215], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["respiratory aspirates", "MULTI-TISSUE_STRUCTURE", 137, 158], ["patient", "ORGANISM", 172, 179], ["CoV", "ORGANISM", 216, 219], ["human", "ORGANISM", 269, 274], ["serum", "ORGANISM_SUBSTANCE", 275, 280], ["patient", "SPECIES", 172, 179], ["human", "SPECIES", 269, 274], ["SARS-CoV", "SPECIES", 211, 219], ["human", "SPECIES", 269, 274], ["The specimens", "TREATMENT", 0, 13], ["sterile vials", "TREATMENT", 27, 40], ["Samples", "TEST", 81, 88], ["Other Analyses", "TEST", 93, 107], ["positive serum", "TEST", 118, 132], ["respiratory aspirates", "TEST", 137, 158], ["the SARS-CoV suspension", "TREATMENT", 207, 230], ["human serum", "TEST", 269, 280], ["NSP", "PROBLEM", 284, 287], ["respiratory", "ANATOMY", 137, 148], ["aspirates", "OBSERVATION", 149, 158]]], ["Most samples were prepared with 3.3 \u00c2 10, 3 \u00c2 10 2 , and 3 \u00c2 10 3 fold dilutions of the stock suspension (7.87 \u00c2 10 4 TCID 50 /mL) using normal serum (and NSP) and subjected to RICT assays, in which the lowest concentration of SARS-CoV was 2.63 \u00c2 10 TCID 50 /mL at 3 \u00c2 10 3 fold dilution.Samples for Other AnalysesAll samples of Coxsackie virus types A-7 and -9 and B-1-6, parainfluenza virus types 1-4, adenovirus type 3, mumps virus, rubella virus, measles virus, and respiratory syncytial virus were purchased from a manufacturer (Denka-Seiken, Tokyo, Japan).", [["samples", "ANATOMY", 5, 12], ["serum", "ANATOMY", 144, 149], ["samples", "ANATOMY", 318, 325], ["SARS", "DISEASE", 227, 231], ["A-7 and -9 and B-1-6, parainfluenza virus types 1-4, adenovirus type 3,", "CHEMICAL", 351, 422], ["mumps virus", "DISEASE", 423, 434], ["rubella virus", "DISEASE", 436, 449], ["measles virus", "DISEASE", 451, 464], ["respiratory syncytial virus", "DISEASE", 470, 497], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 227, 235], ["Coxsackie virus types A-7", "ORGANISM", 329, 354], ["-9", "ORGANISM", 359, 361], ["B-1-6,", "ORGANISM", 366, 372], ["parainfluenza virus types 1-4", "ORGANISM", 373, 402], ["adenovirus type 3", "ORGANISM", 404, 421], ["mumps virus", "ORGANISM", 423, 434], ["rubella virus", "ORGANISM", 436, 449], ["measles virus", "ORGANISM", 451, 464], ["respiratory syncytial virus", "ORGANISM", 470, 497], ["Coxsackie virus", "SPECIES", 329, 344], ["B-1-", "SPECIES", 366, 370], ["parainfluenza virus types 1", "SPECIES", 373, 400], ["mumps virus", "SPECIES", 423, 434], ["rubella virus", "SPECIES", 436, 449], ["measles virus", "SPECIES", 451, 464], ["respiratory syncytial virus", "SPECIES", 470, 497], ["SARS-CoV", "SPECIES", 227, 235], ["Coxsackie virus", "SPECIES", 329, 344], ["mumps virus", "SPECIES", 423, 434], ["rubella virus", "SPECIES", 436, 449], ["measles virus", "SPECIES", 451, 464], ["respiratory syncytial virus", "SPECIES", 470, 497], ["the stock suspension", "TREATMENT", 84, 104], ["RICT assays", "TEST", 177, 188], ["SARS", "TEST", 227, 231], ["CoV", "TEST", 232, 235], ["TCID", "TEST", 250, 254], ["fold dilution", "TEST", 274, 287], ["Samples", "TEST", 288, 295], ["Other Analyses", "TEST", 300, 314], ["All samples", "TEST", 314, 325], ["Coxsackie virus types", "TEST", 329, 350], ["B", "TEST", 366, 367], ["parainfluenza virus types", "TEST", 373, 398], ["adenovirus type", "TEST", 404, 419], ["mumps virus", "PROBLEM", 423, 434], ["rubella virus", "PROBLEM", 436, 449], ["measles virus", "PROBLEM", 451, 464], ["respiratory syncytial virus", "PROBLEM", 470, 497], ["Coxsackie virus", "OBSERVATION", 329, 344], ["rubella virus", "OBSERVATION", 436, 449], ["respiratory", "ANATOMY", 470, 481], ["syncytial virus", "OBSERVATION", 482, 497]]], ["These samples were treated with UV irradiation and/or b-propionlactone by the manufacturer.Expression of Recombinant N-Ag in the E. coli SystemA recombinant nucleocapsid protein of SARS-CoV, obtained in mostly soluble proteins, was highly expressed in the E. coli system (Fig. 2) .", [["samples", "ANATOMY", 6, 13], ["UV", "CHEMICAL", 32, 34], ["b-propionlactone", "CHEMICAL", 54, 70], ["N-Ag", "CHEMICAL", 117, 121], ["propionlactone", "CHEMICAL", 56, 70], ["Ag", "CHEMICAL", 119, 121], ["b-propionlactone", "SIMPLE_CHEMICAL", 54, 70], ["Recombinant N-Ag", "GENE_OR_GENE_PRODUCT", 105, 121], ["E. coli", "ORGANISM", 129, 136], ["SystemA", "ORGANISM", 137, 144], ["SARS-CoV", "ORGANISM", 181, 189], ["E. coli", "ORGANISM", 256, 263], ["Recombinant N-Ag", "PROTEIN", 105, 121], ["E. coli SystemA recombinant nucleocapsid protein", "PROTEIN", 129, 177], ["SARS-CoV", "PROTEIN", 181, 189], ["soluble proteins", "PROTEIN", 210, 226], ["E. coli", "SPECIES", 129, 136], ["E. coli", "SPECIES", 256, 263], ["E. coli", "SPECIES", 129, 136], ["SARS-CoV", "SPECIES", 181, 189], ["E. coli", "SPECIES", 256, 263], ["UV irradiation", "TREATMENT", 32, 46], ["b-propionlactone", "TREATMENT", 54, 70], ["Recombinant N-Ag", "PROBLEM", 105, 121], ["the E. coli", "TEST", 125, 136], ["SARS", "PROBLEM", 181, 185], ["CoV", "PROBLEM", 186, 189], ["mostly soluble proteins", "PROBLEM", 203, 226], ["nucleocapsid protein", "OBSERVATION", 157, 177]]], ["The expressed proteins were purified and subjected to WB analysis.", [["WB analysis", "TEST", 54, 65]]], ["A major band of molecular mass 47.2 KDa was observed from Coomassie brilliant blue staining of the gels on the SDS-PAGE, and also on WB using mouse anti-SN-5 peptide serum (Fig. 2, lanes 3 and 6) .Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBMoAbs were produced by immunizing the protein of recombinant N-Ag or synthetic peptide to mice.", [["serum", "ANATOMY", 166, 171], ["N-Ag", "CHEMICAL", 244, 248], ["N-Ag", "CHEMICAL", 337, 341], ["Coomassie brilliant blue", "CHEMICAL", 58, 82], ["Ag", "CHEMICAL", 246, 248], ["Ag", "CHEMICAL", 339, 341], ["Coomassie", "SIMPLE_CHEMICAL", 58, 67], ["mouse", "ORGANISM", 142, 147], ["serum", "ORGANISM_SUBSTANCE", 166, 171], ["MoAbs", "GENE_OR_GENE_PRODUCT", 235, 240], ["N-Ag", "GENE_OR_GENE_PRODUCT", 244, 248], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 252, 260], ["N-Ag", "GENE_OR_GENE_PRODUCT", 337, 341], ["mice", "ORGANISM", 366, 370], ["MoAbs", "PROTEIN", 235, 240], ["N-Ag", "PROTEIN", 244, 248], ["Abs", "PROTEIN", 278, 281], ["recombinant N-Ag", "PROTEIN", 325, 341], ["mouse", "SPECIES", 142, 147], ["mice", "SPECIES", 366, 370], ["mouse", "SPECIES", 142, 147], ["SARS-CoV", "SPECIES", 252, 260], ["mice", "SPECIES", 366, 370], ["A major band of molecular mass", "PROBLEM", 0, 30], ["the SDS", "TEST", 107, 114], ["WB", "TEST", 133, 135], ["mouse anti", "TREATMENT", 142, 152], ["Evaluation", "TEST", 197, 207], ["the MoAbs", "TREATMENT", 231, 240], ["SARS", "PROBLEM", 252, 256], ["synthetic peptide", "TREATMENT", 345, 362], ["major", "OBSERVATION_MODIFIER", 2, 7], ["band", "OBSERVATION_MODIFIER", 8, 12], ["molecular", "OBSERVATION_MODIFIER", 16, 25], ["mass", "OBSERVATION", 26, 30], ["47.2 KDa", "OBSERVATION_MODIFIER", 31, 39]]], ["Six MoAbs were screened for their ability to bind to recombinant N-Ag immobilized on the wells (their titration curves are shown in Fig. 3 ).", [["N-Ag", "CHEMICAL", 65, 69], ["N-Ag", "CHEMICAL", 65, 69], ["MoAbs", "GENE_OR_GENE_PRODUCT", 4, 9], ["N-Ag", "GENE_OR_GENE_PRODUCT", 65, 69], ["MoAbs", "PROTEIN", 4, 9], ["recombinant N-Ag", "PROTEIN", 53, 69], ["their titration curves", "TREATMENT", 96, 118]]], ["Four MoAbs (rSN18, rSN150, rSN122, and SN5-25) gave concentrations of about 70 ng/mL at 50% of the maximum absorbance and had a relatively high apparent affinity, while the corresponding values of rSN21-2 and rSN29 were about 200 ng/mL, indicating nearly three times less affinity compared to that of the above antibodies.Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBThe MoAbs were compared with each other for binding to recombinant N-Ag by a competitive ELISA assay.", [["SN5-25", "CHEMICAL", 39, 45], ["N-Ag", "CHEMICAL", 369, 373], ["N-Ag", "CHEMICAL", 468, 472], ["Ag", "CHEMICAL", 371, 373], ["Ag", "CHEMICAL", 470, 472], ["MoAbs", "GENE_OR_GENE_PRODUCT", 5, 10], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 197, 204], ["rSN29", "SIMPLE_CHEMICAL", 209, 214], ["MoAbs", "GENE_OR_GENE_PRODUCT", 360, 365], ["N-Ag", "GENE_OR_GENE_PRODUCT", 369, 373], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 377, 385], ["MoAbs", "GENE_OR_GENE_PRODUCT", 405, 410], ["N-Ag", "GENE_OR_GENE_PRODUCT", 468, 472], ["MoAbs", "PROTEIN", 5, 10], ["rSN18", "PROTEIN", 12, 17], ["rSN150", "PROTEIN", 19, 25], ["rSN122", "PROTEIN", 27, 33], ["SN5", "PROTEIN", 39, 42], ["rSN21", "PROTEIN", 197, 202], ["antibodies", "PROTEIN", 311, 321], ["MoAbs", "PROTEIN", 360, 365], ["N-Ag", "PROTEIN", 369, 373], ["WBThe MoAbs", "PROTEIN", 399, 410], ["recombinant N-Ag", "PROTEIN", 456, 472], ["SARS-CoV", "SPECIES", 377, 385], ["Four MoAbs", "TEST", 0, 10], ["SN5", "TEST", 39, 42], ["concentrations", "TREATMENT", 52, 66], ["the maximum absorbance", "TEST", 95, 117], ["a relatively high apparent affinity", "PROBLEM", 126, 161], ["the corresponding values", "TEST", 169, 193], ["rSN21", "TEST", 197, 202], ["Evaluation", "TEST", 322, 332], ["the MoAbs", "TREATMENT", 356, 365], ["SARS", "PROBLEM", 377, 381]]], ["Typical examples are shown in Table 1 , i.e., the absorbance at 405 nm for ALP-labeled rSN122 was significantly reduced by the presence of free SN122 as a competitor, while small changes in absorbance occurred in the presence of other MoAbs.", [["SN122", "CHEMICAL", 144, 149], ["rSN122", "CHEMICAL", 87, 93], ["SN122", "CHEMICAL", 144, 149], ["ALP", "SIMPLE_CHEMICAL", 75, 78], ["rSN122", "SIMPLE_CHEMICAL", 87, 93], ["SN122", "SIMPLE_CHEMICAL", 144, 149], ["MoAbs", "GENE_OR_GENE_PRODUCT", 235, 240], ["ALP", "PROTEIN", 75, 78], ["MoAbs", "PROTEIN", 235, 240], ["the absorbance", "TEST", 46, 60], ["ALP", "TEST", 75, 78], ["small changes in absorbance", "PROBLEM", 173, 200], ["other MoAbs", "TREATMENT", 229, 240], ["small", "OBSERVATION_MODIFIER", 173, 178], ["changes", "OBSERVATION", 179, 186], ["absorbance", "OBSERVATION_MODIFIER", 190, 200], ["MoAbs", "OBSERVATION", 235, 240]]], ["Based on the competitive method described above, MoAbs of rSN18, rSN150, rSN122, and SN5-25 each appeared to bind at different epitopes, but rSN21-2 and rSN29 appeared to bind at the same epitope on the recombinant N-Ag (data not shown).Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBTo confirm immunoreactivity with native antigens of SARS-CoV, the six MoAbs were subjected to WB and compared with recombinant N-Ag.", [["N-Ag", "CHEMICAL", 215, 219], ["N-Ag", "CHEMICAL", 284, 288], ["Ag", "CHEMICAL", 217, 219], ["Ag", "CHEMICAL", 286, 288], ["MoAbs", "GENE_OR_GENE_PRODUCT", 49, 54], ["rSN18", "GENE_OR_GENE_PRODUCT", 58, 63], ["rSN150", "GENE_OR_GENE_PRODUCT", 65, 71], ["rSN122", "GENE_OR_GENE_PRODUCT", 73, 79], ["SN5-25", "ORGANISM", 85, 91], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 141, 148], ["rSN29", "GENE_OR_GENE_PRODUCT", 153, 158], ["N-Ag", "GENE_OR_GENE_PRODUCT", 215, 219], ["MoAbs", "GENE_OR_GENE_PRODUCT", 275, 280], ["N-Ag", "GENE_OR_GENE_PRODUCT", 284, 288], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 292, 300], ["WBTo", "SIMPLE_CHEMICAL", 314, 318], ["SARS-CoV", "ORGANISM", 368, 376], ["MoAbs", "GENE_OR_GENE_PRODUCT", 386, 391], ["MoAbs", "PROTEIN", 49, 54], ["rSN18", "PROTEIN", 58, 63], ["rSN150", "PROTEIN", 65, 71], ["rSN122", "PROTEIN", 73, 79], ["SN5", "PROTEIN", 85, 88], ["epitopes", "PROTEIN", 127, 135], ["rSN21", "PROTEIN", 141, 146], ["rSN29", "PROTEIN", 153, 158], ["recombinant N-Ag", "PROTEIN", 203, 219], ["MoAbs", "PROTEIN", 275, 280], ["N-Ag", "PROTEIN", 284, 288], ["native antigens", "PROTEIN", 349, 364], ["MoAbs", "PROTEIN", 386, 391], ["WB", "PROTEIN", 410, 412], ["SARS-CoV", "SPECIES", 292, 300], ["SARS-CoV", "SPECIES", 368, 376], ["MoAbs", "TEST", 49, 54], ["SN5", "TEST", 85, 88], ["rSN21", "TEST", 141, 146], ["Evaluation", "TEST", 237, 247], ["the MoAbs", "TEST", 271, 280], ["SARS", "PROBLEM", 292, 296], ["ELISA", "TEST", 304, 309], ["immunoreactivity", "PROBLEM", 327, 343], ["SARS", "PROBLEM", 368, 372], ["CoV", "PROBLEM", 373, 376], ["the six MoAbs", "TEST", 378, 391], ["WB", "TEST", 410, 412]]], ["Using recombinant N-Ag, we found that all of the MoAbs were reactive to the protein at a molecular mass of 47.2 Kda (Fig. 4a) .", [["N-Ag", "CHEMICAL", 18, 22], ["N-Ag", "CHEMICAL", 18, 22], ["N-Ag", "GENE_OR_GENE_PRODUCT", 18, 22], ["MoAbs", "GENE_OR_GENE_PRODUCT", 49, 54], ["recombinant N-Ag", "PROTEIN", 6, 22], ["MoAbs", "PROTEIN", 49, 54], ["a molecular mass", "TEST", 87, 103], ["mass", "OBSERVATION", 99, 103]]], ["When native SARS-CoV was used, banding patterns similar to those of recombinant proteins were observed (Fig. 4b) .", [["SARS-CoV", "ORGANISM", 12, 20], ["recombinant proteins", "PROTEIN", 68, 88], ["SARS-CoV", "SPECIES", 12, 20], ["native SARS-CoV", "PROBLEM", 5, 20], ["banding patterns", "PROBLEM", 31, 47], ["recombinant proteins", "PROBLEM", 68, 88]]], ["No detectable bands were observed when mouse MoAb E2CT-38, which is not related to SARS-CoV, was applied (lane 1 in Fig. 4a and b) .Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBPreliminary experiments were carried out to evaluate these MoAbs in the sandwich format of the ELISA assay.", [["N-Ag", "CHEMICAL", 179, 183], ["Ag", "CHEMICAL", 181, 183], ["mouse", "ORGANISM", 39, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["MoAbs", "GENE_OR_GENE_PRODUCT", 170, 175], ["N-Ag", "GENE_OR_GENE_PRODUCT", 179, 183], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 187, 195], ["MoAbs", "GENE_OR_GENE_PRODUCT", 270, 275], ["mouse MoAb E2CT-38", "DNA", 39, 57], ["MoAbs", "PROTEIN", 170, 175], ["N-Ag", "PROTEIN", 179, 183], ["MoAbs", "PROTEIN", 270, 275], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["SARS-CoV", "SPECIES", 83, 91], ["SARS-CoV", "SPECIES", 187, 195], ["detectable bands", "PROBLEM", 3, 19], ["mouse MoAb E2CT", "TEST", 39, 54], ["SARS", "PROBLEM", 83, 87], ["CoV", "PROBLEM", 88, 91], ["Evaluation", "TEST", 132, 142], ["the MoAbs", "TEST", 166, 175], ["SARS", "PROBLEM", 187, 191], ["ELISA and WBPreliminary experiments", "TEST", 199, 234], ["the ELISA assay", "TEST", 302, 317], ["detectable", "OBSERVATION_MODIFIER", 3, 13], ["bands", "OBSERVATION", 14, 19], ["not related to", "UNCERTAINTY", 68, 82], ["SARS", "OBSERVATION", 83, 87]]], ["All possible pair combinations of the ELISA assay using MoAbs were performed.", [["MoAbs", "GENE_OR_GENE_PRODUCT", 56, 61], ["MoAbs", "PROTEIN", 56, 61], ["the ELISA assay", "TEST", 34, 49], ["MoAbs", "TEST", 56, 61]]], ["Four pairs of MoAbs (rSN150/rSN122, rSN18/rSN122, rSN122/ rSN21-2, and rSN122/rSN29 pairs; the first and second antibodies were for solid-phase and ALP labeling, respectively) were successful, and a linear dose dependency was obtained for recombinant N-Ag up to 5 ng/ mL (curves J, &, K, and ' in Fig. 5) .Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBQualitatively similar results were obtained for the SARS-CoV up to 6.8 \u00c2 10 4 TCID 50 /mL (data not shown).Evaluation of Immunoreactivity of the MoAbs to N-Ag of SARS-CoV by ELISA and WBThe detection limits of the ELISA were 0.031-0.107 ng/mL for recombinant N-Ag, and 6.33 \u00c2 10 2 -2.88 \u00c2 10 3 TCID 50 /mL for native N-Ag of SARS-CoV.Performance of RICTOn the basis of the ELISA results, we further evaluated five MoAbs (rSN122, rSN150, rSN18, rSN21-2, and rSN29) using the optimized conditions for sandwich-format RICT.", [["N-Ag", "CHEMICAL", 251, 255], ["N-Ag", "CHEMICAL", 353, 357], ["SARS", "DISEASE", 437, 441], ["N-Ag", "CHEMICAL", 539, 543], ["N-Ag", "CHEMICAL", 644, 648], ["N-Ag", "CHEMICAL", 702, 706], ["Ag", "CHEMICAL", 253, 255], ["Ag", "CHEMICAL", 355, 357], ["Ag", "CHEMICAL", 541, 543], ["Ag", "CHEMICAL", 646, 648], ["Ag", "CHEMICAL", 704, 706], ["MoAbs", "GENE_OR_GENE_PRODUCT", 14, 19], ["rSN122", "GENE_OR_GENE_PRODUCT", 28, 34], ["rSN18", "GENE_OR_GENE_PRODUCT", 36, 41], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 58, 65], ["ALP", "SIMPLE_CHEMICAL", 148, 151], ["N-Ag", "GENE_OR_GENE_PRODUCT", 251, 255], ["MoAbs", "GENE_OR_GENE_PRODUCT", 344, 349], ["N-Ag", "GENE_OR_GENE_PRODUCT", 353, 357], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 361, 369], ["MoAbs", "GENE_OR_GENE_PRODUCT", 530, 535], ["N-Ag", "GENE_OR_GENE_PRODUCT", 539, 543], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 547, 555], ["N-Ag", "GENE_OR_GENE_PRODUCT", 644, 648], ["N-Ag", "SIMPLE_CHEMICAL", 702, 706], ["SARS-CoV", "ORGANISM", 710, 718], ["MoAbs", "GENE_OR_GENE_PRODUCT", 799, 804], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 829, 836], ["MoAbs", "PROTEIN", 14, 19], ["rSN150", "PROTEIN", 21, 27], ["rSN122", "PROTEIN", 28, 34], ["rSN18", "PROTEIN", 36, 41], ["rSN122", "PROTEIN", 42, 48], ["rSN122", "PROTEIN", 50, 56], ["rSN21", "PROTEIN", 58, 63], ["2", "PROTEIN", 64, 65], ["rSN122", "PROTEIN", 71, 77], ["rSN29 pairs", "PROTEIN", 78, 89], ["antibodies", "PROTEIN", 112, 122], ["ALP", "PROTEIN", 148, 151], ["Ag", "PROTEIN", 253, 255], ["MoAbs", "PROTEIN", 344, 349], ["N-Ag", "PROTEIN", 353, 357], ["MoAbs", "PROTEIN", 530, 535], ["N-Ag", "PROTEIN", 539, 543], ["Ag", "PROTEIN", 646, 648], ["Ag", "PROTEIN", 704, 706], ["MoAbs", "PROTEIN", 799, 804], ["rSN122", "PROTEIN", 806, 812], ["rSN150", "PROTEIN", 814, 820], ["rSN18", "PROTEIN", 822, 827], ["rSN21", "PROTEIN", 829, 834], ["rSN29", "PROTEIN", 842, 847], ["SARS-CoV", "SPECIES", 361, 369], ["SARS-CoV", "SPECIES", 437, 445], ["SARS-CoV", "SPECIES", 547, 555], ["SARS-CoV", "SPECIES", 710, 718], ["MoAbs", "TEST", 14, 19], ["rSN18", "TEST", 36, 41], ["rSN21", "TEST", 58, 63], ["second antibodies", "TEST", 105, 122], ["ALP labeling", "TEST", 148, 160], ["a linear dose dependency", "PROBLEM", 197, 221], ["Ag", "TEST", 253, 255], ["curves J", "TEST", 272, 280], ["K", "TEST", 285, 286], ["Evaluation", "TEST", 306, 316], ["the MoAbs", "TREATMENT", 340, 349], ["SARS", "PROBLEM", 361, 365], ["the SARS", "TEST", 433, 441], ["CoV", "TEST", 442, 445], ["Evaluation", "TEST", 492, 502], ["the MoAbs", "TREATMENT", 526, 535], ["SARS", "PROBLEM", 547, 551], ["the ELISA", "TEST", 595, 604], ["SARS", "PROBLEM", 710, 714], ["CoV", "PROBLEM", 715, 718], ["MoAbs", "TEST", 799, 804], ["rSN21", "TEST", 829, 834], ["sandwich", "TEST", 884, 892]]], ["RICT was developed as a qualitative assay method to detect N-Ag of SARS-CoV, and the appearance of a blue line at the T position of the device 15 min after sample application is judged as positive.", [["sample", "ANATOMY", 156, 162], ["N-Ag", "CHEMICAL", 59, 63], ["Ag", "CHEMICAL", 61, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 67, 75], ["N-Ag", "PROTEIN", 59, 63], ["SARS-CoV", "SPECIES", 67, 75], ["a qualitative assay method", "TEST", 22, 48], ["SARS", "PROBLEM", 67, 71], ["CoV", "PROBLEM", 72, 75], ["a blue line", "TREATMENT", 99, 110], ["the device", "TREATMENT", 132, 142], ["sample application", "TEST", 156, 174], ["blue line", "OBSERVATION", 101, 110]]], ["All possible pair combinations among these MoAbs were tested, and four sets of MoAb pairs (rSN150/rSN122, rSN18/rSN122, rSN122/rSN21-2, and rSN122/rSN29 (the first MoAb was immobilized and the second was the labeling antibody)) were selected using SARS-CoV as possible candidates for RICT in terms of detectability of N-Ag by a serial 10-fold dilution of samples (Table 2) .", [["samples", "ANATOMY", 355, 362], ["N-Ag", "CHEMICAL", 318, 322], ["N-Ag", "CHEMICAL", 318, 322], ["MoAbs", "GENE_OR_GENE_PRODUCT", 43, 48], ["MoAb", "GENE_OR_GENE_PRODUCT", 79, 83], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 127, 134], ["MoAb", "GENE_OR_GENE_PRODUCT", 164, 168], ["N-Ag", "SIMPLE_CHEMICAL", 318, 322], ["MoAbs", "PROTEIN", 43, 48], ["MoAb pairs", "PROTEIN", 79, 89], ["rSN150", "PROTEIN", 91, 97], ["rSN122", "PROTEIN", 98, 104], ["rSN18", "PROTEIN", 106, 111], ["rSN122", "PROTEIN", 112, 118], ["rSN122", "PROTEIN", 120, 126], ["rSN21", "PROTEIN", 127, 132], ["rSN122", "PROTEIN", 140, 146], ["rSN29", "PROTEIN", 147, 152], ["MoAb", "PROTEIN", 164, 168], ["labeling antibody", "PROTEIN", 208, 225], ["N-Ag", "PROTEIN", 318, 322], ["SARS-CoV", "SPECIES", 248, 256], ["these MoAbs", "TEST", 37, 48], ["MoAb pairs", "TEST", 79, 89], ["RICT", "TREATMENT", 284, 288], ["a serial 10-fold dilution of samples", "TREATMENT", 326, 362]]], ["Table 3 shows the analytical sensitivity of four MoAb pair systems.", [["MoAb", "PROTEIN", 49, 53]]], ["The highest analytical sensitivity obtained using rSN122/rSN21-2 was 31 pg/mL for recombinant N-Ag, and 1.99 \u00c2 10 2 TCID 50 /mL for native antigen of SARS-CoV.", [["N-Ag", "CHEMICAL", 94, 98], ["Ag", "CHEMICAL", 96, 98], ["N-Ag", "GENE_OR_GENE_PRODUCT", 94, 98], ["SARS-CoV", "ORGANISM", 150, 158], ["rSN122", "PROTEIN", 50, 56], ["Ag", "PROTEIN", 96, 98], ["SARS-CoV", "SPECIES", 150, 158], ["rSN122", "TEST", 50, 56], ["Ag", "TEST", 96, 98], ["SARS", "PROBLEM", 150, 154], ["CoV", "PROBLEM", 155, 158]]], ["Figure 6 shows the test results for the most sensitive detection of the RICT system using rSN122 and rSN21-2 as solid-phase and ALP labeling, respectively.", [["rSN122", "SIMPLE_CHEMICAL", 90, 96], ["ALP", "SIMPLE_CHEMICAL", 128, 131], ["rSN122", "PROTEIN", 90, 96], ["rSN21", "PROTEIN", 101, 106], ["ALP", "PROTEIN", 128, 131], ["the test", "TEST", 15, 23], ["the RICT system", "TEST", 68, 83], ["rSN21", "TEST", 101, 106], ["ALP labeling", "TEST", 128, 140]]], ["Prior to analysis, test samples containing SARS-CoV were heat-treated at 561C and diluted with a buffer containing NP-40, as described in Materials and Methods.", [["samples", "ANATOMY", 24, 31], ["NP-40", "CHEMICAL", 115, 120], ["SARS-CoV", "ORGANISM", 43, 51], ["SARS-CoV", "SPECIES", 43, 51], ["analysis", "TEST", 9, 17], ["test samples", "TEST", 19, 31], ["SARS", "PROBLEM", 43, 47], ["a buffer containing NP", "TREATMENT", 95, 117]]], ["The intensity of the blue line observed at the T position gradually weakened with consecutive 10-fold dilution of applied samples, and could be detected up to a 10-fold dilution, in which the TCID 50 /mL was 1.59 \u00c2 10 3 (Fig. 6, lane 3) .", [["samples", "ANATOMY", 122, 129], ["the blue line", "TREATMENT", 17, 30], ["consecutive 10-fold dilution", "TREATMENT", 82, 110], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["blue line", "OBSERVATION", 21, 30]]], ["However, a line could not be observed at the 10fold dilution (1.59 \u00c2 10 2 TCID 50 /mL) at 15 min (Fig. 6 , lane 2).", [["a line", "TREATMENT", 9, 15], ["line", "OBSERVATION", 11, 15]]], ["To further probe the limit of analytical sensitivity, we tested nine further dilutions.", [["analytical sensitivity", "TEST", 30, 52]]], ["The highest dilution (8-fold) with a positive judgment was equivalent to the concentrations of 1.99 \u00c2 10 2 TCID 50 /mL), while a 9-fold dilution (1.77 \u00c2 10 2 TCID 50 /mL) remained negative.", [["The highest dilution", "TEST", 0, 20], ["a 9-fold dilution", "TREATMENT", 127, 144], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["negative", "OBSERVATION", 180, 188]]], ["We thus took the value at 1.99 \u00c2 10 2 TCID 50 /mL as the limit of analytical sensitivity.Performance of RICTWe also performed RICT using samples in the absence of NP-40 without heat treatment, and obtained similar results (data not shown).Specificity of RICTFor the RICT specificity and reproducibility analyses, all tests were performed using the rSN122/rSN21-2 pair system.", [["samples", "ANATOMY", 137, 144], ["NP-40", "CHEMICAL", 163, 168], ["RICTFor", "DNA", 254, 261], ["rSN122", "DNA", 348, 354], ["rSN21", "DNA", 355, 360], ["analytical sensitivity", "TEST", 66, 88], ["NP", "TEST", 163, 165], ["heat treatment", "TREATMENT", 177, 191], ["the RICT specificity", "TEST", 262, 282], ["reproducibility analyses", "TEST", 287, 311], ["all tests", "TEST", 313, 322]]], ["As positive controls, we prepared mimicked serum and NSPs of SARS patients containing cultured SARS-CoV.", [["serum", "ANATOMY", 43, 48], ["SARS", "DISEASE", 61, 65], ["SARS", "DISEASE", 95, 99], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["NSPs", "SIMPLE_CHEMICAL", 53, 57], ["patients", "ORGANISM", 66, 74], ["SARS-CoV", "ORGANISM", 95, 103], ["patients", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 95, 103]]], ["The results were all positive for both samples down to 2.65 \u00c2 10 2 TCID 50 /mL; however, the result using 2.65 \u00c2 10 TCID 50 /mL was negative.", [["samples", "ANATOMY", 39, 46]]], ["The specificity of the RICT assay was 100% (150/150: 50 normal sera, 50 rheumatoid arthritis, and 50 pregnancy sera) for the sera, and 100% (50/50) for the NSPs (Table 4 ). rSN122 labeled with ALP was used for detection of recombinant N-Ag immobilized on the wells.", [["sera", "ANATOMY", 63, 67], ["sera", "ANATOMY", 111, 115], ["sera", "ANATOMY", 125, 129], ["rheumatoid arthritis", "DISEASE", 72, 92], ["rSN122", "CHEMICAL", 173, 179], ["N-Ag", "CHEMICAL", 235, 239], ["rSN122", "CHEMICAL", 173, 179], ["N-Ag", "CHEMICAL", 235, 239], ["sera", "ORGANISM_SUBSTANCE", 63, 67], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["sera", "ORGANISM_SUBSTANCE", 125, 129], ["rSN122", "SIMPLE_CHEMICAL", 173, 179], ["ALP", "GENE_OR_GENE_PRODUCT", 193, 196], ["N-Ag", "GENE_OR_GENE_PRODUCT", 235, 239], ["rSN122", "PROTEIN", 173, 179], ["ALP", "PROTEIN", 193, 196], ["recombinant N-Ag", "PROTEIN", 223, 239], ["the RICT assay", "TEST", 19, 33], ["sera", "TEST", 63, 67], ["rheumatoid arthritis", "PROBLEM", 72, 92], ["pregnancy sera", "TEST", 101, 115], ["the sera", "TEST", 121, 129], ["the NSPs", "TEST", 152, 160], ["ALP", "TEST", 193, 196], ["recombinant N-Ag immobilized", "TREATMENT", 223, 251]]], ["Free MoAb(A) used as competitor was added together with ALP-labeled MoAb into the wells as described in Materials and Methods.", [["MoAb", "GENE_OR_GENE_PRODUCT", 5, 9], ["ALP", "SIMPLE_CHEMICAL", 56, 59], ["MoAb", "GENE_OR_GENE_PRODUCT", 68, 72], ["MoAb", "PROTEIN", 5, 9], ["ALP", "PROTEIN", 56, 59], ["MoAb", "PROTEIN", 68, 72], ["Free MoAb(A) used as competitor", "TREATMENT", 0, 31], ["ALP", "TEST", 56, 59]]], ["Absorbance measured at 405 nm is indicated.", [["Absorbance", "TEST", 0, 10]]], ["E2CT-38 MoAb (antibody against estradiol) was used as control.", [["E2CT-38 MoAb", "CHEMICAL", 0, 12], ["estradiol", "CHEMICAL", 31, 40], ["estradiol", "CHEMICAL", 31, 40], ["E2CT-38 MoAb", "GENE_OR_GENE_PRODUCT", 0, 12], ["estradiol", "SIMPLE_CHEMICAL", 31, 40], ["E2CT-38 MoAb", "PROTEIN", 0, 12], ["antibody", "PROTEIN", 14, 22], ["E2CT", "TEST", 0, 4], ["MoAb", "TEST", 8, 12], ["antibody", "TEST", 14, 22], ["estradiol", "TREATMENT", 31, 40]]], ["Percentages were indicated using control absorbance as 100%.", [["Percentages", "TEST", 0, 11], ["control absorbance", "TEST", 33, 51]]], ["Of the 50 NSP results, 14 were influenza-infected samples (influenza viruse types A (n=12) and B (n=2)).", [["samples", "ANATOMY", 50, 57], ["influenza-infected", "DISEASE", 31, 49], ["influenza viruse", "DISEASE", 59, 75], ["the 50 NSP results", "TEST", 3, 21], ["influenza", "PROBLEM", 31, 40], ["infected samples", "PROBLEM", 41, 57], ["influenza viruse types", "TEST", 59, 81]]], ["Thus, the results from the 14 influenza samples also showed that no cross-reactivity with SARS-CoV occurred.", [["SARS-CoV", "DISEASE", 90, 98], ["SARS-CoV", "ORGANISM", 90, 98], ["SARS-CoV", "SPECIES", 90, 98], ["the 14 influenza samples", "TEST", 23, 47], ["cross-reactivity", "PROBLEM", 68, 84], ["SARS", "PROBLEM", 90, 94], ["CoV", "PROBLEM", 95, 98]]], ["Furthermore, infectious viruses of the respiratory tract, such as Coxsackie virus types A-7 and -9 and B-1-6, parainfluenza virus types 1-4, adenovirus type 3, mumps virus, rubella virus, measles virus, and respiratory syncytial virus, were tested by RICT.", [["respiratory tract", "ANATOMY", 39, 56], ["infectious viruses of the respiratory tract", "DISEASE", 13, 56], ["Coxsackie virus types A-7 and -9 and B-1-6, parainfluenza virus types 1-4, adenovirus type 3,", "CHEMICAL", 66, 159], ["mumps virus", "DISEASE", 160, 171], ["rubella virus", "DISEASE", 173, 186], ["measles virus", "DISEASE", 188, 201], ["respiratory syncytial virus", "DISEASE", 207, 234], ["respiratory tract", "ORGANISM_SUBDIVISION", 39, 56], ["Coxsackie virus types A-7", "ORGANISM", 66, 91], ["-9", "ORGANISM", 96, 98], ["B-1-6,", "ORGANISM", 103, 109], ["parainfluenza virus types 1-4", "ORGANISM", 110, 139], ["adenovirus type 3", "ORGANISM", 141, 158], ["mumps virus", "ORGANISM", 160, 171], ["rubella virus", "ORGANISM", 173, 186], ["measles virus", "ORGANISM", 188, 201], ["respiratory syncytial virus", "ORGANISM", 207, 234], ["Coxsackie virus", "SPECIES", 66, 81], ["B-1-6", "SPECIES", 103, 108], ["parainfluenza virus types 1", "SPECIES", 110, 137], ["mumps virus", "SPECIES", 160, 171], ["rubella virus", "SPECIES", 173, 186], ["measles virus", "SPECIES", 188, 201], ["respiratory syncytial virus", "SPECIES", 207, 234], ["Coxsackie virus", "SPECIES", 66, 81], ["mumps virus", "SPECIES", 160, 171], ["rubella virus", "SPECIES", 173, 186], ["measles virus", "SPECIES", 188, 201], ["respiratory syncytial virus", "SPECIES", 207, 234], ["infectious viruses of the respiratory tract", "PROBLEM", 13, 56], ["Coxsackie virus types", "TEST", 66, 87], ["B", "TEST", 103, 104], ["parainfluenza virus types", "TEST", 110, 135], ["adenovirus type", "TEST", 141, 156], ["mumps virus", "PROBLEM", 160, 171], ["rubella virus", "PROBLEM", 173, 186], ["measles virus", "PROBLEM", 188, 201], ["respiratory syncytial virus", "PROBLEM", 207, 234], ["infectious", "OBSERVATION", 13, 23], ["respiratory tract", "ANATOMY", 39, 56], ["respiratory syncytial", "ANATOMY", 207, 228]]], ["None of these samples gave positive results.Reproducibility of RICTWe evaluated the reproducibility of the RICT using five different samples (10 4 , 2 \u00c2 10 4 , 3 \u00c2 10 4 , 4 \u00c2 10 4 , and 5 \u00c2 10 4 fold dilutions of the original viral suspension atDISCUSSIONWe have demonstrated that our RICT with an all-inone device using mouse MoAbs (rSN122 for immobilized antibody, and rSN21-2 for enzyme labeling) can be used to detect the N-Ag of SARS-CoV.DISCUSSIONAlthough we could not confirm the sensitivity of RICT due to a lack of available human SARS patient samples, the results were all positive for both samples down to 7.87 \u00c2 10 2 TCID 50 /mL of SARS-CoV using mimicked serum and NSPs of SARS patients containing cultured SARS-CoV as positive controls.", [["samples", "ANATOMY", 14, 21], ["samples", "ANATOMY", 133, 140], ["samples", "ANATOMY", 553, 560], ["samples", "ANATOMY", 601, 608], ["serum", "ANATOMY", 668, 673], ["N-Ag", "CHEMICAL", 426, 430], ["SARS", "DISEASE", 540, 544], ["SARS", "DISEASE", 644, 648], ["SARS", "DISEASE", 686, 690], ["N-Ag", "CHEMICAL", 426, 430], ["samples", "CANCER", 14, 21], ["mouse", "ORGANISM", 321, 326], ["MoAbs", "GENE_OR_GENE_PRODUCT", 327, 332], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 371, 378], ["human", "ORGANISM", 534, 539], ["patient", "ORGANISM", 545, 552], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 644, 652], ["serum", "ORGANISM_SUBSTANCE", 668, 673], ["NSPs", "SIMPLE_CHEMICAL", 678, 682], ["patients", "ORGANISM", 691, 699], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 720, 728], ["mouse MoAbs", "PROTEIN", 321, 332], ["rSN122", "PROTEIN", 334, 340], ["immobilized antibody", "PROTEIN", 345, 365], ["rSN21", "PROTEIN", 371, 376], ["N-Ag", "PROTEIN", 426, 430], ["mouse", "SPECIES", 321, 326], ["human", "SPECIES", 534, 539], ["patient", "SPECIES", 545, 552], ["patients", "SPECIES", 691, 699], ["mouse", "SPECIES", 321, 326], ["human", "SPECIES", 534, 539], ["SARS-CoV", "SPECIES", 644, 652], ["SARS-CoV", "SPECIES", 720, 728], ["these samples", "TEST", 8, 21], ["five different samples", "TEST", 118, 140], ["the original viral suspension atDISCUSSIONWe", "TREATMENT", 213, 257], ["an all-inone device", "TREATMENT", 295, 314], ["mouse MoAbs", "TREATMENT", 321, 332], ["immobilized antibody", "TEST", 345, 365], ["rSN21", "TEST", 371, 376], ["enzyme labeling", "TEST", 383, 398], ["SARS", "PROBLEM", 644, 648], ["CoV", "TEST", 649, 652], ["serum", "TEST", 668, 673], ["SARS", "PROBLEM", 686, 690], ["cultured SARS", "TEST", 711, 724]]], ["The specificity of the RICT assay was 100% for sera, and 100% for NSPs (Table 4 ).", [["sera", "ANATOMY", 47, 51], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["the RICT assay", "TEST", 19, 33], ["sera", "TEST", 47, 51]]], ["However, cross-reactivity using human coronavirus OC43 and 229E remains to be confirmed.DISCUSSIONAs for the analytical sensitivities of RICT between recombinant and native N-Ag of SARS-CoV (Table 3) , the ratio of TCID 50 and concentration of recombinant N-Ag was more or less consistent, except for the rSN18/ rSN122 pair system, which resulted in less sensitivity for native SARS-CoV as compared to recombinant N-Ag.", [["N-Ag", "CHEMICAL", 173, 177], ["N-Ag", "CHEMICAL", 256, 260], ["SARS", "DISEASE", 378, 382], ["Ag", "CHEMICAL", 175, 177], ["Ag", "CHEMICAL", 258, 260], ["human", "ORGANISM", 32, 37], ["coronavirus OC43", "ORGANISM", 38, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 181, 189], ["N-Ag", "GENE_OR_GENE_PRODUCT", 256, 260], ["rSN18", "GENE_OR_GENE_PRODUCT", 305, 310], ["rSN122", "GENE_OR_GENE_PRODUCT", 312, 318], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 378, 386], ["RICT", "PROTEIN", 137, 141], ["Ag", "PROTEIN", 175, 177], ["recombinant N-Ag", "PROTEIN", 244, 260], ["rSN18", "PROTEIN", 305, 310], ["rSN122", "PROTEIN", 312, 318], ["human", "SPECIES", 32, 37], ["coronavirus", "SPECIES", 38, 49], ["human coronavirus", "SPECIES", 32, 49], ["SARS-CoV", "SPECIES", 181, 189], ["SARS-CoV", "SPECIES", 378, 386], ["human coronavirus OC43", "TEST", 32, 54], ["the analytical sensitivities", "TEST", 105, 133], ["RICT", "TEST", 137, 141], ["SARS", "PROBLEM", 181, 185], ["CoV (Table", "TEST", 186, 196], ["the ratio", "TEST", 202, 211], ["TCID", "TEST", 215, 219], ["native SARS", "PROBLEM", 371, 382], ["CoV", "PROBLEM", 383, 386], ["SARS", "OBSERVATION", 378, 382]]], ["These results may indicate that some changes in the reactivity of rSN18 occur only for native N-Ag of SRAS-CoV due to immobilization on the membrane of the device.", [["membrane", "ANATOMY", 140, 148], ["N-Ag", "CHEMICAL", 94, 98], ["N-Ag", "CHEMICAL", 94, 98], ["rSN18", "GENE_OR_GENE_PRODUCT", 66, 71], ["SRAS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["rSN18", "PROTEIN", 66, 71], ["N-Ag", "PROTEIN", 94, 98], ["SRAS", "PROTEIN", 102, 106], ["CoV", "PROTEIN", 107, 110], ["some changes", "PROBLEM", 32, 44], ["SRAS", "TEST", 102, 106], ["CoV", "PROBLEM", 107, 110], ["immobilization", "TREATMENT", 118, 132], ["the membrane of the device", "TREATMENT", 136, 162], ["immobilization", "OBSERVATION", 118, 132]]], ["Despite the lower apparent affinity (Fig. 3) , rSN21-2 and rSN29 showed highly sensitive results when used for labeling antibody, indicating that they can bind more strongly to free-form N-Ag than to immobilized N-Ag.", [["N-Ag", "CHEMICAL", 187, 191], ["N-Ag.", "CHEMICAL", 212, 217], ["N-Ag", "CHEMICAL", 187, 191], ["rSN21-2", "GENE_OR_GENE_PRODUCT", 47, 54], ["rSN29", "SIMPLE_CHEMICAL", 59, 64], ["N-Ag", "SIMPLE_CHEMICAL", 187, 191], ["rSN21", "PROTEIN", 47, 52], ["rSN29", "PROTEIN", 59, 64], ["N-Ag", "PROTEIN", 187, 191], ["the lower apparent affinity", "PROBLEM", 8, 35], ["rSN21", "TEST", 47, 52], ["labeling antibody", "TEST", 111, 128]]], ["A high analytical sensitivity for RICT using the rSN122/rSN21-2 pair was obtained at 31 pg/mL for recombinant N-Ag and 1.99 \u00c2 10 2 TCID 50 /mL for SARS-CoV (Table 2) , because the EIA method was employed.", [["N-Ag", "CHEMICAL", 110, 114], ["Ag", "CHEMICAL", 112, 114], ["N-Ag", "GENE_OR_GENE_PRODUCT", 110, 114], ["rSN122", "DNA", 49, 55], ["rSN21", "DNA", 56, 61], ["SARS-CoV", "SPECIES", 147, 155], ["RICT", "TEST", 34, 38], ["Ag", "TEST", 112, 114], ["SARS", "PROBLEM", 147, 151], ["CoV (Table", "TEST", 152, 162], ["the EIA method", "TEST", 176, 190]]], ["The analytical sensitivity for RICT was more or less consistent with the lower limit of detection on ELISA (Fig. 5 ).", [["The analytical sensitivity", "TEST", 0, 26], ["RICT", "PROBLEM", 31, 35], ["ELISA", "TEST", 101, 106], ["lower limit", "OBSERVATION_MODIFIER", 73, 84]]], ["The analytical sensitivity was similar to that obtained by ELISA using a mixture of MoAbs for capturing N-Ag and polyclonal antibodies as the detectors (7).DISCUSSIONOur results suggest that the presence of Triton X-100 enables the detection of N-Ag of SARS-CoV under conditions in which this would not otherwise be possible.", [["N-Ag", "CHEMICAL", 104, 108], ["Triton X-100", "CHEMICAL", 207, 219], ["N-Ag", "CHEMICAL", 245, 249], ["SARS", "DISEASE", 253, 257], ["Ag", "CHEMICAL", 106, 108], ["Triton X-100", "CHEMICAL", 207, 219], ["N-Ag", "CHEMICAL", 245, 249], ["MoAbs", "SIMPLE_CHEMICAL", 84, 89], ["N-Ag", "SIMPLE_CHEMICAL", 104, 108], ["Triton X-100", "SIMPLE_CHEMICAL", 207, 219], ["N-Ag", "SIMPLE_CHEMICAL", 245, 249], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 253, 261], ["MoAbs", "PROTEIN", 84, 89], ["N", "PROTEIN", 104, 105], ["Ag", "PROTEIN", 106, 108], ["polyclonal antibodies", "PROTEIN", 113, 134], ["N-Ag", "PROTEIN", 245, 249], ["SARS-CoV", "SPECIES", 253, 261], ["The analytical sensitivity", "TEST", 0, 26], ["ELISA", "TEST", 59, 64], ["a mixture of MoAbs", "TREATMENT", 71, 89], ["polyclonal antibodies", "TEST", 113, 134], ["the detection", "TEST", 228, 241], ["SARS", "PROBLEM", 253, 257], ["CoV under conditions", "PROBLEM", 258, 278]]], ["Triton X-100 may cause the destruction of SARS-CoV particles, and the viral N-antigen may thus become detectable by RICT.", [["Triton X-100", "CHEMICAL", 0, 12], ["SARS", "DISEASE", 42, 46], ["Triton X-100", "CHEMICAL", 0, 12], ["Triton X-100", "SIMPLE_CHEMICAL", 0, 12], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["viral N-antigen", "PROTEIN", 70, 85], ["RICT", "PROTEIN", 116, 120], ["SARS-CoV", "SPECIES", 42, 50], ["Triton", "TREATMENT", 0, 6], ["the destruction of SARS", "PROBLEM", 23, 46], ["CoV particles", "PROBLEM", 47, 60], ["the viral N-antigen", "TEST", 66, 85], ["destruction", "OBSERVATION", 27, 38], ["SARS", "OBSERVATION", 42, 46]]], ["The effect of Triton X-100 on transmissible gastroenteritis virus, a member of the coronavirus family, was addressed, and it was confirmed that the spherical core structure of the virus is maintained after treatment by Triton X-100 and can react with MoAb specific to N-Ag of transmissible gastroenteritis virus (17) .DISCUSSIONGiven the results obtained by ELISA and RICT that confirmed the detection of N-Ag of SARS-CoV using a heat-treated SARS-CoV sample without Triton X-100 by ELISA, and a sample without heat treatment in the absence of NP-40 by RICT, we conclude that treatment with either heat or Triton X-100 allows the N-Ag of SARS-CoV to be detected.DISCUSSIONThe molecular mass of N-Ag (46.7 KDa) calculated from its amino acid sequence was consistent with the 47.2 KDa observed by SDS-PAGE and WB (Figs.", [["sample", "ANATOMY", 496, 502], ["Triton X-100", "CHEMICAL", 14, 26], ["transmissible gastroenteritis", "DISEASE", 30, 59], ["Triton X-100", "CHEMICAL", 219, 231], ["N-Ag", "CHEMICAL", 268, 272], ["transmissible gastroenteritis", "DISEASE", 276, 305], ["N-Ag", "CHEMICAL", 405, 409], ["Triton X-100", "CHEMICAL", 467, 479], ["NP-40", "CHEMICAL", 544, 549], ["Triton X-100", "CHEMICAL", 606, 618], ["N-Ag", "CHEMICAL", 630, 634], ["N-Ag", "CHEMICAL", 694, 698], ["amino acid", "CHEMICAL", 730, 740], ["Triton X-100", "CHEMICAL", 14, 26], ["Ag", "CHEMICAL", 270, 272], ["Ag", "CHEMICAL", 407, 409], ["Triton X-100", "CHEMICAL", 467, 479], ["Triton X-100", "CHEMICAL", 606, 618], ["Ag", "CHEMICAL", 632, 634], ["N-Ag", "CHEMICAL", 694, 698], ["amino acid", "CHEMICAL", 730, 740], ["Triton X-100", "SIMPLE_CHEMICAL", 14, 26], ["transmissible gastroenteritis virus", "ORGANISM", 30, 65], ["coronavirus", "ORGANISM", 83, 94], ["Triton X-100", "SIMPLE_CHEMICAL", 219, 231], ["MoAb", "GENE_OR_GENE_PRODUCT", 251, 255], ["transmissible gastroenteritis virus", "ORGANISM", 276, 311], ["N-Ag", "SIMPLE_CHEMICAL", 405, 409], ["SARS-CoV", "ORGANISM", 413, 421], ["Triton X-100", "SIMPLE_CHEMICAL", 467, 479], ["NP-40", "SIMPLE_CHEMICAL", 544, 549], ["Triton X-100", "SIMPLE_CHEMICAL", 606, 618], ["N-Ag", "SIMPLE_CHEMICAL", 630, 634], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 638, 646], ["N-Ag", "GENE_OR_GENE_PRODUCT", 694, 698], ["amino acid", "AMINO_ACID", 730, 740], ["MoAb", "PROTEIN", 251, 255], ["N-Ag", "PROTEIN", 268, 272], ["N-Ag", "PROTEIN", 405, 409], ["N-Ag", "PROTEIN", 630, 634], ["N-Ag", "PROTEIN", 694, 698], ["46.7 KDa", "PROTEIN", 700, 708], ["47.2 KDa", "PROTEIN", 774, 782], ["transmissible gastroenteritis virus", "SPECIES", 30, 65], ["transmissible gastroenteritis virus", "SPECIES", 276, 311], ["transmissible gastroenteritis virus", "SPECIES", 30, 65], ["transmissible gastroenteritis virus", "SPECIES", 276, 311], ["SARS-CoV", "SPECIES", 413, 421], ["SARS-CoV", "SPECIES", 443, 451], ["SARS-CoV", "SPECIES", 638, 646], ["Triton X", "TREATMENT", 14, 22], ["transmissible gastroenteritis virus", "PROBLEM", 30, 65], ["the virus", "PROBLEM", 176, 185], ["transmissible gastroenteritis virus", "PROBLEM", 276, 311], ["the detection", "TEST", 388, 401], ["SARS", "PROBLEM", 413, 417], ["CoV", "PROBLEM", 418, 421], ["a heat", "TREATMENT", 428, 434], ["CoV sample", "TEST", 448, 458], ["Triton X", "TEST", 467, 475], ["heat treatment", "TREATMENT", 511, 525], ["NP", "TEST", 544, 546], ["heat or Triton", "TREATMENT", 598, 612], ["SARS", "PROBLEM", 638, 642], ["CoV", "PROBLEM", 643, 646], ["molecular mass", "PROBLEM", 676, 690], ["Ag", "TEST", 696, 698], ["KDa", "TEST", 705, 708], ["its amino acid sequence", "TEST", 726, 749], ["SDS", "TEST", 795, 798], ["virus", "OBSERVATION", 180, 185], ["mass", "OBSERVATION", 686, 690], ["consistent with", "UNCERTAINTY", 754, 769]]], ["It is most likely that the viral antigen that is reactive with MoAbs is a nucleocapsid protein.", [["MoAbs", "GENE_OR_GENE_PRODUCT", 63, 68], ["viral antigen", "PROTEIN", 27, 40], ["MoAbs", "PROTEIN", 63, 68], ["nucleocapsid protein", "PROTEIN", 74, 94], ["the viral antigen", "TEST", 23, 40], ["a nucleocapsid protein", "PROBLEM", 72, 94], ["most likely", "UNCERTAINTY", 6, 17], ["viral", "OBSERVATION", 27, 32], ["reactive", "OBSERVATION_MODIFIER", 49, 57]]], ["Also, the immunoreactivity of recombinant N-Ag appeared to be qualitatively similar to that of the native N-Ag.", [["N-Ag", "CHEMICAL", 42, 46], ["N-Ag", "CHEMICAL", 42, 46], ["N-Ag", "GENE_OR_GENE_PRODUCT", 42, 46], ["recombinant N-Ag", "PROTEIN", 30, 46]]], ["Regardless of the protein configuration used (denatured or intact), the MoAbs reacted not only with the recombinant N-Ag but also with native N-Ag (Fig. 4) , indicating that the MoAbs are able to recognize epitopes of N-Ag independently of a higher-order protein configuration.DISCUSSIONWe constructed DNA based on the Urbani strain for the expression of N-Ag in an E. coli system.", [["N-Ag", "CHEMICAL", 116, 120], ["N-Ag", "CHEMICAL", 142, 146], ["N-Ag", "CHEMICAL", 218, 222], ["N-Ag", "CHEMICAL", 355, 359], ["Ag", "CHEMICAL", 118, 120], ["N-Ag", "CHEMICAL", 142, 146], ["N-Ag", "CHEMICAL", 218, 222], ["N-Ag", "CHEMICAL", 355, 359], ["MoAbs", "GENE_OR_GENE_PRODUCT", 72, 77], ["N-Ag", "GENE_OR_GENE_PRODUCT", 116, 120], ["N-Ag", "SIMPLE_CHEMICAL", 142, 146], ["MoAbs", "GENE_OR_GENE_PRODUCT", 178, 183], ["N-Ag", "GENE_OR_GENE_PRODUCT", 218, 222], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["N-Ag", "GENE_OR_GENE_PRODUCT", 355, 359], ["E. coli", "ORGANISM", 366, 373], ["MoAbs", "PROTEIN", 72, 77], ["recombinant N-Ag", "PROTEIN", 104, 120], ["Ag", "PROTEIN", 144, 146], ["Fig. 4", "PROTEIN", 148, 154], ["MoAbs", "PROTEIN", 178, 183], ["epitopes", "PROTEIN", 206, 214], ["N-Ag", "PROTEIN", 218, 222], ["N-Ag", "PROTEIN", 355, 359], ["E. coli", "SPECIES", 366, 373], ["E. coli", "SPECIES", 366, 373], ["the protein configuration", "PROBLEM", 14, 39], ["the MoAbs", "PROBLEM", 174, 183], ["constructed DNA", "PROBLEM", 290, 305], ["the Urbani strain", "TREATMENT", 315, 332], ["an E. coli system", "TREATMENT", 363, 380], ["protein configuration", "OBSERVATION", 18, 39]]], ["Genomic N-Ag sequences of SARS-CoV, such as Urbani, CUHK-W1, Tor2, Franlfurt1, HSR1, TWH, BJ01, Shanghai QXC1, etc., have been reported in GenBank, and some changes in the nucleic acids of the sequences have been found (18) .", [["N-Ag", "CHEMICAL", 8, 12], ["nucleic acids", "CHEMICAL", 172, 185], ["SARS-CoV", "ORGANISM", 26, 34], ["Urbani", "GENE_OR_GENE_PRODUCT", 44, 50], ["CUHK-W1", "GENE_OR_GENE_PRODUCT", 52, 59], ["Tor2", "GENE_OR_GENE_PRODUCT", 61, 65], ["Franlfurt1", "GENE_OR_GENE_PRODUCT", 67, 77], ["HSR1", "GENE_OR_GENE_PRODUCT", 79, 83], ["TWH", "GENE_OR_GENE_PRODUCT", 85, 88], ["BJ01", "GENE_OR_GENE_PRODUCT", 90, 94], ["QXC1", "GENE_OR_GENE_PRODUCT", 105, 109], ["Genomic N-Ag sequences", "DNA", 0, 22], ["CUHK", "DNA", 52, 56], ["W1", "DNA", 57, 59], ["Tor2", "DNA", 61, 65], ["Franlfurt1", "DNA", 67, 77], ["HSR1", "DNA", 79, 83], ["TWH", "DNA", 85, 88], ["BJ01", "DNA", 90, 94], ["Shanghai QXC1", "DNA", 96, 109], ["SARS-CoV", "SPECIES", 26, 34], ["Genomic N", "TEST", 0, 9], ["SARS", "PROBLEM", 26, 30], ["Urbani", "TEST", 44, 50], ["CUHK", "TEST", 52, 56], ["HSR1", "TEST", 79, 83], ["TWH", "TEST", 85, 88], ["the nucleic acids", "TEST", 168, 185]]], ["However, the putative amino acid sequences for N-Ag were the same in most of the strains, except for a few strains in which one or two amino acids were changed due to nucleic acid mutation, i.e., Frankfurt 1 and FRA (amino acid change; Thr 50 Ile), BJ03 (amino acid change; Asn 154 Tyr), CUHK-Su10 (amino acid change; Gly 193 Cys), and Shanghai LY (amino acid changes; Val 325 Ala and Thr 326 Ala).", [["amino acid", "CHEMICAL", 22, 32], ["N-Ag", "CHEMICAL", 47, 51], ["amino acids", "CHEMICAL", 135, 146], ["nucleic acid", "CHEMICAL", 167, 179], ["amino acid", "CHEMICAL", 217, 227], ["amino acid", "CHEMICAL", 255, 265], ["Asn 154 Tyr", "CHEMICAL", 274, 285], ["amino acid", "CHEMICAL", 299, 309], ["Gly 193 Cys", "CHEMICAL", 318, 329], ["amino acid", "CHEMICAL", 349, 359], ["Val 325 Ala", "CHEMICAL", 369, 380], ["Thr 326 Ala", "CHEMICAL", 385, 396], ["amino acid", "CHEMICAL", 22, 32], ["N-Ag", "CHEMICAL", 47, 51], ["amino acids", "CHEMICAL", 135, 146], ["amino acid", "CHEMICAL", 217, 227], ["Thr", "CHEMICAL", 236, 239], ["Ile", "CHEMICAL", 243, 246], ["BJ03", "CHEMICAL", 249, 253], ["amino acid", "CHEMICAL", 255, 265], ["Asn", "CHEMICAL", 274, 277], ["Tyr", "CHEMICAL", 282, 285], ["CUHK-Su10", "CHEMICAL", 288, 297], ["amino acid", "CHEMICAL", 299, 309], ["Gly", "CHEMICAL", 318, 321], ["Cys", "CHEMICAL", 326, 329], ["amino acid", "CHEMICAL", 349, 359], ["Val", "CHEMICAL", 369, 372], ["Ala", "CHEMICAL", 377, 380], ["Thr", "CHEMICAL", 385, 388], ["Ala", "CHEMICAL", 393, 396], ["amino acid", "AMINO_ACID", 22, 32], ["N-Ag", "GENE_OR_GENE_PRODUCT", 47, 51], ["amino acids", "AMINO_ACID", 135, 146], ["FRA", "GENE_OR_GENE_PRODUCT", 212, 215], ["amino acid", "AMINO_ACID", 217, 227], ["Thr 50 Ile", "AMINO_ACID", 236, 246], ["amino acid", "AMINO_ACID", 255, 265], ["Asn 154 Tyr", "AMINO_ACID", 274, 285], ["amino acid", "AMINO_ACID", 299, 309], ["Gly 193 Cys", "AMINO_ACID", 318, 329], ["LY", "SIMPLE_CHEMICAL", 345, 347], ["amino acid", "AMINO_ACID", 349, 359], ["Thr 326 Ala", "AMINO_ACID", 385, 396], ["N-Ag", "PROTEIN", 47, 51], ["FRA", "PROTEIN", 212, 215], ["the putative amino acid sequences", "TEST", 9, 42], ["N-Ag", "TEST", 47, 51], ["a few strains", "PROBLEM", 101, 114], ["two amino acids", "TREATMENT", 131, 146], ["nucleic acid mutation", "PROBLEM", 167, 188], ["amino acid change", "TEST", 217, 234], ["BJ03", "TEST", 249, 253], ["amino acid change", "TEST", 255, 272], ["Asn", "TEST", 274, 277], ["CUHK", "TEST", 288, 292], ["amino acid change", "TEST", 299, 316], ["Cys", "TEST", 326, 329], ["Shanghai LY (amino acid changes", "TREATMENT", 336, 367]]], ["Among the four mutated strains, we expressed the recombinant N-Ag of Frankfurt 1, CUHK-Su10, and Shanghai LY strains in the E. coli system and detected them by RICT in a preliminary experiment.", [["N-Ag", "CHEMICAL", 61, 65], ["Ag", "CHEMICAL", 63, 65], ["N-Ag", "GENE_OR_GENE_PRODUCT", 61, 65], ["Frankfurt 1", "ORGANISM", 69, 80], ["CUHK-Su10", "CELL", 82, 91], ["Shanghai LY strains", "ORGANISM", 97, 116], ["E. coli", "ORGANISM", 124, 131], ["recombinant N-Ag", "PROTEIN", 49, 65], ["E. coli", "SPECIES", 124, 131], ["E. coli", "SPECIES", 124, 131], ["CUHK", "TEST", 82, 86], ["Shanghai LY strains in the E. coli system", "PROBLEM", 97, 138], ["E. coli", "ANATOMY", 124, 131]]], ["Further studies are needed to confirm the reactivity of these N-Ag variants by the RICT method described here.DISCUSSIONIn conclusion, although RICT's analytical sensitivity may be lower than that of PCR, but comparable with the ELISA method, it is nonetheless useful for the detection of N-Ag.", [["N-Ag", "CHEMICAL", 62, 66], ["N-Ag.", "CHEMICAL", 289, 294], ["N-Ag", "CHEMICAL", 62, 66], ["N-Ag", "GENE_OR_GENE_PRODUCT", 62, 66], ["N-Ag variants", "DNA", 62, 75], ["Further studies", "TEST", 0, 15], ["RICT's analytical sensitivity", "TEST", 144, 173], ["PCR", "TEST", 200, 203], ["the ELISA method", "TEST", 225, 241], ["the detection", "TEST", 272, 285]]], ["In addition, the assay involves a simple manipulation and a short detection time, and there was no cross-reactivity with the other respiratoryrelated viruses described in this study.", [["the assay", "TEST", 13, 22], ["a short detection time", "TEST", 58, 80], ["cross-reactivity", "PROBLEM", 99, 115], ["the other respiratoryrelated viruses", "PROBLEM", 121, 157], ["this study", "TEST", 171, 181], ["no", "UNCERTAINTY", 96, 98], ["cross-reactivity", "OBSERVATION", 99, 115], ["viruses", "OBSERVATION", 150, 157]]], ["Thus, we believe that RICT will be an equally useful method for point-ofcare testing to diagnose and treat SARS-suspected patients.", [["SARS", "DISEASE", 107, 111], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["ofcare testing", "TEST", 70, 84], ["SARS", "PROBLEM", 107, 111]]]], "PMC7258706": [["Important initial questions to askMake every effort to speak directly to the paramedics, the patient, patient\u2019s family, and any eyewitness to obtain the most reliable medical history.", [["patient", "ORGANISM", 93, 100], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 93, 100], ["patient", "SPECIES", 102, 109]]], ["There are 6 key questions to ask first, before we get a more detailed history and understand exactly what happened (specific symptoms and chronology):1.Clarify the time the patient was \u201clast seen normal\u201d and the exact time of onset of symptoms, or the time the patient was found with symptoms.2.What are the main neurological deficits?", [["neurological", "ANATOMY", 313, 325], ["neurological deficits", "DISEASE", 313, 334], ["patient", "ORGANISM", 173, 180], ["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 173, 180], ["patient", "SPECIES", 261, 268], ["symptoms", "PROBLEM", 235, 243], ["symptoms", "PROBLEM", 284, 292], ["the main neurological deficits", "PROBLEM", 304, 334], ["main", "OBSERVATION_MODIFIER", 308, 312], ["neurological", "OBSERVATION_MODIFIER", 313, 325], ["deficits", "OBSERVATION", 326, 334]]], ["Did they improve or worsen en route?3.Relevant past medical history and medications (do they have known atrial fibrillation?", [["atrial", "ANATOMY", 104, 110], ["atrial fibrillation", "DISEASE", 104, 123], ["atrial", "MULTI-TISSUE_STRUCTURE", 104, 110], ["medications", "TREATMENT", 72, 83], ["known atrial fibrillation", "PROBLEM", 98, 123], ["atrial", "ANATOMY", 104, 110], ["fibrillation", "OBSERVATION", 111, 123]]], ["Are they taking anticoagulant medications?", [["anticoagulant medications", "TREATMENT", 16, 41]]], ["Do they have an allergy to contrast dye?).4.Baseline functional status and occupation.5.If arriving by EMS: vitals en route, EMS cardiac rhythm (normal sinus or atrial fibrillation or other?), blood glucose.6.Did they bypass a closer hospital en route?Alt-text: Unlabelled Box(1)The most important initial question to clarify with the patient, family, or witness is the stroke onset time and the patient\u2019s \u201clast seen normal time,\u201d as it starts the clock on eligibility for acute treatment, i.e., thrombolytic therapy with tPA and/or endovascular therapy.", [["cardiac", "ANATOMY", 129, 136], ["sinus", "ANATOMY", 152, 157], ["atrial", "ANATOMY", 161, 167], ["blood", "ANATOMY", 193, 198], ["allergy", "DISEASE", 16, 23], ["cardiac rhythm", "DISEASE", 129, 143], ["atrial fibrillation", "DISEASE", 161, 180], ["glucose", "CHEMICAL", 199, 206], ["stroke", "DISEASE", 370, 376], ["EMS", "CHEMICAL", 103, 106], ["glucose", "CHEMICAL", 199, 206], ["sinus", "MULTI-TISSUE_STRUCTURE", 152, 157], ["atrial", "MULTI-TISSUE_STRUCTURE", 161, 167], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["glucose", "SIMPLE_CHEMICAL", 199, 206], ["patient", "ORGANISM", 335, 342], ["patient", "ORGANISM", 396, 403], ["tPA", "GENE_OR_GENE_PRODUCT", 522, 525], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 533, 545], ["patient", "SPECIES", 335, 342], ["patient", "SPECIES", 396, 403], ["contrast dye", "TREATMENT", 27, 39], ["vitals", "TEST", 108, 114], ["EMS cardiac rhythm", "TEST", 125, 143], ["atrial fibrillation", "PROBLEM", 161, 180], ["blood glucose", "TEST", 193, 206], ["acute treatment", "TREATMENT", 473, 488], ["thrombolytic therapy", "TREATMENT", 496, 516], ["tPA", "TREATMENT", 522, 525], ["endovascular therapy", "TREATMENT", 533, 553], ["atrial", "ANATOMY", 161, 167], ["fibrillation", "OBSERVATION", 168, 180], ["bypass", "OBSERVATION", 218, 224]]], ["Use clock time (i.e., 23:00), rather than \u201c2 h ago,\u201d or \u201c30 min ago.\u201dIf the patient woke up with symptoms (i.e., a wake-up stroke), when were they last seen well?", [["stroke", "DISEASE", 123, 129], ["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["symptoms", "PROBLEM", 97, 105], ["stroke", "PROBLEM", 123, 129]]], ["Did they get up in the middle of the night to use the washroom and were they normal then?", [["normal", "OBSERVATION", 77, 83]]], ["If the patient woke up with symptoms in the morning without previous awakenings, we must use their last seen normal time which is typically when they went to bed.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["symptoms", "PROBLEM", 28, 36]]], ["A common reason for ineligibility for tPA is arrival at the hospital too late, beyond the time window for treatment (although this is an evolving area of clinical research, and advanced imaging may enable the use of tPA outside the traditional time window).(2)Now we need to clarify the neurological deficits.Clinical features in favor of an acute arterial stroke diagnosis:\u274fSudden onset of persistent focal neurological symptoms\u274fSymptoms compatible with a vascular territory (see Chapter 4\u2014stroke syndromes).", [["neurological", "ANATOMY", 287, 299], ["arterial", "ANATOMY", 348, 356], ["neurological", "ANATOMY", 408, 420], ["vascular", "ANATOMY", 457, 465], ["neurological deficits", "DISEASE", 287, 308], ["acute arterial stroke", "DISEASE", 342, 363], ["stroke syndromes", "DISEASE", 491, 507], ["tPA", "GENE_OR_GENE_PRODUCT", 38, 41], ["tPA", "GENE_OR_GENE_PRODUCT", 216, 219], ["arterial", "MULTI-TISSUE_STRUCTURE", 348, 356], ["vascular", "MULTI-TISSUE_STRUCTURE", 457, 465], ["tPA", "PROTEIN", 38, 41], ["tPA", "PROTEIN", 216, 219], ["tPA", "TREATMENT", 38, 41], ["treatment", "TREATMENT", 106, 115], ["advanced imaging", "TEST", 177, 193], ["tPA", "TREATMENT", 216, 219], ["the neurological deficits", "PROBLEM", 283, 308], ["an acute arterial stroke", "PROBLEM", 339, 363], ["persistent focal neurological symptoms", "PROBLEM", 391, 429], ["Symptoms", "PROBLEM", 430, 438], ["a vascular territory", "PROBLEM", 455, 475], ["stroke syndromes", "PROBLEM", 491, 507], ["acute", "OBSERVATION_MODIFIER", 342, 347], ["arterial", "ANATOMY", 348, 356], ["stroke", "OBSERVATION", 357, 363], ["persistent", "OBSERVATION_MODIFIER", 391, 401], ["focal", "OBSERVATION_MODIFIER", 402, 407], ["vascular", "ANATOMY", 457, 465], ["territory", "ANATOMY_MODIFIER", 466, 475]]]], "951402d20823a92d1ec9656902d0820d852dbfab": [["COVID-19 is caused by a virus belonging to the Coronaviridae (CoV) family, which are typically harboured in mammals and other animals.", [["COVID-19", "CHEMICAL", 0, 8], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 47, 60], ["CoV", "ORGANISM", 62, 65], ["Coronaviridae (CoV) family", "PROTEIN", 47, 73], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["a virus", "PROBLEM", 22, 29]]], ["Coronaviruses cause severe acute respiratory syndrome (SARS), infect unciliated bronchial epithelial cells and type II pneumonocytes, which in turn causes fever, cough, shortness of breath and severe complications like pneumonia (Ashour et al., 2020) .", [["bronchial epithelial cells", "ANATOMY", 80, 106], ["type II pneumonocytes", "ANATOMY", 111, 132], ["Coronaviruses", "DISEASE", 0, 13], ["acute respiratory syndrome", "DISEASE", 27, 53], ["SARS", "DISEASE", 55, 59], ["fever", "DISEASE", 155, 160], ["cough", "DISEASE", 162, 167], ["shortness of breath", "DISEASE", 169, 188], ["pneumonia", "DISEASE", 219, 228], ["bronchial epithelial cells", "CELL", 80, 106], ["type II pneumonocytes", "CELL", 111, 132], ["unciliated bronchial epithelial cells", "CELL_TYPE", 69, 106], ["type II pneumonocytes", "CELL_TYPE", 111, 132], ["Coronaviruses", "PROBLEM", 0, 13], ["severe acute respiratory syndrome", "PROBLEM", 20, 53], ["SARS", "PROBLEM", 55, 59], ["infect unciliated bronchial epithelial cells", "PROBLEM", 62, 106], ["type II pneumonocytes", "PROBLEM", 111, 132], ["fever", "PROBLEM", 155, 160], ["cough", "PROBLEM", 162, 167], ["shortness of breath", "PROBLEM", 169, 188], ["severe complications", "PROBLEM", 193, 213], ["pneumonia", "PROBLEM", 219, 228], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome", "OBSERVATION", 33, 53], ["bronchial", "ANATOMY", 80, 89], ["epithelial cells", "OBSERVATION", 90, 106], ["type II", "OBSERVATION_MODIFIER", 111, 118], ["pneumonocytes", "OBSERVATION", 119, 132], ["fever", "OBSERVATION_MODIFIER", 155, 160], ["cough", "OBSERVATION", 162, 167], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["complications", "OBSERVATION", 200, 213], ["pneumonia", "OBSERVATION", 219, 228]]], ["These are typical characteristics of all common influenzas.", [["influenzas", "DISEASE", 48, 58], ["influenzas", "CANCER", 48, 58], ["all common influenzas", "PROBLEM", 37, 58], ["all", "OBSERVATION_MODIFIER", 37, 40], ["common influenzas", "OBSERVATION", 41, 58]]], ["Over the past 8 weeks, many professional bodies, including the American College of Obstetricians and Gynecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) have provided specific recommendations regarding COVID-19 and pregnant women.", [["women", "ORGANISM", 258, 263], ["women", "SPECIES", 258, 263], ["COVID", "TEST", 236, 241]]], ["The limited data cannot support the notion that pregnant women are a group with higher risk of illness, since there are reports where women positive to SARS-CoV-2 delivered healthy infants (in Greece there are currently three cases).", [["illness", "DISEASE", 95, 102], ["SARS", "DISEASE", 152, 156], ["women", "ORGANISM", 57, 62], ["women", "ORGANISM", 134, 139], ["SARS-CoV-2", "ORGANISM", 152, 162], ["infants", "ORGANISM", 181, 188], ["women", "SPECIES", 57, 62], ["women", "SPECIES", 134, 139], ["infants", "SPECIES", 181, 188], ["illness", "PROBLEM", 95, 102]]], ["This could be an indication against the intrauterine transmission of the virus.", [["intrauterine", "ANATOMY", 40, 52], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 52], ["the intrauterine transmission of the virus", "PROBLEM", 36, 78], ["virus", "OBSERVATION", 73, 78]]], ["Nevertheless, there is mounting evidence pointing to the possible transmission from positive SARS-CoV-2 mothers to newborns and this, together with the presence of antibodies in an infant born to a positive SARS-CoV-2 mother (Dong et al., 2020; Zheng et al., 2020) , places pregnant women in the group with higher risk of illness.", [["SARS", "DISEASE", 93, 97], ["SARS", "DISEASE", 207, 211], ["illness", "DISEASE", 322, 329], ["SARS-CoV-2", "ORGANISM", 93, 103], ["mothers", "ORGANISM", 104, 111], ["newborns", "ORGANISM", 115, 123], ["women", "ORGANISM", 283, 288], ["antibodies", "PROTEIN", 164, 174], ["infant", "SPECIES", 181, 187], ["women", "SPECIES", 283, 288], ["SARS-CoV", "SPECIES", 93, 101], ["positive SARS", "PROBLEM", 84, 97], ["antibodies", "PROBLEM", 164, 174], ["illness", "PROBLEM", 322, 329], ["illness", "OBSERVATION", 322, 329]]]], "PMC7118783": [["Geographical Distribution and Taxonomical Aspects ::: IntroductionThe genus Narcissus L. belongs to the Narcisseae, one of the 15 tribes of the Amaryllidaceae, a widely distributed monocotyledonous family of 59 genera and about 850 species (1).", [["Narcissus L.", "ORGANISM", 76, 88], ["Amaryllidaceae", "GENE_OR_GENE_PRODUCT", 144, 158], ["Narcissus L.", "SPECIES", 76, 88], ["Narcissus L.", "SPECIES", 76, 88], ["Distribution", "OBSERVATION_MODIFIER", 13, 25], ["Taxonomical Aspects", "OBSERVATION", 30, 49], ["Amaryllidaceae", "ANATOMY", 144, 158]]], ["The Amaryllidaceae are richly represented in the tropics and have pronounced centers of diversity in South Africa and the Andean region.", [["Amaryllidaceae", "GENE_OR_GENE_PRODUCT", 4, 18], ["Amaryllidaceae", "OBSERVATION", 4, 18], ["pronounced", "OBSERVATION_MODIFIER", 66, 76], ["diversity", "OBSERVATION", 88, 97], ["Andean", "ANATOMY_MODIFIER", 122, 128], ["region", "ANATOMY_MODIFIER", 129, 135]]], ["Some genera are also found in the Mediterranean area and the temperate regions of Asia.", [["genera", "OBSERVATION_MODIFIER", 5, 11], ["temperate", "OBSERVATION_MODIFIER", 61, 70]]], ["The hypothesis that the family evolved in Africa and subsequently spread to other continents, further suggesting that South America is the center of secondary diversification is supported by the matK sequence data (2).Geographical Distribution and Taxonomical Aspects ::: Introduction", [["matK sequence", "DNA", 195, 208], ["Africa", "PROBLEM", 42, 48], ["the matK sequence data", "TEST", 191, 213], ["secondary diversification", "OBSERVATION", 149, 174], ["Distribution", "OBSERVATION_MODIFIER", 231, 243], ["Taxonomical Aspects", "OBSERVATION", 248, 267]]]], "PMC7514051": [["IntroductionA heated dispute about the effectiveness versus risk of smallpox inoculation was playing out in eighteenth-century France, which was to launch the use of mathematical models in epidemiology.", [["smallpox", "DISEASE", 68, 76], ["smallpox inoculation", "PROBLEM", 68, 88], ["smallpox", "OBSERVATION_MODIFIER", 68, 76], ["inoculation", "OBSERVATION", 77, 88]]], ["This dispute moved inoculation from the domain of philosophy, religion, and disjointed trials plagued by high uncertainty into a debate about mathematical models\u2014put forth by Daniel Bernoulli (in 1766) and Jean-Baptiste le Rond D\u2019Alembert (in 1761), both dealing with competing risks of death and interpretation of trials [1].", [["death", "DISEASE", 287, 292], ["Jean-Baptiste le Rond D\u2019Alembert", "SPECIES", 206, 238]]], ["Since then, the mathematical description of infectious diseases continues to draw significant attention from researchers and practitioners in governments and health agencies alike.", [["infectious diseases", "DISEASE", 44, 63], ["infectious diseases", "PROBLEM", 44, 63], ["infectious", "OBSERVATION", 44, 54]]], ["Even news agencies are now seeking out explanations to models so as to offer advice and clarity to their audiences during the (near-continuous) coverage of the spread of COVID-19 [2].", [["COVID-19", "CHEMICAL", 170, 178], ["the (near-continuous) coverage", "TREATMENT", 122, 152]]], ["A quotation from this abstract below, which foreshadows the requirements and challenges for mathematical models to describe emerging epidemics such as COVID-19 [4, 5], needs no further elaboration:IntroductionThe classic susceptible-infectious-recovered (SIR) paradigm, initiated in the late 1920s [6], now provides a mathematical framework that describes the core transmission dynamics of a wide range of human diseases [7\u201312], including COVID-19 [13].", [["COVID-19", "CHEMICAL", 151, 159], ["human", "ORGANISM", 406, 411], ["human", "SPECIES", 406, 411], ["human", "SPECIES", 406, 411], ["mathematical models", "TREATMENT", 92, 111], ["emerging epidemics", "PROBLEM", 124, 142], ["COVID", "TEST", 151, 156], ["human diseases", "PROBLEM", 406, 420], ["COVID", "TEST", 439, 444], ["infectious", "OBSERVATION", 233, 243]]], ["The Ro is defined by the average number of secondary cases arising from a typical primary case in an entirely susceptible population of size So [14\u2013 16].", [["Ro", "CHEMICAL", 4, 6], ["secondary cases", "PROBLEM", 43, 58], ["size", "OBSERVATION_MODIFIER", 136, 140]]], ["The usefulness of Ro and uncertainty in its estimation are not a subject of debate, as reviewed elsewhere [17], and therefore are not further discussed here.IntroductionThe Ro for COVID-19 and other diseases is commonly estimated directly from case data or by fitting the SIR model or one of its many variants to the data [14, 18\u201322].", [["Ro", "CHEMICAL", 18, 20], ["Ro", "CHEMICAL", 173, 175], ["COVID-19", "CHEMICAL", 180, 188], ["COVID", "TEST", 180, 185], ["other diseases", "PROBLEM", 193, 207]]], ["Unsurprisingly, the Ro estimates often exhibit large uncertainty.", [["large uncertainty", "PROBLEM", 47, 64], ["large", "OBSERVATION_MODIFIER", 47, 52], ["uncertainty", "OBSERVATION", 53, 64]]], ["For COVID-19, mean estimated Ro ranges between 1.95 and 6.47, with corresponding error estimates giving upper and lower bounds of 1.4 and 8.9 (Fig 1).", [["COVID", "TEST", 4, 9], ["mean estimated Ro", "TEST", 14, 31], ["upper", "ANATOMY_MODIFIER", 104, 109], ["lower", "ANATOMY_MODIFIER", 114, 119]]], ["For a given virus, such variability in Ro is attributed to local spatio-temporal variability in public health resources, interventions, and how individuals in a population interact, among others, as well as the estimation method used [15, 17].", [["Ro", "CHEMICAL", 39, 41], ["virus", "PROBLEM", 12, 17], ["temporal", "OBSERVATION_MODIFIER", 72, 80], ["variability", "OBSERVATION_MODIFIER", 81, 92]]], ["Due to this local variability, it is commonly held that Ro is a site-specific parameter that cannot be directly transferred between sites.", [["Ro", "CHEMICAL", 56, 58], ["Ro", "SIMPLE_CHEMICAL", 56, 58]]], ["The rapid availability of global data for COVID-19 has allowed an unprecedented comparison across a diverse array of populations, which is absent from the prior literature on Ro estimation.IntroductionIn the analysis herein, the SIR model is used to uncover generic spread mechanisms observed by COVID-19 dynamics globally, especially in the early phases of infectious spread.", [["Ro", "SIMPLE_CHEMICAL", 175, 177], ["COVID-19", "DNA", 42, 50], ["global data", "TEST", 26, 37], ["COVID", "TEST", 42, 47], ["Ro estimation", "TEST", 175, 188], ["the SIR model", "TREATMENT", 225, 238], ["infectious spread", "PROBLEM", 358, 375], ["populations", "OBSERVATION", 117, 128], ["early phases", "OBSERVATION_MODIFIER", 342, 354], ["infectious", "OBSERVATION", 358, 368]]], ["Hence, the early phases of COVID-19 spread in many countries where controls were weak offer a unique perspective on the ensemble-behavior of COVID-19 Ro.", [["Ro", "CHEMICAL", 150, 152], ["COVID-19", "CHEMICAL", 27, 35], ["COVID", "TEST", 27, 32], ["COVID", "TEST", 141, 146]]], ["The analysis shows that there is global convergence (i.e. across many nations) to an uncontrolled Ro = 4.5 for COVID-19 describing early times spread from the SIR model.", [["The analysis", "TEST", 0, 12], ["global convergence", "PROBLEM", 33, 51], ["an uncontrolled Ro", "PROBLEM", 82, 100], ["COVID", "TEST", 111, 116], ["global", "OBSERVATION_MODIFIER", 33, 39], ["convergence", "OBSERVATION_MODIFIER", 40, 51]]], ["This value is compared to a number of published Ro estimates for COVID-19 with a timeline summary featured in Fig 1.", [["COVID", "TEST", 65, 70]]], ["These published estimates along with the methods used to infer Ro, the published uncertainty, and the original data source are provided in the Appendix.IntroductionClearly, such wide ranging values of Ro in Fig 1 motivate further analysis of Ro variability across populations, the objective of this analysis.", [["Ro", "CHEMICAL", 63, 65], ["Ro", "CHEMICAL", 201, 203], ["Ro", "CHEMICAL", 242, 244], ["Ro", "SIMPLE_CHEMICAL", 242, 244], ["the methods", "TREATMENT", 37, 48], ["further analysis", "TEST", 222, 238], ["Ro variability across populations", "PROBLEM", 242, 275], ["this analysis", "TEST", 294, 307], ["Appendix", "ANATOMY", 143, 151]]], ["Other aspects that are considered in the estimation of Ro from SIR are the effects of ramp-up in testing at the early phases of disease spread and the role of super-spreaders.", [["Ro", "CHEMICAL", 55, 57], ["ramp-up in testing", "TEST", 86, 104], ["disease spread", "PROBLEM", 128, 142], ["early phases", "OBSERVATION_MODIFIER", 112, 124], ["disease", "OBSERVATION", 128, 135]]], ["These two effects are briefly discussed using idealized scenarios and model calculations.", [["model calculations", "TEST", 70, 88]]], ["The implications for evaluating potential control strategies from this uncontrolled Ro are considered in the context of mortality and maximum infections.Definitions and nomenclature ::: TheoryMathematical models of disease spread assume that a population within a compartment (e.g., city, region, country) can be subdivided into a set of distinct classes [11].", [["Ro", "CHEMICAL", 84, 86], ["infections", "DISEASE", 142, 152], ["Ro", "SIMPLE_CHEMICAL", 84, 86], ["potential control strategies", "TREATMENT", 32, 60], ["maximum infections", "PROBLEM", 134, 152], ["disease spread", "PROBLEM", 215, 229], ["maximum", "OBSERVATION_MODIFIER", 134, 141], ["infections", "OBSERVATION", 142, 152], ["disease", "OBSERVATION", 215, 222], ["population", "OBSERVATION_MODIFIER", 244, 254]]], ["The SIR model classifies individuals in the compartment as one of three classes: susceptible (S), infectious (I), and recovered or removed (R).", [["compartment", "ANATOMY_MODIFIER", 44, 55], ["susceptible", "OBSERVATION_MODIFIER", 81, 92], ["infectious", "OBSERVATION", 98, 108]]], ["Infectious individuals spread the disease to susceptible individuals and remain in the infectious class for a given period of time known as the infectious period before moving into the recovered (or removed) class.", [["infectious", "OBSERVATION", 87, 97], ["infectious", "OBSERVATION", 144, 154]]], ["For the total population N = S + I + R, the dynamical system describing the SIR equations are given asdSdt=-(\u03b2IN)S(1)dIdt=+(\u03b2IN)S-\u03b3I(2)dRdt=+\u03b3I,(3)where \u03b2(I/N) is known as the force of infection and coefficients \u03b2 and \u03b3 must be externally supplied.", [["infection", "DISEASE", 185, 194], ["\u03b3I", "PROTEIN", 141, 143], ["\u03b2", "PROTEIN", 153, 154], ["\u03b3", "PROTEIN", 218, 219], ["the total population", "TEST", 4, 24], ["the SIR equations", "TEST", 72, 89], ["Sdt", "TEST", 103, 106], ["Idt", "TEST", 118, 121], ["dRdt", "TEST", 135, 139], ["infection", "PROBLEM", 185, 194], ["infection", "OBSERVATION", 185, 194]]], ["For COVID-19, it is assumed that R(0) = 0 and I(0)\u226aS(0) at the initial outbreak.", [["COVID", "TEST", 4, 9], ["outbreak", "OBSERVATION", 71, 79]]], ["For the initial conditions selected here, N = S(0) + I(0) + R(0) \u2248 S(0), which is labeled So for notational simplicity and consistency with the SIR literature.", [["N = S(0) + I(0)", "CHEMICAL", 42, 57], ["S(0)", "CHEMICAL", 67, 71], ["R(0) \u2248 S(0)", "SIMPLE_CHEMICAL", 60, 71]]], ["The dynamical system in Eqs (1), (2), (3) has only one equilibrium point: I = 0 for any S > 0, which is a disease-free stable equilibrium (i.e. as t \u2192 \u221e, I(t) \u2192 0).SIR model assumptions ::: TheoryThe SIR model makes a number of assumptions, including a closed system with no changes in natural births or natural deaths occurring during the short-lived outbreak.", [["deaths", "DISEASE", 312, 318], ["any S", "TEST", 84, 89], ["a disease", "PROBLEM", 104, 113], ["a closed system", "TREATMENT", 251, 266], ["natural deaths", "PROBLEM", 304, 318]]], ["The infection is assumed to have negligible latent period so that an individual becomes infectious when infected.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infectious", "PROBLEM", 88, 98], ["infected", "PROBLEM", 104, 112], ["infection", "OBSERVATION", 4, 13], ["negligible", "OBSERVATION_MODIFIER", 33, 43], ["latent", "OBSERVATION_MODIFIER", 44, 50], ["infectious", "OBSERVATION", 88, 98]]], ["For this reason, the SIR model might underestimate Ro but the uncertainty surrounding the incubation period possibly precludes any advantage of adding a \u2018incubation\u2019 compartment to the SIR model [23] at this stage.", [["Ro", "CHEMICAL", 51, 53], ["a \u2018incubation", "TREATMENT", 151, 164]]], ["Recovering from infection is also assumed to confer long-term immunity, yet to be verified for COVID-19.SIR model assumptions ::: TheoryThe most objectionable assumption in SIR dynamics is the use of the so-called \u2018mass-action\u2019 principle.", [["infection", "DISEASE", 16, 25], ["infection", "PROBLEM", 16, 25], ["long-term immunity", "TREATMENT", 52, 70], ["COVID", "TEST", 95, 100], ["the so-called \u2018mass", "PROBLEM", 200, 219], ["infection", "OBSERVATION", 16, 25], ["mass", "OBSERVATION", 215, 219]]], ["As with all compartment models, mass action assumes that the rate of encounter between I and S is proportional to their product.", [["all compartment models", "TEST", 8, 30], ["mass action", "PROBLEM", 32, 43], ["mass", "OBSERVATION", 32, 36]]], ["For this assumption to hold, it requires that members of I and S be uniformly distributed in the space of the compartment [24].", [["I and S", "PROTEIN", 57, 64], ["compartment", "ANATOMY", 110, 121]]], ["Individuals\u2014unlike molecules in an ideal solution within a closed container\u2014do not mix homogeneously.", [["Individuals\u2014unlike molecules", "PROBLEM", 0, 28], ["an ideal solution", "TREATMENT", 32, 49]]], ["Nonetheless, the use of the mass action principle serves as one reference to estimate Ro in a consistent manner across differing countries using the SIR framework.", [["Ro", "CHEMICAL", 86, 88], ["the mass action principle", "TREATMENT", 24, 49], ["mass", "OBSERVATION", 28, 32]]], ["The presence of super-spreaders on Ro estimates using spatially-extended analysis of SIR is to be discussed later on.SIR model assumptions ::: TheoryThe parameters \u03b3 and \u03b2 encode the main properties of the epidemics and the population response to it.", [["\u03b3", "GENE_OR_GENE_PRODUCT", 164, 165], ["\u03b2", "GENE_OR_GENE_PRODUCT", 170, 171], ["\u03b3 and \u03b2", "PROTEIN", 164, 171], ["the epidemics", "PROBLEM", 202, 215], ["main", "OBSERVATION_MODIFIER", 183, 187], ["epidemics", "OBSERVATION", 206, 215]]], ["The \u03b3 = 1/D is generally interpreted as the inverse of the mean recovery time D. The D varies with the nature of the disease and the recovery from it, which depends on the medical facilities and resources available.", [["the disease", "PROBLEM", 113, 124], ["disease", "OBSERVATION", 117, 124]]], ["For COVID-19, the best information on the speed of recovery comes from a World Health Organization study examining more than 55,000 cases in China [25].", [["COVID", "TEST", 4, 9]]], ["They found that for mild illness, the time from the onset of symptoms to natural recovery is, on average, 14 days.", [["illness", "DISEASE", 25, 32], ["mild illness", "PROBLEM", 20, 32], ["symptoms", "PROBLEM", 61, 69], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["illness", "OBSERVATION", 25, 32]]], ["This estimate was also supported in other published studies (e.g., [26]), though as much as 6-8 weeks were recorded for severe infections.", [["infections", "DISEASE", 127, 137], ["severe infections", "PROBLEM", 120, 137], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["infections", "OBSERVATION", 127, 137]]], ["Because I is dominated by mild cases thus far, D = 14 d is selected here.SIR model assumptions ::: TheoryWith this assumption, the remaining model parameter \u03b2 must be determined empirically or from separate studies.", [["mild cases", "PROBLEM", 26, 36], ["separate studies", "TEST", 198, 214], ["mild", "OBSERVATION_MODIFIER", 26, 30]]], ["The \u03b2 reflects the multiplicative effect of two factors: (1) the transmissibility of the infectious disease (= Tr) or the probability of disease transmission after an encounter between a susceptible and an infected and (2) the number of contacts per unit time k each infected individual has with susceptibles.", [["infectious disease", "DISEASE", 89, 107], ["\u03b2", "PROTEIN", 4, 5], ["the infectious disease", "PROBLEM", 85, 107], ["disease transmission", "PROBLEM", 137, 157], ["infectious", "OBSERVATION", 89, 99], ["infected", "OBSERVATION", 206, 214]]], ["Factors such as hand-washing and sanitizing or wearing masks reduce Tr whereas social distancing, self-isolation, and closure of public or crowded spaces reduce k.", [["hand", "ANATOMY", 16, 20], ["hand-washing", "TREATMENT", 16, 28], ["sanitizing", "TREATMENT", 33, 43], ["self-isolation", "TREATMENT", 98, 112], ["closure", "TREATMENT", 118, 125], ["crowded spaces", "PROBLEM", 139, 153]]], ["From Eq (2), it is evident that dI/dt will be positive (outbreak) or negative (epidemic contained) depending on the sign of (\u03b2(S/So) \u2212 \u03b3), which is one of the main reasons the basic reproduction number is sought.The basic reproduction number Ro ::: TheoryAs earlier stated, the average rate of recovery is set to \u03b3 = 1/D. Given the value of D (in days), the probability that an individual remains infected in an infinitesimal time period \u03b4\u03c4 is 1 \u2212 \u03b3(\u03b4\u03c4).", [["dI/dt", "PROBLEM", 32, 37], ["infected", "PROBLEM", 397, 405], ["infected", "OBSERVATION", 397, 405]]], ["Therefore, the probability that this individual remains infected for an amount of time \u03c4 is lim\u03b4\u03c4 \u2192 0(1 \u2212 \u03b3\u03b4\u03c4)\u03c4/(\u03b4\u03c4) = exp(\u2212\u03b3\u03c4).", [["\u2212\u03b3\u03c4", "GENE_OR_GENE_PRODUCT", 123, 126], ["lim\u03b4\u03c4", "PROTEIN", 92, 97], ["\u03b4\u03c4", "PROTEIN", 113, 115], ["\u2212\u03b3\u03c4", "PROTEIN", 123, 126], ["infected", "PROBLEM", 56, 64], ["lim\u03b4\u03c4", "TEST", 92, 97], ["infected", "OBSERVATION", 56, 64]]], ["In other words, \u03c4, the time that an infected individual remains infected, is exponentially distributed with an average of D = 1/\u03b3.The basic reproduction number Ro ::: TheoryIn a compartmental model such as the SIR, every individual is initially susceptible and the average number of susceptibles that encounter an infected individual over a period \u03c4 is simply \u03b2\u03c4.", [["\u03b2\u03c4", "PROTEIN", 360, 362], ["an infected individual remains infected", "PROBLEM", 33, 72], ["infected", "OBSERVATION", 36, 44], ["infected", "OBSERVATION", 64, 72], ["infected", "OBSERVATION_MODIFIER", 314, 322]]], ["It follows that the average number of new infections caused by an infected individual, which is the basic reproduction number Ro, is given by [27]Ro=\u03b2\u222b0\u221e\u03c4p(\u03c4)d\u03c4=\u03b2\u03b3\u222b0\u221e\u03c4e-\u03b3\u03c4d\u03c4=\u03b2\u03b3,(4)where the \u03b3 after the second equality is to normalize p(\u03c4)d\u03c4.The basic reproduction number Ro ::: TheoryTwo assumptions underlying the compartmental SIR model are unrealistic, but a proven correspondence between the compartmental SIR and a Poisson graph SIR model justifies its applicability.", [["infections", "DISEASE", 42, 52], ["\u03b3", "PROTEIN", 190, 191], ["p(\u03c4)d\u03c4", "PROTEIN", 234, 240], ["new infections", "PROBLEM", 38, 52], ["a Poisson graph SIR model", "TREATMENT", 418, 443], ["new", "OBSERVATION_MODIFIER", 38, 41], ["infections", "OBSERVATION", 42, 52], ["infected", "OBSERVATION", 66, 74], ["compartmental SIR model", "OBSERVATION", 315, 338]]], ["In the compartmental (or fully-mixed) SIR model, the recovery times are exponentially distributed and every individual has an equal chance per unit time of encountering all other So \u2212 1 individuals [27].", [["compartmental", "ANATOMY_MODIFIER", 7, 20], ["exponentially", "OBSERVATION_MODIFIER", 72, 85], ["distributed", "OBSERVATION_MODIFIER", 86, 97]]], ["However, COVID-19 recovery times have been determined to concentrate around D = 1/\u03b3 = 14 days.", [["COVID", "TEST", 9, 14]]], ["Moreover, infected individuals come in contact with only a handful of other people.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["infected", "OBSERVATION", 10, 18]]], ["It is this correspondence between the SIR model and the random graph that makes the SIR model an appropriate tool to explore the early-time dynamics of COVID-19 spread.Early-times dynamics of the SIR system ::: TheoryAs common with dynamical systems, non-dimensional variables are preferred in the analysis of the phase-space to be conducted next.", [["COVID", "TEST", 152, 157], ["the analysis", "TEST", 294, 306]]], ["Here, \u03b3 and So are obvious choices for normalizing time and population pools.", [["\u03b3", "GENE_OR_GENE_PRODUCT", 6, 7]]], ["Hence, a dimensionless time t* = \u03b3t and a dimensionless fraction of individuals s = S/So, i = I/So, and r = R/So are introduced so that the original SIR system is nowdsdt=+(Roi)s-i(6)drdt(< 1), s \u2248 1 as seen from Fig 2a.", [["a dimensionless fraction", "TEST", 40, 64], ["individuals s", "TEST", 68, 81]]], ["In this early phase, s(\u2248 1) can be \u2018de-coupled\u2019 from i resulting in an autonomous budget for i given asdidt > 0 leading to an epidemic or, conversely, a containment of the disease.", [["the disease", "PROBLEM", 168, 179], ["epidemic", "OBSERVATION", 126, 134], ["disease", "OBSERVATION", 172, 179]]], ["The solution of Eq (8) is an exponential function i(t)/i(0) = exp[(Ro \u2212 1)t*] shown in Fig 2b.Early-times dynamics of the SIR system ::: TheoryThe Ro may be determined by regressing log(i) against t, and the slope of this regression determines Ro when \u03b3 can be separately estimated.", [["Ro", "CHEMICAL", 147, 149], ["Ro", "CHEMICAL", 244, 246], ["Ro \u2212 1)t*", "SIMPLE_CHEMICAL", 67, 76], ["Ro", "SIMPLE_CHEMICAL", 244, 246], ["an exponential function i", "TEST", 26, 51], ["this regression", "PROBLEM", 217, 232], ["Fig 2b", "OBSERVATION", 87, 93]]], ["More sophisticated fitting procedures can also be conducted on sampled I(t) versus t.", [["sophisticated fitting procedures", "TREATMENT", 5, 37]]], ["An alternative is to regress di/dt* upon i at early times to detect the highest slope, which can then be used to infer Ro.", [["Ro", "CHEMICAL", 119, 121]]], ["This approach is featured in Fig 2c, which illustrates that the SIR dynamics exhibit rapid deviations from a linear di/dt* with i set by early times thereby underestimating Ro (for a given \u03b3).", [["Ro", "CHEMICAL", 173, 175], ["rapid deviations", "PROBLEM", 85, 101], ["Fig 2c", "OBSERVATION", 29, 35]]], ["Evidently, inference of Ro requires estimates of early time slope, which cannot be easily detected in practice.Early-times dynamics of the SIR system ::: TheoryA non-conventional approach is to present confirmed infection data using a double-log representation of di/dt* versus i, which is featured in Fig 2d.", [["Ro", "CHEMICAL", 24, 26], ["infection", "DISEASE", 212, 221], ["infection data", "PROBLEM", 212, 226], ["infection", "OBSERVATION", 212, 221]]], ["This presentation has a number of advantages and limitations in the analysis of COVID-19 discussed elsewhere [29].", [["the analysis", "TEST", 64, 76], ["COVID", "TEST", 80, 85]]], ["The main advantage is that the early time slope (= Ro \u2212 1) visually persists over much of the graph.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["A significant decline in di/dt* is also required before \u2018registering\u2019 a drop in such a representation.", [["A significant decline", "PROBLEM", 0, 21], ["a drop", "PROBLEM", 70, 76], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["decline", "OBSERVATION", 14, 21]]], ["This insensitivity to moderate declines in di/dt* from its initial value may be advantageous in Ro estimates.", [["This insensitivity", "PROBLEM", 0, 18], ["moderate", "OBSERVATION_MODIFIER", 22, 30], ["declines", "OBSERVATION_MODIFIER", 31, 39]]], ["The other main limitation, which is inherent to all such analyses, is shifts in testing frequency at high i, and thus the increase in confirmed cases due to expanded testing.", [["testing frequency", "TEST", 80, 97], ["expanded testing", "TEST", 157, 173], ["main", "OBSERVATION_MODIFIER", 10, 14], ["limitation", "OBSERVATION", 15, 25]]], ["It is to be noted that a log-log representation will be more robust to these shifts, because the overall graph will be biased by the initial slope prior to the initialization of expanded testing.", [["expanded testing", "TEST", 178, 194]]], ["As later shown, such an increase has been noted in several data sets.Early-times dynamics of the SIR system ::: TheoryWith this representation, it is now shown that initial inaction to COVID-19 across many countries around the globe allowed an ensemble estimate of the uncontrolled Ro.", [["Ro", "CHEMICAL", 282, 284], ["COVID", "TEST", 185, 190], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["globe", "ANATOMY", 227, 232]]], ["Because Ro is likely to be at maximum when no action to COVID-19 are implemented early on, a maximum theoretical \u2018boundary-line\u2019 can then be derived to describe the spread of COVID-19 for large So (on log-log representation).", [["Ro", "CHEMICAL", 8, 10], ["COVID-19", "CHEMICAL", 56, 64], ["Ro", "SIMPLE_CHEMICAL", 8, 10], ["COVID-19", "DNA", 56, 64], ["COVID", "TEST", 56, 61], ["a maximum theoretical \u2018boundary-line", "TREATMENT", 91, 127], ["COVID", "TEST", 175, 180], ["large So", "PROBLEM", 188, 196], ["likely to be", "UNCERTAINTY", 14, 26]]], ["This boundary-line analysis can then be used as a logical reference to assess whether measures to reduce \u03b2 are effective.Estimating an early-time Ro ::: Results and discussionThe same log-log scheme featured in Fig 2d is now applied to the global data set supplied by the European Center for Disease Prevention and Control (ECDPC).", [["\u03b2", "PROTEIN", 105, 106], ["This boundary-line analysis", "TREATMENT", 0, 27], ["Disease Prevention", "TREATMENT", 292, 310], ["line", "OBSERVATION", 14, 18]]], ["The data source provides daily confirmed infections I(t) and deaths reported for each country.", [["infections", "DISEASE", 41, 51], ["deaths", "DISEASE", 61, 67]]], ["For this reason, daily data on infections were smoothed with a 7 day block-average and dI/dt was estimated from the smoothed data.", [["infections", "DISEASE", 31, 41], ["infections", "PROBLEM", 31, 41], ["dI/dt", "PROBLEM", 87, 92]]], ["The 7-day block smooths out some of the spurious reporting during certain time periods (e.g. over weekends or during days when the health-care system was overwhelmed and processing along with reporting delayed by few days).", [["spurious", "OBSERVATION", 40, 48]]], ["The results show a global convergence to Ro = 4.5 from early time-analysis in Fig 3.", [["a global convergence", "PROBLEM", 17, 37], ["Ro", "TEST", 41, 43]]], ["Examples for specific countries are also featured in Fig 4 illustrating the same early slope patterns.", [["early slope", "OBSERVATION_MODIFIER", 81, 92]]], ["Mindful of all the pitfalls in determining Ro [17], the global estimate here of Ro = 4.5 is roughly commensurate with other entirely independent estimates for COVID-19 discussed in the appendix and featured in Fig 1.", [["Ro", "CHEMICAL", 80, 82], ["appendix", "ORGAN", 185, 193], ["COVID", "TEST", 159, 164], ["appendix", "ANATOMY", 185, 193]]], ["The most recent update from a China study suggests an Ro = 4.1 [30] whereas for France, the most recent estimate for early times is Ro = 4.9 [31].", [["Ro", "CHEMICAL", 132, 134], ["a China study", "TEST", 28, 41]]], ["A more elaborate estimate of Ro based on case reports, incubation periods, high-resolution real-time human travel data, infection data combined with agent-based mathematical models result in Ro = 4.7 \u2212 6.6 [32].", [["Ro", "CHEMICAL", 29, 31], ["infection", "DISEASE", 120, 129], ["Ro", "CHEMICAL", 191, 193], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["infection data", "PROBLEM", 120, 134], ["agent", "TREATMENT", 149, 154], ["Ro", "TEST", 191, 193]]], ["Other studies report values between 3.3 and 6.6 [33].", [["Other studies", "TEST", 0, 13], ["values", "TEST", 21, 27]]], ["It must be emphasized that the Ro determined here reflects \u2018country-scale\u2019 early times assuming the entire country population to be So, \u03b3 = (1/14)d\u22121 and does not accommodate any early measures enacted to reduce \u03b2 or increase \u03b3, which were undertaken in China [13] and other countries (e.g. Germany).Sub-national dynamics and interventions ::: Results and discussionThe same analysis performed for World countries is now applied at a sub-national level, considering Upper Tier Local Authorities (UTLAs) in the UK and provinces in Italy (Fig 5).", [["Ro", "CHEMICAL", 31, 33], ["\u03b2", "PROTEIN", 212, 213], ["The same analysis", "TEST", 366, 383], ["Upper", "ANATOMY_MODIFIER", 466, 471]]], ["Results show a higher variability than country-level data (as expected) but the theoretical \u2018boundary-line\u2019 of Ro = 4.5 is shown to hold also at finer spatial scales.", [["Ro", "CHEMICAL", 111, 113], ["a higher variability", "PROBLEM", 13, 33], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["variability", "OBSERVATION_MODIFIER", 22, 33]]], ["Cases reported at the beginning of April demonstrate that UK regions are at an early phase of the epidemics (with more ramp-up in testing as later discussed), while Italian provinces are approaching the peak of infections due to strict interventions put in place by national authorities.Sub-national dynamics and interventions ::: Results and discussionNon-pharmaceutical interventions (e.g., social distancing, hand washing, universal masking) are the only measures currently available to limit the spread of COVID-19 [34], while contact tracing and isolation have been implemented to contain infected individuals [35].", [["hand", "ANATOMY", 412, 416], ["infections", "DISEASE", 211, 221], ["hand", "ORGANISM_SUBDIVISION", 412, 416], ["infections", "PROBLEM", 211, 221], ["strict interventions", "TREATMENT", 229, 249], ["Non-pharmaceutical interventions", "TREATMENT", 353, 385], ["hand washing", "TREATMENT", 412, 424], ["universal masking", "TREATMENT", 426, 443], ["COVID", "TEST", 510, 515], ["contact tracing", "TEST", 531, 546], ["isolation", "TREATMENT", 551, 560], ["infections", "OBSERVATION", 211, 221]]], ["Simulation results [35] showed that a COVID-19 outbreak can be controlled within 3 months if such strategies are put in place rapidly and effectively.", [["a COVID", "TEST", 36, 43]]], ["This has been confirmed in another study [36] that showed that the containment measures employed in China and aimed at reducing human-to-human aerial transmission, succeeded in reducing the reproduction number to below unity within 30 days from implementation.Sub-national dynamics and interventions ::: Results and discussionTo consider the impact of interventions that reduce the infection rate over time and have direct effects on local scale dynamics [13], a time-varying Ro, labelled as Ro,d (i.e. dynamic) can be implemented in the SIR model.", [["infection", "DISEASE", 382, 391], ["Ro", "CHEMICAL", 476, 478], ["human", "ORGANISM", 128, 133], ["human", "ORGANISM", 137, 142], ["aerial", "DEVELOPING_ANATOMICAL_STRUCTURE", 143, 149], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 137, 142], ["another study", "TEST", 27, 40], ["interventions", "TREATMENT", 352, 365], ["the infection rate", "PROBLEM", 378, 396], ["local scale dynamics", "TEST", 434, 454], ["containment", "OBSERVATION", 67, 78], ["infection", "OBSERVATION", 382, 391]]], ["A logistic function captures temporal patterns in Ro,d, the effective reproduction number, consistent with those estimated for other outbreaks [36\u201339],Ro,d=Rc+Ro-Rc1+exp(kc(t-t50)),(9)where Rc is the controlled value of the dynamic Ro,d, kc is the steepness of the intervention curve, and t50 is the time when Ro,d = (Rc + Ro)/2.", [["Ro", "CHEMICAL", 151, 153], ["Ro,d=Rc+Ro-Rc1", "CHEMICAL", 151, 165], ["other outbreaks", "PROBLEM", 127, 142], ["Ro", "TEST", 151, 153], ["Rc+Ro", "TEST", 156, 161], ["kc", "TEST", 170, 172], ["exp", "ANATOMY", 166, 169]]], ["It is assumed that, through interventions, the initial Ro = 4.5 is reduced to a controlled value of Rc = 1.1 after 2/\u03b3 days.Sub-national dynamics and interventions ::: Results and discussionModel results accounting for different intervention scenarios (Fig 6) resemble the trends observed in the Italian provinces with the timing and magnitude of Ro reductions shifting the linear relation down and decreasing the maximum fraction of infected individuals.", [["Ro", "CHEMICAL", 55, 57], ["Ro", "CHEMICAL", 347, 349], ["Ro", "SIMPLE_CHEMICAL", 347, 349], ["the initial Ro", "TEST", 43, 57], ["Rc", "TEST", 100, 102], ["different intervention scenarios", "TREATMENT", 219, 251], ["Ro reductions", "TREATMENT", 347, 360], ["infected individuals", "PROBLEM", 434, 454], ["infected", "OBSERVATION", 434, 442]]], ["Such jumps are smoothed over at the national level where a clear deviation from exponential is observed (Fig 4).An alternative hypothesis: Power-law vs exponential ::: Results and discussionWhether these results are suggestive of a global convergence to an uncontrolled Ro = 4.5 or to some other dimensionless property must not be overlooked.", [["a clear deviation", "PROBLEM", 57, 74], ["a global convergence", "PROBLEM", 230, 250], ["an uncontrolled Ro", "PROBLEM", 254, 272], ["jumps", "OBSERVATION_MODIFIER", 5, 10], ["smoothed", "OBSERVATION_MODIFIER", 15, 23], ["clear", "OBSERVATION_MODIFIER", 59, 64], ["deviation", "OBSERVATION", 65, 74], ["must not be", "UNCERTAINTY", 319, 330]]], ["A linear relation on a log-log representation may also be indicative of power-law solutions at early times, already documented in a number of studies for COVID-19 [40, 41].", [["COVID", "TEST", 154, 159], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["may also be indicative", "UNCERTAINTY", 46, 68], ["law solutions", "OBSERVATION", 78, 91]]], ["In fact, published analysis of infection data from the top 25 affected countries reveals approximate power-law behavior of the form I(t) \u223c ta (or log(i) = a log(t) + b) with two different growth patterns [40]: steady power law growth with moderate scaling exponents (i.e., a = 3-5) or explosive power law growth with dramatic scaling exponents (i.e., a = 8-11).An alternative hypothesis: Power-law vs exponential ::: Results and discussionWithin the confines of the SIR dynamical system framework here, we ask: what are the necessary modifications to obtain power-law solutions at early times?", [["infection", "DISEASE", 31, 40], ["infection data", "PROBLEM", 31, 45], ["two different growth patterns", "PROBLEM", 174, 203], ["moderate scaling exponents", "PROBLEM", 239, 265], ["explosive power law growth", "PROBLEM", 285, 311], ["dramatic scaling exponents", "PROBLEM", 317, 343], ["power-law solutions", "TREATMENT", 558, 577], ["infection", "OBSERVATION", 31, 40], ["growth", "OBSERVATION_MODIFIER", 227, 233], ["moderate", "OBSERVATION_MODIFIER", 239, 247], ["scaling", "OBSERVATION_MODIFIER", 248, 255], ["exponents", "OBSERVATION", 256, 265], ["law", "OBSERVATION_MODIFIER", 301, 304], ["growth", "OBSERVATION_MODIFIER", 305, 311], ["dramatic", "OBSERVATION_MODIFIER", 317, 325], ["scaling", "OBSERVATION_MODIFIER", 326, 333], ["exponents", "OBSERVATION_MODIFIER", 334, 343]]], ["Such a solution, while not unique, may be possible by revising the force of infection as \u03b2im.", [["infection", "DISEASE", 76, 85], ["\u03b2im", "GENE_OR_GENE_PRODUCT", 89, 92], ["a solution", "TREATMENT", 5, 15], ["infection", "PROBLEM", 76, 85], ["infection", "OBSERVATION", 76, 85]]], ["For this non-linear force of infection, the SIR system becomesdSdt=\u2212\u03b2(ISo)mS(10)dIdt=+\u03b2(ISo)mS\u2212\u03b3I(11)dRdt=+\u03b3I.(12)This revision ensures that the total population maintains its constant value (\u2248 So here).", [["infection", "DISEASE", 29, 38], ["Sdt=\u2212\u03b2(ISo)mS(10)dIdt=+\u03b2(ISo)mS\u2212\u03b3I(11)", "CHEMICAL", 63, 101], ["infection", "PROBLEM", 29, 38], ["the SIR system", "TEST", 40, 54], ["Sdt", "TEST", 63, 66], ["ISo", "TEST", 70, 73], ["Idt", "TEST", 81, 84], ["ISo", "TEST", 88, 91], ["dRdt", "TEST", 101, 105], ["This revision", "TREATMENT", 114, 127], ["the total population", "PROBLEM", 141, 161], ["infection", "OBSERVATION", 29, 38], ["revision", "OBSERVATION", 119, 127]]], ["The early times dynamics (i.e. S(t) \u2248 So) for the non-dimensional infection compartment i are now governed bydidt and i, the linear term can be dropped so that di/dt* \u2248 Roim (only a growth phase).", [["infection", "DISEASE", 66, 75], ["the non-dimensional infection compartment i", "PROBLEM", 46, 89], ["infection", "OBSERVATION", 66, 75]]], ["On a log-log representation, log(di/dt = 5.", [["log(di/dt", "TEST", 29, 38]]], ["The main difference between Fig 2 and the spatially aggregated SIR model in Fig 8 is an initial delay and the occurrence of a rapid rise resembling the data from the UK and Italy regions at early times.", [["a rapid rise", "PROBLEM", 124, 136], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["rapid", "OBSERVATION_MODIFIER", 126, 131], ["rise", "OBSERVATION_MODIFIER", 132, 136]]], ["However, beyond this initial delay in spreading, the early times dynamics with super-spreaders and without them are commensurate.", [["this initial delay", "PROBLEM", 16, 34], ["spreading", "OBSERVATION_MODIFIER", 38, 47]]], ["That is, the effects of super-spreaders resembles the impact of testing ramp-up earlier discussed on the phase-space of di/dt* versus i but with delays.Size of the epidemic ::: Results and discussionThe maximum infections Imax (where dI/dt = 0) can be derived as a function of So and Ro by first dividing the budgets of dS/dt and dI/dt, solving the resulting equation, and noting that dI/dt = 0 when S(t)/So = \u03b3/\u03b2 = 1/Ro at Imax to yieldimax=ImaxSo=1-1Ro[1+log(Ro)].(20)Variations of imax versus Ro are featured in Fig 9.Size of the epidemic ::: Results and discussionFor Ro = 4.5, imax = 0.44, which is much higher than values obtained for the common cold or the flu (Ro = 2 \u2212 3) or influenza (Ro = 1.4 \u2212 2.8).Size of the epidemic ::: Results and discussionThe most significant use of Ro is an estimate of the size of the epidemic.", [["infections", "DISEASE", 211, 221], ["Ro", "CHEMICAL", 284, 286], ["Ro", "CHEMICAL", 496, 498], ["flu", "DISEASE", 664, 667], ["influenza", "DISEASE", 684, 693], ["Ro", "CHEMICAL", 786, 788], ["1-1Ro", "CHEMICAL", 449, 454], ["Ro", "SIMPLE_CHEMICAL", 496, 498], ["testing ramp", "TEST", 64, 76], ["The maximum infections Imax", "PROBLEM", 199, 226], ["dt", "PROBLEM", 323, 325], ["dt", "PROBLEM", 333, 335], ["yieldimax", "TEST", 432, 441], ["ImaxSo", "TEST", 442, 448], ["Ro", "TEST", 572, 574], ["imax", "TEST", 582, 586], ["the common cold", "PROBLEM", 641, 656], ["the flu (Ro", "TEST", 660, 671], ["influenza", "PROBLEM", 684, 693], ["the epidemic", "PROBLEM", 819, 831], ["epidemic", "OBSERVATION", 164, 172], ["epidemic", "OBSERVATION", 533, 541], ["epidemic", "OBSERVATION", 723, 731], ["most", "OBSERVATION_MODIFIER", 762, 766], ["significant", "OBSERVATION_MODIFIER", 767, 778], ["size", "OBSERVATION_MODIFIER", 811, 815], ["epidemic", "OBSERVATION", 823, 831]]], ["The total fraction of infected individuals may be inferred from 1 \u2212 S(\u221e)/S(0), where S(\u221e)/S(0) = 1 \u2212 R(\u221e)/S(0) > 0 because I(\u221e) = 0.", [["The total fraction", "TEST", 0, 18], ["infected individuals", "PROBLEM", 22, 42], ["S", "TEST", 85, 86], ["S", "TEST", 90, 91], ["S", "TEST", 106, 107], ["infected", "OBSERVATION", 22, 30]]], ["The relation between S(t) and R(t) can be deriveddSdR=-\u03b2\u03b3SSo,(21)which when integrated between t = 0 and t = \u221e yields,log[S(\u221e)So]=Ro(S(\u221e)So-1).(22)The solution for S(\u221e)/So can be analytically derived and linked to the total infected individuals IT usingITSo=1-S(\u221e)So=1+W[-Roexp(-Ro)]Ro,(23)where W[z] is the Lambert W-function of argument z.", [["SdR=-\u03b2\u03b3SSo", "CHEMICAL", 50, 60], ["W[-Roexp(-Ro)]Ro", "CHEMICAL", 269, 285], ["SdR=-\u03b2\u03b3SSo", "SIMPLE_CHEMICAL", 50, 60], ["S(\u221e)", "SIMPLE_CHEMICAL", 164, 168], ["[-Roexp(-Ro)]Ro", "SIMPLE_CHEMICAL", 270, 285], ["ITSo", "TEST", 253, 257]]], ["For pre-specified Ro, the behavior of the IT/So individuals is shown in Fig 10.", [["Ro", "CHEMICAL", 18, 20]]], ["With such a high Ro = 4.5, some 98% of the population will be infected as t* \u2192 \u221e.", [["a high Ro", "PROBLEM", 10, 19], ["infected", "OBSERVATION", 62, 70]]], ["When mortality is assumed to be some fraction of IT, then the mortality fraction is Mo/So = \u03b1m[1\u2212S(\u221e)/S(0)].Size of the epidemic ::: Results and discussionDifferent definitions of the global mortality rate \u03b1m have been considered but, for the purposes of the present study, the ratio of deaths to both symptomatic and asymptomatic cases is most appropriate.", [["deaths", "DISEASE", 287, 293], ["the mortality fraction", "TEST", 58, 80], ["Mo", "TEST", 84, 86], ["the present study", "TEST", 255, 272], ["symptomatic and asymptomatic cases", "PROBLEM", 302, 336], ["epidemic", "OBSERVATION", 120, 128], ["symptomatic", "OBSERVATION_MODIFIER", 302, 313]]], ["This ratio is dubbed the Infection Fatality Rate (IFR) and is different from the Case Fatality Rate (CFR), which is the ratio of deaths to the number of confirmed cases.", [["deaths", "DISEASE", 129, 135], ["This ratio", "TEST", 0, 10], ["Infection", "OBSERVATION", 25, 34]]], ["The IFR is more appropriate because the \u2018Infected\u2019 compartment of the SIR model comprises of both symptomatic and asymptomatic individuals.", [["both symptomatic and asymptomatic individuals", "PROBLEM", 93, 138], ["Infected", "OBSERVATION", 41, 49], ["symptomatic", "OBSERVATION_MODIFIER", 98, 109]]], ["According to the latest IFR estimates, \u03b1m ranges between 0.53 and 0.82% with a mean value of 0.68% [46].Size of the epidemic ::: Results and discussionFor the USA, the epicenter of COVID-19 at the time of submission of this article on April 10, 2020, we asked how much Ro should be reduced by deliberate intervention to maintain mortality below a certain threshold size Mo.", [["Ro", "CHEMICAL", 269, 271], ["a mean value", "TEST", 77, 89], ["COVID", "TEST", 181, 186], ["epidemic", "OBSERVATION", 116, 124]]], ["With S(0) = 327M, we determine how much Ro should be reduced as a function of Mo assuming different values of \u03b1m.", [["Ro", "CHEMICAL", 40, 42], ["Ro", "CHEMICAL", 40, 42], ["\u03b1m", "GENE_OR_GENE_PRODUCT", 110, 112], ["Mo", "CELL_TYPE", 78, 80], ["\u03b1m", "PROTEIN", 110, 112]]], ["These results are featured in Fig 11 and suggest that to maintain mortality below 1 million, Ro < 1.5 when \u03b1m = 0.53%, a reduction factor of 3 over its uncontrolled value.", [["a reduction factor", "TREATMENT", 119, 137]]], ["Under the same scenario, to limit the death toll below 300 thousand people, Ro should be reduced to 1.1, a reduction factor of 4.", [["death", "DISEASE", 38, 43], ["Ro", "CHEMICAL", 76, 78], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["a reduction factor", "TEST", 105, 123]]], ["These reduction factors are not entirely unreasonable using non-pharmaceutical measures (social distancing, masks, hand sanitizing, etc\u2026).Size of the epidemic ::: Results and discussionA natural extension of this exercise is to consider temporal changes in Ro following the logistic form in Eq (9).", [["hand", "ANATOMY", 115, 119], ["Ro", "CHEMICAL", 257, 259], ["hand", "ORGANISM_SUBDIVISION", 115, 119], ["These reduction factors", "PROBLEM", 0, 23], ["non-pharmaceutical measures", "TREATMENT", 60, 87], ["temporal changes", "PROBLEM", 237, 253], ["epidemic", "OBSERVATION", 150, 158]]], ["The maximum number of infected Imax at time t and cumulative number of infections R(\u221e) \u2248 R(t* \u2248 14) can be made to vary as the slope kc and t50 are changed (Eq (9)).", [["infections", "DISEASE", 71, 81], ["infected Imax", "PROBLEM", 22, 35], ["infections", "TEST", 71, 81], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["infected", "OBSERVATION_MODIFIER", 22, 30], ["Imax", "OBSERVATION_MODIFIER", 31, 35], ["infections", "OBSERVATION", 71, 81]]], ["A larger kc signifies more rapid enforcement of intervention policies and a larger t50 represents later enforcement.", [["intervention policies", "TREATMENT", 48, 69], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["kc", "OBSERVATION", 9, 11], ["more", "OBSERVATION_MODIFIER", 22, 26], ["rapid", "OBSERVATION_MODIFIER", 27, 32], ["larger", "OBSERVATION_MODIFIER", 76, 82]]], ["To provide a physical meaning for kc, we define tfo as the time after first infection at which Ro is fo% of the way through its total decline from Ro,u to Ro,c.", [["infection", "DISEASE", 76, 85], ["Ro", "CHEMICAL", 95, 97], ["Ro", "CHEMICAL", 147, 149], ["first infection", "PROBLEM", 70, 85], ["infection", "OBSERVATION", 76, 85]]], ["With these definitions, tfo=t50+log[fo/(1-fo)]/kc.", [["these definitions", "TEST", 5, 22], ["tfo", "TEST", 24, 27]]], ["An obvious choice for Ro,u = 4.5, the global average when no intervention is enforced.", [["Ro", "CHEMICAL", 22, 24], ["Ro,u", "TEST", 22, 26], ["intervention", "TREATMENT", 61, 73]]], ["We choose Ro,c = 1.0 to represent the most optimistic scenario of a near-containment by non-pharmaceutical intervention.", [["Ro", "CHEMICAL", 10, 12], ["non-pharmaceutical intervention", "TREATMENT", 88, 119]]], ["For reference, the South Korea data suggests that early intervention, even when rapidly enforced shortly after the outbreak, resulted in Ro = 1.5 [47].", [["Ro", "CHEMICAL", 137, 139], ["early intervention", "TREATMENT", 50, 68]]], ["The effectiveness of interventions and any delays can now be linked to mortality and severity by varying t50 and t80.", [["interventions", "TREATMENT", 21, 34], ["any delays", "PROBLEM", 39, 49]]], ["The R(t* \u2248 14) represents the cumulative number of fatalities and Imax is proportional to the degree to which resources, like hospital intensive care units, will be overwhelmed at peak infection rate.", [["fatalities", "DISEASE", 51, 61], ["infection", "DISEASE", 185, 194], ["peak infection rate", "PROBLEM", 180, 199], ["infection", "OBSERVATION", 185, 194]]], ["The results in Fig 12 indicate that if Ro > 2.7 within t = 3.5/\u03b3 (about 49 d here), a more than 10% reduction relative to So in Imax or R(\u221e) is unlikely.Size of the epidemic ::: Results and discussionAn implication of Fig 12 is that if Ro does not decrease to at least 2.7 by 44 days after first infection, more than a million people are expected to die with an assumed constant mortality rate of 0.53%.", [["Ro", "CHEMICAL", 39, 41], ["Ro", "CHEMICAL", 236, 238], ["infection", "DISEASE", 296, 305], ["Ro", "CHEMICAL", 236, 238], ["R(\u221e", "SIMPLE_CHEMICAL", 136, 139], ["people", "ORGANISM", 327, 333], ["people", "SPECIES", 327, 333], ["Ro", "TEST", 39, 41], ["10% reduction", "TREATMENT", 96, 109], ["first infection", "PROBLEM", 290, 305], ["constant mortality rate", "TEST", 370, 393], ["epidemic", "OBSERVATION", 165, 173], ["infection", "OBSERVATION", 296, 305]]], ["For mortality to be confined to a range in the 100,000, then a reduction of Ro from 4.5 to 2.7 must be achieved within 14 days of first infection, which did not occur in the USA.", [["Ro", "CHEMICAL", 76, 78], ["infection", "DISEASE", 136, 145], ["a reduction of Ro", "TREATMENT", 61, 78], ["first infection", "PROBLEM", 130, 145], ["infection", "OBSERVATION", 136, 145]]], ["As of July 30, 2020, confirmed fatalities in the USA have exceeded 150,000.Size of the epidemic ::: Results and discussionLast, it is to be noted that the fraction of individuals that must be immune (either through vaccination or recovery from prior COVID-19 infections) must exceed the herd immune threshold (HIT), which is given bypc=1-1Ro=0.78.(24)This estimate of HIT sets the limit on the immune population needed to overcome another COVID-19 pandemic (assuming a global constant Ro = 4.5 and no intervention).", [["fatalities", "DISEASE", 31, 41], ["infections", "DISEASE", 259, 269], ["HIT", "DISEASE", 310, 313], ["HIT", "DISEASE", 368, 371], ["individuals", "ORGANISM", 167, 178], ["prior COVID-19 infections", "PROBLEM", 244, 269], ["bypc", "TEST", 331, 335], ["HIT sets the limit", "PROBLEM", 368, 386], ["the immune population", "TREATMENT", 390, 411], ["another COVID", "TEST", 431, 444], ["pandemic", "PROBLEM", 448, 456], ["a global constant Ro", "TEST", 467, 487], ["intervention", "TREATMENT", 501, 513], ["epidemic", "OBSERVATION", 87, 95]]], ["Should immunity from prior COVID-19 infections be transient, this estimate then sets the upper bound on the fraction of population that must be vaccinated and the vaccine needed in the future.ConclusionThe work here has shown a global convergence of Ro = 4.5 when no deliberate intervention was taken for COVID-19.", [["infections", "DISEASE", 36, 46], ["COVID-19", "ORGANISM", 27, 35], ["prior COVID", "TEST", 21, 32], ["infections", "PROBLEM", 36, 46], ["the upper bound", "PROBLEM", 85, 100], ["the vaccine", "TREATMENT", 159, 170], ["deliberate intervention", "TREATMENT", 267, 290], ["COVID", "TEST", 305, 310], ["upper bound", "OBSERVATION_MODIFIER", 89, 100]]], ["This Ro was shown to describe reasonably the maximum initial exponential growth rate of COVID-19 (=(Ro \u2212 1)\u03b3, where \u03b3 = (1/14)d\u22121) in many countries that did not initiate preventive measures within \u03b3t = 2.", [["Ro", "CHEMICAL", 5, 7], ["COVID-19", "CHEMICAL", 88, 96], ["COVID", "TEST", 88, 93]]], ["The findings here further support the growing consensus that the initial Ro = 2.2 estimate from Wuhan, China is low.", [["the initial Ro", "TEST", 61, 75], ["low", "OBSERVATION_MODIFIER", 112, 115]]], ["The value of Ro = 4.5 is much more in line with other estimates (Ro = 4 \u2212 6) derived from far more complex models.", [["Ro", "CHEMICAL", 13, 15], ["The value of Ro", "TEST", 0, 15], ["other estimates", "TEST", 48, 63]]], ["Model calculations and theoretical considerations offered here delineate the conditions when this Ro estimate is robust to the inclusion of other mechanisms such as super-spreaders and ramp-up in initial testing.", [["Model calculations", "TREATMENT", 0, 18], ["initial testing", "TEST", 196, 211]]], ["The critical herd immunity level that must be reached is 78% to ensure COVID-19 does not become an epidemic again.", [["herd", "ORGANISM", 13, 17], ["COVID", "TEST", 71, 76], ["epidemic", "OBSERVATION", 99, 107]]], ["This estimate sets a maximum limit on the vaccination required.Appendix: Compilation of R&!start&o&!end& estimates from previous studiesA recent review [21] showed that existing estimates of Ro range from 1.4 to 6.49, with a mean of 3.28 and an interquartile range of 1.16.", [["Ro", "CHEMICAL", 191, 193], ["the vaccination", "TREATMENT", 38, 53], ["an interquartile range", "TEST", 242, 264]]], ["Early studies reported lower Ro values [21] and results often vary with the estimation method.", [["Early studies", "TEST", 0, 13], ["lower Ro values", "TEST", 23, 38], ["the estimation method", "TEST", 72, 93]]], ["Similar results were presented in another meta-analysis [48] reporting a mean R0 of 3.38 (values ranging between 1.90 to 6.49) but did not find a significant effect of different estimation methods.", [["a mean R0", "TEST", 71, 80], ["values", "TEST", 90, 96], ["different estimation methods", "PROBLEM", 168, 196]]]], "05f2d4c337413ae496e31e2259020f3e328dcfa1": [["IntroductionDengue virus (DENV) is a mosquito-transmitted virus that causes mild ((dengue fever (DF)) to severe disease ((dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)) in humans [1] .", [["mosquito-transmitted virus", "DISEASE", 37, 63], ["dengue fever", "DISEASE", 83, 95], ["DF", "DISEASE", 97, 99], ["dengue hemorrhagic fever", "DISEASE", 122, 146], ["DHF", "DISEASE", 148, 151], ["dengue shock syndrome", "DISEASE", 157, 178], ["DSS", "DISEASE", 180, 183], ["IntroductionDengue virus", "ORGANISM", 0, 24], ["DENV", "ORGANISM", 26, 30], ["humans", "ORGANISM", 189, 195], ["dengue hemorrhagic fever", "SPECIES", 122, 146], ["humans", "SPECIES", 189, 195], ["IntroductionDengue virus", "SPECIES", 0, 24], ["DENV", "SPECIES", 26, 30], ["humans", "SPECIES", 189, 195], ["IntroductionDengue virus (DENV", "PROBLEM", 0, 30], ["a mosquito-transmitted virus", "PROBLEM", 35, 63], ["mild ((dengue fever (DF)", "PROBLEM", 76, 100], ["severe disease ((dengue hemorrhagic fever (DHF)", "PROBLEM", 105, 152], ["dengue shock syndrome", "PROBLEM", 157, 178], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["disease", "OBSERVATION", 112, 119], ["hemorrhagic", "OBSERVATION_MODIFIER", 129, 140], ["shock syndrome", "OBSERVATION", 164, 178]]], ["DENV consists of four serotypes (DENV1-4) each comprising multiple genotypes and belongs to the genus Flavivirus of the family Flaviviridae [2] .IntroductionBefore 1970 DENV outbreaks were reported in nine countries but has since expanded to more than 100 countries, with an estimated 96 million apparent and 294 million unapparent cases in 2010 [3] .", [["DENV", "ORGANISM", 0, 4], ["DENV1-4", "ORGANISM", 33, 40], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4], ["four", "OBSERVATION_MODIFIER", 17, 21], ["serotypes", "OBSERVATION_MODIFIER", 22, 31]]], ["Two and a half billion people are at risk of infection worldwide [4] .", [["infection", "DISEASE", 45, 54], ["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["a half billion people", "TREATMENT", 8, 29], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["Since specific treatment or a vaccine are currently not available [5] , early detection plays a key role for initiation of control and preventive measures in dengue endemic regions such as mosquito control and social mobilization [6] .IntroductionDENV is detectable in blood up to 5-7 days after the onsets of symptoms.", [["blood", "ANATOMY", 269, 274], ["dengue", "DISEASE", 158, 164], ["blood", "ORGANISM_SUBSTANCE", 269, 274], ["dengue", "SPECIES", 158, 164], ["specific treatment", "TREATMENT", 6, 24], ["a vaccine", "TREATMENT", 28, 37], ["initiation of control", "TREATMENT", 109, 130], ["preventive measures", "TREATMENT", 135, 154], ["dengue endemic regions", "TREATMENT", 158, 180], ["mosquito control", "TREATMENT", 189, 205], ["symptoms", "PROBLEM", 310, 318]]], ["From the 5 th day, diagnosis depends mainly on detection of specific IgM and IgG antibodies using ELISA methods [7, 8] .", [["IgM", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 77, 91], ["IgM", "PROTEIN", 69, 72], ["IgG antibodies", "PROTEIN", 77, 91], ["specific IgM", "TEST", 60, 72], ["IgG antibodies", "TEST", 77, 91], ["ELISA methods", "TEST", 98, 111]]], ["Therefore, both virus and antibody detection are crucial for the identification of infected cases.", [["antibody detection", "TEST", 26, 44], ["infected cases", "PROBLEM", 83, 97], ["infected", "OBSERVATION", 83, 91]]], ["The reference method of DENV diagnosis is virus isolation [9, 10] , which takes a week and requires highly equipped laboratories.", [["DENV", "ORGANISM", 24, 28], ["DENV", "SPECIES", 24, 28], ["virus isolation", "PROBLEM", 42, 57], ["DENV", "OBSERVATION", 24, 28]]], ["The most widely used methods are antigen detection in ELISA or rapid diagnostic tests (RDTs) formats [8] .", [["antigen detection", "TEST", 33, 50], ["rapid diagnostic tests", "TEST", 63, 85], ["most widely", "OBSERVATION_MODIFIER", 4, 15]]], ["Antigen detection is based on the non-structural protein 1 (NS1) of the DENV [11] .", [["non-structural protein 1", "GENE_OR_GENE_PRODUCT", 34, 58], ["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["non-structural protein 1", "PROTEIN", 34, 58], ["NS1", "PROTEIN", 60, 63], ["Antigen detection", "TEST", 0, 17], ["the non-structural protein", "TEST", 30, 56]]], ["RDTs are fast (10-15 minutes) and suitable for point-of-care screening.", [["RDTs", "TEST", 0, 4], ["care screening", "TEST", 56, 70]]], ["However, RDTs clinical sensitivity (21-99%) and specificity (77%-98%) vary greatly [7, 8, 12, 13] .", [["RDTs clinical sensitivity", "TEST", 9, 34], ["specificity", "TEST", 48, 59]]], ["The gold standard method for molecular detection of DENV is real-time RT-PCR, which detects DENV RNA within 60-90 minutes [14] [15] [16] .", [["DENV", "ORGANISM", 52, 56], ["DENV", "ORGANISM", 92, 96], ["DENV RNA", "RNA", 92, 100], ["DENV", "SPECIES", 52, 56], ["DENV", "SPECIES", 92, 96], ["DENV", "PROBLEM", 52, 56], ["RT-PCR", "TEST", 70, 76], ["DENV RNA", "TEST", 92, 100]]], ["Realtime RT-PCR is highly sensitive and specific [14, [16] [17] [18] .", [["[16] [17] [18]", "SIMPLE_CHEMICAL", 54, 68], ["Realtime RT-PCR", "TEST", 0, 15]]], ["It requires precautions (carry over prevention systems and physical separation of pipetting sites), sophisticated equipment, and is cold chain dependent, which makes it difficult to implement at the point-of-need.IntroductionIsothermal DNA amplification methods represent an alternative to real-time PCR.", [["DNA", "CELLULAR_COMPONENT", 236, 239], ["precautions", "TREATMENT", 12, 23], ["prevention systems", "TREATMENT", 36, 54], ["physical separation of pipetting sites", "TREATMENT", 59, 97], ["IntroductionIsothermal DNA amplification methods", "TREATMENT", 213, 261]]], ["There is only one development for the application of Nucleic acid sequence based amplification (NASBA) [19] but several applications of reverse transcription Loop mediated isothermal amplification (RT-LAMP) for the detection and differentiation of DENV serotypes have been described [20] [21] [22] [23] .", [["Nucleic acid", "CHEMICAL", 53, 65], ["Nucleic acid", "SIMPLE_CHEMICAL", 53, 65], ["DENV", "ORGANISM", 248, 252], ["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 283, 302], ["DENV", "SPECIES", 248, 252], ["Nucleic acid sequence", "TREATMENT", 53, 74], ["reverse transcription Loop mediated isothermal amplification (RT-LAMP", "TREATMENT", 136, 205], ["the detection", "TEST", 211, 224], ["DENV serotypes", "PROBLEM", 248, 262], ["DENV", "OBSERVATION", 248, 252]]], ["RT-LAMP reactions are performed at 60\u00b0C, tests run for more than 30 minutes, and results are measured either by turbidity index or by visual qualitative fluorescence detection of SYBR Green [24] .", [["SYBR Green", "CHEMICAL", 179, 189], ["LAMP reactions", "TEST", 3, 17], ["tests run", "TEST", 41, 50], ["turbidity index", "TEST", 112, 127]]], ["In contrast, real-time recombinase polymerase amplification (RPA) amplifies at 39-42\u00b0C and uses a fluorescent exo-probe for detection [25] .", [["recombinase polymerase", "GENE_OR_GENE_PRODUCT", 23, 45]]], ["The RPA assay is very fast (3-15 minutes) and can be operated on a portable device, the tubescanner (19x17.5 cm).", [["RPA", "PROTEIN", 4, 7], ["The RPA assay", "TEST", 0, 13], ["a portable device", "TREATMENT", 65, 82]]], ["In this study, a-point-of-need reverse transcription RPA (RT-RPA) assays for the detection of DENV1-4 without differentiation between the serotypes were developed and evaluated with samples from Senegal and Thailand.", [["DENV1-4", "CELL", 94, 101], ["RPA", "PROTEIN", 61, 64], ["DENV1-4", "DNA", 94, 101], ["this study", "TEST", 3, 13], ["the detection", "TEST", 77, 90], ["DENV1", "TEST", 94, 99], ["the serotypes", "PROBLEM", 134, 147]]], ["A mobile RPA unit was deployed to Kedougou in Senegal and to Bangkok, Thailand.Ethics StatementHuman samples tested in Senegal were provided by the WHO collaborating center for Abovirus and Viral Hemorrhagic Fever at the Institute Pasteur de Dakar (IPD).", [["Viral Hemorrhagic Fever", "DISEASE", 190, 213], ["mobile RPA unit", "DNA", 2, 17], ["A mobile RPA unit", "TREATMENT", 0, 17], ["Ethics StatementHuman samples", "TEST", 79, 108], ["Abovirus", "PROBLEM", 177, 185], ["Viral Hemorrhagic Fever", "PROBLEM", 190, 213], ["Viral", "OBSERVATION_MODIFIER", 190, 195], ["Hemorrhagic", "OBSERVATION_MODIFIER", 196, 207]]], ["The IPD has the required ethical approvals from the Senegalese National Health Research Council and the signed consent forms from patients.", [["IPD", "DISEASE", 4, 7], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["ethical approvals", "TREATMENT", 25, 42]]], ["Human samples tested during the field trial in Thailand were used after an approval of Faculty of Medicine, Vajira Hospital, Bangkok, Thailand Research Ethics Committee (Certificate of approval number: COA29/2012) and signed consent forms from patients.VirusesRobert Koch Institute, Berlin, Germany provided the viruses and/or nucleic acids used in this study.", [["samples", "ANATOMY", 6, 13], ["nucleic acids", "CHEMICAL", 327, 340], ["Human", "ORGANISM", 0, 5], ["patients", "ORGANISM", 244, 252], ["nucleic acids", "SIMPLE_CHEMICAL", 327, 340], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 244, 252], ["Human", "SPECIES", 0, 5], ["Human samples", "TEST", 0, 13], ["the viruses", "TREATMENT", 308, 319], ["nucleic acids", "TREATMENT", 327, 340], ["this study", "TEST", 349, 359], ["viruses", "OBSERVATION", 312, 319]]], ["Viruses are listed in Table 1 .Generation of molecular RNA standardAccording to a previously published protocol, two in vitro transcribed RNA standards were prepared [26, 27] .", [["molecular RNA", "OBSERVATION", 45, 58]]], ["PCR primers used for the amplification of the target region for ligation into the TA cloning vector pCRII are listed in Table 2 .", [["pCRII", "GENE_OR_GENE_PRODUCT", 100, 105], ["PCR primers", "DNA", 0, 11], ["TA cloning vector pCRII", "DNA", 82, 105], ["PCR primers", "TEST", 0, 11], ["ligation", "TREATMENT", 64, 72], ["the TA cloning vector pCRII", "TREATMENT", 78, 105], ["ligation", "OBSERVATION", 64, 72]]], ["DENV1-3 and DEN4 RNA molecular standards cover 242 and 248 bp of the 3' non-translated region (3'NTR) (10462-10703 nt and 10398-10645 nt of GenBank accession numbers AY662691.1 and GU289913.1), respectively.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["DEN4", "GENE_OR_GENE_PRODUCT", 12, 16], ["3' non-translated region", "CELLULAR_COMPONENT", 69, 93], ["DENV1", "DNA", 0, 5], ["3' non-translated region", "DNA", 69, 93], ["3'NTR", "DNA", 95, 100], ["10462-10703 nt", "DNA", 103, 117], ["DENV1", "TEST", 0, 5], ["bp", "TEST", 59, 61], ["nt", "TEST", 115, 117], ["GenBank accession numbers", "TEST", 140, 165]]], ["The Light Cycler 2.0 and the LightCycler 480 RNA Master Hydrolysis Probes kit (Roche, Manheim, Germany) were used.", [["The Light Cycler", "TEST", 0, 16], ["the LightCycler", "TREATMENT", 25, 40], ["RNA Master Hydrolysis Probes kit (Roche, Manheim, Germany)", "TREATMENT", 45, 103]]], ["The following temperature profile was used: RT step 63\u00b0C/3 minutes, initial activation at 95\u00b0C/30 seconds, 45 cycles of 95\u00b0C/15 seconds and 60\u00b0C/60 seconds, and a final cooling step of 40\u00b0C/30 seconds.RT-RPA primers and exo-probesTwo RT-RPA assays were developed to cover DENV1-4, one to detect DENV1-3 and another to detect DENV4.", [["DENV1-4", "CELL", 272, 279], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 295, 302], ["DENV4", "GENE_OR_GENE_PRODUCT", 325, 330], ["RT-RPA primers", "DNA", 201, 215], ["RPA", "PROTEIN", 237, 240], ["DENV1-4", "DNA", 272, 279], ["DENV1", "DNA", 295, 300], ["DENV4", "DNA", 325, 330], ["The following temperature profile", "TEST", 0, 33], ["RPA primers", "TEST", 204, 215], ["exo-probes", "TEST", 220, 230], ["Two RT-RPA assays", "TEST", 230, 247], ["DENV1", "TEST", 272, 277], ["DENV1", "TEST", 295, 300], ["RPA", "ANATOMY_MODIFIER", 204, 207]]], ["The assays were not used for distinguishing between DENV serotypes.", [["DENV", "ORGANISM", 52, 56], ["DENV", "SPECIES", 52, 56], ["The assays", "TEST", 0, 10], ["DENV serotypes", "PROBLEM", 52, 66]]], ["Nineteen forward primers (FP), 5 reverse primers (RP), and 3 exo-probes (exo-Ps) (S1 FigRT-RPA assay conditionsIn the laboratory, the RT-RPA assay was carried out using the TwistAmp exo kit (TwistDx, Cambridge, UK) and the reverse transcriptase (RT) Transcriptor (Roche, Mannheim, Germany) was added as described [29, 30] .", [["forward primers", "DNA", 9, 24], ["reverse primers", "DNA", 33, 48], ["exo-Ps", "DNA", 73, 79], ["RPA", "DNA", 91, 94], ["RPA", "PROTEIN", 137, 140], ["reverse transcriptase", "PROTEIN", 223, 244], ["Nineteen forward primers", "TEST", 0, 24], ["RP", "TEST", 50, 52], ["exo-Ps", "TEST", 73, 79], ["the RT-RPA assay", "TEST", 130, 146], ["the reverse transcriptase", "TREATMENT", 219, 244]]], ["In the field trials in Senegal and Thailand, the RT-RPA assay was performed using the ready-to-use TwistAmp RT exo (TwistDx, Cambridge, UK) as described previously [26] .Analytical sensitivity of RT-RPA assaysA dilution range from 10 7 to 10 1 RNA molecules/\u03bcl of the molecular standards in eight replicates was used to determine the analytical sensitivity of RT-RPA assays.", [["RPA", "PROTEIN", 52, 55], ["Twist", "PROTEIN", 99, 104], ["RPA", "PROTEIN", 199, 202], ["RPA", "PROTEIN", 363, 366], ["the RT-RPA assay", "TEST", 45, 61], ["TwistAmp RT exo", "TREATMENT", 99, 114], ["Analytical sensitivity", "TEST", 170, 192], ["RT-RPA assaysA dilution", "TEST", 196, 219], ["RNA molecules", "TEST", 244, 257], ["RPA", "ANATOMY", 199, 202]]], ["A semi-log and probit regression analyses were performed as stated in the statistical analysis section (see below).Specificity and cross-reactivity of RT-RPA assaysThe specificity of the DENV RT-RPA assays was determined by testing 64 DENV-real-time RT-PCR negative plasma samples (41 samples during the field trial in Thailand and 23 in Senegal).", [["plasma samples", "ANATOMY", 266, 280], ["samples", "ANATOMY", 285, 292], ["RT-RPA", "GENE_OR_GENE_PRODUCT", 151, 157], ["DENV", "ORGANISM", 187, 191], ["plasma samples", "ORGANISM_SUBSTANCE", 266, 280], ["RPA", "PROTEIN", 154, 157], ["RPA", "PROTEIN", 195, 198], ["DENV", "SPECIES", 187, 191], ["DENV", "SPECIES", 235, 239], ["A semi-log and probit regression analyses", "TEST", 0, 41], ["the statistical analysis section", "TEST", 70, 102], ["Specificity", "TEST", 115, 126], ["cross-reactivity", "TEST", 131, 147], ["RT-RPA assays", "TEST", 151, 164], ["the DENV RT-RPA assays", "TEST", 183, 205], ["DENV", "TEST", 235, 239], ["RT-PCR", "TEST", 250, 256], ["plasma samples", "TEST", 266, 280], ["RPA", "ANATOMY", 154, 157], ["DENV", "OBSERVATION", 187, 191]]], ["In addition, genomic RNA of the Yellow Fever virus, Tick-borne encephalitis virus, Tick-borne encephalitis virus-Far East, Chikungunya virus, Zika virus, Japanese encephalitis virus and West Nile virus were tested for cross-reactivity.Differentiation between specific and non-specific signals of the RT-RPAReal-time fluorescence development in the RT-RPA reaction was measured with the tubescanner (Qiagen Lake Constance GmbH, Stockach, Germany).", [["Yellow Fever", "DISEASE", 32, 44], ["Tick-borne encephalitis", "DISEASE", 52, 75], ["Tick-borne encephalitis", "DISEASE", 83, 106], ["Chikungunya virus", "DISEASE", 123, 140], ["Japanese encephalitis", "DISEASE", 154, 175], ["Yellow Fever virus", "ORGANISM", 32, 50], ["Tick-borne encephalitis virus", "ORGANISM", 52, 81], ["Tick-borne encephalitis virus-Far East", "ORGANISM", 83, 121], ["Chikungunya virus", "ORGANISM", 123, 140], ["Zika virus", "ORGANISM", 142, 152], ["Japanese encephalitis virus", "ORGANISM", 154, 181], ["West Nile virus", "ORGANISM", 186, 201], ["Yellow Fever virus", "SPECIES", 32, 50], ["Tick-borne encephalitis virus", "SPECIES", 52, 81], ["Tick-borne encephalitis virus", "SPECIES", 83, 112], ["Chikungunya virus", "SPECIES", 123, 140], ["Zika virus", "SPECIES", 142, 152], ["Japanese encephalitis virus", "SPECIES", 154, 181], ["West Nile virus", "SPECIES", 186, 201], ["Yellow Fever virus", "SPECIES", 32, 50], ["Tick-borne encephalitis virus", "SPECIES", 52, 81], ["Tick-borne encephalitis virus", "SPECIES", 83, 112], ["Chikungunya virus", "SPECIES", 123, 140], ["Zika virus", "SPECIES", 142, 152], ["Japanese encephalitis virus", "SPECIES", 154, 181], ["West Nile virus", "SPECIES", 186, 201], ["genomic RNA", "TEST", 13, 24], ["the Yellow Fever virus", "PROBLEM", 28, 50], ["Tick-borne encephalitis virus", "PROBLEM", 52, 81], ["Tick-borne encephalitis virus", "PROBLEM", 83, 112], ["Chikungunya virus", "PROBLEM", 123, 140], ["Zika virus", "PROBLEM", 142, 152], ["Japanese encephalitis virus", "PROBLEM", 154, 181], ["West Nile virus", "PROBLEM", 186, 201], ["cross-reactivity", "PROBLEM", 218, 234], ["the RT", "TEST", 296, 302], ["RPA reaction", "PROBLEM", 351, 363], ["genomic RNA", "OBSERVATION", 13, 24], ["non-specific", "OBSERVATION_MODIFIER", 272, 284], ["RT", "ANATOMY_MODIFIER", 348, 350], ["RPA", "ANATOMY", 351, 354], ["reaction", "OBSERVATION", 355, 363]]], ["Fluorescence signals were analyzed by using the tubescanner studio software (Qiagen Lake Constance GmbH, Stockach, Germany).", [["Fluorescence signals", "TEST", 0, 20]]], ["It allows an analysis of accumulative fluorescence intensity over time by threshold validation to identify the increase of fluorescence over time above the mean background signal (raw data, Fig 1A and 1C ).", [["an analysis", "TEST", 10, 21], ["accumulative fluorescence intensity", "PROBLEM", 25, 60], ["threshold validation", "TEST", 74, 94], ["the increase of fluorescence", "PROBLEM", 107, 135], ["accumulative", "OBSERVATION_MODIFIER", 25, 37], ["fluorescence", "OBSERVATION_MODIFIER", 38, 50], ["intensity", "OBSERVATION_MODIFIER", 51, 60], ["increase", "OBSERVATION_MODIFIER", 111, 119]]], ["Additionally, slope validation is used to verify that the increase of fluorescence occurs at a sufficiently high rate, this can be displayed as a 1 st derivative analysis (1 st derivative analysis, Fig 1B and 1D ).", [["slope validation", "TEST", 14, 30], ["the increase of fluorescence", "PROBLEM", 54, 82], ["a 1 st derivative analysis", "TEST", 144, 170], ["1 st derivative analysis", "TREATMENT", 172, 196]]], ["Specific amplification (black curves Fig 1) should present ascending curves indicating increase of florescence over time in both analyses.", [["Specific amplification (black curves Fig", "TREATMENT", 0, 40], ["increase of florescence", "PROBLEM", 87, 110], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["Negative or non-specific amplification (blue curves Fig 1) might in a few cases develop fluorescence in the raw data view but never in the 1 st derivative analysis.", [["non-specific amplification (blue curves Fig", "PROBLEM", 12, 55], ["non-specific", "OBSERVATION_MODIFIER", 12, 24]]], ["The derivative analysis is therefore necessary to confirm true amplification.RT-RPA mobile laboratoryThe mobile laboratory was organized into four sites in close proximity, which included the extraction, the master mix, the sample mix, and the detection-sites (Fig 2) .", [["The derivative analysis", "TEST", 0, 23], ["true amplification", "PROBLEM", 58, 76], ["the extraction", "TREATMENT", 188, 202], ["the sample mix", "TEST", 220, 234], ["the detection", "TEST", 240, 253], ["RPA", "ANATOMY", 80, 83]]], ["The RNA extraction was done by using a extraction kit based on magnetic beads (Dynabeads SILANE viral NA, Life Technologies, Darmstadt, Germany) according to the manufacturer instructions.", [["The RNA extraction", "TREATMENT", 0, 18], ["a extraction kit", "TREATMENT", 37, 53], ["magnetic beads", "TREATMENT", 63, 77], ["Dynabeads SILANE viral NA", "TREATMENT", 79, 104], ["Life Technologies", "TREATMENT", 106, 123], ["Darmstadt", "TREATMENT", 125, 134]]], ["The DENV RT-RPA assays were performed by using the ready-to-use TwistAmp exo RT kits (TwistDx, Cambridge, UK), dried DENV1-3 and DENV4 in vitro transcribed RNA (using the RNAstable Oligonucleotide sets were ordered as dried pellets at an absolute concentration of 840 pmol primers/400 pmol probe.", [["UK", "GENE_OR_GENE_PRODUCT", 106, 108], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 117, 124], ["RPA", "PROTEIN", 12, 15], ["DENV1", "PROTEIN", 117, 122], ["DENV4 in vitro transcribed RNA", "RNA", 129, 159], ["DENV", "SPECIES", 4, 8], ["The DENV RT-RPA assays", "TEST", 0, 22], ["TwistAmp exo RT kits", "TREATMENT", 64, 84], ["DENV4 in vitro transcribed RNA", "TREATMENT", 129, 159], ["the RNAstable Oligonucleotide sets", "TREATMENT", 167, 201], ["dried pellets", "TREATMENT", 218, 231], ["an absolute concentration of 840 pmol primers", "TREATMENT", 235, 280], ["DENV", "OBSERVATION", 4, 8]]], ["The addition of 200 \u03bcl water yielded a stock solution of 4.2 \u03bcM/2 \u03bcM from which the final concentration of 420 nM/200 nM of the RT-RPA reaction was derived by 10-fold dilution.", [["RPA", "PROTEIN", 131, 134], ["a stock solution", "TREATMENT", 37, 53], ["the RT-RPA reaction", "TREATMENT", 124, 143], ["RPA", "ANATOMY", 131, 134]]], ["One 200 \u03bcl 40x stock solution thus allowed pipette eight 9-volume master mixes to fill eight 8-tube strips for the tubescanner device.", [["pipette eight 9-volume master mixes", "TREATMENT", 43, 78], ["eight 8-tube strips", "TREATMENT", 87, 106], ["the tubescanner device", "TREATMENT", 111, 133]]], ["For the positive control, one volume of the master-mix was added to a dried positive control tube.RT-RPA mobile laboratoryAll reagents used for the mobile laboratory were cold-chain independent, i.e. used stored, and transported at ambient temperature.", [["tube", "TISSUE", 93, 97], ["the positive control", "TREATMENT", 4, 24], ["the master-mix", "TREATMENT", 40, 54], ["a dried positive control tube", "TREATMENT", 68, 97], ["All reagents", "TREATMENT", 122, 134], ["control tube", "OBSERVATION", 85, 97], ["RPA", "ANATOMY", 101, 104]]], ["Electricity was either tapped from a motor vehicle battery via inverter (HPL 1200-D-12 inverter 12V 1200W) or supplied via solar panel and power pack (Yeti 1250 set, GOALZERO, South Bluffdale, UT, USA).Field trial in the Kedougou region, SenegalThe mobile RPA was tested in the field station of the IPD in Kedougou, Senegal.", [["IPD", "DISEASE", 299, 302], ["power pack", "TREATMENT", 139, 149], ["Field trial in the Kedougou region", "TREATMENT", 202, 236]]], ["The extraction area encompassing magnetic separator stand, vortex, rotator, 1.5-2 ml eppendorf tube rack, automatic 100-1000 \u03bcl micopipette, micropipette tips, digital timer, 1.5 ml disposable plastic Eppendorf tubes, and a waste container with autoclavable plastic bags.", [["The extraction area", "TREATMENT", 0, 19], ["magnetic separator stand", "TREATMENT", 33, 57], ["rotator", "TREATMENT", 67, 74], ["2 ml eppendorf tube rack", "TREATMENT", 80, 104], ["automatic", "TEST", 106, 115], ["micropipette tips", "TREATMENT", 141, 158], ["disposable plastic Eppendorf tubes", "TREATMENT", 182, 216], ["a waste container", "TREATMENT", 222, 239], ["autoclavable plastic bags", "TREATMENT", 245, 270], ["rotator", "ANATOMY", 67, 74], ["Eppendorf tubes", "OBSERVATION", 201, 216], ["plastic bags", "OBSERVATION", 258, 270]]], ["Both master mix and sample mix areas contain vortex, minicentrifuge, automatic 1-10 and 10-100 \u03bcl micopipettes, micropipette tips, scissor, and 0.2 ml tubes rack.", [["micropipette tips", "TREATMENT", 112, 129], ["scissor", "TREATMENT", 131, 138], ["0.2 ml tubes rack", "TREATMENT", 144, 161], ["mix", "OBSERVATION_MODIFIER", 12, 15], ["vortex", "OBSERVATION_MODIFIER", 45, 51]]], ["The detection was done using the tubescanner (Twista device, TwistDx, Cambridge, UK).", [["The detection", "TEST", 0, 13], ["the tubescanner (Twista device", "TREATMENT", 29, 59]]], ["In addition to a waste container, gloves, disposable towels, and aluminum box with trolley (740x490x450 mm, ZARGES, Weilheim, Germany).Field trial in the Kedougou region, Senegaldoi:10.1371/journal.pone.0129682.g002 use in very simple conditions with auxiliary electricity tapped from a motor vehicle.", [["aluminum", "CHEMICAL", 65, 73], ["aluminum", "CHEMICAL", 65, 73], ["a waste container", "TREATMENT", 15, 32], ["gloves", "TREATMENT", 34, 40], ["disposable towels", "TREATMENT", 42, 59], ["aluminum box", "TREATMENT", 65, 77], ["auxiliary electricity", "TREATMENT", 251, 272]]], ["Inactivated DENV1-4 cell culture supernatants (heating at 56\u00b0C/1 hour and gamma irradiation with 30 kGy) and thirty-one DENV RNA positive samples were tested in triplicate.Field trial in the Kedougou region, SenegalEvaluation of RT-RPA assay using RNA extracts in Bangkok, Thailand RNA extracted from ninety selected samples, positive by SD Dengue Duo Rapid Test (Standard Diagnostic, Inc, Republic of Korea), by QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and stored between 6-18 months at -80\u00b0C. RNA was retested simultaneously with realtime RT-PCR and the RT-RPA assays, each sample was tested at least twice.", [["cell", "ANATOMY", 20, 24], ["supernatants", "ANATOMY", 33, 45], ["samples", "ANATOMY", 138, 145], ["extracts", "ANATOMY", 252, 260], ["samples", "ANATOMY", 317, 324], ["sample", "ANATOMY", 587, 593], ["DENV1-4 cell", "CELL", 12, 24], ["DENV", "ORGANISM", 120, 124], ["RPA", "PROTEIN", 232, 235], ["RNA", "RNA", 506, 509], ["RPA", "PROTEIN", 570, 573], ["DENV", "SPECIES", 120, 124], ["Inactivated DENV1", "TEST", 0, 17], ["cell culture supernatants", "TEST", 20, 45], ["gamma irradiation", "TREATMENT", 74, 91], ["DENV RNA positive samples", "TEST", 120, 145], ["Field trial in the Kedougou region", "TREATMENT", 172, 206], ["RT-RPA assay", "TEST", 229, 241], ["RNA extracts", "TREATMENT", 248, 260], ["Rapid Test", "TEST", 352, 362], ["realtime RT-PCR", "TEST", 543, 558], ["the RT-RPA assays", "TEST", 563, 580]]], ["The real-time RT-PCR was performed by using the Light Cycler 480 RNA Master Hydrolysis Probes kit (Roche, Germany) using the following temperature profile: 61\u00b0C for 10 minutes, 95\u00b0C for 2 minutes followed by 45 cycles of 95\u00b0C for 15 seconds and 60\u00b0C for 30 seconds on a 7500 Fast Real-Time PCR system.", [["the Light Cycler", "TREATMENT", 44, 60], ["temperature profile", "TEST", 135, 154]]], ["The primers and probe targeted the NS5 gene (S1 Table, [14] ).Statistical analysisThe semi-log regression analyses of the analytical sensitivity of RT-RPA assays were performed using PRISM (Graphpad Software Inc., San Diego, CA, USA) and the probit anylsis by STA-TISTICA (StatSoft, Hamburg, Germany).", [["NS5 gene", "DNA", 35, 43], ["RPA", "PROTEIN", 151, 154], ["The primers", "TREATMENT", 0, 11], ["Statistical analysis", "TEST", 62, 82], ["RT-RPA assays", "TEST", 148, 161], ["PRISM", "TEST", 183, 188], ["the probit anylsis", "TEST", 238, 256]]], ["Comparison between real-time RT-PCR and RT-RPA for the detection of DENV was performed by linear regression analysis using Prism.Analytical sensitivity of DENV1-3, and DENV4 RT-RPA assaysDue to the variability of DENV sequences in the 3'NTR, two RT-RPA assays were designed, one for the detection of DENV1-3 and one for the detection of DENV4.", [["RT-RPA", "GENE_OR_GENE_PRODUCT", 40, 46], ["DENV", "ORGANISM", 68, 72], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 155, 162], ["NTR", "GENE_OR_GENE_PRODUCT", 237, 240], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 300, 307], ["DENV4", "GENE_OR_GENE_PRODUCT", 337, 342], ["RPA", "PROTEIN", 43, 46], ["DENV1", "PROTEIN", 155, 160], ["RPA", "PROTEIN", 177, 180], ["DENV sequences", "DNA", 213, 227], ["3'NTR", "DNA", 235, 240], ["RPA", "PROTEIN", 249, 252], ["DENV1", "DNA", 300, 305], ["DENV4", "DNA", 337, 342], ["DENV", "SPECIES", 68, 72], ["DENV", "SPECIES", 213, 217], ["PCR", "TEST", 32, 35], ["DENV", "PROBLEM", 68, 72], ["linear regression analysis", "TEST", 90, 116], ["Prism", "TEST", 123, 128], ["Analytical sensitivity", "TEST", 129, 151], ["DENV1", "TEST", 155, 160], ["DENV sequences", "TEST", 213, 227], ["two RT-RPA assays", "TEST", 242, 259], ["the detection", "TEST", 283, 296], ["DENV1", "TEST", 300, 305], ["the detection", "TEST", 320, 333], ["DENV4", "PROBLEM", 337, 342], ["DENV", "OBSERVATION", 68, 72], ["RPA", "ANATOMY", 177, 180]]], ["The primers DENV1-3-RPA-FP13 and RP4 and the primers DENV4-RPA-FP3 and RP2 both in combination with DENV-RPA-P3 yielded analytical sensitivities between 10-100 RNA molecules (Table 2 and Fig 3) .", [["DENV1-3-RPA-FP13", "GENE_OR_GENE_PRODUCT", 12, 28], ["RP4", "GENE_OR_GENE_PRODUCT", 33, 36], ["DENV4-RPA-FP3", "GENE_OR_GENE_PRODUCT", 53, 66], ["RP2", "GENE_OR_GENE_PRODUCT", 71, 74], ["DENV", "ORGANISM", 100, 104], ["DENV1", "DNA", 12, 17], ["3-RPA", "DNA", 18, 23], ["FP13", "DNA", 24, 28], ["RP4", "DNA", 33, 36], ["DENV4", "DNA", 53, 58], ["RPA", "DNA", 59, 62], ["FP3", "DNA", 63, 66], ["RP2", "DNA", 71, 74], ["RPA", "PROTEIN", 105, 108], ["P3", "DNA", 109, 111], ["DENV", "SPECIES", 100, 104], ["The primers", "TEST", 0, 11], ["DENV1", "TEST", 12, 17], ["3-RPA", "TEST", 18, 23], ["RP4", "TEST", 33, 36], ["the primers", "TEST", 41, 52], ["DENV4", "TEST", 53, 58], ["RPA", "TEST", 59, 62], ["RP2", "TEST", 71, 74], ["DENV", "TEST", 100, 104], ["RPA", "TEST", 105, 108], ["analytical sensitivities", "TEST", 120, 144]]], ["Most of the other primer and exo-P combinations produced either non-specific amplification (S3 Fig) or analytical sensitivity between 10 5 -10 3 RNA molecules (S4 Fig).", [["primer and exo-P combinations", "DNA", 18, 47], ["either non-specific amplification (S3 Fig", "PROBLEM", 57, 98], ["analytical sensitivity", "TEST", 103, 125]]], ["Using the data of eight RT-RPA runs on the quantitative RNA standard, a semi-log regression (Fig 4) and probit regression analysis were performed.", [["RPA", "PROTEIN", 27, 30], ["a semi-log regression (Fig", "TREATMENT", 70, 96], ["probit regression analysis", "TEST", 104, 130]]], ["For both assays, the runtime was 3-7 minutes at an efficiency of 0.24 and 0.27 calculated from the linear slopes (-0.2366 and -0.1655) of the semi-log standard regression (E = 10 (-1/slope)-1) for DEN1-3 and DEN4 RT-RPA assays, respectively.", [["DEN1-3", "GENE_OR_GENE_PRODUCT", 197, 203], ["RPA", "PROTEIN", 216, 219], ["both assays", "TEST", 4, 15], ["the linear slopes", "TEST", 95, 112], ["E", "TEST", 172, 173], ["DEN1", "TEST", 197, 201]]], ["Probit regression yielded a sensitivity at 95% of 241 and 14 RNA molecules detected for the DENV1-3 and the DENV4 RT-RPA assays, respectively.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 92, 99], ["241 and 14 RNA molecules", "RNA", 50, 74], ["RPA", "PROTEIN", 117, 120], ["a sensitivity", "TEST", 26, 39], ["RNA molecules", "TEST", 61, 74], ["the DENV1", "TEST", 88, 97]]], ["Additionally, inactivated whole DENV1-4 (strains are listed in Table 1 ) were spiked into plasma samples.", [["plasma samples", "ANATOMY", 90, 104], ["DENV1-4", "ORGANISM", 32, 39], ["plasma samples", "ORGANISM_SUBSTANCE", 90, 104], ["inactivated whole DENV1-4", "DNA", 14, 39], ["plasma samples", "TEST", 90, 104]]], ["Serial dilutions of each spiked sample were tested with real-time RT-PCR and RT-RPA assays simultaneously (S2 Table) .", [["sample", "ANATOMY", 32, 38], ["Serial dilutions", "TEST", 0, 16], ["PCR", "TEST", 69, 72], ["RT-RPA assays", "TEST", 77, 90]]], ["Limits of detection in RT-RPA were 237, 618, 363, and 383 RNA molecules detected/reaction of DENV serotypes 1, 2, 3, and 4, respectively (Fig 5) .Specificity and cross-reactivity of DENV1-3, and DENV4 RT-RPA assaysSixty-four DENV-PCR negative samples were tested by both DENV RT-RPA assays.", [["samples", "ANATOMY", 243, 250], ["RT-RPA", "GENE_OR_GENE_PRODUCT", 23, 29], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 182, 189], ["DENV4 RT-RPA", "ORGANISM", 195, 207], ["DENV", "ORGANISM", 225, 229], ["samples", "CANCER", 243, 250], ["DENV1-3, and DENV4 RT-RPA assaysSixty", "DNA", 182, 219], ["RPA", "PROTEIN", 279, 282], ["DENV", "SPECIES", 225, 229], ["DENV", "SPECIES", 271, 275], ["RT-RPA", "TEST", 23, 29], ["RNA molecules", "TEST", 58, 71], ["DENV serotypes", "TEST", 93, 107], ["Specificity", "TEST", 146, 157], ["cross-reactivity", "TEST", 162, 178], ["DENV1", "TEST", 182, 187], ["PCR", "TEST", 230, 233], ["RPA", "ANATOMY", 26, 29], ["DENV serotypes", "OBSERVATION", 93, 107]]], ["Non-specific amplification was not detected.", [["Non-specific amplification", "PROBLEM", 0, 26], ["not detected", "UNCERTAINTY", 31, 43]]], ["DENV1-3 RT-RPA assay detected DENV serotypes 1, 2, and 3, while DENV4 RT-RPA identified DENV serotypes 2 and 4 ( Table 1) .", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["DENV serotypes 1", "ORGANISM", 30, 46], ["3", "GENE_OR_GENE_PRODUCT", 55, 56], ["DENV1", "PROTEIN", 0, 5], ["RPA", "PROTEIN", 11, 14], ["RPA", "PROTEIN", 73, 76], ["DENV", "SPECIES", 30, 34], ["DENV1", "TEST", 0, 5], ["RT-RPA assay", "TEST", 8, 20], ["DENV serotypes", "TEST", 30, 44], ["DENV serotypes", "TREATMENT", 88, 102], ["RPA", "ANATOMY", 73, 76], ["DENV", "OBSERVATION", 88, 92]]], ["No cross detection with viruses listed in Table 2 was observed.RPA mobile laboratory in Kedougou region in SenegalIn the field, setting up the mobile laboratory including hooking electricity from a motor vehicle battery took about 20 minutes.", [["cross detection", "TEST", 3, 18], ["viruses", "PROBLEM", 24, 31], ["viruses", "OBSERVATION", 24, 31], ["Senegal", "OBSERVATION", 107, 114]]], ["A magnetic beads based extraction method was used to avoid the use of a centrifuge and the generation of aerosols.RPA mobile laboratory in Kedougou region in SenegalUsing the inactivated DENV1-4 spiked plasma as well as 31 DENV positive samples, the DENV RT-RPA assays and the mobile laboratory format were tested in a healthcare center without electricity in Bandafassi (S5 Fig) to simulate an outbreak situation.", [["plasma", "ANATOMY", 202, 208], ["samples", "ANATOMY", 237, 244], ["DENV1-4", "CELL", 187, 194], ["plasma", "ORGANISM_SUBSTANCE", 202, 208], ["DENV", "ORGANISM", 223, 227], ["Kedougou region", "DNA", 139, 154], ["DENV1", "PROTEIN", 187, 192], ["RPA", "PROTEIN", 258, 261], ["DENV", "SPECIES", 223, 227], ["DENV", "SPECIES", 250, 254], ["A magnetic beads based extraction method", "TREATMENT", 0, 40], ["a centrifuge", "TREATMENT", 70, 82], ["the generation of aerosols", "TREATMENT", 87, 113], ["RPA mobile laboratory", "TEST", 114, 135], ["31 DENV positive samples", "PROBLEM", 220, 244], ["the DENV RT-RPA assays", "TEST", 246, 268]]], ["Extraction and RT-RPA assays were carried out at an ambient temperature of 38\u00b0C. The RT-RPA assays were used successfully to detect DENV RNA in the spiked plasma.", [["plasma", "ANATOMY", 155, 161], ["DENV", "ORGANISM", 132, 136], ["plasma", "ORGANISM_SUBSTANCE", 155, 161], ["RPA", "PROTEIN", 88, 91], ["DENV RNA", "RNA", 132, 140], ["DENV", "SPECIES", 132, 136], ["Extraction", "TREATMENT", 0, 10], ["RT-RPA assays", "TEST", 15, 28], ["an ambient temperature", "TEST", 49, 71], ["The RT-RPA assays", "TEST", 81, 98], ["DENV RNA", "PROBLEM", 132, 140], ["the spiked plasma", "TEST", 144, 161], ["RPA", "ANATOMY", 88, 91], ["DENV", "OBSERVATION", 132, 136]]], ["In comparison to the real-time RT-PCR results, 30 out of 31 DENV-3-positive samples were positive in RT-RPA assays (clinical sensitivity 98%, Fig 6) .", [["samples", "ANATOMY", 76, 83], ["DENV-3", "ORGANISM", 60, 66], ["DENV", "TEST", 60, 64], ["positive samples", "TEST", 67, 83], ["RT", "TEST", 101, 103], ["RPA assays", "TEST", 104, 114], ["clinical sensitivity", "TEST", 116, 136], ["Fig", "TEST", 142, 145], ["RPA", "ANATOMY", 104, 107]]], ["Samples with high cycle threshold (Ct) value (35) (36) (37) (38) in real-time RT-PCR were detected by RT-RPA in a maximum of 8 minutes.Assay performance on RNA extracts in ThailandIn Bangkok, Thailand, the RNA of ninety plasma samples extracted and tested between 2012-2013 by RT-PCR, and stored at -80\u00b0C was tested.", [["Samples", "ANATOMY", 0, 7], ["extracts", "ANATOMY", 160, 168], ["plasma samples", "ANATOMY", 220, 234], ["plasma samples", "ORGANISM_SUBSTANCE", 220, 234], ["Samples", "TEST", 0, 7], ["high cycle threshold", "TEST", 13, 33], ["Ct) value", "TEST", 35, 44], ["RT-PCR", "TEST", 78, 84], ["Assay performance", "TEST", 135, 152], ["ninety plasma samples", "TEST", 213, 234], ["RT", "TEST", 277, 279], ["PCR", "TEST", 280, 283]]], ["RNA was simultaneously screened by RT-RPA assays and serotype specific real-time RT-PCR (S1 Table) .", [["RNA", "RNA", 0, 3], ["RT", "TEST", 35, 37], ["RPA assays", "TEST", 38, 48]]], ["The sensitivity was 72% and 94.4% for RT-RPA and real-time RT-PCR, respectively (S3 Table) .", [["The sensitivity", "TEST", 0, 15], ["RT-RPA", "TEST", 38, 44]]], ["RT-RPA assays sensitivities for DENV serotypes were 66.6% (16/24), 44% (4/9), 80.9% (34/42) , and 60% (6/10) for DENV1, 2, 3, and 4, respectively.", [["DENV", "ORGANISM", 32, 36], ["RPA", "PROTEIN", 3, 6], ["DENV", "SPECIES", 32, 36], ["RT-RPA assays sensitivities", "TEST", 0, 27], ["DENV serotypes", "TEST", 32, 46], ["DENV1", "TEST", 113, 118]]], ["Five samples were only positive in RT-RPA and therefore the DENV serotype was not determined.", [["samples", "ANATOMY", 5, 12], ["RT-RPA", "GENE_OR_GENE_PRODUCT", 35, 41], ["DENV", "ORGANISM", 60, 64], ["RPA", "PROTEIN", 38, 41], ["DENV", "SPECIES", 60, 64], ["Five samples", "TEST", 0, 12], ["the DENV serotype", "PROBLEM", 56, 73], ["RPA", "ANATOMY", 38, 41], ["DENV", "OBSERVATION", 60, 64]]], ["No correlation was found between threshold time values of RT-RPA and Ct of the real-time RT-PCR (S6 Fig, R 2 = 0.179) .", [["RPA", "PROTEIN", 61, 64], ["RT", "TEST", 58, 60], ["Ct", "TEST", 69, 71], ["Fig", "TEST", 100, 103], ["RPA", "ANATOMY", 61, 64]]], ["Limits of detection in RT-RPA assays were 237, 618, 363, and 383 RNA copies of DENV serotypes 1, 2, 3, and 4, respectively.DiscussionIn their review, Peeling et al., [8] mention characteristics of the future diagnostic test for early detection of DENV.", [["DENV", "DISEASE", 247, 251], ["DENV", "ORGANISM", 247, 251], ["DENV", "SPECIES", 79, 83], ["DENV", "SPECIES", 247, 251], ["RT-RPA assays", "TEST", 23, 36], ["RNA copies", "TEST", 65, 75], ["DENV serotypes", "TEST", 79, 93], ["diagnostic test", "TEST", 208, 223], ["DENV", "PROBLEM", 247, 251], ["RPA", "ANATOMY", 26, 29], ["DENV", "OBSERVATION", 247, 251]]], ["It should be rapid, sensitive, specific, stable at high temperatures (>30\u00b0C), and cheap.", [["rapid", "OBSERVATION_MODIFIER", 13, 18], ["stable", "OBSERVATION_MODIFIER", 41, 47]]], ["Currently point-of-care DENV detection is carried out with RDT assays.", [["DENV", "SPECIES", 24, 28], ["DENV detection", "TEST", 24, 38], ["RDT assays", "TEST", 59, 69]]], ["RDTs are simple and rapid but of limited sensitivity and specificity [7, 13] .", [["RDTs", "TEST", 0, 4], ["specificity", "TEST", 57, 68], ["simple", "OBSERVATION_MODIFIER", 9, 15], ["rapid", "OBSERVATION_MODIFIER", 20, 25]]], ["Real-time RT-PCR is highly sensitive, usually performed in highly equipped laboratories and not suitable for point-of-care testing.", [["time RT-PCR", "TEST", 5, 16], ["care testing", "TEST", 118, 130]]], ["In contrast, RPA technology is as sensitive and specific as real-time RT-PCR, isothermal and easy to use at point-of-need [26, [29] [30] [31] [32] [33] [34] [35] .", [["RPA", "GENE_OR_GENE_PRODUCT", 13, 16], ["[29] [30] [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 127, 161], ["RPA", "PROTEIN", 13, 16], ["RPA technology", "TEST", 13, 27], ["PCR", "TEST", 73, 76], ["isothermal", "TEST", 78, 88]]], ["In addition, RPA is fast (3-5 minutes including the reverse transcription step) and can be performed on a portable device (tubescanner).", [["RPA", "GENE_OR_GENE_PRODUCT", 13, 16], ["RPA", "PROTEIN", 13, 16], ["RPA", "TEST", 13, 16], ["a portable device", "TREATMENT", 104, 121]]], ["In this study, two RT-RPA assays for detection of DENV (DENV1-3 and DENV4) were developed which cover but do not differentially determine DENV1-4, as required for molecular epidemiological studies.", [["DENV", "ORGANISM", 50, 54], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 56, 63], ["DENV4", "ORGANISM", 68, 73], ["DENV1-4", "GENE_OR_GENE_PRODUCT", 138, 145], ["RPA", "PROTEIN", 22, 25], ["DENV1", "PROTEIN", 138, 143], ["DENV", "SPECIES", 50, 54], ["this study", "TEST", 3, 13], ["two RT-RPA assays", "TEST", 15, 32], ["DENV", "PROBLEM", 50, 54], ["DENV1", "TEST", 56, 61], ["molecular epidemiological studies", "TEST", 163, 196], ["DENV", "OBSERVATION", 50, 54]]], ["Distinguishing DENV1-4 at the point-of-care is not clinically relevant.", [["DENV1-4", "GENE_OR_GENE_PRODUCT", 15, 22], ["DENV1-4", "DNA", 15, 22], ["DENV1", "TEST", 15, 20]]], ["The assays were very sensitive with a respective limit of detection of 241 and 14 molecules detected, highly specific, and were evaluated as mobile tests in a low resource setting in Kedougou in Senegal.", [["The assays", "TEST", 0, 10], ["mobile tests", "TEST", 141, 153]]], ["Several isothermal amplification technologies were developed in the last two decades, e.g. RT-LAMP [24] , NASBA [36] , nicking enzyme amplification reaction [37] , rolling circle amplification methods [38] , helicase dependent amplification [39] , and RPA [25] .", [["Several isothermal amplification technologies", "PROBLEM", 0, 45], ["NASBA", "TEST", 106, 111], ["nicking enzyme amplification reaction", "PROBLEM", 119, 156], ["rolling circle amplification methods", "TREATMENT", 164, 200], ["helicase dependent amplification", "TREATMENT", 208, 240]]], ["They differ in the amplification temperature, run time, number of primers used for DNA amplification, detection method (probe-based or intercalating dye dependent) and commercial availability.DiscussionMany RT-LAMP assays have been developed for DENV detection using between 6-24 primers [20] [21] [22] [23] and yielding results in 30 minutes based on visual inspection (turbidity index, fluorescence) [20] [21] [22] [23] .", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["DENV", "SPECIES", 246, 250], ["DNA amplification", "TREATMENT", 83, 100], ["detection method (probe", "TREATMENT", 102, 125], ["intercalating dye dependent", "PROBLEM", 135, 162], ["RT-LAMP assays", "TEST", 207, 221], ["DENV detection", "TEST", 246, 260], ["visual inspection", "TEST", 352, 369], ["turbidity index", "TEST", 371, 386]]], ["While SYBR Green detection of the RT-LAMP reaction could basically also be done with the tubescanner, RPA is much faster (3-15 minutes) and utilizes only three oligonucleotides (two primers, one exo-P).", [["SYBR", "GENE_OR_GENE_PRODUCT", 6, 10], ["RPA", "GENE_OR_GENE_PRODUCT", 102, 105], ["RPA", "PROTEIN", 102, 105], ["P", "DNA", 199, 200], ["LAMP reaction", "PROBLEM", 37, 50], ["RPA", "TEST", 102, 105], ["three oligonucleotides", "TREATMENT", 154, 176]]], ["Recent advances in software development to assist LAMP design may help overcome challenges for highly variant viruses, the tolerance for mismatches in LAMP assays however still needs to be explored [40] .", [["LAMP design", "TREATMENT", 50, 61], ["highly variant viruses", "PROBLEM", 95, 117], ["LAMP assays", "TEST", 151, 162]]], ["The tolerance of RPA oligonucleotide sets and in particular, of the exo-P probe portions to mismatches [26, 33] are advantageous for RPA amplicon design but remain subject to testing.DiscussionPrevious work had shown that for RNA viruses the best sensitivity is achieved with an exo-P, encompassing 15 nt 5' (short section), and 30 nt 3' (long section) of a basic site mimic (Tetrahydrofuran, THF) and a phosphate at the 3' end of the exo-P [25, 26] .", [["Tetrahydrofuran", "CHEMICAL", 376, 391], ["phosphate", "CHEMICAL", 404, 413], ["Tetrahydrofuran", "CHEMICAL", 376, 391], ["THF", "CHEMICAL", 393, 396], ["phosphate", "CHEMICAL", 404, 413], ["RPA", "GENE_OR_GENE_PRODUCT", 17, 20], ["RPA", "GENE_OR_GENE_PRODUCT", 133, 136], ["Tetrahydrofuran", "SIMPLE_CHEMICAL", 376, 391], ["phosphate", "SIMPLE_CHEMICAL", 404, 413], ["RPA", "PROTEIN", 17, 20], ["exo-P probe portions", "DNA", 68, 88], ["exo-P", "DNA", 279, 284], ["15 nt 5'", "DNA", 299, 307], ["30 nt 3'", "DNA", 329, 337], ["3' end", "DNA", 421, 427], ["exo-P [25, 26]", "DNA", 435, 449], ["RPA oligonucleotide sets", "TREATMENT", 17, 41], ["the exo-P probe portions", "TREATMENT", 64, 88], ["RPA amplicon design", "TREATMENT", 133, 152], ["testing", "TEST", 175, 182], ["RNA viruses", "PROBLEM", 226, 237], ["a phosphate", "TREATMENT", 402, 413]]], ["The phosphate blocks any primer type interference of the long section with the RPA reaction after Exonuclease nicking [25] .", [["phosphate", "CHEMICAL", 4, 13], ["phosphate", "CHEMICAL", 4, 13], ["phosphate", "SIMPLE_CHEMICAL", 4, 13], ["RPA", "GENE_OR_GENE_PRODUCT", 79, 82], ["RPA", "PROTEIN", 79, 82], ["Exonuclease", "PROTEIN", 98, 109], ["The phosphate blocks", "TREATMENT", 0, 20], ["the long section", "TREATMENT", 53, 69], ["the RPA reaction", "TREATMENT", 75, 91], ["Exonuclease nicking", "TREATMENT", 98, 117]]], ["In contrast of all tested probes, DENV-RPA-P3 consisting of the standard inverse exo-P structure with a long 32 nt section 5' and a short 16 nt section 3' of the THF site (Table 2 ) yielded the highest sensitivity.", [["THF", "CHEMICAL", 162, 165], ["RPA", "PROTEIN", 39, 42], ["P3", "DNA", 43, 45], ["P structure", "DNA", 85, 96], ["long 32 nt section", "DNA", 104, 122], ["THF site", "DNA", 162, 170], ["all tested probes", "TEST", 15, 32], ["DENV", "PROBLEM", 34, 38], ["RPA", "TEST", 39, 42], ["a long 32 nt section", "TREATMENT", 102, 122], ["a short 16 nt section", "TREATMENT", 130, 151], ["the THF site", "TREATMENT", 158, 170], ["RPA", "ANATOMY", 39, 42]]], ["Here the long section can act as a primer and contribute to, the sensitivity of the assay [25] as observed for other RPA assays [29, 30] .DiscussionOf all reverse primers tested DENV1-3 RP4 and DENV4 RP2 yielded the highest assay sensitivities although overlapping the long exo-P 3' section of DENV-RPA-P3 by 28 nt (S1 and S2 Figs).", [["RPA", "GENE_OR_GENE_PRODUCT", 117, 120], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 178, 185], ["RP4", "GENE_OR_GENE_PRODUCT", 186, 189], ["DENV4 RP2", "GENE_OR_GENE_PRODUCT", 194, 203], ["RPA", "PROTEIN", 117, 120], ["DENV1-3 RP4", "DNA", 178, 189], ["DENV4 RP2", "DNA", 194, 203], ["long exo-P 3' section", "DNA", 269, 290], ["RPA", "DNA", 299, 302], ["P3", "DNA", 303, 305], ["28 nt", "DNA", 309, 314], ["DENV4", "SPECIES", 194, 199], ["the assay", "TEST", 80, 89], ["other RPA assays", "TEST", 111, 127], ["DENV1", "TEST", 178, 183], ["DENV4 RP2", "TEST", 194, 203], ["the highest assay sensitivities", "TEST", 212, 243], ["DENV", "TEST", 294, 298], ["RPA", "TEST", 299, 302], ["RPA", "ANATOMY", 299, 302]]], ["The best forward primer for the DENV4 assay DENV4 FP3 overlapped the short exo-P 3' end by 6 nt (S2 Fig).", [["DENV4", "DNA", 32, 37], ["DENV4 FP3", "DNA", 44, 53], ["short exo-P 3' end", "DNA", 69, 87], ["the DENV4 assay", "TEST", 28, 43], ["FP3", "TEST", 50, 53]]], ["Non-specific amplification was not observed in any of these cases.", [["Non-specific amplification", "PROBLEM", 0, 26]]], ["Therefore, the selection of primer and probe format is still down to trial and error.", [["the selection of primer", "TREATMENT", 11, 34]]], ["The factors that determine efficient strand invasion may be a combination of binding enthalpy and local secondary structure.", [["efficient strand invasion", "PROBLEM", 27, 52], ["binding enthalpy and local secondary structure", "PROBLEM", 77, 123], ["strand invasion", "OBSERVATION", 37, 52], ["binding enthalpy", "OBSERVATION", 77, 93], ["secondary structure", "OBSERVATION", 104, 123]]], ["Although advances in calculating these values for PCR primers have been made, they cannot as yet be deduced for RPA [41] .DiscussionDEN RPA P3 is shared by both assays but carries 4 mismatches (S2 and S7 Figs) in the smaller 13 nt 3' section of the probe.", [["PCR primers", "DNA", 50, 61], ["P3", "DNA", 140, 142], ["13 nt 3' section", "DNA", 225, 241], ["PCR primers", "TREATMENT", 50, 61]]], ["Efficient RPA tolerates mismatches per primer which should not accumulate at the termini or at the center of the primers and in concordance with what is known about PCR primers mismatches at the 3' end of the primers impede the RPA reaction [42] .", [["RPA", "CHEMICAL", 10, 13], ["RPA", "GENE_OR_GENE_PRODUCT", 10, 13], ["3' end", "CELLULAR_COMPONENT", 195, 201], ["RPA", "PROTEIN", 10, 13], ["PCR primers", "DNA", 165, 176], ["3' end", "DNA", 195, 201], ["mismatches per primer", "TREATMENT", 24, 45], ["PCR primers mismatches", "PROBLEM", 165, 187], ["the primers", "TREATMENT", 205, 216], ["the RPA reaction", "PROBLEM", 224, 240]]], ["As a whole RPA amplification systems appear to tolerate the presence of 5-9 mismatches in a primer and probe set [26, 33] .", [["RPA", "GENE_OR_GENE_PRODUCT", 11, 14], ["RPA", "PROTEIN", 11, 14], ["a whole RPA amplification systems", "TREATMENT", 3, 36]]], ["We assume that the long 32 nt 5' section of DEN RPA P3, which matches almost perfectly to DENV1-4, allows for tolerance of the accumulation of the mismatches in the smaller 3' portion of the probe since it does not conflict with the principle of dissociation of the smaller section the exo-P after Exonuclease action.", [["DEN RPA", "GENE_OR_GENE_PRODUCT", 44, 51], ["DENV1-4", "GENE_OR_GENE_PRODUCT", 90, 97], ["Exonuclease", "GENE_OR_GENE_PRODUCT", 298, 309], ["long 32 nt 5' section", "DNA", 19, 40], ["DEN RPA P3", "DNA", 44, 54], ["DENV1-4", "DNA", 90, 97], ["3' portion", "DNA", 173, 183], ["P", "DNA", 290, 291], ["Exonuclease", "PROTEIN", 298, 309], ["the long 32 nt 5' section of DEN RPA P3", "TREATMENT", 15, 54], ["Exonuclease action", "TREATMENT", 298, 316], ["mismatches", "OBSERVATION", 147, 157], ["smaller", "OBSERVATION_MODIFIER", 165, 172], ["dissociation", "OBSERVATION", 246, 258], ["smaller", "OBSERVATION_MODIFIER", 266, 273]]], ["Shifting the mismatches into the smaller section of the probes may thus be exploited for the design of exo-P for the detection of other highly variable RNA target sequences.", [["P", "DNA", 107, 108], ["RNA target sequences", "DNA", 152, 172], ["Shifting the mismatches", "PROBLEM", 0, 23], ["the detection", "TEST", 113, 126], ["mismatches", "OBSERVATION", 13, 23], ["smaller", "OBSERVATION_MODIFIER", 33, 40]]], ["In contrast, real-time PCR, which utilized shorter primers and probes, is more sensitive to the presence of mismatches in the target sequence [43] .", [["real-time PCR", "TEST", 13, 26], ["shorter primers", "TEST", 43, 58], ["mismatches", "OBSERVATION", 108, 118]]], ["The linearity of the assay also does not represent a correlation of linearity and sensitivity as seen in real-time PCR assays [29] .DiscussionReal-time RT-PCR can be used for both qualitative and quantitative analysis of RNA in a sample.", [["the assay", "TEST", 17, 26], ["sensitivity", "TEST", 82, 93], ["real-time PCR assays", "TEST", 105, 125], ["PCR", "TEST", 155, 158], ["quantitative analysis", "TEST", 196, 217], ["linearity", "OBSERVATION_MODIFIER", 4, 13], ["does not represent", "UNCERTAINTY", 32, 50]]], ["In contrast, RT-RPA can currently only be used for qualitative detection of RNA.", [["RT-RPA", "GENE_OR_GENE_PRODUCT", 13, 19], ["RPA", "PROTEIN", 16, 19], ["RNA", "RNA", 76, 79], ["RT-RPA", "TREATMENT", 13, 19], ["qualitative detection", "TEST", 51, 72], ["RNA", "PROBLEM", 76, 79], ["RPA", "ANATOMY", 16, 19]]], ["As shown in Fig 6, the TT values of the RT-RPA can be classified into two groups, before 3 and after 5 minutes.", [["RT-RPA", "GENE_OR_GENE_PRODUCT", 40, 46], ["RPA", "PROTEIN", 43, 46], ["the TT values", "TEST", 19, 32], ["RPA", "ANATOMY", 43, 46]]], ["The main reason is the interruption of the fluorescence read by the mixing step after three minutes, which is crucial for the assay sensitivity.", [["the fluorescence", "TEST", 39, 55], ["the assay sensitivity", "TEST", 122, 143], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["During mixing, fluoresces signal are not measured (Figs 3 and 6) , therefore, TT values can`t be calculated.", [["fluoresces signal", "TEST", 15, 32], ["Figs", "TEST", 51, 55], ["TT values can`t", "TEST", 78, 93]]], ["This however does not lead to false negatives.DiscussionThe characteristics of the mobile laboratory (23kg including the aluminium case) are 1) easy transportation by car and airplane, 2) power source from motor vehicle batteries or solar panel with power pack, 3) easy implementation in low resource settings.", [["aluminium", "CHEMICAL", 121, 130], ["aluminium", "CHEMICAL", 121, 130], ["false negatives", "TEST", 30, 45], ["the aluminium case", "TREATMENT", 117, 135], ["motor vehicle batteries", "TREATMENT", 206, 229], ["solar panel", "TEST", 233, 244], ["power pack", "TREATMENT", 250, 260]]], ["A magnetic bead extraction was applied to avoid the creation of aerosols and because trials at the Institute Pasteur in Paris in a climate chamber have shown that most commercial centrifuges short-circuited at 80% humidity and temperatures above 38\u00b0C (Jean-Claude Manuguerra, personal communication).", [["A magnetic bead extraction", "TREATMENT", 0, 26], ["aerosols", "TREATMENT", 64, 72], ["temperatures", "TEST", 227, 239]]], ["We were able to run the laboratory in the open air and observed no influence of dust on the assay quality.", [["air", "OBSERVATION", 47, 50]]], ["Further work will attempt to reduce pipetting steps by drying RPA primers and probe into the RPA reagent pellet, implementing a multiplex RT-RPA assay combining the two DENV RPA assays into one reaction and identifying even simpler extraction protocols.DiscussionThe DENV RT-RPA assays were evaluated with plasma samples and RNA extracts in Senegal and Thailand.", [["plasma samples", "ANATOMY", 306, 320], ["extracts", "ANATOMY", 329, 337], ["plasma samples", "ORGANISM_SUBSTANCE", 306, 320], ["extracts", "ORGANISM_SUBSTANCE", 329, 337], ["RPA primers", "DNA", 62, 73], ["RPA", "PROTEIN", 174, 177], ["RPA", "PROTEIN", 275, 278], ["DENV", "SPECIES", 169, 173], ["DENV", "SPECIES", 267, 271], ["pipetting steps", "TREATMENT", 36, 51], ["drying RPA primers", "TREATMENT", 55, 73], ["a multiplex RT-RPA assay", "TREATMENT", 126, 150], ["the two DENV RPA assays", "TEST", 161, 184], ["simpler extraction protocols", "TREATMENT", 224, 252], ["The DENV RT-RPA assays", "TEST", 263, 285], ["plasma samples", "TEST", 306, 320], ["RNA extracts", "TEST", 325, 337]]], ["The RT-RPA clinical sensitivities were 98% for samples tested in Senegal and 72% for RNA extracts in Thailand, whereas real-time RT-PCR sensitivity was 98% and 94.4%, respectively.", [["samples", "ANATOMY", 47, 54], ["extracts", "ANATOMY", 89, 97], ["extracts", "ORGANISM_SUBSTANCE", 89, 97], ["The RT-RPA clinical sensitivities", "TEST", 0, 33], ["samples", "TEST", 47, 54], ["Senegal", "TEST", 65, 72], ["RNA extracts", "TEST", 85, 97], ["PCR sensitivity", "TEST", 132, 147], ["RPA", "ANATOMY", 7, 10]]], ["The lower clinical sensitivity of the RT-RPA assays on the RNA extracts in Thailand might not be due to the assay detection limit, which is between 10-100 RNA copies (Figs 3, 4 and 5).", [["extracts", "ANATOMY", 63, 71], ["RPA", "PROTEIN", 41, 44], ["the RT-RPA assays", "TEST", 34, 51], ["the assay detection limit", "TEST", 104, 129], ["Figs", "TEST", 167, 171], ["lower", "OBSERVATION_MODIFIER", 4, 9]]], ["As shown in S3 Table, most of the samples, which were negative in RT-RPA had Ct values between 14-30 in real-time RT-PCR.", [["samples", "ANATOMY", 34, 41], ["samples", "CANCER", 34, 41], ["RT-RPA", "GENE_OR_GENE_PRODUCT", 66, 72], ["the samples", "TEST", 30, 41], ["Ct values", "TEST", 77, 86], ["RPA", "ANATOMY", 69, 72]]], ["Genetic variations between Asian and African DENV strain could not be the reason for the difference in the assay sensitivity [44] [45] [46] [47] .", [["DENV", "ORGANISM", 45, 49], ["African DENV", "SPECIES", 37, 49], ["Genetic variations", "PROBLEM", 0, 18], ["African DENV strain", "PROBLEM", 37, 56], ["the assay sensitivity", "TEST", 103, 124]]], ["As mentioned above, the RPA targeted the conserved 3' NTR of the DENV genome and RPA amplification can tolerate 5-9 mismatches.", [["RPA", "GENE_OR_GENE_PRODUCT", 24, 27], ["3' NTR", "GENE_OR_GENE_PRODUCT", 51, 57], ["DENV", "ORGANISM", 65, 69], ["RPA", "GENE_OR_GENE_PRODUCT", 81, 84], ["RPA", "PROTEIN", 24, 27], ["conserved 3' NTR", "DNA", 41, 57], ["DENV genome", "DNA", 65, 76], ["RPA", "DNA", 81, 84], ["DENV", "SPECIES", 65, 69], ["the DENV genome", "TREATMENT", 61, 76], ["RPA amplification", "TREATMENT", 81, 98], ["DENV genome", "OBSERVATION", 65, 76]]], ["In Senegal, RNA was extracted from plasma samples and screened directly with the RT-RPA assays, while in Thailand, RNA stored at -80\u00b0C for 6-18 months was tested.", [["plasma samples", "ANATOMY", 35, 49], ["plasma samples", "ORGANISM_SUBSTANCE", 35, 49], ["plasma samples", "TEST", 35, 49], ["the RT-RPA assays", "TEST", 77, 94], ["RNA", "TEST", 115, 118]]], ["The integrity of the RNA is affected by freezing and thawing, albeit, freezing of clinical samples has a less pronounced effect [48, 49] .", [["samples", "ANATOMY", 91, 98], ["clinical samples", "TEST", 82, 98], ["integrity", "OBSERVATION_MODIFIER", 4, 13], ["RNA", "ANATOMY", 21, 24], ["affected", "OBSERVATION_MODIFIER", 28, 36], ["freezing", "OBSERVATION_MODIFIER", 40, 48], ["less pronounced", "OBSERVATION_MODIFIER", 105, 120]]], ["It appears that in contrast to real-time RT-PCR [50] , RT-RPA performance is influenced by the quality of the RNA confirming an observation we described earlier [26] .DiscussionIn conclusion, two DENV RT-RPA assays were developed for rapid identification of DENV1-4.", [["DENV1-4", "GENE_OR_GENE_PRODUCT", 258, 265], ["RPA", "PROTEIN", 58, 61], ["RPA", "PROTEIN", 204, 207], ["DENV1-4", "DNA", 258, 265], ["DENV", "SPECIES", 196, 200], ["PCR", "TEST", 44, 47], ["RT-RPA performance", "TEST", 55, 73], ["an observation", "TEST", 125, 139], ["DENV RT-RPA assays", "TEST", 196, 214], ["DENV1", "TEST", 258, 263]]], ["RPA was easy to implement in low resource settings and high ambient temperatures did not affect its performance.DiscussionSupporting Information S1 Fig. DENV1 -3 RT-RPA primers and probes sequence aligned with the DENV1-3 amplicon.", [["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["DENV1 -3", "GENE_OR_GENE_PRODUCT", 153, 161], ["DENV1-3", "GENE_OR_GENE_PRODUCT", 214, 221], ["RPA", "PROTEIN", 0, 3], ["DENV1 -3 RT-RPA primers", "DNA", 153, 176], ["DENV1-3 amplicon", "DNA", 214, 230], ["high ambient temperatures", "PROBLEM", 55, 80], ["DENV1", "TEST", 153, 158], ["RT-RPA primers", "TREATMENT", 162, 176], ["probes sequence", "TEST", 181, 196], ["the DENV1-3 amplicon", "TREATMENT", 210, 230]]], ["Three RPA exo probes (P), 19 forward primers (FP), and 5 reverse primers (RP) were tested to select combinations yielding the highest analytical DENV1-3 RT-RPA sensitivity.", [["RPA exo probes", "DNA", 6, 20], ["P", "DNA", 22, 23], ["19 forward primers", "DNA", 26, 44], ["reverse primers", "DNA", 57, 72], ["RPA", "PROTEIN", 156, 159], ["Three RPA exo probes", "TEST", 0, 20], ["forward primers", "TEST", 29, 44], ["FP", "TEST", 46, 48], ["5 reverse primers", "PROBLEM", 55, 72]]], ["FP13, RP4, and P3 produced the best RT-RPA assay sensitivity.", [["FP13", "GENE_OR_GENE_PRODUCT", 0, 4], ["RP4", "GENE_OR_GENE_PRODUCT", 6, 9], ["FP13", "DNA", 0, 4], ["RP4", "DNA", 6, 9], ["P3", "DNA", 15, 17], ["RPA", "PROTEIN", 39, 42], ["FP13", "TEST", 0, 4], ["RP4", "TEST", 6, 9]]], ["NNN are sites of the quencher and fluorophore in following order (BHQ1-dT) (Tetrahydrofuran) (FAM-dT).", [["NNN", "CHEMICAL", 0, 3], ["BHQ1-dT", "CHEMICAL", 66, 73], ["Tetrahydrofuran", "CHEMICAL", 76, 91], ["FAM-dT", "CHEMICAL", 94, 100], ["NNN", "CHEMICAL", 0, 3], ["Tetrahydrofuran", "CHEMICAL", 76, 91], ["FAM-dT", "CHEMICAL", 94, 100], ["NNN", "SIMPLE_CHEMICAL", 0, 3], ["BHQ1-dT", "SIMPLE_CHEMICAL", 66, 73], ["Tetrahydrofuran", "SIMPLE_CHEMICAL", 76, 91], ["FAM-dT", "SIMPLE_CHEMICAL", 94, 100], ["the quencher and fluorophore", "TREATMENT", 17, 45]]], ["(DOCX) S2 Fig. DENV4 RT-RPA primers and probes sequences aligned with the DENV4 amplicon.", [["DENV4", "GENE_OR_GENE_PRODUCT", 15, 20], ["DENV4 RT-RPA primers", "DNA", 15, 35], ["DENV4 amplicon", "DNA", 74, 88], ["RT-RPA primers", "TREATMENT", 21, 35], ["probes sequences", "TEST", 40, 56], ["the DENV4 amplicon", "TREATMENT", 70, 88], ["S2 Fig", "OBSERVATION", 7, 13], ["RPA", "ANATOMY_MODIFIER", 24, 27]]], ["Two RPA exo probes (P), 3 forward primers (FP), and 2 reverse primers (RP) were tested to select combinations yielding the highest analytical DENV4 RT-RPA sensitivity.", [["RPA exo probes", "DNA", 4, 18], ["P", "DNA", 20, 21], ["reverse primers", "DNA", 54, 69], ["RPA", "PROTEIN", 151, 154], ["Two RPA exo probes", "TEST", 0, 18], ["FP", "TEST", 43, 45], ["2 reverse primers", "PROBLEM", 52, 69]]], ["FP3, RP2, and P3 produced the best RT-RPA assay sensitivity.", [["FP3", "GENE_OR_GENE_PRODUCT", 0, 3], ["RP2", "GENE_OR_GENE_PRODUCT", 5, 8], ["FP3", "DNA", 0, 3], ["RP2", "DNA", 5, 8], ["P3", "DNA", 14, 16], ["RPA", "PROTEIN", 38, 41], ["FP3", "TEST", 0, 3], ["RP2", "TEST", 5, 8]]], ["NNN are sites of the quencher and fluorophore in following order (BHQ1-dT) (Tetrahydrofuran) (FAM-dT).", [["NNN", "CHEMICAL", 0, 3], ["BHQ1-dT", "CHEMICAL", 66, 73], ["Tetrahydrofuran", "CHEMICAL", 76, 91], ["FAM-dT", "CHEMICAL", 94, 100], ["NNN", "CHEMICAL", 0, 3], ["Tetrahydrofuran", "CHEMICAL", 76, 91], ["FAM-dT", "CHEMICAL", 94, 100], ["NNN", "SIMPLE_CHEMICAL", 0, 3], ["BHQ1-dT", "SIMPLE_CHEMICAL", 66, 73], ["Tetrahydrofuran", "SIMPLE_CHEMICAL", 76, 91], ["FAM-dT", "SIMPLE_CHEMICAL", 94, 100], ["the quencher and fluorophore", "TREATMENT", 17, 45]]], ["(DOCX) S3 Fig. DENV1-3 RT-RPA assay with non-specific amplification.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 15, 22], ["DENV1", "PROTEIN", 15, 20], ["RPA", "PROTEIN", 26, 29], ["DENV1", "TEST", 15, 20], ["non-specific amplification", "TREATMENT", 41, 67], ["S3 Fig", "OBSERVATION", 7, 13]]], ["Fluorescence development via real-time detection by using a dilution range of 10 7 -10 1 RNA molecules/\u03bcl of the DENV1-3 molecular standard.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 113, 120], ["DENV1", "PROTEIN", 113, 118], ["a dilution range", "TEST", 58, 74], ["the DENV1", "TEST", 109, 118]]], ["10 7 represented by black line; 10 6 , gray; 10 5 , red; 10 4 , blue; 10 3 , green; 10 2 , cyan; 10 1 , dark khaki; negative control, orange.", [["black line", "TEST", 20, 30], ["gray", "TEST", 39, 43], ["blue", "TEST", 64, 68], ["green", "TEST", 77, 82], ["cyan", "TEST", 91, 95], ["dark khaki", "TEST", 104, 114], ["black line", "OBSERVATION", 20, 30]]], ["(DOCX) S4 Fig. DENV1-3 RT-RPA assay with 10 4 analytical sensitivity.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 15, 22], ["DENV1", "PROTEIN", 15, 20], ["RPA", "PROTEIN", 26, 29], ["DENV1", "TEST", 15, 20], ["RT-RPA assay", "TEST", 23, 35]]], ["Fluorescence development via real-time detection by using a dilution range of 10 7 -10 1 RNA molecules/\u03bcl of the DENV1-3 molecular standard.", [["DENV1-3", "GENE_OR_GENE_PRODUCT", 113, 120], ["DENV1", "PROTEIN", 113, 118], ["a dilution range", "TEST", 58, 74], ["the DENV1", "TEST", 109, 118]]], ["10 7 represented by black line; 10 6 , gray; 10 5 , red; 10 4 , blue; 10 3 , green; 10 2 , cyan; 10 1 , dark khaki; negative control, orange.", [["black line", "TEST", 20, 30], ["gray", "TEST", 39, 43], ["blue", "TEST", 64, 68], ["green", "TEST", 77, 82], ["cyan", "TEST", 91, 95], ["dark khaki", "TEST", 104, 114], ["black line", "OBSERVATION", 20, 30]]]], "c4fea55f763ab9d90cc735c3fb4e8acd952dc258": [["INTRODUCTIONOn March 11 th , 2020, the World Health Organization declared the outbreak caused by the novel coronavirus (SARS-CoV-2), the coronavirus disease 2019 (covid- 19) , as pandemic.", [["SARS", "DISEASE", 120, 124], ["coronavirus disease", "DISEASE", 137, 156], ["coronavirus", "ORGANISM", 107, 118], ["SARS-CoV-2", "ORGANISM", 120, 130], ["coronavirus", "ORGANISM", 137, 148], ["coronavirus", "SPECIES", 107, 118], ["coronavirus", "SPECIES", 137, 148], ["SARS-CoV-2", "SPECIES", 120, 130], ["the novel coronavirus", "PROBLEM", 97, 118], ["SARS-CoV", "TEST", 120, 128], ["the coronavirus disease", "PROBLEM", 133, 156], ["covid", "TEST", 163, 168], ["pandemic", "PROBLEM", 179, 187], ["coronavirus", "ANATOMY", 137, 148]]], ["The disease is responsible for more than 180 thousand deaths worldwide, with approximately 4,000 occurring in Brazil until the end of April 2020 (https://coronavirus.saude.gov.br/).", [["deaths", "DISEASE", 54, 60], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Fatality rates have varied among countries depending on factors that influence both numbers of confirmed cases and registered deaths, as well as the proportion of at-risk individuals in the population (older adults, people with chronic diseases), access to health services, availability of accurate diagnostic tests and resources to deal with severe and critical cases (ICU, mechanical ventilators, trained health care professionals).INTRODUCTIONA huge number of studies has helped clarify clinical profiles of SARS-CoV-2 infection, showing consistently that the presence of chronic morbidities such as diabetes mellitus (DM) and its associated diseases (obesity, hypertension, and cardiovascular disease) represent major risk factors for the severity and prognosis of the disease, in addition to advanced age.", [["cardiovascular", "ANATOMY", 682, 696], ["deaths", "DISEASE", 126, 132], ["chronic diseases", "DISEASE", 228, 244], ["SARS-CoV-2 infection", "DISEASE", 511, 531], ["chronic morbidities", "DISEASE", 575, 594], ["diabetes mellitus", "DISEASE", 603, 620], ["DM", "DISEASE", 622, 624], ["obesity", "DISEASE", 655, 662], ["hypertension", "DISEASE", 664, 676], ["cardiovascular disease", "DISEASE", 682, 704], ["SARS-CoV-2", "ORGANISM", 511, 521], ["cardiovascular", "ANATOMICAL_SYSTEM", 682, 696], ["people", "SPECIES", 216, 222], ["SARS-CoV-2", "SPECIES", 511, 521], ["Fatality rates", "PROBLEM", 0, 14], ["chronic diseases", "PROBLEM", 228, 244], ["accurate diagnostic tests", "TEST", 290, 315], ["mechanical ventilators", "TREATMENT", 375, 397], ["studies", "TEST", 463, 470], ["SARS", "PROBLEM", 511, 515], ["CoV-2 infection", "PROBLEM", 516, 531], ["chronic morbidities", "PROBLEM", 575, 594], ["diabetes mellitus", "PROBLEM", 603, 620], ["DM", "PROBLEM", 622, 624], ["its associated diseases", "PROBLEM", 630, 653], ["obesity", "PROBLEM", 655, 662], ["hypertension", "PROBLEM", 664, 676], ["cardiovascular disease)", "PROBLEM", 682, 705], ["the severity", "PROBLEM", 739, 751], ["the disease", "PROBLEM", 769, 780], ["infection", "OBSERVATION", 522, 531], ["chronic", "OBSERVATION_MODIFIER", 575, 582], ["morbidities", "OBSERVATION", 583, 594], ["obesity", "OBSERVATION", 655, 662], ["hypertension", "OBSERVATION", 664, 676], ["cardiovascular disease", "OBSERVATION", 682, 704], ["disease", "OBSERVATION", 773, 780]]], ["Accumulated evidence has caused a great concern in countries with high prevalence of these morbidities such as Brazil.INTRODUCTIONThis text shows the picture of diabetes in Brazil, followed by epidemiological data and explanatory hypothesis for the association between diabetes and covid-19.", [["diabetes", "DISEASE", 161, 169], ["diabetes", "DISEASE", 269, 277], ["these morbidities", "PROBLEM", 85, 102], ["diabetes", "PROBLEM", 161, 169], ["explanatory hypothesis", "PROBLEM", 218, 240], ["diabetes", "PROBLEM", 269, 277], ["covid", "TEST", 282, 287], ["great", "OBSERVATION_MODIFIER", 34, 39], ["diabetes", "OBSERVATION", 161, 169]]], ["We also emphasize how the burden of these two morbidities in a middle-income country may aggravate this pandemic scenario.The Actual Burden of Diabetes in BrazilBrazil is a typical example of the alarming picture of DM in emergent societies for this century, being the fourth country with the largest number of diabetic people.", [["Diabetes", "DISEASE", 143, 151], ["DM", "DISEASE", 216, 218], ["diabetic", "DISEASE", 311, 319], ["people", "ORGANISM", 320, 326], ["people", "SPECIES", 320, 326], ["Diabetes", "PROBLEM", 143, 151], ["DM", "PROBLEM", 216, 218], ["Burden", "OBSERVATION_MODIFIER", 133, 139], ["Diabetes", "OBSERVATION", 143, 151], ["largest", "OBSERVATION_MODIFIER", 293, 300]]], ["In 2019, it was estimated that 16.8 million individuals, aged between 20 and 79 years had DM in Brazil, with projection of 55% increase until 2045 1 .The Actual Burden of Diabetes in BrazilIn the 1980s, a multicenter prevalence study, including 21,847 Brazilians aged between 30 and 69 years submitted to oral glucose tolerance test, found that 7.6% had DM 2 .", [["oral", "ANATOMY", 305, 309], ["DM", "DISEASE", 90, 92], ["Diabetes", "DISEASE", 171, 179], ["glucose", "CHEMICAL", 310, 317], ["DM", "DISEASE", 354, 356], ["glucose", "CHEMICAL", 310, 317], ["oral", "ORGANISM_SUBDIVISION", 305, 309], ["glucose", "SIMPLE_CHEMICAL", 310, 317], ["DM", "PROBLEM", 90, 92], ["Diabetes", "PROBLEM", 171, 179], ["a multicenter prevalence study", "TEST", 203, 233], ["oral glucose tolerance test", "TEST", 305, 332], ["DM", "PROBLEM", 354, 356], ["Diabetes", "OBSERVATION", 171, 179]]], ["Most individuals had type 2 DM as occurs worldwide.", [["type 2 DM", "DISEASE", 21, 30], ["type 2 DM", "PROBLEM", 21, 30]]], ["We also found that almost half of individuals with DM were unaware of their condition.", [["DM", "DISEASE", 51, 53], ["DM", "PROBLEM", 51, 53]]], ["Even more impressive was the rate of undiagnosed DM registered in 2014 in the Estudo Longitudinal de Sa\u00fade do Adulto (ELSA-Brasil-Brazilian Longitudinal Study of Adult Health) that found the same proportion in 15,000 participants of a non-representative sample 3 .The Actual Burden of Diabetes in BrazilA nationwide system of surveillance of risk and protective factors for chronic diseases by telephone survey (VIGITEL) in Brazil has yearly provided epidemiological data about non-communicable chronic diseases (NCCD) in individuals older than 18 years.", [["DM", "DISEASE", 49, 51], ["Diabetes", "DISEASE", 285, 293], ["chronic diseases", "DISEASE", 374, 390], ["non-communicable chronic diseases", "DISEASE", 478, 511], ["NCCD", "DISEASE", 513, 517], ["participants", "SPECIES", 217, 229], ["undiagnosed DM", "PROBLEM", 37, 51], ["a non-representative sample", "PROBLEM", 233, 260], ["Diabetes", "PROBLEM", 285, 293], ["chronic diseases", "PROBLEM", 374, 390], ["non-communicable chronic diseases", "PROBLEM", 478, 511], ["impressive", "OBSERVATION_MODIFIER", 10, 20], ["Diabetes", "OBSERVATION", 285, 293]]], ["A rate of 5.5% of self-reported DM was described in 2016 and two years later it reached 8.0% 4 .", [["DM", "DISEASE", 32, 34], ["A rate", "TEST", 0, 6], ["DM", "PROBLEM", 32, 34]]], ["Since previous studies have shown that half of diabetic Brazilians were undiagnosed, those frequencies were certainly underestimated.", [["diabetic", "DISEASE", 47, 55], ["Brazilians", "ORGANISM", 56, 66], ["previous studies", "TEST", 6, 22]]], ["As expected, rates vary according to age group, but also according to schooling, being 23.1% for individuals older than 65 years and 15.2% for those with less than 8 years of total schooling 4 .The Actual Burden of Diabetes in BrazilAnother aspect of DM in Brazil refers to its metabolic control.", [["Diabetes", "DISEASE", 215, 223], ["DM", "DISEASE", 251, 253], ["total schooling 4", "PROBLEM", 175, 192], ["Diabetes", "PROBLEM", 215, 223], ["DM", "PROBLEM", 251, 253], ["Diabetes", "OBSERVATION", 215, 223], ["DM", "OBSERVATION", 251, 253]]], ["A nationwide crosssectional study, evaluating 5,750 patients with type 2 DM attending the public health care system between 2006 and 2011 5 , reported a mean glycated hemoglobin (HbA1c) of 8.6% (SD 2.2).", [["type 2 DM", "DISEASE", 66, 75], ["patients", "ORGANISM", 52, 60], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 167, 177], ["glycated hemoglobin", "PROTEIN", 158, 177], ["patients", "SPECIES", 52, 60], ["A nationwide crosssectional study", "TEST", 0, 33], ["type 2 DM", "PROBLEM", 66, 75], ["a mean glycated hemoglobin", "TEST", 151, 177], ["HbA1c", "TEST", 179, 184], ["SD", "TEST", 195, 197]]], ["Targets (HbA1c <7%) recommended by scientific societies, such as the Brazilian Society of Diabetes, are achieved by a minority of patients even when a less strict target is considered.", [["Diabetes", "DISEASE", 90, 98], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["Targets", "TEST", 0, 7], ["HbA1c", "TEST", 9, 14], ["Diabetes", "PROBLEM", 90, 98], ["Diabetes", "OBSERVATION", 90, 98]]], ["Only 48.5% of Brazilian patients sustain HbA1c < 8% which is poorer glycemic control than the observed in Europe and the USA.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["HbA1c", "TEST", 41, 46]]], ["A multicenter study conducted in private health care system of Latin American countries showed that, among 878 Brazilian patients, approximately 40% had HbA1c levels higher than 7% 6 .The Actual Burden of Diabetes in BrazilAs in other countries, in Brazil, NCCD are responsible for practically two thirds of the causes of death, being 5.2% due to DM 7 .", [["Diabetes", "DISEASE", 205, 213], ["NCCD", "DISEASE", 257, 261], ["death", "DISEASE", 322, 327], ["DM", "DISEASE", 347, 349], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["A multicenter study", "TEST", 0, 19], ["HbA1c levels", "TEST", 153, 165], ["Diabetes", "PROBLEM", 205, 213], ["death", "PROBLEM", 322, 327], ["DM", "PROBLEM", 347, 349], ["Diabetes", "OBSERVATION", 205, 213]]], ["Furthermore, DM represents an important risk factor for cardiovascular disease (CVD), which accounts for 31.3% of deaths in Brazil 8 .The Actual Burden of Diabetes in BrazilThis scenario of high DM prevalence (mainly in older adults and low socioeconomic stratus) associated with late diagnosis and poor glycemic control has a deleterious effect on the occurrence of long-term complications of the disease -macroangiopathy, retinopathy, nephropathy and neuropathy.", [["cardiovascular", "ANATOMY", 56, 70], ["DM", "DISEASE", 13, 15], ["cardiovascular disease", "DISEASE", 56, 78], ["CVD", "DISEASE", 80, 83], ["deaths", "DISEASE", 114, 120], ["Diabetes", "DISEASE", 155, 163], ["DM", "DISEASE", 195, 197], ["macroangiopathy", "DISEASE", 407, 422], ["retinopathy", "DISEASE", 424, 435], ["nephropathy", "DISEASE", 437, 448], ["neuropathy", "DISEASE", 453, 463], ["cardiovascular", "ANATOMICAL_SYSTEM", 56, 70], ["DM", "PROBLEM", 13, 15], ["cardiovascular disease", "PROBLEM", 56, 78], ["CVD", "PROBLEM", 80, 83], ["Diabetes", "PROBLEM", 155, 163], ["high DM prevalence", "PROBLEM", 190, 208], ["poor glycemic control", "PROBLEM", 299, 320], ["long-term complications", "PROBLEM", 367, 390], ["the disease", "PROBLEM", 394, 405], ["macroangiopathy", "PROBLEM", 407, 422], ["retinopathy", "PROBLEM", 424, 435], ["nephropathy", "PROBLEM", 437, 448], ["neuropathy", "PROBLEM", 453, 463], ["Diabetes", "OBSERVATION", 155, 163], ["high DM", "OBSERVATION_MODIFIER", 190, 197], ["long-term", "OBSERVATION_MODIFIER", 367, 376], ["disease", "OBSERVATION", 398, 405], ["macroangiopathy", "OBSERVATION", 407, 422], ["retinopathy", "OBSERVATION", 424, 435], ["nephropathy", "OBSERVATION", 437, 448], ["neuropathy", "OBSERVATION", 453, 463]]], ["Considering the covid-19 pandemic, global concerns on public health systems visibly increased, worsening the prognosis of diabetic individuals affected by the SARS-Cov-2 infection.Diabetes and Covid-19: Epidemiological EvidenceSince the first reports of covid-19 in Wuhan, China, high frequencies of diabetic individuals among hospitalized patients and those with fatal outcome have shown the importance of DM as a risk factor.", [["diabetic", "DISEASE", 122, 130], ["SARS", "DISEASE", 159, 163], ["infection", "DISEASE", 170, 179], ["Diabetes", "DISEASE", 180, 188], ["diabetic", "DISEASE", 300, 308], ["DM", "DISEASE", 407, 409], ["Cov-2", "GENE_OR_GENE_PRODUCT", 164, 169], ["patients", "ORGANISM", 340, 348], ["patients", "SPECIES", 340, 348], ["global concerns on public health systems", "PROBLEM", 35, 75], ["diabetic individuals", "PROBLEM", 122, 142], ["the SARS", "PROBLEM", 155, 163], ["Cov-2 infection", "PROBLEM", 164, 179], ["Diabetes", "PROBLEM", 180, 188], ["Covid", "TEST", 193, 198], ["covid", "TEST", 254, 259], ["DM", "PROBLEM", 407, 409], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["worsening", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 170, 179]]], ["Currently, type 2 DM is followed by other risky conditions such as advanced age, obesity, hypertension and CVD.Diabetes and Covid-19: Epidemiological EvidenceA Chinese study of 1,099 individuals with covid-19 showed that among 173 with severe disease 23.7% had hypertension, 16.2% DM, 5.8% coronary heart disease, and 2.3% cerebrovascular disease 9 .", [["coronary", "ANATOMY", 290, 298], ["heart", "ANATOMY", 299, 304], ["cerebrovascular", "ANATOMY", 323, 338], ["DM", "DISEASE", 18, 20], ["obesity", "DISEASE", 81, 88], ["hypertension", "DISEASE", 90, 102], ["CVD", "DISEASE", 107, 110], ["Diabetes", "DISEASE", 111, 119], ["hypertension", "DISEASE", 261, 273], ["DM", "DISEASE", 281, 283], ["coronary heart disease", "DISEASE", 290, 312], ["cerebrovascular disease", "DISEASE", 323, 346], ["heart", "ORGAN", 299, 304], ["type 2 DM", "PROBLEM", 11, 20], ["obesity", "PROBLEM", 81, 88], ["hypertension", "PROBLEM", 90, 102], ["CVD", "PROBLEM", 107, 110], ["Diabetes", "PROBLEM", 111, 119], ["Covid", "TEST", 124, 129], ["Epidemiological EvidenceA Chinese study", "TEST", 134, 173], ["covid", "TEST", 200, 205], ["severe disease", "PROBLEM", 236, 250], ["hypertension", "PROBLEM", 261, 273], ["DM", "PROBLEM", 281, 283], ["5.8% coronary heart disease", "PROBLEM", 285, 312], ["2.3% cerebrovascular disease", "PROBLEM", 318, 346], ["DM", "OBSERVATION", 18, 20], ["obesity", "OBSERVATION", 81, 88], ["hypertension", "OBSERVATION", 90, 102], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["disease", "OBSERVATION", 243, 250], ["hypertension", "OBSERVATION", 261, 273], ["coronary heart", "ANATOMY", 290, 304], ["disease", "OBSERVATION", 305, 312], ["cerebrovascular disease", "OBSERVATION", 323, 346]]], ["Another study with 140 patients admitted to the hospital reported similar rates, 30% of hypertension and 12% of DM 10 .Diabetes and Covid-19: Epidemiological EvidenceThe most robust one conducted in China assessed a total of 44,672 cases of covid-19 11 .", [["hypertension", "DISEASE", 88, 100], ["DM", "DISEASE", 112, 114], ["Diabetes", "DISEASE", 119, 127], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["Another study", "TEST", 0, 13], ["hypertension", "PROBLEM", 88, 100], ["DM", "PROBLEM", 112, 114], ["Diabetes", "PROBLEM", 119, 127], ["Covid", "TEST", 132, 137], ["covid", "TEST", 241, 246], ["hypertension", "OBSERVATION", 88, 100]]], ["The fatality rate was 2.3%, which differs according to age and severity of manifestations.", [["The fatality rate", "TEST", 0, 17], ["manifestations", "PROBLEM", 75, 89]]], ["Death occurred in 14.8% of patients older than 80 years (208 out of 1,408), 8.0% between 70 and 79 years (312 out of 3,918) and in 49.0% of severe cases (1,023 of 2,087).", [["Death", "DISEASE", 0, 5], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Death", "PROBLEM", 0, 5], ["severe cases", "PROBLEM", 140, 152], ["severe", "OBSERVATION_MODIFIER", 140, 146]]], ["Among those who died and had chronic diseases, 10.5% had CVD, 7.3% DM, 6.3% chronic respiratory disease, 6.0% hypertension, and 5.6% cancer.", [["respiratory", "ANATOMY", 84, 95], ["cancer", "ANATOMY", 133, 139], ["chronic diseases", "DISEASE", 29, 45], ["CVD", "DISEASE", 57, 60], ["DM", "DISEASE", 67, 69], ["chronic respiratory disease", "DISEASE", 76, 103], ["hypertension", "DISEASE", 110, 122], ["cancer", "DISEASE", 133, 139], ["cancer", "CANCER", 133, 139], ["chronic diseases", "PROBLEM", 29, 45], ["CVD", "PROBLEM", 57, 60], ["7.3% DM", "PROBLEM", 62, 69], ["6.3% chronic respiratory disease", "PROBLEM", 71, 103], ["6.0% hypertension", "PROBLEM", 105, 122], ["5.6% cancer", "PROBLEM", 128, 139], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["diseases", "OBSERVATION", 37, 45], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["respiratory disease", "OBSERVATION", 84, 103], ["hypertension", "OBSERVATION", 110, 122], ["5.6%", "OBSERVATION_MODIFIER", 128, 132], ["cancer", "OBSERVATION", 133, 139]]], ["An analysis of 52 critical ill patients reinforced the role of age, male sex (67%) and previous chronic disease (40%) as risk factors 12 .", [["chronic disease", "DISEASE", 96, 111], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["An analysis", "TEST", 0, 11], ["previous chronic disease", "PROBLEM", 87, 111], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["disease", "OBSERVATION", 104, 111]]], ["Authors reported that non-survivors at 28 days (n = 32) neither presented difference in relation to the time from the onset of symptomatology, type of symptoms nor radiological changes until hospitalization.", [["symptomatology", "PROBLEM", 127, 141], ["type of symptoms", "PROBLEM", 143, 159], ["radiological changes", "PROBLEM", 164, 184]]], ["Non-survivors and survivors differed by age (64.6 versus 51.9 years, respectively) and proportion of concomitant chronic diseases (53% versus 20%).Diabetes and Covid-19: Epidemiological EvidenceFactors associated with mortality were also analyzed in 191 severe cases in China; 54 died and 137 discharged 13 .", [["chronic diseases", "DISEASE", 113, 129], ["Diabetes", "DISEASE", 147, 155], ["concomitant chronic diseases", "PROBLEM", 101, 129], ["Diabetes", "PROBLEM", 147, 155], ["Covid", "TEST", 160, 165], ["Epidemiological EvidenceFactors", "PROBLEM", 170, 201], ["concomitant", "OBSERVATION_MODIFIER", 101, 112], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["diseases", "OBSERVATION", 121, 129]]], ["The strongest association was found with coronary heart disease (OR 21.4, 95%CI 4.6-98.8), but also hypertension (OR 3.0, 95%CI 1.6-5.9), DM (OR 2.9, 95%CI % 1.3-6.1), COPD (OR 5.4, 95%CI 1.0-30.4), and multiple organ failure (OR 6.1, 95%CI 3.5-10.8) which increase the risk of death.", [["coronary", "ANATOMY", 41, 49], ["heart", "ANATOMY", 50, 55], ["organ", "ANATOMY", 212, 217], ["coronary heart disease", "DISEASE", 41, 63], ["hypertension", "DISEASE", 100, 112], ["DM", "DISEASE", 138, 140], ["COPD", "DISEASE", 168, 172], ["multiple organ failure", "DISEASE", 203, 225], ["death", "DISEASE", 278, 283], ["heart", "ORGAN", 50, 55], ["organ", "ORGAN", 212, 217], ["coronary heart disease", "PROBLEM", 41, 63], ["CI", "TEST", 77, 79], ["hypertension", "PROBLEM", 100, 112], ["CI", "TEST", 125, 127], ["DM", "PROBLEM", 138, 140], ["CI", "TEST", 153, 155], ["COPD", "PROBLEM", 168, 172], ["CI", "TEST", 185, 187], ["multiple organ failure", "PROBLEM", 203, 225], ["CI", "TEST", 238, 240], ["death", "PROBLEM", 278, 283], ["coronary heart", "ANATOMY", 41, 55], ["disease", "OBSERVATION", 56, 63], ["hypertension", "OBSERVATION", 100, 112], ["COPD", "OBSERVATION", 168, 172], ["multiple", "OBSERVATION_MODIFIER", 203, 211], ["organ", "ANATOMY", 212, 217], ["failure", "OBSERVATION", 218, 225]]], ["Altered circulating biomarkers (ferritin, interleukin 6, D-dimer, troponin) were associated with fatal outcome.", [["ferritin", "GENE_OR_GENE_PRODUCT", 32, 40], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 42, 55], ["D-dimer", "GENE_OR_GENE_PRODUCT", 57, 64], ["troponin", "GENE_OR_GENE_PRODUCT", 66, 74], ["ferritin", "PROTEIN", 32, 40], ["interleukin 6", "PROTEIN", 42, 55], ["D-dimer", "PROTEIN", 57, 64], ["troponin", "PROTEIN", 66, 74], ["Altered circulating biomarkers", "PROBLEM", 0, 30], ["ferritin", "TEST", 32, 40], ["interleukin", "TEST", 42, 53], ["D-dimer", "TEST", 57, 64], ["troponin", "TEST", 66, 74], ["fatal outcome", "PROBLEM", 97, 110]]], ["Considering the total of risk markers, independent predictors of mortality were older age, CVD, multiple organ failure and D-dimer concentration >1 mcg/mL 13 .", [["organ", "ANATOMY", 105, 110], ["CVD", "DISEASE", 91, 94], ["multiple organ failure", "DISEASE", 96, 118], ["D-dimer", "CHEMICAL", 123, 130], ["organ", "ORGAN", 105, 110], ["D-dimer", "SIMPLE_CHEMICAL", 123, 130], ["CVD", "PROBLEM", 91, 94], ["multiple organ failure", "PROBLEM", 96, 118], ["D-dimer concentration", "TREATMENT", 123, 144], ["organ", "ANATOMY", 105, 110], ["failure", "OBSERVATION", 111, 118]]], ["Notably, DM and hypertension could have not appeared as independent predictors considering that they are mediators of cardiovascular events and mortality, which should imply underestimation of the effect of these diseases for the fatal outcomes 13 .Diabetes and Covid-19: Epidemiological EvidenceAs the pandemic advanced to other continents, data from Europe and Americas have confirmed this worrying relationship between DM and covid-19 prognosis.", [["cardiovascular", "ANATOMY", 118, 132], ["DM", "DISEASE", 9, 11], ["hypertension", "DISEASE", 16, 28], ["Diabetes", "DISEASE", 249, 257], ["DM", "DISEASE", 422, 424], ["cardiovascular", "ANATOMICAL_SYSTEM", 118, 132], ["DM", "PROBLEM", 9, 11], ["hypertension", "PROBLEM", 16, 28], ["cardiovascular events", "PROBLEM", 118, 139], ["these diseases", "PROBLEM", 207, 221], ["the fatal outcomes", "PROBLEM", 226, 244], ["Diabetes", "PROBLEM", 249, 257], ["Covid", "TEST", 262, 267], ["DM", "PROBLEM", 422, 424], ["covid", "TEST", 429, 434], ["DM", "OBSERVATION", 9, 11], ["hypertension", "OBSERVATION", 16, 28]]], ["In the Lombardy region of Italy, among 1,591 ICU patients affected between February and March 2020, 68% had at least one comorbidity, 49% systemic hypertension, 21% CVD, 17% type 2 DM, 8% cancer, and 4% COPD 14 .Diabetes and Covid-19: Epidemiological EvidenceIn the USA, the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) showed that 89.3% of 178 adults had one or more underlying morbidities; the most common was hypertension (49.7%), followed by obesity (48.3%), chronic lung disease (34.6%), DM (28.3%) and CVD (27.8%).", [["cancer", "ANATOMY", 188, 194], ["lung", "ANATOMY", 511, 515], ["hypertension", "DISEASE", 147, 159], ["CVD", "DISEASE", 165, 168], ["type 2 DM", "DISEASE", 174, 183], ["cancer", "DISEASE", 188, 194], ["COPD", "DISEASE", 203, 207], ["Diabetes", "DISEASE", 212, 220], ["hypertension", "DISEASE", 452, 464], ["obesity", "DISEASE", 486, 493], ["chronic lung disease", "DISEASE", 503, 523], ["DM", "DISEASE", 533, 535], ["CVD", "DISEASE", 548, 551], ["patients", "ORGANISM", 49, 57], ["cancer", "CANCER", 188, 194], ["adults", "ORGANISM", 385, 391], ["lung", "ORGAN", 511, 515], ["patients", "SPECIES", 49, 57], ["systemic hypertension", "PROBLEM", 138, 159], ["21% CVD", "PROBLEM", 161, 168], ["17% type 2 DM", "PROBLEM", 170, 183], ["8% cancer", "PROBLEM", 185, 194], ["4% COPD", "PROBLEM", 200, 207], ["Diabetes", "PROBLEM", 212, 220], ["Covid", "TEST", 225, 230], ["the Coronavirus Disease", "PROBLEM", 271, 294], ["hypertension", "PROBLEM", 452, 464], ["obesity", "PROBLEM", 486, 493], ["chronic lung disease", "PROBLEM", 503, 523], ["DM", "PROBLEM", 533, 535], ["CVD", "PROBLEM", 548, 551], ["Lombardy", "ANATOMY_MODIFIER", 7, 15], ["hypertension", "OBSERVATION", 147, 159], ["cancer", "OBSERVATION", 188, 194], ["Coronavirus Disease", "OBSERVATION", 275, 294], ["hypertension", "OBSERVATION", 452, 464], ["obesity", "OBSERVATION", 486, 493], ["chronic", "OBSERVATION_MODIFIER", 503, 510], ["lung", "ANATOMY", 511, 515], ["disease", "OBSERVATION", 516, 523]]], ["In individuals aged between 18 and 49 years, obesity was the most frequent condition, followed by chronic lung disease (primarily asthma) and DM while in those aged between 50 and 64 years the most frequent diseases were hypertension and DM 15 .", [["lung", "ANATOMY", 106, 110], ["obesity", "DISEASE", 45, 52], ["chronic lung disease", "DISEASE", 98, 118], ["asthma", "DISEASE", 130, 136], ["DM", "DISEASE", 142, 144], ["hypertension", "DISEASE", 221, 233], ["DM", "DISEASE", 238, 240], ["lung", "ORGAN", 106, 110], ["obesity", "PROBLEM", 45, 52], ["chronic lung disease", "PROBLEM", 98, 118], ["asthma", "PROBLEM", 130, 136], ["DM", "PROBLEM", 142, 144], ["the most frequent diseases", "PROBLEM", 189, 215], ["hypertension", "PROBLEM", 221, 233], ["DM", "PROBLEM", 238, 240], ["most frequent", "OBSERVATION_MODIFIER", 61, 74], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["lung", "ANATOMY", 106, 110], ["disease", "OBSERVATION", 111, 118], ["asthma", "OBSERVATION", 130, 136], ["hypertension", "OBSERVATION", 221, 233]]], ["Further report confirmed that age > 60 years with a BMI 30-34 kg/ m 2 doubled the chance of being admitted to hospital (HR 2.0, p < 0.0001) and critical care (HR 1.8; p = 0.006) compared to age < 60 years with a BMI < 30 kg/m 2 16 .Diabetes and Covid-19: Epidemiological EvidenceIn Brazil, data from the Ministry of Health also identify DM and previous CVD as the comorbidities mostly associated with death in individuals affected by the SARS-Cov-2.", [["Diabetes", "DISEASE", 232, 240], ["DM", "DISEASE", 337, 339], ["CVD", "DISEASE", 353, 356], ["death", "DISEASE", 401, 406], ["SARS", "DISEASE", 438, 442], ["HR", "TEST", 120, 122], ["HR", "TEST", 159, 161], ["a BMI", "TEST", 210, 215], ["Diabetes", "PROBLEM", 232, 240], ["Covid", "TEST", 245, 250], ["DM", "PROBLEM", 337, 339], ["previous CVD", "PROBLEM", 344, 356], ["the comorbidities", "PROBLEM", 360, 377], ["death", "PROBLEM", 401, 406]]], ["DM and CVD can be seen as the same disease since atherosclerosis is present in the natural history of long-term DM.", [["DM", "DISEASE", 0, 2], ["CVD", "DISEASE", 7, 10], ["atherosclerosis", "DISEASE", 49, 64], ["DM", "DISEASE", 112, 114], ["DM", "PROBLEM", 0, 2], ["CVD", "PROBLEM", 7, 10], ["the same disease", "PROBLEM", 26, 42], ["atherosclerosis", "PROBLEM", 49, 64], ["long-term DM", "PROBLEM", 102, 114], ["CVD", "OBSERVATION", 7, 10], ["disease", "OBSERVATION", 35, 42], ["atherosclerosis", "OBSERVATION", 49, 64], ["long-term DM", "OBSERVATION_MODIFIER", 102, 114]]], ["Also, hyperglycemia can firstly manifest during an acute cardiovascular event.Diabetes and Covid-19: Epidemiological EvidenceThe concern about the relationship between cardiometabolic diseases and covid-19 is not unprecedented.", [["cardiovascular", "ANATOMY", 57, 71], ["hyperglycemia", "DISEASE", 6, 19], ["Diabetes", "DISEASE", 78, 86], ["cardiometabolic diseases", "DISEASE", 168, 192], ["hyperglycemia", "PROBLEM", 6, 19], ["an acute cardiovascular event", "PROBLEM", 48, 77], ["Diabetes", "PROBLEM", 78, 86], ["Covid", "TEST", 91, 96], ["cardiometabolic diseases", "PROBLEM", 168, 192], ["covid", "TEST", 197, 202], ["hyperglycemia", "OBSERVATION", 6, 19], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["cardiovascular", "OBSERVATION", 57, 71]]], ["Previous studies have improved knowledge on the associations of DM and CVD with influenza epidemics, H1N1 or MERS 17 and this knowledge supports researchers to provide clues to manage the current pandemic.Diabetes and Covid-19: Epidemiological EvidenceThe understanding of the biological plausibility for the association of DM and covid-19 might clarify underlying mechanisms, reinforcing possible causal relationships, thus enabling more effective prevention strategies to face viral epidemics.Advances in Plausibility of the Association between DM and Covid-19 SeverityInvestigations on the biological plausibility of the association between DM and the severity of covid-19 are ongoing but it remains unclear.Advances in Plausibility of the Association between DM and Covid-19 SeverityAdequate glycemic control reduces predisposition and improves prognosis against infections in people with DM.", [["DM", "DISEASE", 64, 66], ["CVD", "DISEASE", 71, 74], ["influenza epidemics", "DISEASE", 80, 99], ["H1N1", "DISEASE", 101, 105], ["Diabetes", "DISEASE", 205, 213], ["DM", "DISEASE", 324, 326], ["DM", "DISEASE", 547, 549], ["DM", "DISEASE", 644, 646], ["DM", "DISEASE", 763, 765], ["infections", "DISEASE", 867, 877], ["DM", "DISEASE", 893, 895], ["covid-19", "GENE_OR_GENE_PRODUCT", 331, 339], ["people", "ORGANISM", 881, 887], ["people", "SPECIES", 881, 887], ["Previous studies", "TEST", 0, 16], ["DM", "PROBLEM", 64, 66], ["CVD", "PROBLEM", 71, 74], ["influenza epidemics", "PROBLEM", 80, 99], ["H1N1", "PROBLEM", 101, 105], ["Diabetes", "PROBLEM", 205, 213], ["Covid", "TEST", 218, 223], ["DM", "PROBLEM", 324, 326], ["covid", "TEST", 331, 336], ["underlying mechanisms", "PROBLEM", 354, 375], ["face viral epidemics", "PROBLEM", 474, 494], ["DM", "PROBLEM", 547, 549], ["Covid", "TEST", 554, 559], ["SeverityInvestigations", "TEST", 563, 585], ["DM", "PROBLEM", 644, 646], ["covid", "TEST", 667, 672], ["DM", "PROBLEM", 763, 765], ["Covid", "TEST", 770, 775], ["SeverityAdequate glycemic control", "TREATMENT", 779, 812], ["infections", "PROBLEM", 867, 877], ["DM", "PROBLEM", 893, 895]]], ["A recent study, including individuals without DM, showed that high levels of fasting plasma glucose were a predictor of poor outcomes and death in covid-19 patients 18 .", [["plasma", "ANATOMY", 85, 91], ["DM", "DISEASE", 46, 48], ["glucose", "CHEMICAL", 92, 99], ["death", "DISEASE", 138, 143], ["glucose", "CHEMICAL", 92, 99], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["glucose", "SIMPLE_CHEMICAL", 92, 99], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["A recent study", "TEST", 0, 14], ["DM", "PROBLEM", 46, 48], ["fasting plasma glucose", "TEST", 77, 99], ["death", "PROBLEM", 138, 143], ["covid", "TEST", 147, 152]]], ["Direct role of the disturbance of glucose metabolism and its contribution to the covid-19 severity has to be shown.", [["glucose", "CHEMICAL", 34, 41], ["glucose", "CHEMICAL", 34, 41], ["glucose", "SIMPLE_CHEMICAL", 34, 41], ["the disturbance of glucose metabolism", "PROBLEM", 15, 52], ["the covid", "TEST", 77, 86]]], ["DM is a low-grade inflammation state, and a high-grade of systemic inflammation occurs in covid-19, reflected by elevations in inflammatory markers such as C-reactive protein, dimer-D and ferritin 13 .", [["DM", "DISEASE", 0, 2], ["inflammation", "DISEASE", 18, 30], ["inflammation", "DISEASE", 67, 79], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 156, 174], ["dimer-D", "SIMPLE_CHEMICAL", 176, 183], ["ferritin 13", "GENE_OR_GENE_PRODUCT", 188, 199], ["inflammatory markers", "PROTEIN", 127, 147], ["C-reactive protein", "PROTEIN", 156, 174], ["dimer-D", "PROTEIN", 176, 183], ["ferritin 13", "PROTEIN", 188, 199], ["DM", "PROBLEM", 0, 2], ["a low-grade inflammation state", "PROBLEM", 6, 36], ["systemic inflammation", "PROBLEM", 58, 79], ["covid", "TEST", 90, 95], ["elevations in inflammatory markers", "PROBLEM", 113, 147], ["C-reactive protein", "TEST", 156, 174], ["ferritin", "TEST", 188, 196], ["low-grade", "OBSERVATION_MODIFIER", 8, 17], ["inflammation", "OBSERVATION", 18, 30], ["high-grade", "OBSERVATION_MODIFIER", 44, 54], ["systemic", "OBSERVATION_MODIFIER", 58, 66], ["inflammation", "OBSERVATION", 67, 79], ["elevations", "OBSERVATION_MODIFIER", 113, 123], ["inflammatory markers", "OBSERVATION", 127, 147], ["reactive protein", "OBSERVATION", 158, 174]]], ["Therefore, DM and its associated diseases could provide a background to exacerbate inflammatory process contributing to the progression of covid-19 in diabetic individuals.Advances in Plausibility of the Association between DM and Covid-19 SeverityIn the same context, the association of obesity with covid-19 could corroborate this hypothesis considering that the former is also a pro-inflammatory state and a risk factor for type 2 DM.", [["DM", "DISEASE", 11, 13], ["diabetic", "DISEASE", 151, 159], ["DM", "DISEASE", 224, 226], ["obesity", "DISEASE", 288, 295], ["type 2 DM", "DISEASE", 427, 436], ["individuals", "ORGANISM", 160, 171], ["DM", "PROBLEM", 11, 13], ["its associated diseases", "PROBLEM", 18, 41], ["inflammatory process", "PROBLEM", 83, 103], ["covid", "TEST", 139, 144], ["diabetic individuals", "PROBLEM", 151, 171], ["DM", "PROBLEM", 224, 226], ["Covid", "TEST", 231, 236], ["obesity", "PROBLEM", 288, 295], ["covid", "TEST", 301, 306], ["a pro-inflammatory state", "PROBLEM", 380, 404], ["type 2 DM", "PROBLEM", 427, 436], ["progression", "OBSERVATION_MODIFIER", 124, 135], ["19 Severity", "OBSERVATION_MODIFIER", 237, 248], ["obesity", "OBSERVATION", 288, 295]]], ["Excessive adiposity produce cytokines and generates insulin resistance and endothelial dysfunction, an early event in atherogenesis.", [["endothelial", "ANATOMY", 75, 86], ["endothelial dysfunction", "DISEASE", 75, 98], ["atherogenesis", "DISEASE", 118, 131], ["insulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["endothelial", "TISSUE", 75, 86], ["cytokines", "PROTEIN", 28, 37], ["Excessive adiposity produce cytokines", "PROBLEM", 0, 37], ["insulin resistance", "PROBLEM", 52, 70], ["endothelial dysfunction", "PROBLEM", 75, 98], ["atherogenesis", "PROBLEM", 118, 131], ["adiposity", "OBSERVATION", 10, 19], ["cytokines", "OBSERVATION", 28, 37], ["insulin resistance", "OBSERVATION", 52, 70], ["endothelial dysfunction", "OBSERVATION", 75, 98], ["early", "OBSERVATION_MODIFIER", 103, 108], ["atherogenesis", "OBSERVATION_MODIFIER", 118, 131]]], ["Reasons why obesity has been associated with covid-19 hospitalization and severity 15 , especially in people under 60 years of age 16 are under discussion.", [["obesity", "DISEASE", 12, 19], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["obesity", "PROBLEM", 12, 19], ["severity", "PROBLEM", 74, 82], ["obesity", "OBSERVATION", 12, 19]]], ["As previously mentioned, atherosclerosis is the macrovascular complication of DM and its presence could contribute to understanding the increased covid-19 severity and mortality.", [["macrovascular", "ANATOMY", 48, 61], ["atherosclerosis", "DISEASE", 25, 40], ["DM", "DISEASE", 78, 80], ["atherosclerosis", "PROBLEM", 25, 40], ["the macrovascular complication", "PROBLEM", 44, 74], ["DM", "PROBLEM", 78, 80], ["the increased covid-19 severity", "PROBLEM", 132, 163], ["atherosclerosis", "OBSERVATION", 25, 40], ["macrovascular", "OBSERVATION_MODIFIER", 48, 61], ["complication", "OBSERVATION", 62, 74]]], ["In some studies, and also in Brazil (unpublished data), CVD has been considered the strongest predictor of severity and mortality due to SARS-Cov-2 infection.", [["CVD", "DISEASE", 56, 59], ["SARS", "DISEASE", 137, 141], ["infection", "DISEASE", 148, 157], ["Cov-2", "GENE_OR_GENE_PRODUCT", 142, 147], ["some studies", "TEST", 3, 15], ["CVD", "PROBLEM", 56, 59], ["SARS", "PROBLEM", 137, 141], ["Cov", "PROBLEM", 142, 145], ["2 infection", "PROBLEM", 146, 157], ["infection", "OBSERVATION", 148, 157]]], ["The effect of cardiovascular causes of death on hospitalized patients, including myocarditis, arrhythmias, myocardial infarction and systemic thrombosis is highlighted in recent review 17 .Advances in Plausibility of the Association between DM and Covid-19 SeverityA possible deleterious role of medications to treat these morbidities was raised.", [["cardiovascular", "ANATOMY", 14, 28], ["myocardial", "ANATOMY", 107, 117], ["death", "DISEASE", 39, 44], ["myocarditis", "DISEASE", 81, 92], ["arrhythmias", "DISEASE", 94, 105], ["myocardial infarction", "DISEASE", 107, 128], ["systemic thrombosis", "DISEASE", 133, 152], ["DM", "DISEASE", 241, 243], ["cardiovascular", "ANATOMICAL_SYSTEM", 14, 28], ["patients", "ORGANISM", 61, 69], ["myocardial", "MULTI-TISSUE_STRUCTURE", 107, 117], ["patients", "SPECIES", 61, 69], ["death", "PROBLEM", 39, 44], ["myocarditis", "PROBLEM", 81, 92], ["arrhythmias", "PROBLEM", 94, 105], ["myocardial infarction", "PROBLEM", 107, 128], ["systemic thrombosis", "PROBLEM", 133, 152], ["DM", "PROBLEM", 241, 243], ["Covid", "TEST", 248, 253], ["medications", "TREATMENT", 296, 307], ["these morbidities", "PROBLEM", 317, 334], ["myocarditis", "OBSERVATION", 81, 92], ["arrhythmias", "OBSERVATION", 94, 105], ["myocardial", "ANATOMY", 107, 117], ["infarction", "OBSERVATION", 118, 128], ["systemic", "OBSERVATION_MODIFIER", 133, 141], ["thrombosis", "OBSERVATION", 142, 152]]], ["Pathophysiological pathways of DM and hypertension were demonstrated to worsen SARS-Cov-2 infection 19 and some medications mechanism of action were based on these pathways.", [["DM", "DISEASE", 31, 33], ["hypertension", "DISEASE", 38, 50], ["SARS", "DISEASE", 79, 83], ["infection", "DISEASE", 90, 99], ["DM", "MULTI-TISSUE_STRUCTURE", 31, 33], ["DM", "PROBLEM", 31, 33], ["hypertension", "PROBLEM", 38, 50], ["SARS", "PROBLEM", 79, 83], ["Cov-2 infection", "PROBLEM", 84, 99], ["some medications mechanism", "TREATMENT", 107, 133], ["DM", "OBSERVATION", 31, 33], ["hypertension", "OBSERVATION", 38, 50]]], ["Coronaviruses were able to bind to target cells through angiotensin-converting enzyme 2 (ACE2) receptor which is expressed in several tissues.", [["cells", "ANATOMY", 42, 47], ["tissues", "ANATOMY", 134, 141], ["angiotensin", "CHEMICAL", 56, 67], ["cells", "CELL", 42, 47], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 56, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["tissues", "TISSUE", 134, 141], ["target cells", "CELL_TYPE", 35, 47], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 56, 103], ["Coronaviruses", "PROBLEM", 0, 13], ["angiotensin-converting enzyme 2 (ACE2) receptor", "TREATMENT", 56, 103], ["several tissues", "OBSERVATION", 126, 141]]], ["Researchers documented that ECA2 is increased in individuals with type 1 and type 2 DM and that some medications can increase ACE2 expression, such as ACE inhibitors, angiotensin 2 receptor blockers (ARB), thiazolidinediones and ibuprofen.", [["type 1 and type 2 DM", "DISEASE", 66, 86], ["angiotensin 2 receptor blockers", "CHEMICAL", 167, 198], ["ARB", "CHEMICAL", 200, 203], ["thiazolidinediones", "CHEMICAL", 206, 224], ["ibuprofen", "CHEMICAL", 229, 238], ["thiazolidinediones", "CHEMICAL", 206, 224], ["ibuprofen", "CHEMICAL", 229, 238], ["ECA2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 126, 130], ["ACE", "GENE_OR_GENE_PRODUCT", 151, 154], ["angiotensin 2 receptor blockers", "SIMPLE_CHEMICAL", 167, 198], ["ARB", "SIMPLE_CHEMICAL", 200, 203], ["thiazolidinediones", "SIMPLE_CHEMICAL", 206, 224], ["ibuprofen", "SIMPLE_CHEMICAL", 229, 238], ["ECA2", "PROTEIN", 28, 32], ["ACE2", "PROTEIN", 126, 130], ["type 2 DM", "PROBLEM", 77, 86], ["some medications", "TREATMENT", 96, 112], ["ACE2 expression", "TREATMENT", 126, 141], ["ACE inhibitors", "TREATMENT", 151, 165], ["angiotensin 2 receptor blockers", "TREATMENT", 167, 198], ["ARB", "TREATMENT", 200, 203], ["thiazolidinediones", "TREATMENT", 206, 224], ["ibuprofen", "TREATMENT", 229, 238], ["increased", "OBSERVATION_MODIFIER", 36, 45]]], ["However, no evidence indicates potential adverse effects https://doi.org/10.11606/s1518-8787.2020054002577 of these agents on the prognosis of diabetic and hypertensive individuals with covid-19.", [["diabetic", "DISEASE", 143, 151], ["hypertensive", "DISEASE", 156, 168], ["potential adverse effects", "PROBLEM", 31, 56], ["these agents", "TREATMENT", 110, 122], ["diabetic and hypertensive individuals", "PROBLEM", 143, 180], ["covid", "TEST", 186, 191], ["no evidence indicates", "UNCERTAINTY", 9, 30]]], ["Therefore, scientific societies such as the Brazilian Diabetes Society 20 have not recommended the withdrawal of these drugs due to SARS-Cov-2 infection 21, 22 .FINAL CONSIDERATIONSWhile advances in the knowledge of the relationship between DM and covid-19 occur, health professionals have experienced difficulties in clinical management and public health systems in the support of the heavy burden of these two morbidities in populations.", [["Diabetes", "DISEASE", 54, 62], ["SARS", "DISEASE", 132, 136], ["infection", "DISEASE", 143, 152], ["DM", "DISEASE", 241, 243], ["these drugs", "TREATMENT", 113, 124], ["SARS", "PROBLEM", 132, 136], ["Cov-2 infection", "PROBLEM", 137, 152], ["DM", "PROBLEM", 241, 243], ["difficulties in clinical management and public health systems", "PROBLEM", 302, 363]]], ["Pathophysiological relationship must be well understood to plan preventive measures and/or to propose more effective therapeutic strategies.", [["preventive measures", "TREATMENT", 64, 83], ["therapeutic strategies", "TREATMENT", 117, 139]]], ["In this context, we could indicate some gaps regarding the severity of DM and SARS-Cov-2 infection that should be focused in future studies.", [["DM", "DISEASE", 71, 73], ["SARS", "DISEASE", 78, 82], ["infection", "DISEASE", 89, 98], ["Cov-2", "CELL", 83, 88], ["DM", "PROBLEM", 71, 73], ["SARS", "PROBLEM", 78, 82], ["Cov-2 infection", "PROBLEM", 83, 98], ["future studies", "TEST", 125, 139], ["DM", "OBSERVATION", 71, 73], ["infection", "OBSERVATION", 89, 98]]], ["It is possible that susceptibility and prognosis vary according to the type of DM, age, duration of illness, degree of glycemic control, presence of complications and medications in use.FINAL CONSIDERATIONSIn summary, DM in individuals with covid-19 is more than the simple sum of two morbidities in prognostic terms.", [["DM", "DISEASE", 79, 81], ["illness", "DISEASE", 100, 107], ["DM", "DISEASE", 218, 220], ["DM", "PROBLEM", 79, 81], ["illness", "PROBLEM", 100, 107], ["glycemic control", "TREATMENT", 119, 135], ["complications", "PROBLEM", 149, 162], ["medications", "TREATMENT", 167, 178], ["DM", "PROBLEM", 218, 220], ["covid", "TEST", 241, 246], ["glycemic control", "OBSERVATION", 119, 135], ["complications", "OBSERVATION", 149, 162]]], ["Understanding underlying mechanisms of this association are urgently necessary to face the current SARS-Cov-2, to propose in effective prevention through vaccination and pharmacological agents as well as to prepare the health care systems for future challenges.", [["vaccination", "TREATMENT", 154, 165], ["pharmacological agents", "TREATMENT", 170, 192]]]], "b0642d72a502831e4e54e55e509b2ad5b9f9086d": [["IntroductionBiodegradable and bio-based polymers have recently drawn more and more attention in several applications, including composites [1] [2] [3] , packaging [4] and medicine [5] .", [["[1] [2] [3]", "SIMPLE_CHEMICAL", 139, 150], ["IntroductionBiodegradable and bio-based polymers", "TREATMENT", 0, 48]]], ["Polyesters are considered to be one of the most important classes of biomaterials [6] .", [["Polyesters", "SIMPLE_CHEMICAL", 0, 10], ["Polyesters", "TREATMENT", 0, 10]]], ["Poly(lactic acid) (PLA), linear polyester, is extensively tested in medicine and tissue engineering, due to its biodegradability, non-toxicity and biocompatibility [7, 8] .", [["tissue", "ANATOMY", 81, 87], ["Poly(lactic acid", "CHEMICAL", 0, 16], ["PLA", "CHEMICAL", 19, 22], ["Poly(lactic acid)", "CHEMICAL", 0, 17], ["PLA", "CHEMICAL", 19, 22], ["polyester", "CHEMICAL", 32, 41], ["Poly(lactic acid", "SIMPLE_CHEMICAL", 0, 16], ["PLA", "SIMPLE_CHEMICAL", 19, 22], ["tissue", "TISSUE", 81, 87], ["Poly(lactic acid)", "PROBLEM", 0, 17], ["its biodegradability", "PROBLEM", 108, 128], ["non-toxicity", "PROBLEM", 130, 142], ["linear", "OBSERVATION_MODIFIER", 25, 31], ["polyester", "OBSERVATION", 32, 41]]], ["PLA is a thermoplastic relatively easy to process.", [["PLA", "CHEMICAL", 0, 3], ["PLA", "CHEMICAL", 0, 3], ["PLA", "SIMPLE_CHEMICAL", 0, 3]]], ["In addition, its mechanical properties are similar to commonly used synthetic polymers.", [["synthetic polymers", "TREATMENT", 68, 86], ["mechanical properties", "OBSERVATION", 17, 38]]], ["Physicochemical properties of PLA depend on a stereoisomeric form of polymer [9] .", [["PLA", "CHEMICAL", 30, 33], ["PLA", "CHEMICAL", 30, 33], ["PLA", "SIMPLE_CHEMICAL", 30, 33]]], ["Lactic acid (LAc), a repetitive unit of PLA, consists of two optical isomers: D(\u2212)LAc and L(+)LAc.", [["Lactic acid", "CHEMICAL", 0, 11], ["LAc", "CHEMICAL", 13, 16], ["Lactic acid", "CHEMICAL", 0, 11], ["LAc", "CHEMICAL", 13, 16], ["PLA", "CHEMICAL", 40, 43], ["D(\u2212)LAc", "CHEMICAL", 78, 85], ["L(+)LAc", "CHEMICAL", 90, 97], ["Lactic acid", "SIMPLE_CHEMICAL", 0, 11], ["LAc", "SIMPLE_CHEMICAL", 13, 16], ["PLA", "SIMPLE_CHEMICAL", 40, 43], ["D(\u2212)LAc", "SIMPLE_CHEMICAL", 78, 85], ["L(+)LAc", "SIMPLE_CHEMICAL", 90, 97], ["Lactic acid (LAc", "PROBLEM", 0, 16], ["a repetitive unit of PLA", "TREATMENT", 19, 43], ["LAc", "TEST", 82, 85], ["LAc", "PROBLEM", 94, 97], ["acid", "OBSERVATION_MODIFIER", 7, 11], ["LAc", "ANATOMY", 82, 85], ["L", "ANATOMY_MODIFIER", 90, 91], ["LAc", "ANATOMY", 94, 97]]], ["Homochiral PLA is a semicrystalline, isotactic polymer (PLLA and PDLA).", [["PLA", "CHEMICAL", 11, 14], ["PLLA", "CHEMICAL", 56, 60], ["PLA", "CHEMICAL", 11, 14], ["PLLA", "CHEMICAL", 56, 60], ["PLA", "SIMPLE_CHEMICAL", 11, 14], ["a semicrystalline, isotactic polymer (PLLA and PDLA)", "TREATMENT", 18, 70]]], ["Polymerization of D-and L-LAc mixture leads to the formation of heterochiral, atactic PLDLA with amorphous properties.IntroductionThe PLA is susceptible to hydrolysis and under the conditions of the human body enzymatically decomposes into LAc, which occurs naturally in living organisms.", [["body", "ANATOMY", 205, 209], ["D-and L-LAc", "CHEMICAL", 18, 29], ["PLDLA", "CHEMICAL", 86, 91], ["PLA", "CHEMICAL", 134, 137], ["LAc", "CHEMICAL", 240, 243], ["D-and L-LAc", "CHEMICAL", 18, 29], ["PLDLA", "CHEMICAL", 86, 91], ["PLA", "CHEMICAL", 134, 137], ["D-", "SIMPLE_CHEMICAL", 18, 20], ["L-LAc", "SIMPLE_CHEMICAL", 24, 29], ["PLDLA", "SIMPLE_CHEMICAL", 86, 91], ["human", "ORGANISM", 199, 204], ["body", "ORGANISM_SUBDIVISION", 205, 209], ["LAc", "GENE_OR_GENE_PRODUCT", 240, 243], ["LAc", "PROTEIN", 240, 243], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["Polymerization", "TEST", 0, 14], ["D-and L-LAc mixture", "TREATMENT", 18, 37], ["hydrolysis", "PROBLEM", 156, 166], ["LAc", "PROBLEM", 240, 243], ["L", "ANATOMY_MODIFIER", 24, 25], ["LAc", "ANATOMY", 26, 29], ["heterochiral", "ANATOMY_MODIFIER", 64, 76], ["amorphous properties", "OBSERVATION", 97, 117], ["hydrolysis", "OBSERVATION", 156, 166], ["LAc", "OBSERVATION", 240, 243]]], ["In the citric acid cycle, LAc is converted into carbon dioxide and water [10] .", [["citric acid", "CHEMICAL", 7, 18], ["LAc", "CHEMICAL", 26, 29], ["carbon dioxide", "CHEMICAL", 48, 62], ["citric acid", "CHEMICAL", 7, 18], ["LAc", "CHEMICAL", 26, 29], ["carbon dioxide", "CHEMICAL", 48, 62], ["citric acid", "SIMPLE_CHEMICAL", 7, 18], ["LAc", "SIMPLE_CHEMICAL", 26, 29], ["carbon dioxide", "SIMPLE_CHEMICAL", 48, 62], ["the citric acid cycle", "TREATMENT", 3, 24], ["LAc", "TREATMENT", 26, 29], ["carbon dioxide", "TREATMENT", 48, 62]]], ["Thanks to good mechanical properties that allow PLA to endure the stresses applied in a human body; it is commonly used in implants for bone fixation and absorbable surgical sutures [11] .IntroductionIn tissue engineering, PLA has been utilized as material for drug delivery microspheres [12, 13] and scaffolds [14, 15] for cell growth.", [["body", "ANATOMY", 94, 98], ["bone", "ANATOMY", 136, 140], ["tissue", "ANATOMY", 203, 209], ["cell", "ANATOMY", 324, 328], ["PLA", "CHEMICAL", 223, 226], ["PLA", "CHEMICAL", 48, 51], ["PLA", "CHEMICAL", 223, 226], ["PLA", "SIMPLE_CHEMICAL", 48, 51], ["human", "ORGANISM", 88, 93], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["bone", "TISSUE", 136, 140], ["tissue", "TISSUE", 203, 209], ["PLA", "SIMPLE_CHEMICAL", 223, 226], ["cell", "CELL", 324, 328], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["a human body", "TREATMENT", 86, 98], ["bone fixation", "TREATMENT", 136, 149], ["absorbable surgical sutures", "TREATMENT", 154, 181], ["IntroductionIn tissue engineering", "TREATMENT", 188, 221], ["drug delivery microspheres", "TREATMENT", 261, 287], ["scaffolds", "TREATMENT", 301, 310], ["cell growth", "PROBLEM", 324, 335], ["bone", "ANATOMY", 136, 140], ["fixation", "OBSERVATION", 141, 149], ["surgical sutures", "OBSERVATION", 165, 181]]], ["It is required for scaffold to support regeneration of the tissue in the place of the defect and then degraded when the healing is completed.", [["tissue", "ANATOMY", 59, 65], ["tissue", "TISSUE", 59, 65], ["scaffold", "TREATMENT", 19, 27], ["regeneration of the tissue", "PROBLEM", 39, 65], ["the defect", "PROBLEM", 82, 92], ["tissue", "OBSERVATION", 59, 65], ["defect", "OBSERVATION", 86, 92], ["healing", "OBSERVATION_MODIFIER", 120, 127]]], ["PLA could be easily made in various forms and shape, including microspheres and fibers with diameter that ranges from nanometers to micrometers.", [["fibers", "ANATOMY", 80, 86], ["PLA", "CHEMICAL", 0, 3], ["PLA", "CHEMICAL", 0, 3], ["PLA", "SIMPLE_CHEMICAL", 0, 3], ["fibers", "CELLULAR_COMPONENT", 80, 86], ["microspheres and fibers with diameter", "TREATMENT", 63, 100]]], ["The main advantage of forming 2D and 3D fibrous scaffolds is a strong anisotropy of properties that allows to adapt material to specific requirements, a very high surface area, and the possibility of creating complex microstructures with specific pores and density [16] .", [["surface area", "ANATOMY", 163, 175], ["fibrous scaffolds", "TISSUE", 40, 57], ["forming 2D and 3D fibrous scaffolds", "TREATMENT", 22, 57], ["a strong anisotropy of properties", "TREATMENT", 61, 94], ["a very high surface area", "PROBLEM", 151, 175], ["creating complex microstructures", "PROBLEM", 200, 232], ["main", "OBSERVATION_MODIFIER", 4, 8], ["fibrous scaffolds", "OBSERVATION", 40, 57], ["complex", "OBSERVATION_MODIFIER", 209, 216], ["microstructures", "OBSERVATION", 217, 232]]], ["Thanks to the ability to control the physicochemical properties of fibers; also through the degree of crystallinity, modifications of the volume and surface of the fibers, it is possible to modulate the biological response [17] .IntroductionHere, we report the fabrication of PLA fibers modified with inorganic particles (ZnO, SiO 2 , TiO 2 ) using the electrospinning method (ES).", [["fibers", "ANATOMY", 67, 73], ["surface", "ANATOMY", 149, 156], ["fibers", "ANATOMY", 164, 170], ["ZnO, SiO 2 , TiO 2", "CHEMICAL", 322, 340], ["PLA", "CHEMICAL", 276, 279], ["ZnO", "CHEMICAL", 322, 325], ["SiO 2", "CHEMICAL", 327, 332], ["TiO 2", "CHEMICAL", 335, 340], ["fibers", "CELLULAR_COMPONENT", 67, 73], ["fibers", "CELLULAR_COMPONENT", 164, 170], ["PLA fibers", "SIMPLE_CHEMICAL", 276, 286], ["inorganic particles", "SIMPLE_CHEMICAL", 301, 320], ["ZnO", "SIMPLE_CHEMICAL", 322, 325], ["SiO 2", "SIMPLE_CHEMICAL", 327, 332], ["TiO 2", "SIMPLE_CHEMICAL", 335, 340], ["crystallinity", "PROBLEM", 102, 115], ["the volume and surface of the fibers", "TREATMENT", 134, 170], ["the fabrication of PLA fibers", "TREATMENT", 257, 286], ["inorganic particles (ZnO, SiO 2 , TiO", "TREATMENT", 301, 338], ["the electrospinning method", "TREATMENT", 349, 375], ["crystallinity", "OBSERVATION", 102, 115]]], ["This technique involves electrostatic forces to generate polymer solution jets and induce the ejection through a spinneret.", [["This technique", "TREATMENT", 0, 14], ["polymer solution jets", "TREATMENT", 57, 78], ["electrostatic forces", "OBSERVATION", 24, 44]]], ["An electrical potential is applied between the tip of a needle and a grounded collector.", [["a needle", "TREATMENT", 54, 62], ["a grounded collector", "TREATMENT", 67, 87], ["tip", "OBSERVATION_MODIFIER", 47, 50], ["needle", "OBSERVATION", 56, 62]]], ["In order for the polymer jet to be ejected, the electric field must overcome the surface tension of the drop.", [["surface", "ANATOMY", 81, 88], ["the polymer jet", "TREATMENT", 13, 28], ["the drop", "PROBLEM", 100, 108], ["surface tension", "OBSERVATION", 81, 96], ["drop", "OBSERVATION_MODIFIER", 104, 108]]], ["The fiber morphology is influenced by many parameters, especially concentration of the polymer, molecular weight, distance between tip and collector, solvent content, flow rate, applied voltage and temperature [18] [19] [20] .IntroductionPLA exhibits disadvantages in some key aspects, such as hydrolysis and degradation under UV light exposure [21] , what limits its applicability.", [["fiber", "ANATOMY", 4, 9], ["IntroductionPLA", "CHEMICAL", 226, 241], ["flow rate", "TEST", 167, 176], ["temperature", "TEST", 198, 209], ["IntroductionPLA", "TREATMENT", 226, 241], ["fiber morphology", "OBSERVATION_MODIFIER", 4, 20], ["solvent content", "OBSERVATION", 150, 165]]], ["The resistance to aging is a key factor for outdoor and medicine applications (packaging, stitches, bandage, sterilization).", [["medicine applications", "TREATMENT", 56, 77], ["packaging", "TREATMENT", 79, 88], ["stitches", "TREATMENT", 90, 98], ["bandage", "TREATMENT", 100, 107], ["sterilization", "TREATMENT", 109, 122]]], ["UV stability of PLA-based materials has attracted a lot of attention recently [21] [22] [23] .", [["PLA", "CHEMICAL", 16, 19], ["PLA", "CHEMICAL", 16, 19], ["PLA", "SIMPLE_CHEMICAL", 16, 19], ["[21] [22] [23]", "SIMPLE_CHEMICAL", 78, 92], ["stability", "OBSERVATION_MODIFIER", 3, 12]]], ["However, to the best of our knowledge, there are no studies in the literature regarding the influence of UV exposure on the properties of PLA nanocomposite fibers.", [["UV", "CHEMICAL", 105, 107], ["PLA", "CHEMICAL", 138, 141], ["studies", "TEST", 52, 59], ["UV exposure", "TREATMENT", 105, 116], ["PLA nanocomposite fibers", "TREATMENT", 138, 162]]], ["We hypothesized that modification of fibers with inorganic particles (SiO 2 , ZnO and TiO 2 ) can affect the stability of PLA.", [["fibers", "ANATOMY", 37, 43], ["SiO 2 , ZnO", "CHEMICAL", 70, 81], ["TiO 2", "CHEMICAL", 86, 91], ["PLA", "CHEMICAL", 122, 125], ["SiO 2", "CHEMICAL", 70, 75], ["ZnO", "CHEMICAL", 78, 81], ["TiO 2", "CHEMICAL", 86, 91], ["PLA", "CHEMICAL", 122, 125], ["fibers", "CELLULAR_COMPONENT", 37, 43], ["inorganic particles", "SIMPLE_CHEMICAL", 49, 68], ["SiO 2", "SIMPLE_CHEMICAL", 70, 75], ["ZnO", "SIMPLE_CHEMICAL", 78, 81], ["TiO 2", "SIMPLE_CHEMICAL", 86, 91], ["PLA", "SIMPLE_CHEMICAL", 122, 125], ["inorganic particles (SiO 2 , ZnO and TiO 2", "TREATMENT", 49, 91]]], ["ZnO and TiO 2 are effective absorbers of UV [24, 25] and are commonly used as UV-screen agents in sunblocks.", [["ZnO", "CHEMICAL", 0, 3], ["TiO 2", "CHEMICAL", 8, 13], ["UV", "CHEMICAL", 41, 43], ["ZnO", "CHEMICAL", 0, 3], ["TiO 2", "CHEMICAL", 8, 13], ["ZnO", "SIMPLE_CHEMICAL", 0, 3], ["TiO 2", "SIMPLE_CHEMICAL", 8, 13], ["ZnO and TiO 2", "TREATMENT", 0, 13], ["effective absorbers of UV", "TREATMENT", 18, 43], ["UV-screen agents", "TREATMENT", 78, 94]]], ["Zhang reported that ZnO nanoparticles can stabilize poly(butylene succinate-co-butylene adipate) matrix and hinder the photodegradation of polymer [26] .MaterialsPoly(lactic acid) (PLA, IngeoTMBiopolymer 3251D) with molecular weight M = 70,000-120,000 g mol \u22121 was purchased from NatureWorks LLC, USA.", [["ZnO nanoparticles", "CHEMICAL", 20, 37], ["poly(butylene succinate-co-butylene adipate", "CHEMICAL", 52, 95], ["Poly(lactic acid", "CHEMICAL", 162, 178], ["PLA", "CHEMICAL", 181, 184], ["IngeoTMBiopolymer 3251D", "CHEMICAL", 186, 209], ["ZnO", "CHEMICAL", 20, 23], ["poly(butylene succinate-co-butylene adipate)", "CHEMICAL", 52, 96], ["Poly(lactic acid)", "CHEMICAL", 162, 179], ["PLA", "CHEMICAL", 181, 184], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 20, 37], ["poly(butylene succinate-co-butylene adipate", "SIMPLE_CHEMICAL", 52, 95], ["Poly(lactic acid", "SIMPLE_CHEMICAL", 162, 178], ["PLA", "SIMPLE_CHEMICAL", 181, 184], ["ZnO nanoparticles", "TREATMENT", 20, 37], ["poly(butylene succinate", "TREATMENT", 52, 75], ["co-butylene adipate) matrix", "TREATMENT", 76, 103], ["the photodegradation of polymer", "TREATMENT", 115, 146], ["MaterialsPoly(lactic acid", "TEST", 153, 178], ["IngeoTMBiopolymer", "TEST", 186, 203], ["molecular weight M", "TEST", 216, 234], ["LLC", "ANATOMY", 292, 295]]], ["Dichloromethane (DCM) and dimethylformamide (DMF) were obtained from Avantor Performance Materials Poland S.A., Gliwice, Poland.", [["Dichloromethane", "CHEMICAL", 0, 15], ["DCM", "CHEMICAL", 17, 20], ["dimethylformamide", "CHEMICAL", 26, 43], ["DMF", "CHEMICAL", 45, 48], ["Dichloromethane", "CHEMICAL", 0, 15], ["DCM", "CHEMICAL", 17, 20], ["dimethylformamide", "CHEMICAL", 26, 43], ["DMF", "CHEMICAL", 45, 48], ["Dichloromethane", "SIMPLE_CHEMICAL", 0, 15], ["DCM", "SIMPLE_CHEMICAL", 17, 20], ["dimethylformamide", "SIMPLE_CHEMICAL", 26, 43], ["DMF", "SIMPLE_CHEMICAL", 45, 48], ["Dichloromethane (DCM)", "TREATMENT", 0, 21], ["dimethylformamide (DMF)", "TREATMENT", 26, 49]]], ["Ceramic particles: ZnO particles (1 \u03bcm), SiO 2 nanaoparticles (12 nm) and TiO 2 nanoparticles (100 nm) were purchased from Merck KGaA, Germany.Preparation of PLA-based solutions for electrospinning processPLA-based solutions for electrospinning process (ES) with concentrations 11, 13 or 15% (w/v) were prepared by dissolving polymer in binary-solvent system of DCM and DMF (2.5:1 v/v or 3:1 v/v).", [["ZnO", "CHEMICAL", 19, 22], ["SiO 2 nanaoparticles", "CHEMICAL", 41, 61], ["TiO 2 nanoparticles", "CHEMICAL", 74, 93], ["PLA", "CHEMICAL", 158, 161], ["processPLA", "CHEMICAL", 198, 208], ["DCM", "CHEMICAL", 362, 365], ["DMF", "CHEMICAL", 370, 373], ["ZnO", "CHEMICAL", 19, 22], ["SiO 2", "CHEMICAL", 41, 46], ["TiO 2", "CHEMICAL", 74, 79], ["PLA", "CHEMICAL", 158, 161], ["DMF", "CHEMICAL", 370, 373], ["ZnO particles", "SIMPLE_CHEMICAL", 19, 32], ["SiO 2 nanaoparticles", "SIMPLE_CHEMICAL", 41, 61], ["TiO 2 nanoparticles", "SIMPLE_CHEMICAL", 74, 93], ["PLA", "SIMPLE_CHEMICAL", 158, 161], ["processPLA", "SIMPLE_CHEMICAL", 198, 208], ["DCM", "SIMPLE_CHEMICAL", 362, 365], ["DMF", "SIMPLE_CHEMICAL", 370, 373], ["Ceramic particles", "TEST", 0, 17], ["ZnO particles", "TEST", 19, 32], ["SiO", "TEST", 41, 44], ["TiO 2 nanoparticles", "TREATMENT", 74, 93], ["PLA-based solutions", "TREATMENT", 158, 177], ["electrospinning processPLA-based solutions", "TREATMENT", 182, 224], ["electrospinning process", "TREATMENT", 229, 252], ["concentrations", "TEST", 263, 277], ["DCM", "PROBLEM", 362, 365], ["ZnO particles", "OBSERVATION", 19, 32]]], ["Solution was stirred for 24 h using magnetic stirrer at about 50 \u00b0C. Next, ceramic particles powder (ZnO, TiO 2 or SiO 2 ) was added and solution was ultrasonicated for 10 min.", [["ZnO, TiO 2 or SiO 2", "CHEMICAL", 101, 120], ["ZnO", "CHEMICAL", 101, 104], ["TiO 2", "CHEMICAL", 106, 111], ["SiO 2", "CHEMICAL", 115, 120], ["ZnO", "SIMPLE_CHEMICAL", 101, 104], ["TiO 2", "SIMPLE_CHEMICAL", 106, 111], ["SiO 2", "SIMPLE_CHEMICAL", 115, 120], ["ceramic particles powder (ZnO, TiO 2 or SiO", "TREATMENT", 75, 118]]], ["Next, PLA solution was stirred for another 24 h.", [["PLA", "CHEMICAL", 6, 9], ["PLA", "SIMPLE_CHEMICAL", 6, 9], ["PLA solution", "TREATMENT", 6, 18]]], ["The concentration of inorganic particles was 6 mass%, beyond that content solution retained its rheological properties.Electrospinning processPLA-based nonwoven was formulated through electrospinning process (ES) using apparatus constructed at Department of Biomaterials and Composites, AGH, Poland.", [["inorganic", "CHEMICAL", 21, 30], ["processPLA", "CHEMICAL", 135, 145], ["processPLA", "SIMPLE_CHEMICAL", 135, 145], ["The concentration of inorganic particles", "TREATMENT", 0, 40], ["Electrospinning processPLA", "TREATMENT", 119, 145], ["Biomaterials and Composites", "TREATMENT", 258, 285], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["inorganic", "OBSERVATION_MODIFIER", 21, 30], ["particles", "OBSERVATION_MODIFIER", 31, 40], ["rheological properties", "OBSERVATION", 96, 118]]], ["The solution was sonicated for 10 min before injection into 10 mL syringe.", [["The solution", "TREATMENT", 0, 12]]], ["A high voltage-power supply (0-25 kV) was used to generate an electric field between needle (0.7 mm) and cylindrical, rotating collector (width: 5 cm) covered with aluminum foil.", [["aluminum", "CHEMICAL", 164, 172], ["aluminum", "CHEMICAL", 164, 172], ["A high voltage-power supply", "TREATMENT", 0, 27], ["an electric field between needle", "TREATMENT", 59, 91], ["cylindrical, rotating collector (width", "TREATMENT", 105, 143], ["aluminum foil", "TREATMENT", 164, 177], ["high", "OBSERVATION_MODIFIER", 2, 6], ["voltage", "OBSERVATION_MODIFIER", 7, 14], ["5 cm", "OBSERVATION_MODIFIER", 145, 149]]], ["The system was encased in a special chamber that allowed to perform ES process at constant temperature (50 \u00b0C) and humidity (10%).", [["a special chamber", "TREATMENT", 26, 43], ["humidity", "TREATMENT", 115, 123], ["encased", "OBSERVATION", 15, 22]]], ["The spinning time of nonwovens was 1 h.Aging testThe aging test was carried out by exposing PLA and PLAcomposite nonwovens to UV light.", [["PLA", "CHEMICAL", 92, 95], ["PLA", "SIMPLE_CHEMICAL", 92, 95], ["The aging test", "TEST", 49, 63]]], ["Samples were placed into the chamber equipped with UV-C lamp (35 W cm \u22122 ).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["UV-C lamp", "TREATMENT", 51, 60], ["chamber", "ANATOMY_MODIFIER", 29, 36]]], ["Air circulation was forced in the chamber ( Fig. 1 ) to remove ozone, which was forming from oxygen by UV irradiation during aging test.", [["ozone", "CHEMICAL", 63, 68], ["oxygen", "CHEMICAL", 93, 99], ["UV", "CHEMICAL", 103, 105], ["ozone", "CHEMICAL", 63, 68], ["oxygen", "CHEMICAL", 93, 99], ["ozone", "SIMPLE_CHEMICAL", 63, 68], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["Air circulation", "TEST", 0, 15], ["oxygen", "TREATMENT", 93, 99], ["UV irradiation", "TREATMENT", 103, 117], ["aging test", "TEST", 125, 135], ["chamber", "ANATOMY_MODIFIER", 34, 41], ["UV irradiation", "OBSERVATION", 103, 117]]], ["The presence of ozone could accelerate degradation of PLA nonwoven.", [["ozone", "CHEMICAL", 16, 21], ["PLA", "CHEMICAL", 54, 57], ["ozone", "CHEMICAL", 16, 21], ["PLA", "CHEMICAL", 54, 57], ["ozone", "SIMPLE_CHEMICAL", 16, 21], ["PLA", "SIMPLE_CHEMICAL", 54, 57], ["PLA nonwoven", "TREATMENT", 54, 66], ["ozone", "OBSERVATION", 16, 21], ["degradation", "OBSERVATION_MODIFIER", 39, 50], ["PLA nonwoven", "OBSERVATION", 54, 66]]], ["The equivalent of exposure time to UV radiation was calculated from the average exposure the Earth to Sun's UV radiation (62 W m \u22122 [27, 28] ).", [["UV radiation", "TREATMENT", 35, 47], ["Sun's UV radiation", "TREATMENT", 102, 120]]], ["One hour in the aging chamber equals 5645 h of exposure to solar radiation, assuming that the Sun shines continuously and all UV irradiation reaches the Earth's surface.", [["surface", "ANATOMY", 161, 168], ["UV", "CHEMICAL", 126, 128], ["surface", "CELLULAR_COMPONENT", 161, 168], ["solar radiation", "TREATMENT", 59, 74], ["the Sun shines", "TREATMENT", 90, 104], ["all UV irradiation", "TREATMENT", 122, 140], ["solar radiation", "OBSERVATION", 59, 74], ["UV irradiation", "OBSERVATION", 126, 140]]], ["The samples were exposed to UV light for 15 min, 1 and 4 h.CharacterizationSurface morphology of PLA nonwovens and composites fibers was studied using scanning electron microscope (SEM, Nova NanoSEM 200) with an accelerating voltage of 18 kV.", [["samples", "ANATOMY", 4, 11], ["PLA", "CHEMICAL", 97, 100], ["PLA nonwovens", "SIMPLE_CHEMICAL", 97, 110], ["The samples", "TEST", 0, 11], ["scanning electron microscope", "TEST", 151, 179], ["an accelerating voltage", "TEST", 209, 232], ["PLA", "ANATOMY", 97, 100]]], ["Samples were mounted onto special holders and coated with conductive carbon layer prior to SEM analysis.", [["Samples", "ANATOMY", 0, 7], ["carbon", "CHEMICAL", 69, 75], ["Samples", "TEST", 0, 7], ["conductive carbon layer", "TREATMENT", 58, 81], ["SEM analysis", "TEST", 91, 103]]], ["Images analysis software (ImageJ) was applied to determine fiber's diameters and distribution of fibers' directions in nonwovens.", [["fiber", "ANATOMY", 59, 64], ["fibers", "ANATOMY", 97, 103], ["Images analysis", "TEST", 0, 15], ["fibers'", "OBSERVATION", 97, 104]]], ["For each material, 30 fibers were measured.", [["fibers", "ANATOMY", 22, 28], ["fibers", "CELLULAR_COMPONENT", 22, 28]]], ["Differential scanning calorimetry (DSC) measurements were taken using DSC1 (Mettler Toledo) in dynamic mode (atmosphere: nitrogen, 200 mL min \u22121 , heating and cooling rates: 10 K min \u22121 , temperature range: \u2212 30-180 \u00b0C).", [["nitrogen", "CHEMICAL", 121, 129], ["Differential scanning calorimetry", "TEST", 0, 33], ["nitrogen", "TREATMENT", 121, 129], ["cooling rates", "TEST", 159, 172], ["temperature range", "TEST", 188, 205]]], ["Samples (6 mg) were sealed in aluminum pans and placed in the equipment sample chamber.", [["Samples", "ANATOMY", 0, 7], ["aluminum", "CHEMICAL", 30, 38], ["aluminum", "CHEMICAL", 30, 38], ["Samples", "TEST", 0, 7], ["aluminum pans", "TREATMENT", 30, 43]]], ["Fourier-transform infrared spectra (ATR-FTIR) of PLA and composite nonwovens before and after different times of UV light aging were recorded using Tensor 27 equipment with ATR mode (diamond crystal), in range 4000-600 cm \u22121 , at resolution 4 cm \u22121 .", [["PLA", "CHEMICAL", 49, 52], ["PLA", "CHEMICAL", 49, 52], ["diamond", "CHEMICAL", 183, 190], ["PLA", "SIMPLE_CHEMICAL", 49, 52], ["Fourier", "TEST", 0, 7], ["UV light aging", "TREATMENT", 113, 127], ["ATR mode (diamond crystal", "TREATMENT", 173, 198], ["PLA", "ANATOMY", 49, 52]]], ["For each sample, 64 scans were performed.Optimization of electrospinning parametersDiameter, quality and direction of fiber arrangement can be controlled by parameters such as polymer concentration in solution, solvents, electrical field voltage, or collector rotation speed.", [["fiber", "ANATOMY", 118, 123], ["each sample, 64 scans", "TEST", 4, 25], ["electrospinning parameters", "TEST", 57, 83], ["fiber arrangement", "TREATMENT", 118, 135], ["polymer concentration in solution, solvents", "TREATMENT", 176, 219], ["electrical field voltage", "TEST", 221, 245], ["collector rotation speed", "TEST", 250, 274]]], ["The needle-collector gap influences jet flying time and evaporation of the solvents.", [["The needle-collector gap", "TREATMENT", 0, 24], ["evaporation of the solvents", "TREATMENT", 56, 83]]], ["Binary-solvent system (DCM and DMF) was used to fabricate PLA-based nonwovens.", [["DCM", "CHEMICAL", 23, 26], ["PLA", "CHEMICAL", 58, 61], ["DMF", "CHEMICAL", 31, 34], ["PLA", "CHEMICAL", 58, 61], ["PLA", "SIMPLE_CHEMICAL", 58, 61], ["Binary-solvent system", "TREATMENT", 0, 21], ["DCM and DMF)", "TREATMENT", 23, 35]]], ["The SEM images were used to evaluate the quality (morphology and diameter) of obtained PLA fibers.", [["PLA fibers", "ANATOMY", 87, 97], ["PLA", "CHEMICAL", 87, 90], ["PLA fibers", "CELL", 87, 97], ["The SEM images", "TEST", 0, 14]]], ["All of the fibers had smooth and defect-free morphology.", [["fibers", "ANATOMY", 11, 17], ["fibers", "CELLULAR_COMPONENT", 11, 17], ["smooth", "OBSERVATION_MODIFIER", 22, 28], ["defect", "OBSERVATION", 33, 39], ["free morphology", "OBSERVATION", 40, 55]]], ["It was observed that ratio of solvent had a great influence on the fiber diameter (Fig. 2) .", [["fiber", "ANATOMY", 67, 72], ["fiber", "TISSUE", 67, 72], ["fiber diameter", "OBSERVATION_MODIFIER", 67, 81]]], ["Thinner fibers were obtained using ratio 2.5:1, regardless of the polymer concentrations.", [["Thinner fibers", "ANATOMY", 0, 14], ["ratio", "TEST", 35, 40], ["the polymer concentrations", "TREATMENT", 62, 88]]], ["The other optimized parameter was gap between tip of needle and collector, and polymer concentration.", [["tip of needle and collector, and polymer concentration", "TREATMENT", 46, 100]]], ["As expected, the diameter of the fibers decreased with increasing needlecollector distance, as shown in Fig. 2a .", [["fibers", "ANATOMY", 33, 39], ["fibers", "CELLULAR_COMPONENT", 33, 39], ["increasing needlecollector distance", "PROBLEM", 55, 90], ["diameter", "OBSERVATION_MODIFIER", 17, 25], ["fibers", "OBSERVATION_MODIFIER", 33, 39], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["increasing", "OBSERVATION_MODIFIER", 55, 65], ["needlecollector distance", "OBSERVATION", 66, 90], ["Fig", "OBSERVATION_MODIFIER", 104, 107]]], ["Also, in most cases, increasing the polymer concentration resulted in obtaining fibers with increased diameters (Fig. 2b) .", [["fibers", "ANATOMY", 80, 86], ["fibers", "CELLULAR_COMPONENT", 80, 86], ["increasing the polymer concentration", "PROBLEM", 21, 57], ["increased diameters (Fig.", "TREATMENT", 92, 117], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["diameters", "OBSERVATION_MODIFIER", 102, 111]]], ["Based on the SEM images, the following parameters were selected to obtain fibers modified with ceramic particles: concentrations of PLA-13%, gap between tip of needle and collector-5 cm, ratio of DCM and DMF-2.5 to 1.Impact of UV aging on fibers morphologyThe morphology of the composite fiber was examined using SEM (Fig. 3) .", [["fibers", "ANATOMY", 74, 80], ["fibers", "ANATOMY", 239, 245], ["fiber", "ANATOMY", 288, 293], ["DCM", "DISEASE", 196, 199], ["DMF", "CHEMICAL", 204, 207], ["PLA", "CHEMICAL", 132, 135], ["DMF", "CHEMICAL", 204, 207], ["fibers", "CELLULAR_COMPONENT", 239, 245], ["the SEM images", "TEST", 9, 23], ["PLA", "TEST", 132, 135], ["collector", "TEST", 171, 180], ["DCM", "PROBLEM", 196, 199], ["DMF", "TEST", 204, 207], ["UV aging", "TREATMENT", 227, 235], ["tip", "OBSERVATION_MODIFIER", 153, 156], ["needle", "ANATOMY", 160, 166], ["5 cm", "OBSERVATION_MODIFIER", 181, 185], ["DCM", "OBSERVATION", 196, 199], ["UV aging", "OBSERVATION", 227, 235], ["fibers morphology", "OBSERVATION_MODIFIER", 239, 256], ["composite fiber", "OBSERVATION", 278, 293]]], ["The pure PLA fibers exhibited smooth and defect-free surface, as shown in Fig. 3a .", [["PLA fibers", "ANATOMY", 9, 19], ["surface", "ANATOMY", 53, 60], ["PLA", "CHEMICAL", 9, 12], ["PLA fibers", "CELL", 9, 19], ["surface", "CELLULAR_COMPONENT", 53, 60], ["smooth and defect", "PROBLEM", 30, 47], ["smooth", "OBSERVATION_MODIFIER", 30, 36], ["defect", "OBSERVATION", 41, 47], ["free", "OBSERVATION_MODIFIER", 48, 52], ["surface", "OBSERVATION_MODIFIER", 53, 60]]], ["However, diameter distribution was wide, from 1.5 to 5.5 \u03bcm, with average diameter 2.91 \u03bcm (Fig. 4a) .", [["diameter", "OBSERVATION_MODIFIER", 9, 17], ["distribution", "OBSERVATION_MODIFIER", 18, 30], ["wide", "OBSERVATION_MODIFIER", 35, 39], ["1.5 to 5.5 \u03bcm", "OBSERVATION_MODIFIER", 46, 59], ["average", "OBSERVATION_MODIFIER", 66, 73], ["diameter", "OBSERVATION_MODIFIER", 74, 82]]], ["It was found that ceramic additives caused a reduction in average fiber diameter.", [["fiber", "ANATOMY", 66, 71], ["fiber", "TISSUE", 66, 71], ["ceramic additives", "TREATMENT", 18, 35], ["a reduction in average fiber diameter", "TREATMENT", 43, 80], ["ceramic additives", "OBSERVATION", 18, 35], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["average", "OBSERVATION_MODIFIER", 58, 65], ["fiber", "OBSERVATION_MODIFIER", 66, 71], ["diameter", "OBSERVATION_MODIFIER", 72, 80]]], ["For SiO 2 , TiO 2 and ZnO, it was 2.12, 1.40 and 2.79 \u03bcm, respectively, as well as narrowing the distribution (Fig. 4b-d) .", [["TiO 2", "CHEMICAL", 12, 17], ["ZnO", "CHEMICAL", 22, 25], ["SiO 2", "CHEMICAL", 4, 9], ["TiO 2", "CHEMICAL", 12, 17], ["ZnO", "CHEMICAL", 22, 25], ["SiO 2", "SIMPLE_CHEMICAL", 4, 9], ["TiO 2", "SIMPLE_CHEMICAL", 12, 17], ["ZnO", "SIMPLE_CHEMICAL", 22, 25], ["narrowing the distribution", "PROBLEM", 83, 109], ["narrowing", "OBSERVATION", 83, 92], ["distribution", "OBSERVATION_MODIFIER", 97, 109]]], ["Figure 3b , c shows that adding SiO 2 and TiO 2 , in contrast to ZnO, changed the morphology significantly.", [["SiO 2", "CHEMICAL", 32, 37], ["TiO 2", "CHEMICAL", 42, 47], ["ZnO", "CHEMICAL", 65, 68], ["SiO 2", "CHEMICAL", 32, 37], ["TiO 2", "CHEMICAL", 42, 47], ["ZnO", "CHEMICAL", 65, 68], ["SiO 2", "SIMPLE_CHEMICAL", 32, 37], ["TiO 2", "SIMPLE_CHEMICAL", 42, 47], ["ZnO", "SIMPLE_CHEMICAL", 65, 68], ["SiO 2 and TiO 2", "TREATMENT", 32, 47]]], ["In both cases, the fiber surface was wrinkled and defected.Impact of UV aging on fibers morphologyThe morphology of fibers after UV degradation was evaluated as well.", [["fiber surface", "ANATOMY", 19, 32], ["fibers", "ANATOMY", 81, 87], ["fibers", "ANATOMY", 116, 122], ["fiber surface", "CELLULAR_COMPONENT", 19, 32], ["fibers", "CELLULAR_COMPONENT", 81, 87], ["fibers", "CELLULAR_COMPONENT", 116, 122], ["UV aging", "TREATMENT", 69, 77], ["UV degradation", "TREATMENT", 129, 143], ["fiber", "OBSERVATION_MODIFIER", 19, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["wrinkled", "OBSERVATION_MODIFIER", 37, 45], ["defected", "OBSERVATION", 50, 58], ["UV aging", "OBSERVATION", 69, 77], ["fibers morphology", "OBSERVATION_MODIFIER", 81, 98], ["fibers", "OBSERVATION_MODIFIER", 116, 122], ["UV degradation", "OBSERVATION", 129, 143]]], ["Exposure of PLA fibers to irradiation for 10 min and 1 h did not significantly affect their morphology.", [["PLA fibers", "ANATOMY", 12, 22], ["PLA", "CHEMICAL", 12, 15], ["PLA fibers", "CELL", 12, 22]]], ["After 4 h, broken and bent fibers were observed (Fig. 3a) .", [["fibers", "ANATOMY", 27, 33], ["broken and bent fibers", "PROBLEM", 11, 33]]], ["A similar phenomenon occurred in composites with SiO 2 and TiO 2 (Fig. 3b, c) .", [["SiO 2", "CHEMICAL", 49, 54], ["TiO 2", "CHEMICAL", 59, 64], ["SiO 2", "SIMPLE_CHEMICAL", 49, 54], ["TiO 2", "SIMPLE_CHEMICAL", 59, 64], ["A similar phenomenon", "PROBLEM", 0, 20], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["phenomenon", "OBSERVATION", 10, 20]]], ["The PLA/ZnO fibers behaved differently under the UV exposure.", [["PLA", "CHEMICAL", 4, 7], ["ZnO", "CHEMICAL", 8, 11], ["UV", "CHEMICAL", 49, 51], ["PLA", "CHEMICAL", 4, 7], ["ZnO", "CHEMICAL", 8, 11], ["PLA", "SIMPLE_CHEMICAL", 4, 7], ["The PLA/ZnO fibers", "TREATMENT", 0, 18], ["the UV exposure", "TREATMENT", 45, 60], ["UV exposure", "OBSERVATION", 49, 60]]], ["Changes in morphology were much more significant.", [["Changes in morphology", "PROBLEM", 0, 21]]], ["Fibers fused together and the original microstructure was completely destroyed after 4 h, as shown in Fig. 4d .", [["Fibers", "ANATOMY", 0, 6], ["Fibers", "MULTI-TISSUE_STRUCTURE", 0, 6], ["microstructure", "OBSERVATION_MODIFIER", 39, 53]]], ["In addition, the change in the distribution of the fiber alignment was also the most significant (Fig. 4d) .", [["fiber", "ANATOMY", 51, 56], ["change", "OBSERVATION_MODIFIER", 17, 23], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["fiber alignment", "OBSERVATION", 51, 66]]], ["Before the degradation, fibers were arranged almost parallel to each other, but after degradation crossed fibers appeared (Fig. 3d) .", [["fibers", "ANATOMY", 24, 30], ["fibers", "ANATOMY", 106, 112], ["fibers", "CELLULAR_COMPONENT", 24, 30], ["fibers", "CELLULAR_COMPONENT", 106, 112]]], ["However, broken fibers weren't observed even after 4 h of UV exposure.", [["fibers", "ANATOMY", 16, 22], ["UV", "CHEMICAL", 58, 60], ["fibers", "CELLULAR_COMPONENT", 16, 22], ["broken fibers", "PROBLEM", 9, 22], ["UV exposure", "TREATMENT", 58, 69]]], ["Fibers in PLA nonwoven were arranged parallel to the direction of the collector rotation in major part, as shown in Fig. 4a (y-axis) .", [["Fibers", "ANATOMY", 0, 6], ["PLA", "CHEMICAL", 10, 13], ["Fibers", "MULTI-TISSUE_STRUCTURE", 0, 6], ["Fibers in PLA nonwoven", "TREATMENT", 0, 22], ["the collector rotation", "TREATMENT", 66, 88]]], ["The aging process resulted with a slight change, the chart became a little wider, but in the range not exceeding 5% after 10 min of UV exposure.", [["UV", "CHEMICAL", 132, 134], ["a slight change", "PROBLEM", 32, 47], ["UV exposure", "TREATMENT", 132, 143], ["slight", "OBSERVATION_MODIFIER", 34, 40], ["change", "OBSERVATION", 41, 47], ["little", "OBSERVATION_MODIFIER", 68, 74], ["wider", "OBSERVATION_MODIFIER", 75, 80]]], ["With longer aging time, the fibers broke during relaxing and changed the orientation, which is clearly visible on the graph for 4 h of UV exposure.", [["fibers", "ANATOMY", 28, 34], ["UV", "CHEMICAL", 135, 137], ["fibers", "CELLULAR_COMPONENT", 28, 34], ["UV exposure", "TREATMENT", 135, 146]]], ["This phenomenon was intensified even more in the case of composite fibers modified with TiO 2 and SiO 2 (Fig. 4b, c) .", [["fibers", "ANATOMY", 67, 73], ["TiO 2", "CHEMICAL", 88, 93], ["TiO 2", "CHEMICAL", 88, 93], ["SiO 2", "CHEMICAL", 98, 103], ["TiO 2", "SIMPLE_CHEMICAL", 88, 93], ["SiO 2", "SIMPLE_CHEMICAL", 98, 103], ["TiO 2 and SiO", "TREATMENT", 88, 101]]], ["Addition of ceramic particles did not promote receiving oriented nonwovens.", [["ceramic particles", "TREATMENT", 12, 29], ["ceramic particles", "OBSERVATION", 12, 29]]], ["They generate additional stresses in the fiber.", [["fiber", "ANATOMY", 41, 46], ["fiber", "CELLULAR_COMPONENT", 41, 46]]], ["When fiber broke under the UV radiation, it relaxed and changed its direction to a more favorable energetically.", [["the UV radiation", "TREATMENT", 23, 39]]], ["This effect is the most significant for PLA/ SiO 2 nonwoven.Impact of UV aging on fibers morphologyThe presence of ceramic particles led to larger deviations in the orientation of the nonwovens.", [["fibers", "ANATOMY", 82, 88], ["PLA", "CHEMICAL", 40, 43], ["SiO 2", "CHEMICAL", 45, 50], ["fibers", "CELLULAR_COMPONENT", 82, 88], ["PLA/ SiO 2 nonwoven", "TREATMENT", 40, 59], ["UV aging", "TREATMENT", 70, 78], ["ceramic particles", "PROBLEM", 115, 132], ["larger deviations", "PROBLEM", 140, 157], ["UV aging", "OBSERVATION", 70, 78], ["fibers morphology", "OBSERVATION_MODIFIER", 82, 99], ["ceramic particles", "OBSERVATION", 115, 132], ["larger", "OBSERVATION_MODIFIER", 140, 146], ["deviations", "OBSERVATION", 147, 157], ["orientation", "OBSERVATION_MODIFIER", 165, 176]]], ["This effect was most significant in the case of fibers with the addition of SiO 2 particles.", [["fibers", "ANATOMY", 48, 54], ["SiO 2", "CHEMICAL", 76, 81], ["fibers", "CELLULAR_COMPONENT", 48, 54], ["SiO 2 particles", "SIMPLE_CHEMICAL", 76, 91], ["the addition of SiO 2 particles", "TREATMENT", 60, 91], ["most significant", "OBSERVATION_MODIFIER", 16, 32]]], ["The spectrum of distribution of fibers collected on the collector during the ES process was the widest.", [["fibers", "ANATOMY", 32, 38], ["fibers", "CELLULAR_COMPONENT", 32, 38], ["fibers", "PROBLEM", 32, 38], ["spectrum", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["fibers", "OBSERVATION_MODIFIER", 32, 38], ["widest", "OBSERVATION_MODIFIER", 96, 102]]], ["The aging process also evidently led to a change in the direction of the fiber.", [["fiber", "ANATOMY", 73, 78], ["fiber", "CELLULAR_COMPONENT", 73, 78]]], ["The UV degradation induced structural changes in polymer, what is directly translated into thermal properties of PLA, which can be seen in Fig. 5a .", [["PLA", "CHEMICAL", 113, 116], ["PLA", "CHEMICAL", 113, 116], ["PLA", "SIMPLE_CHEMICAL", 113, 116], ["The UV degradation", "TREATMENT", 0, 18], ["structural changes in polymer", "PROBLEM", 27, 56], ["UV", "OBSERVATION", 4, 6], ["degradation induced", "OBSERVATION", 7, 26], ["structural changes", "OBSERVATION", 27, 45], ["polymer", "OBSERVATION_MODIFIER", 49, 56], ["PLA", "ANATOMY", 113, 116]]], ["The energy of phase transformations decreased with the aging time.", [["phase transformations", "PROBLEM", 14, 35], ["phase", "OBSERVATION_MODIFIER", 14, 19], ["transformations", "OBSERVATION_MODIFIER", 20, 35], ["decreased", "OBSERVATION_MODIFIER", 36, 45]]], ["A decrease in glass transition temperature (T g ) is due to the less need for fiber to go into a highly elastic state.Impact of UV aging on fibers thermal propertiesCeramic's additions have a significant impact on the degradation process under the UV radiation (Fig. 5b-d) .", [["fibers", "ANATOMY", 140, 146], ["A decrease in glass transition temperature (T g )", "TREATMENT", 0, 49], ["fiber", "TREATMENT", 78, 83], ["UV aging", "TREATMENT", 128, 136], ["fibers thermal propertiesCeramic's additions", "TREATMENT", 140, 184], ["the degradation process", "PROBLEM", 214, 237], ["the UV radiation", "TREATMENT", 244, 260], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["glass transition", "OBSERVATION", 14, 30], ["highly elastic", "OBSERVATION_MODIFIER", 97, 111], ["UV aging", "OBSERVATION", 128, 136]]], ["It seems that TiO 2 even accelerated the degradation of polymer structure.", [["TiO 2", "CHEMICAL", 14, 19], ["TiO 2", "CHEMICAL", 14, 19], ["TiO 2", "SIMPLE_CHEMICAL", 14, 19], ["the degradation of polymer structure", "PROBLEM", 37, 73], ["polymer structure", "OBSERVATION", 56, 73]]], ["Addition of ceramic's particles significantly reduced the temperatures of transformation processes and their energy.", [["ceramic's particles", "TREATMENT", 12, 31], ["transformation processes", "PROBLEM", 74, 98]]], ["Only ten degree separated melting from glass transition with recrystallization.", [["ten degree", "OBSERVATION_MODIFIER", 5, 15], ["melting", "OBSERVATION_MODIFIER", 26, 33], ["glass transition", "OBSERVATION", 39, 55], ["recrystallization", "OBSERVATION_MODIFIER", 61, 78]]], ["Energy of melting decreased as the sample holding time in aging chamber increased.", [["sample", "ANATOMY", 35, 41], ["melting", "OBSERVATION_MODIFIER", 10, 17], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["chamber", "OBSERVATION_MODIFIER", 64, 71], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["Similar situation was observed for fibers modified with SiO 2 .", [["fibers", "ANATOMY", 35, 41], ["SiO 2", "CHEMICAL", 56, 61], ["SiO 2", "CHEMICAL", 56, 61], ["fibers", "CELLULAR_COMPONENT", 35, 41], ["SiO 2", "SIMPLE_CHEMICAL", 56, 61]]], ["The exception here is ZnO; in this case, the drop is insignificant.", [["ZnO", "CHEMICAL", 22, 25], ["ZnO", "CHEMICAL", 22, 25], ["ZnO", "SIMPLE_CHEMICAL", 22, 25], ["ZnO", "TREATMENT", 22, 25], ["insignificant", "OBSERVATION_MODIFIER", 53, 66]]], ["The drop of melting energy after 4 h wasn't that significant.", [["melting energy", "PROBLEM", 12, 26], ["drop", "OBSERVATION_MODIFIER", 4, 8], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["This is consistent with SEM images; PLA/ZnO fibers were the least degraded.", [["PLA/ZnO", "CHEMICAL", 36, 43], ["PLA", "CHEMICAL", 36, 39], ["ZnO", "CHEMICAL", 40, 43], ["ZnO fibers", "SIMPLE_CHEMICAL", 40, 50], ["SEM images", "TEST", 24, 34], ["PLA/ZnO fibers", "TREATMENT", 36, 50], ["consistent with", "UNCERTAINTY", 8, 23]]], ["The exact values of phase transitions' energies are shown in Fig. 6 .", [["phase transitions' energies", "PROBLEM", 20, 47]]], ["Significant differences were also noted in the case of recrystallization energy.", [["recrystallization energy", "PROBLEM", 55, 79]]], ["Over time, the recrystallization energy decreases, with the exception of PLA/ZnO nonwoven.", [["PLA", "CHEMICAL", 73, 76], ["ZnO", "CHEMICAL", 77, 80], ["PLA", "CHEMICAL", 73, 76], ["ZnO", "CHEMICAL", 77, 80], ["PLA", "SIMPLE_CHEMICAL", 73, 76], ["the recrystallization energy decreases", "PROBLEM", 11, 49], ["PLA/ZnO nonwoven", "TREATMENT", 73, 89], ["decreases", "OBSERVATION_MODIFIER", 40, 49], ["ZnO nonwoven", "OBSERVATION", 77, 89]]], ["In this case, a slight increase in energy was observed.", [["a slight increase in energy", "PROBLEM", 14, 41], ["slight", "OBSERVATION_MODIFIER", 16, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["energy", "OBSERVATION", 35, 41]]], ["After 4 h, the energy value doubled.", [["the energy value", "TEST", 11, 27]]], ["The opposite trend was noted for the composite fibers modified with TiO 2 particles.", [["fibers", "ANATOMY", 47, 53], ["TiO 2", "CHEMICAL", 68, 73], ["TiO 2", "CHEMICAL", 68, 73], ["TiO 2 particles", "SIMPLE_CHEMICAL", 68, 83], ["the composite fibers", "TREATMENT", 33, 53], ["TiO 2 particles", "TREATMENT", 68, 83]]], ["After the initial increase, the transformation energy dropped significantly.Impact of UV aging on fibers thermal propertiesMelting of PLA/ZnO composite began at a slightly higher temperature compared to pure PLA and other composites.", [["fibers", "ANATOMY", 98, 104], ["PLA/ZnO", "CHEMICAL", 134, 141], ["PLA", "CHEMICAL", 208, 211], ["PLA", "CHEMICAL", 134, 137], ["ZnO", "CHEMICAL", 138, 141], ["PLA", "CHEMICAL", 208, 211], ["PLA", "SIMPLE_CHEMICAL", 134, 137], ["PLA", "SIMPLE_CHEMICAL", 208, 211], ["the transformation energy", "PROBLEM", 28, 53], ["UV aging", "TREATMENT", 86, 94], ["fibers thermal properties", "TREATMENT", 98, 123], ["PLA/ZnO composite", "TREATMENT", 134, 151], ["a slightly higher temperature", "PROBLEM", 161, 190], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["UV aging", "OBSERVATION", 86, 94], ["PLA", "ANATOMY", 134, 137]]], ["The energy also remained constant throughout the aging test.", [["the aging test", "TEST", 45, 59], ["constant", "OBSERVATION_MODIFIER", 25, 33]]], ["This can be explained by the greater proportion of the crystalline phase in the polymer.", [["crystalline phase", "OBSERVATION", 55, 72]]], ["For this reason, no cold recrystallization was observed.", [["cold recrystallization", "PROBLEM", 20, 42]]], ["ZnO nanoparticles may have acted as place of nucleation starting and promoted the crystallization of PLA.Impact of UV aging on fibers thermal propertiesThe positive impact of ZnO particles on PLA stability was also demonstrated by the lack of a significant increase in glass transition energy.", [["fibers", "ANATOMY", 127, 133], ["ZnO", "CHEMICAL", 0, 3], ["PLA", "CHEMICAL", 101, 104], ["ZnO", "CHEMICAL", 175, 178], ["ZnO", "CHEMICAL", 0, 3], ["PLA", "CHEMICAL", 101, 104], ["ZnO", "CHEMICAL", 175, 178], ["PLA", "CHEMICAL", 192, 195], ["ZnO nanoparticles", "SIMPLE_CHEMICAL", 0, 17], ["PLA", "SIMPLE_CHEMICAL", 101, 104], ["ZnO particles", "SIMPLE_CHEMICAL", 175, 188], ["PLA", "SIMPLE_CHEMICAL", 192, 195], ["ZnO nanoparticles", "TREATMENT", 0, 17], ["the crystallization of PLA", "TREATMENT", 78, 104], ["UV aging", "TREATMENT", 115, 123], ["fibers thermal properties", "TREATMENT", 127, 152], ["ZnO particles", "PROBLEM", 175, 188], ["a significant increase in glass transition energy", "PROBLEM", 243, 292], ["UV aging", "OBSERVATION", 115, 123], ["positive", "OBSERVATION_MODIFIER", 156, 164], ["impact", "OBSERVATION_MODIFIER", 165, 171], ["ZnO particles", "OBSERVATION", 175, 188], ["significant", "OBSERVATION_MODIFIER", 245, 256], ["increase", "OBSERVATION_MODIFIER", 257, 265], ["glass transition energy", "OBSERVATION", 269, 292]]], ["In fact, the value remains almost the same for 4 h of degradation.", [["the value", "TEST", 9, 18]]], ["This may indicate improved stability of the composite fibers.", [["fibers", "ANATOMY", 54, 60], ["fibers", "CELLULAR_COMPONENT", 54, 60], ["may indicate", "UNCERTAINTY", 5, 17], ["improved", "OBSERVATION_MODIFIER", 18, 26], ["stability", "OBSERVATION_MODIFIER", 27, 36], ["composite fibers", "OBSERVATION", 44, 60]]], ["In other cases, including pure PLA, the energy value increases several times.", [["PLA", "CHEMICAL", 31, 34], ["PLA", "SIMPLE_CHEMICAL", 31, 34], ["the energy value", "TEST", 36, 52]]], ["The most dynamic changes were observed for TiO 2 .Impact of UV aging on fibers thermal propertiesTiO 2 particles are used as a material absorbing UV radiation in sunlight [29, 30] .", [["fibers", "ANATOMY", 72, 78], ["TiO 2", "CHEMICAL", 43, 48], ["TiO 2", "CHEMICAL", 43, 48], ["TiO 2", "CHEMICAL", 97, 102], ["TiO 2", "GENE_OR_GENE_PRODUCT", 43, 48], ["TiO 2 particles", "SIMPLE_CHEMICAL", 97, 112], ["UV aging", "TREATMENT", 60, 68], ["fibers thermal propertiesTiO 2 particles", "TREATMENT", 72, 112], ["a material absorbing UV radiation", "TREATMENT", 125, 158], ["most dynamic", "OBSERVATION_MODIFIER", 4, 16], ["UV aging", "OBSERVATION", 60, 68]]], ["Therefore, it was expected that this type of nanoparticles should provide the best protection against photodegradation.", [["this type of nanoparticles", "TREATMENT", 32, 58], ["photodegradation", "TREATMENT", 102, 118]]], ["Even though the effectiveness of UV absorption of TiO 2 is very high, TiO 2 at the same time emits photoelectrons that can be involved in the production of peroxides and other reactive oxygen species (ROS-reactive oxygen species) [31] .Impact of UV aging on fibers thermal propertiesAlso, SiO 2 did not improve the stability of the polymer against UV irradiation.", [["fibers", "ANATOMY", 258, 264], ["TiO 2", "CHEMICAL", 50, 55], ["TiO 2", "CHEMICAL", 70, 75], ["oxygen", "CHEMICAL", 185, 191], ["ROS", "CHEMICAL", 201, 204], ["oxygen", "CHEMICAL", 214, 220], ["SiO 2", "CHEMICAL", 289, 294], ["UV", "CHEMICAL", 348, 350], ["TiO 2", "CHEMICAL", 50, 55], ["TiO 2", "CHEMICAL", 70, 75], ["peroxides", "CHEMICAL", 156, 165], ["oxygen", "CHEMICAL", 185, 191], ["oxygen", "CHEMICAL", 214, 220], ["SiO 2", "CHEMICAL", 289, 294], ["TiO 2", "SIMPLE_CHEMICAL", 50, 55], ["TiO 2", "SIMPLE_CHEMICAL", 70, 75], ["peroxides", "SIMPLE_CHEMICAL", 156, 165], ["reactive oxygen species", "SIMPLE_CHEMICAL", 176, 199], ["ROS", "SIMPLE_CHEMICAL", 201, 204], ["reactive oxygen species", "SIMPLE_CHEMICAL", 205, 228], ["SiO 2", "SIMPLE_CHEMICAL", 289, 294], ["UV absorption of TiO", "TREATMENT", 33, 53], ["peroxides", "TREATMENT", 156, 165], ["other reactive oxygen species", "PROBLEM", 170, 199], ["UV aging", "TREATMENT", 246, 254], ["fibers thermal properties", "TREATMENT", 258, 283], ["the polymer", "TREATMENT", 328, 339], ["UV irradiation", "TREATMENT", 348, 362], ["reactive", "OBSERVATION_MODIFIER", 176, 184], ["oxygen species", "OBSERVATION", 185, 199], ["UV aging", "OBSERVATION", 246, 254], ["UV irradiation", "OBSERVATION", 348, 362]]], ["Of all the ceramic particles tested, SiO 2 is the most transparent to UV radiation.", [["SiO 2", "CHEMICAL", 37, 42], ["UV", "CHEMICAL", 70, 72], ["SiO 2", "CHEMICAL", 37, 42], ["SiO 2", "SIMPLE_CHEMICAL", 37, 42], ["UV radiation", "TREATMENT", 70, 82], ["ceramic particles", "OBSERVATION", 11, 28], ["UV radiation", "OBSERVATION", 70, 82]]], ["Phase transition energies also fell the fastest in this case.", [["Phase transition energies", "PROBLEM", 0, 25]]], ["Also, the presence of SiO 2 in the fibers promoted their degradation due to the possibility of UV radiation passing through the SiO 2 grains (present on the surface and inside the fiber).", [["fibers", "ANATOMY", 35, 41], ["surface", "ANATOMY", 157, 164], ["fiber", "ANATOMY", 180, 185], ["SiO 2", "CHEMICAL", 22, 27], ["UV", "CHEMICAL", 95, 97], ["SiO 2", "CHEMICAL", 22, 27], ["SiO 2", "CHEMICAL", 128, 133], ["SiO 2", "GENE_OR_GENE_PRODUCT", 22, 27], ["fibers", "CELLULAR_COMPONENT", 35, 41], ["surface", "CELLULAR_COMPONENT", 157, 164], ["fiber", "CELLULAR_COMPONENT", 180, 185], ["SiO 2", "PROTEIN", 22, 27], ["UV radiation", "TREATMENT", 95, 107], ["the SiO 2 grains", "TREATMENT", 124, 140], ["radiation", "OBSERVATION", 98, 107]]], ["In addition, the PLA/SiO 2 nonwoven had the lowest cold crystallization energy.", [["PLA", "CHEMICAL", 17, 20], ["SiO", "CHEMICAL", 21, 24], ["PLA", "CHEMICAL", 17, 20], ["SiO 2", "CHEMICAL", 21, 26], ["the PLA/SiO 2 nonwoven", "TREATMENT", 13, 35], ["the lowest cold crystallization energy", "PROBLEM", 40, 78]]], ["This may indicate a large amount of the crystalline phase.Impact of UV aging on fibers chemical structureThe effect of UV aging on the chemical structure of PLAbased fibers was examined by the FITR-ATR method.", [["fibers", "ANATOMY", 80, 86], ["PLAbased fibers", "ANATOMY", 157, 172], ["PLAbased fibers", "CELL", 157, 172], ["UV aging", "TREATMENT", 68, 76], ["UV aging", "TREATMENT", 119, 127], ["large", "OBSERVATION_MODIFIER", 20, 25], ["amount", "OBSERVATION_MODIFIER", 26, 32], ["crystalline phase", "OBSERVATION", 40, 57], ["UV aging", "OBSERVATION", 68, 76], ["UV aging", "OBSERVATION", 119, 127]]], ["ATR spectrum of PLA nonwoven is shown in Fig. 7 .", [["PLA", "CHEMICAL", 16, 19], ["PLA", "CHEMICAL", 16, 19], ["ATR", "PROTEIN", 0, 3], ["PLA nonwoven", "TREATMENT", 16, 28]]], ["Typical bands of PLA can be found in the range 3000-2800 cm \u22121 (asymmetric and symmetric stretching vibrations in CH 3 , CH 2 and CH groups), at 1382.0 cm \u22121 (symmetric bending vibration of C-H) and 866.1 cm \u22121 (stretching vibration of C-C).", [["PLA", "CHEMICAL", 17, 20], ["CH 3", "CHEMICAL", 114, 118], ["CH", "CHEMICAL", 121, 123], ["CH", "CHEMICAL", 130, 132], ["C-H", "CHEMICAL", 190, 193], ["C-C", "CHEMICAL", 236, 239], ["PLA", "SIMPLE_CHEMICAL", 17, 20], ["C-C", "SIMPLE_CHEMICAL", 236, 239], ["PLA", "PROTEIN", 17, 20], ["Typical bands of PLA", "PROBLEM", 0, 20], ["symmetric stretching vibrations in CH", "TEST", 79, 116], ["PLA", "ANATOMY", 17, 20], ["symmetric", "OBSERVATION_MODIFIER", 79, 88], ["stretching vibrations", "OBSERVATION", 89, 110]]], ["Another characteristic peak at 1750.8 cm \u22121 corresponded to C=O groups [32] .", [["C=O", "CHEMICAL", 60, 63], ["peak", "OBSERVATION_MODIFIER", 23, 27]]], ["Bands at 1181.3 cm \u22121 and 1084.4 cm \u22121 can be assigned to C-O-C vibrations of ester groups [33] .", [["ester", "CHEMICAL", 78, 83], ["C-O-C", "CHEMICAL", 58, 63], ["ester", "CHEMICAL", 78, 83], ["C-O-C", "SIMPLE_CHEMICAL", 58, 63], ["ester", "SIMPLE_CHEMICAL", 78, 83], ["Bands", "TEST", 0, 5], ["C", "TEST", 58, 59]]], ["After aging changes in spectra weren't significant.", [["aging changes in spectra", "PROBLEM", 6, 30]]], ["There was no appearance of new peaks as the result of polymer degradation.", [["new peaks", "PROBLEM", 27, 36], ["polymer degradation", "PROBLEM", 54, 73], ["no appearance of", "UNCERTAINTY", 10, 26], ["new", "OBSERVATION_MODIFIER", 27, 30], ["peaks", "OBSERVATION", 31, 36], ["polymer degradation", "OBSERVATION", 54, 73]]], ["Only decrease in some band intensity was observed (Fig. 7a) .", [["some band intensity", "PROBLEM", 17, 36], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["some", "OBSERVATION_MODIFIER", 17, 21], ["band intensity", "OBSERVATION_MODIFIER", 22, 36]]], ["The spectra of different composite nonwovens looked similarly to this made of pure PLA (Fig. 7b-d) .", [["PLA", "CHEMICAL", 83, 86], ["PLA", "SIMPLE_CHEMICAL", 83, 86]]], ["The main bands of ceramic fillers could be overlapped and covered by the bands from the polymeric matrix.", [["matrix", "CELLULAR_COMPONENT", 98, 104], ["The main bands of ceramic fillers", "TREATMENT", 0, 33], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bands", "OBSERVATION_MODIFIER", 9, 14], ["ceramic fillers", "OBSERVATION", 18, 33], ["bands", "OBSERVATION_MODIFIER", 73, 78], ["polymeric matrix", "OBSERVATION", 88, 104]]], ["In addition, method (ATR) chosen to study the effect of photodegradation on composites chemical structure measures only a thin layer having direct contact with the crystal.", [["method (ATR)", "TREATMENT", 13, 25], ["photodegradation on composites chemical structure", "TREATMENT", 56, 105]]], ["The infrared analysis of PLA after UV aging test did not show any significant changes of the spectrum or formation of new bands.", [["PLA", "CHEMICAL", 25, 28], ["PLA", "CHEMICAL", 25, 28], ["PLA", "SIMPLE_CHEMICAL", 25, 28], ["The infrared analysis", "TEST", 0, 21], ["UV aging test", "TEST", 35, 48], ["new bands", "PROBLEM", 118, 127], ["new", "OBSERVATION_MODIFIER", 118, 121], ["bands", "OBSERVATION", 122, 127]]], ["The characteristic bands of the PLA decreased their intensities, due to the photodegradation of the polymer structure (smaller graphs show peaks for C-H stretching vibrations in PLA chains).", [["PLA", "CHEMICAL", 32, 35], ["C-H", "CHEMICAL", 149, 152], ["PLA", "CHEMICAL", 32, 35], ["C-H", "CHEMICAL", 149, 152], ["PLA", "CHEMICAL", 178, 181], ["PLA", "SIMPLE_CHEMICAL", 32, 35], ["PLA chains", "PROTEIN", 178, 188], ["the photodegradation of the polymer structure", "PROBLEM", 72, 117], ["smaller graphs", "TEST", 119, 133], ["C-H stretching vibrations in PLA chains", "TREATMENT", 149, 188], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["bands", "OBSERVATION_MODIFIER", 19, 24]]], ["In the case of pure PLA fibers, the intensity of bands in the range 3000-2800 cm \u22121 clearly decreased after just 10 min of UV exposure.", [["PLA fibers", "ANATOMY", 20, 30], ["UV", "CHEMICAL", 123, 125], ["PLA", "CHEMICAL", 20, 23], ["PLA fibers", "CELL", 20, 30], ["bands", "TEST", 49, 54], ["UV exposure", "TREATMENT", 123, 134], ["bands", "OBSERVATION_MODIFIER", 49, 54], ["decreased", "OBSERVATION_MODIFIER", 92, 101]]], ["However, an intensity of whole spectra did not change in a significant way even after 4 h (Fig. 7a ).", [["intensity", "OBSERVATION_MODIFIER", 12, 21]]], ["For composites with ZnO, an intensity of the C-H stretching vibrations decreased more gradually over time.", [["ZnO", "CHEMICAL", 20, 23], ["C-H", "CHEMICAL", 45, 48], ["ZnO", "CHEMICAL", 20, 23], ["C-H", "CHEMICAL", 45, 48], ["ZnO", "SIMPLE_CHEMICAL", 20, 23], ["C-H", "SIMPLE_CHEMICAL", 45, 48], ["ZnO", "TREATMENT", 20, 23], ["the C-H stretching vibrations", "PROBLEM", 41, 70]]], ["After 10 min, the change seems to be less rapid than in the case of pure PLA (Fig. 7b) .", [["PLA", "CHEMICAL", 73, 76], ["less", "OBSERVATION_MODIFIER", 37, 41], ["rapid", "OBSERVATION_MODIFIER", 42, 47]]], ["Again, the decrease in peaks in this area was also observed for PLA composites with TiO 2 and SiO 2 .", [["TiO 2", "CHEMICAL", 84, 89], ["PLA", "CHEMICAL", 64, 67], ["TiO 2", "CHEMICAL", 84, 89], ["SiO 2", "CHEMICAL", 94, 99], ["TiO 2", "SIMPLE_CHEMICAL", 84, 89], ["SiO 2", "SIMPLE_CHEMICAL", 94, 99], ["the decrease in peaks", "PROBLEM", 7, 28], ["PLA composites with TiO 2 and SiO 2", "TREATMENT", 64, 99], ["decrease", "OBSERVATION_MODIFIER", 11, 19], ["peaks", "OBSERVATION_MODIFIER", 23, 28]]], ["However, in these cases, the changes are much more significant, and after 4 h of UV exposure, the bands almost completely disappeared.", [["UV", "CHEMICAL", 81, 83], ["UV exposure", "TREATMENT", 81, 92], ["the bands", "PROBLEM", 94, 103], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["Polymer degradation is also indicated by gradual disappearance of peaks in the whole range of spectra (Fig. 7c, d) .Impact of UV aging on fibers chemical structureThe UV absorbers in the form of ceramic nanoparticles were added to slow down the UV degradation of", [["fibers", "ANATOMY", 138, 144], ["ceramic nanoparticles", "SIMPLE_CHEMICAL", 195, 216], ["Polymer degradation", "PROBLEM", 0, 19], ["gradual disappearance of peaks", "PROBLEM", 41, 71], ["UV aging", "TREATMENT", 126, 134], ["The UV absorbers", "TREATMENT", 163, 179], ["ceramic nanoparticles", "TREATMENT", 195, 216], ["the UV degradation", "TREATMENT", 241, 259], ["gradual", "OBSERVATION_MODIFIER", 41, 48], ["disappearance", "OBSERVATION_MODIFIER", 49, 62], ["peaks", "OBSERVATION_MODIFIER", 66, 71], ["UV aging", "OBSERVATION", 126, 134], ["UV absorbers", "OBSERVATION", 167, 179], ["ceramic nanoparticles", "OBSERVATION", 195, 216]]]], "7501758136e59d92ca0ae6ab34c1c2a030117fc5": [["IntroductionThe family of picornaviruses has more than 200 known members, divided into six genera, and contains pathogens such as poliovirus, human rhinovirus (HRV), encephalornyocarditis virus, foot and mouth disease virus and hepatitis A virus (HAV).", [["human rhinovirus (HRV), encephalornyocarditis virus", "DISEASE", 142, 193], ["foot and mouth disease", "DISEASE", 195, 217], ["hepatitis A", "DISEASE", 228, 239], ["HAV", "DISEASE", 247, 250], ["picornaviruses", "ORGANISM", 26, 40], ["poliovirus", "ORGANISM", 130, 140], ["human rhinovirus", "ORGANISM", 142, 158], ["encephalornyocarditis virus", "ORGANISM", 166, 193], ["foot and mouth disease virus", "ORGANISM", 195, 223], ["hepatitis A virus", "ORGANISM", 228, 245], ["HAV", "ORGANISM", 247, 250], ["human", "SPECIES", 142, 147], ["rhinovirus", "SPECIES", 148, 158], ["encephalornyocarditis virus", "SPECIES", 166, 193], ["foot and mouth disease virus", "SPECIES", 195, 223], ["hepatitis A virus", "SPECIES", 228, 245], ["human rhinovirus", "SPECIES", 142, 158], ["HRV", "SPECIES", 160, 163], ["encephalornyocarditis virus", "SPECIES", 166, 193], ["foot and mouth disease virus", "SPECIES", 195, 223], ["hepatitis A virus", "SPECIES", 228, 245], ["HAV", "SPECIES", 247, 250], ["picornaviruses", "PROBLEM", 26, 40], ["pathogens", "PROBLEM", 112, 121], ["poliovirus", "PROBLEM", 130, 140], ["human rhinovirus (HRV)", "PROBLEM", 142, 164], ["encephalornyocarditis virus", "PROBLEM", 166, 193], ["foot and mouth disease virus", "PROBLEM", 195, 223], ["hepatitis A virus", "PROBLEM", 228, 245], ["foot", "ANATOMY", 195, 199], ["mouth", "ANATOMY", 204, 209], ["disease", "OBSERVATION", 210, 217], ["hepatitis", "OBSERVATION", 228, 237]]], ["1\u00b14 These viruses possess a positive single-stranded RNA genome whose translation in mammalian cells produces a large protein product.", [["mammalian cells", "ANATOMY", 85, 100], ["mammalian cells", "CELL", 85, 100], ["positive single-stranded RNA genome", "DNA", 28, 63], ["mammalian cells", "CELL_TYPE", 85, 100], ["These viruses", "PROBLEM", 4, 17], ["a positive single-stranded RNA genome", "PROBLEM", 26, 63], ["a large protein product", "PROBLEM", 110, 133], ["positive", "OBSERVATION_MODIFIER", 28, 36], ["single-stranded RNA genome", "OBSERVATION_MODIFIER", 37, 63], ["mammalian cells", "OBSERVATION", 85, 100], ["large", "OBSERVATION_MODIFIER", 112, 117], ["protein product", "OBSERVATION", 118, 133]]], ["The co-and post-translational processing of this initial polyprotein relies on highly speci\u00aec and organized cleavage by viral cysteine proteinases, which are attractive targets for development of therapeutic agents.", [["cysteine", "CHEMICAL", 126, 134], ["viral cysteine proteinases", "PROTEIN", 120, 146], ["this initial polyprotein relies", "PROBLEM", 44, 75], ["viral cysteine proteinases", "PROBLEM", 120, 146], ["therapeutic agents", "TREATMENT", 196, 214], ["viral cysteine proteinases", "OBSERVATION", 120, 146]]], ["4,5 Among these, the 3C cysteine proteinases have been the subject of extensive structural investigation, with crystal structures reported for HAV 3C, 6, 7 HRV 3C, 8 and poliovirus 3C proteins.", [["cysteine", "CHEMICAL", 24, 32], ["HAV 3C", "ORGANISM", 143, 149], ["poliovirus 3C", "GENE_OR_GENE_PRODUCT", 170, 183], ["3C cysteine proteinases", "PROTEIN", 21, 44], ["HAV 3C, 6, 7 HRV 3C, 8 and poliovirus 3C proteins", "PROTEIN", 143, 192], ["HAV 3C", "SPECIES", 143, 149], ["the 3C cysteine proteinases", "TREATMENT", 17, 44], ["crystal structures", "PROBLEM", 111, 129], ["HAV 3C", "TEST", 143, 149], ["HRV 3C", "TEST", 156, 162], ["poliovirus 3C proteins", "TREATMENT", 170, 192], ["extensive", "OBSERVATION_MODIFIER", 70, 79]]], ["9 Analogous 3C proteinases have also been detected in human and avian coronaviruses.", [["human", "ORGANISM", 54, 59], ["avian coronaviruses", "ORGANISM", 64, 83], ["3C proteinases", "PROTEIN", 12, 26], ["human", "SPECIES", 54, 59], ["avian", "SPECIES", 64, 69], ["human", "SPECIES", 54, 59]]], ["10, 11 These essential viral enzymes are especially appealing as targets for pharmaceutical intervention because their unique active site geometry 1 makes them highly speci\u00aec in their choice of substrates and cleavage sites that are absent in non-infected mammalian cells.", [["cells", "ANATOMY", 266, 271], ["mammalian cells", "CELL", 256, 271], ["essential viral enzymes", "PROTEIN", 13, 36], ["non-infected mammalian cells", "CELL_TYPE", 243, 271], ["These essential viral enzymes", "TEST", 7, 36], ["pharmaceutical intervention", "TREATMENT", 77, 104], ["cleavage sites", "PROBLEM", 209, 223], ["viral", "OBSERVATION", 23, 28], ["non-infected mammalian cells", "OBSERVATION", 243, 271]]], ["In addition, the active site residues appear to be relatively invariant in rhinovirus, where large numbers of serotypes (>100) make vaccine development dicult.", [["rhinovirus", "ORGANISM", 75, 85], ["the active site residues", "PROBLEM", 13, 37], ["rhinovirus", "PROBLEM", 75, 85], ["serotypes", "PROBLEM", 110, 119], ["active", "OBSERVATION_MODIFIER", 17, 23], ["site residues", "OBSERVATION", 24, 37], ["appear to be", "UNCERTAINTY", 38, 50], ["relatively", "OBSERVATION_MODIFIER", 51, 61], ["invariant", "OBSERVATION_MODIFIER", 62, 71], ["rhinovirus", "OBSERVATION", 75, 85], ["large", "OBSERVATION_MODIFIER", 93, 98], ["numbers", "OBSERVATION_MODIFIER", 99, 106]]], ["12 Structurally the 3C proteinases have topologies that resemble the two domain b-barrel fold of the chymotrypsin-like serine proteinases.", [["serine", "CHEMICAL", 119, 125], ["chymotrypsin-like serine proteinases", "GENE_OR_GENE_PRODUCT", 101, 137], ["3C proteinases", "PROTEIN", 20, 34], ["domain b-barrel fold", "PROTEIN", 73, 93], ["chymotrypsin-like serine proteinases", "PROTEIN", 101, 137], ["the chymotrypsin", "TEST", 97, 113], ["serine proteinases", "PROBLEM", 119, 137]]], ["1,5\u00b18 The active site cysteine (Cys-172 in HAV 3C) is in close proximity to a histidine residue (His-44 in HAV 3C) that acts as a general base to form the nucleophilic thiolate anion.", [["1,5\u00b18", "CHEMICAL", 0, 5], ["cysteine", "CHEMICAL", 22, 30], ["Cys-172", "CHEMICAL", 32, 39], ["histidine", "CHEMICAL", 78, 87], ["His-44", "CHEMICAL", 97, 103], ["cysteine", "CHEMICAL", 22, 30], ["Cys", "CHEMICAL", 32, 35], ["histidine", "CHEMICAL", 78, 87], ["His", "CHEMICAL", 97, 100], ["thiolate", "CHEMICAL", 168, 176], ["cysteine", "AMINO_ACID", 22, 30], ["Cys-172", "AMINO_ACID", 32, 39], ["HAV 3C", "GENE_OR_GENE_PRODUCT", 43, 49], ["HAV 3C", "ORGANISM", 107, 113], ["nucleophilic thiolate anion", "SIMPLE_CHEMICAL", 155, 182], ["Cys", "TEST", 32, 35], ["HAV 3C", "TREATMENT", 43, 49], ["a histidine residue", "PROBLEM", 76, 95], ["HAV 3C", "TREATMENT", 107, 113], ["the nucleophilic thiolate anion", "TREATMENT", 151, 182], ["active", "OBSERVATION_MODIFIER", 10, 16], ["site cysteine", "OBSERVATION", 17, 30], ["histidine residue", "OBSERVATION", 78, 95], ["nucleophilic thiolate", "OBSERVATION", 155, 176]]], ["Substrate recognition, by analogy to the chymotrypsin family, is believed to involve anti-parallel binding of the backbone of the peptide to the proteinase and the interaction of the side chains with the enzyme in several key subsites.", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 41, 53], ["chymotrypsin family", "PROTEIN", 41, 60], ["proteinase", "PROTEIN", 145, 155], ["side chains", "PROTEIN", 183, 194], ["enzyme", "PROTEIN", 204, 210], ["the enzyme", "TEST", 200, 210]]], ["Hydrogen-bonding between the carbonyl oxygen of the side chain of the P 1 glutamine of the substrate (or peptidic inhibitor) and a histidine at the S 1 subsite (His-191 in HAV 3C) is probably one of the key recognition events (1, 5\u00b18).", [["Hydrogen", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 38, 44], ["glutamine", "CHEMICAL", 74, 83], ["histidine", "CHEMICAL", 131, 140], ["His-191", "CHEMICAL", 161, 168], ["Hydrogen", "CHEMICAL", 0, 8], ["carbonyl", "CHEMICAL", 29, 37], ["oxygen", "CHEMICAL", 38, 44], ["glutamine", "CHEMICAL", 74, 83], ["histidine", "CHEMICAL", 131, 140], ["His", "CHEMICAL", 161, 164], ["Hydrogen", "SIMPLE_CHEMICAL", 0, 8], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 29, 44], ["glutamine", "AMINO_ACID", 74, 83], ["histidine", "AMINO_ACID", 131, 140], ["Hydrogen-bonding", "TREATMENT", 0, 16], ["the carbonyl oxygen", "TREATMENT", 25, 44], ["the P 1 glutamine", "TREATMENT", 66, 83], ["the substrate", "TREATMENT", 87, 100], ["peptidic inhibitor", "TREATMENT", 105, 123], ["a histidine", "TREATMENT", 129, 140]]], ["The wild type HAV 3C has 219 amino acids with a molecular weight of 24 kilodaltons and exists as an active monomer.", [["amino acids", "CHEMICAL", 29, 40], ["amino acids", "CHEMICAL", 29, 40], ["HAV 3C", "ORGANISM", 14, 20], ["amino acids", "AMINO_ACID", 29, 40], ["HAV 3C", "SPECIES", 14, 20], ["amino acids", "TEST", 29, 40], ["active", "OBSERVATION_MODIFIER", 100, 106], ["monomer", "OBSERVATION", 107, 114]]], ["For peptide substrates mimicking the 2B/2C junction of the large precursor polyprotein, the k cat of this enzyme is typically about 1.8 s \u00c01 with a K m of 2.1 mM at a pH of 7.5.", [["2B/2C junction", "PROTEIN", 37, 51], ["peptide substrates", "PROBLEM", 4, 22], ["the large precursor polyprotein", "PROBLEM", 55, 86], ["this enzyme", "TEST", 101, 112], ["a K m", "TEST", 146, 151], ["a pH", "TEST", 165, 169], ["large", "OBSERVATION_MODIFIER", 59, 64], ["precursor polyprotein", "OBSERVATION", 65, 86]]], ["5 In the search for therapeutic leads, enzyme inhibition studies on HAV 3C and HRV 3C proteins have employed a large variety of compounds, including peptide aldehydes, 13\u00b115 peptide\u00afuoromethyl ketones, 16 b-lactams, 17 isatins, 18 homophthalimides, 19 vinylogous esters and sulfones, 12, 20, 21 and halomethyl carbonyl compounds.", [["aldehydes", "CHEMICAL", 157, 166], ["peptide\u00afuoromethyl ketones", "CHEMICAL", 174, 200], ["16 b-lactams", "CHEMICAL", 202, 214], ["isatins", "CHEMICAL", 219, 226], ["homophthalimides", "CHEMICAL", 231, 247], ["vinylogous esters", "CHEMICAL", 252, 269], ["12, 20, 21 and halomethyl carbonyl", "CHEMICAL", 284, 318], ["aldehydes", "CHEMICAL", 157, 166], ["peptide\u00afuoromethyl ketones", "CHEMICAL", 174, 200], ["isatins", "CHEMICAL", 219, 226], ["homophthalimides", "CHEMICAL", 231, 247], ["vinylogous esters", "CHEMICAL", 252, 269], ["sulfones", "CHEMICAL", 274, 282], ["12, 20, 21 and halomethyl carbonyl", "CHEMICAL", 284, 318], ["HAV 3C", "ORGANISM", 68, 74], ["HRV 3C", "GENE_OR_GENE_PRODUCT", 79, 85], ["peptide aldehydes", "SIMPLE_CHEMICAL", 149, 166], ["peptide\u00afuoromethyl ketones", "SIMPLE_CHEMICAL", 174, 200], ["b-lactams", "SIMPLE_CHEMICAL", 205, 214], ["isatins", "SIMPLE_CHEMICAL", 219, 226], ["homophthalimides", "SIMPLE_CHEMICAL", 231, 247], ["vinylogous esters", "SIMPLE_CHEMICAL", 252, 269], ["sulfones", "SIMPLE_CHEMICAL", 274, 282], ["12, 20, 21", "SIMPLE_CHEMICAL", 284, 294], ["halomethyl carbonyl compounds", "SIMPLE_CHEMICAL", 299, 328], ["HAV 3C and HRV 3C proteins", "PROTEIN", 68, 94], ["HAV 3C", "SPECIES", 68, 74], ["therapeutic leads", "TREATMENT", 20, 37], ["enzyme inhibition studies", "TEST", 39, 64], ["HAV 3C", "TEST", 68, 74], ["HRV 3C proteins", "TEST", 79, 94], ["a large variety of compounds", "PROBLEM", 109, 137], ["peptide aldehydes", "TEST", 149, 166], ["peptide\u00afuoromethyl ketones", "TEST", 174, 200], ["lactams", "TEST", 207, 214], ["isatins", "TEST", 219, 226], ["vinylogous esters", "TEST", 252, 269], ["sulfones", "TEST", 274, 282], ["halomethyl carbonyl compounds", "TREATMENT", 299, 328], ["large", "OBSERVATION_MODIFIER", 111, 116], ["variety", "OBSERVATION_MODIFIER", 117, 124], ["carbonyl compounds", "OBSERVATION", 310, 328]]], ["22, 23 Some of these compounds do show in vitro antiviral activity in cell culture, 12,15,16,18\u00b121 but toxicity can be a problem for substances that are generally reactive with thiols.", [["cell culture", "ANATOMY", 70, 82], ["12,15,16,18\u00b121", "CHEMICAL", 84, 98], ["toxicity", "DISEASE", 103, 111], ["thiols", "CHEMICAL", 177, 183], ["cell", "CELL", 70, 74], ["thiols", "SIMPLE_CHEMICAL", 177, 183], ["cell culture", "TEST", 70, 82], ["toxicity", "PROBLEM", 103, 111], ["antiviral activity", "OBSERVATION", 48, 66], ["reactive", "OBSERVATION_MODIFIER", 163, 171]]], ["18 In the present study we examine a number of sulfurcontaining azaglutamine derivatives as potential inhibitors of HAV 3C proteinase.", [["azaglutamine", "CHEMICAL", 64, 76], ["azaglutamine", "CHEMICAL", 64, 76], ["sulfurcontaining azaglutamine derivatives", "SIMPLE_CHEMICAL", 47, 88], ["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 116, 133], ["HAV 3C proteinase", "PROTEIN", 116, 133], ["HAV", "SPECIES", 116, 119], ["sulfurcontaining azaglutamine derivatives", "TREATMENT", 47, 88], ["potential inhibitors", "TREATMENT", 92, 112], ["HAV 3C proteinase", "TREATMENT", 116, 133]]], ["Incorporation of hydrazino functionality into peptide backbones (azapeptides) is well-established for generation of proteinase inhibitors, 24, 25 including cysteine proteinases.", [["hydrazino", "CHEMICAL", 17, 26], ["azapeptides", "CHEMICAL", 65, 76], ["hydrazino", "CHEMICAL", 17, 26], ["azapeptides", "CHEMICAL", 65, 76], ["cysteine", "CHEMICAL", 156, 164], ["hydrazino", "SIMPLE_CHEMICAL", 17, 26], ["peptide backbones", "SIMPLE_CHEMICAL", 46, 63], ["azapeptides", "SIMPLE_CHEMICAL", 65, 76], ["proteinase", "GENE_OR_GENE_PRODUCT", 116, 126], ["cysteine proteinases", "GENE_OR_GENE_PRODUCT", 156, 176], ["cysteine proteinases", "PROTEIN", 156, 176], ["hydrazino functionality into peptide backbones (azapeptides", "TREATMENT", 17, 76], ["proteinase inhibitors", "TREATMENT", 116, 137], ["cysteine proteinases", "TREATMENT", 156, 176]]], ["26 Recently such analogues have been shown to act as active site titrants for cysteine proteinase, 27 and certain symmetrical bishydrazides are extremely potent nanomolar inhibitors of cathepsin K, a cysteine proteinase involved in boneremodeling.", [["bishydrazides", "CHEMICAL", 126, 139], ["cysteine", "CHEMICAL", 78, 86], ["bishydrazides", "CHEMICAL", 126, 139], ["cysteine", "CHEMICAL", 200, 208], ["cysteine proteinase", "GENE_OR_GENE_PRODUCT", 78, 97], ["bishydrazides", "SIMPLE_CHEMICAL", 126, 139], ["cathepsin K", "GENE_OR_GENE_PRODUCT", 185, 196], ["cysteine proteinase", "GENE_OR_GENE_PRODUCT", 200, 219], ["cathepsin K", "PROTEIN", 185, 196], ["cysteine proteinase", "PROTEIN", 200, 219], ["cysteine proteinase", "TREATMENT", 78, 97], ["certain symmetrical bishydrazides", "TREATMENT", 106, 139], ["extremely potent nanomolar inhibitors", "TREATMENT", 144, 181], ["cathepsin K", "TREATMENT", 185, 196], ["a cysteine proteinase", "TREATMENT", 198, 219]]], ["28, 29 In one study on HRV 3C proteinase, an N-bromoacetyl azaglutamine dipeptide analogue 1 was shown to have an IC 50 of approximately 48 nM and to be a time-dependent irreversible inactivator with a k inact /K i value >2500 M \u00c01 s \u00c01 .", [["N-bromoacetyl azaglutamine", "CHEMICAL", 45, 71], ["N-bromoacetyl azaglutamine dipeptide", "CHEMICAL", 45, 81], ["HRV 3C proteinase", "GENE_OR_GENE_PRODUCT", 23, 40], ["N-bromoacetyl azaglutamine", "SIMPLE_CHEMICAL", 45, 71], ["HRV 3C proteinase", "PROTEIN", 23, 40], ["one study", "TEST", 10, 19], ["HRV 3C proteinase", "TREATMENT", 23, 40], ["an N-bromoacetyl azaglutamine dipeptide analogue", "TREATMENT", 42, 90], ["dependent irreversible inactivator", "PROBLEM", 160, 194], ["a k inact", "TEST", 200, 209], ["K i value", "TEST", 211, 220]]], ["22 However, in this case the inhibitory activity depends on the highly reactive bromoacetyl moiety, which is likely to react non-speci-\u00aecally with a variety of thiols present in mammalian cells.", [["cells", "ANATOMY", 188, 193], ["bromoacetyl", "CHEMICAL", 80, 91], ["thiols", "CHEMICAL", 160, 166], ["bromoacetyl", "CHEMICAL", 80, 91], ["thiols", "CHEMICAL", 160, 166], ["bromoacetyl moiety", "SIMPLE_CHEMICAL", 80, 98], ["thiols", "SIMPLE_CHEMICAL", 160, 166], ["mammalian cells", "CELL", 178, 193], ["mammalian cells", "CELL_TYPE", 178, 193], ["the highly reactive bromoacetyl moiety", "PROBLEM", 60, 98], ["reactive", "OBSERVATION_MODIFIER", 71, 79], ["bromoacetyl moiety", "OBSERVATION", 80, 98], ["mammalian cells", "OBSERVATION", 178, 193]]], ["The amide character of sulfenamides and the use of aryl sulfenamides as amino acid protecting groups which are removable by thiols under acidic conditions (Scheme 1), 30\u00b132 suggested that such functionality could display suciently low intrinsic reactivity and still form a disul\u00aede with the active site thiol (Cys-172) of HAV 3C cysteine proteinase.", [["sulfenamides", "CHEMICAL", 23, 35], ["aryl sulfenamides", "CHEMICAL", 51, 68], ["amino acid", "CHEMICAL", 72, 82], ["thiols", "CHEMICAL", 124, 130], ["thiol", "CHEMICAL", 303, 308], ["Cys-172", "CHEMICAL", 310, 317], ["amide", "CHEMICAL", 4, 9], ["sulfenamides", "CHEMICAL", 23, 35], ["aryl sulfenamides", "CHEMICAL", 51, 68], ["amino acid", "CHEMICAL", 72, 82], ["thiols", "CHEMICAL", 124, 130], ["thiol", "CHEMICAL", 303, 308], ["Cys", "CHEMICAL", 310, 313], ["cysteine", "CHEMICAL", 329, 337], ["sulfenamides", "SIMPLE_CHEMICAL", 23, 35], ["aryl sulfenamides", "SIMPLE_CHEMICAL", 51, 68], ["amino acid", "SIMPLE_CHEMICAL", 72, 82], ["thiols", "SIMPLE_CHEMICAL", 124, 130], ["HAV 3C cysteine proteinase", "GENE_OR_GENE_PRODUCT", 322, 348], ["HAV 3C cysteine proteinase", "PROTEIN", 322, 348], ["sulfenamides", "TREATMENT", 23, 35], ["aryl sulfenamides", "TREATMENT", 51, 68], ["amino acid protecting groups", "TREATMENT", 72, 100], ["suciently low intrinsic reactivity", "PROBLEM", 221, 255], ["Cys", "TEST", 310, 313], ["HAV 3C cysteine proteinase", "TREATMENT", 322, 348]]], ["Thus sulfenamide azaglutamine analogues of type A and B, as well as sulfonamide derivatives C, were synthesized and investigated for inhibition of this enzyme.", [["sulfenamide", "CHEMICAL", 5, 16], ["azaglutamine", "CHEMICAL", 17, 29], ["type A and B", "CHEMICAL", 43, 55], ["sulfonamide", "CHEMICAL", 68, 79], ["sulfenamide azaglutamine", "CHEMICAL", 5, 29], ["sulfonamide", "CHEMICAL", 68, 79], ["sulfenamide azaglutamine analogues", "SIMPLE_CHEMICAL", 5, 39], ["type A", "SIMPLE_CHEMICAL", 43, 49], ["B", "SIMPLE_CHEMICAL", 54, 55], ["sulfonamide derivatives C", "SIMPLE_CHEMICAL", 68, 93], ["enzyme", "PROTEIN", 152, 158], ["sulfenamide azaglutamine analogues", "TREATMENT", 5, 39], ["type A and B", "TREATMENT", 43, 55], ["sulfonamide derivatives C", "TREATMENT", 68, 93], ["this enzyme", "TEST", 147, 158]]], ["Although the sulfonamides C would not be expected to react with the active site cysteine, they have some potential to bind to active site residues, and they also provide a new sulfur-containing aza analogue motif for investigation.", [["sulfonamides", "CHEMICAL", 13, 25], ["cysteine", "CHEMICAL", 80, 88], ["sulfur", "CHEMICAL", 176, 182], ["sulfonamides C", "CHEMICAL", 13, 27], ["cysteine", "CHEMICAL", 80, 88], ["sulfur", "CHEMICAL", 176, 182], ["aza", "CHEMICAL", 194, 197], ["sulfonamides C", "SIMPLE_CHEMICAL", 13, 27], ["cysteine", "AMINO_ACID", 80, 88], ["sulfur", "SIMPLE_CHEMICAL", 176, 182], ["aza", "SIMPLE_CHEMICAL", 194, 197], ["the sulfonamides C", "TREATMENT", 9, 27], ["the active site cysteine", "PROBLEM", 64, 88], ["active site residues", "PROBLEM", 126, 146], ["a new sulfur-containing aza analogue motif", "TREATMENT", 170, 212], ["investigation", "TEST", 217, 230]]], ["The haloacetyl azaglutamine analogues 2 and 3 were also prepared for comparison.", [["haloacetyl azaglutamine", "CHEMICAL", 4, 27], ["haloacetyl azaglutamine", "CHEMICAL", 4, 27], ["haloacetyl azaglutamine", "SIMPLE_CHEMICAL", 4, 27], ["The haloacetyl azaglutamine analogues", "TREATMENT", 0, 37]]], ["In each case the side chain amide functionality bears two methyls since such groups are wellaccepted by the HAV 3C enzyme and hinder interactions with possible reactive intermediates, especially at the P 1 carbonyl site.", [["methyls", "CHEMICAL", 58, 65], ["amide", "CHEMICAL", 28, 33], ["methyls", "CHEMICAL", 58, 65], ["carbonyl", "CHEMICAL", 206, 214], ["methyls", "SIMPLE_CHEMICAL", 58, 65], ["HAV 3C enzyme", "PROTEIN", 108, 121], ["P 1 carbonyl site", "PROTEIN", 202, 219], ["reactive intermediates", "PROBLEM", 160, 182], ["possible", "UNCERTAINTY", 151, 159], ["reactive intermediates", "OBSERVATION", 160, 182]]], ["13, 16, 33 Results and Discussion Synthesis and testing of peptidosulfonamides C Examination of structure C indicates that condensation of the known a-bromoketone 4 34,35 with the anion derived from sulfonamide 5 or 6 of b-alanine dimethylamide using the procedure of Jones 36 would aord the dipeptide analogues 7 or 8, respectively (Scheme 2).", [["peptidosulfonamides", "CHEMICAL", 59, 78], ["a-bromoketone 4 34,35", "CHEMICAL", 149, 170], ["sulfonamide 5 or 6 of b-alanine dimethylamide", "CHEMICAL", 199, 244], ["peptidosulfonamides C", "CHEMICAL", 59, 80], ["a-bromoketone", "CHEMICAL", 149, 162], ["sulfonamide", "CHEMICAL", 199, 210], ["b-alanine dimethylamide", "CHEMICAL", 221, 244], ["dipeptide", "CHEMICAL", 292, 301], ["peptidosulfonamides C", "SIMPLE_CHEMICAL", 59, 80], ["a-bromoketone 4 34,35", "SIMPLE_CHEMICAL", 149, 170], ["anion", "SIMPLE_CHEMICAL", 180, 185], ["sulfonamide 5", "SIMPLE_CHEMICAL", 199, 212], ["b-alanine dimethylamide", "SIMPLE_CHEMICAL", 221, 244], ["structure C", "PROTEIN", 96, 107], ["Discussion Synthesis", "TEST", 23, 43], ["peptidosulfonamides", "TREATMENT", 59, 78], ["Examination", "TEST", 81, 92], ["condensation of the known a-bromoketone 4", "PROBLEM", 123, 164], ["sulfonamide", "TREATMENT", 199, 210], ["b-alanine dimethylamide", "TREATMENT", 221, 244], ["the procedure of Jones", "TREATMENT", 251, 273], ["the dipeptide analogues", "TREATMENT", 288, 311]]], ["The required sulfonamides are readily available by deprotection of N-Boc-b-alanine dimethylamide 37 followed by reaction with the appropriate sulfonyl chloride.", [["sulfonamides", "CHEMICAL", 13, 25], ["N-Boc-b-alanine dimethylamide 37", "CHEMICAL", 67, 99], ["sulfonyl chloride", "CHEMICAL", 142, 159], ["sulfonamides", "CHEMICAL", 13, 25], ["N-Boc-b-alanine dimethylamide 37", "CHEMICAL", 67, 99], ["sulfonyl chloride", "CHEMICAL", 142, 159], ["sulfonamides", "SIMPLE_CHEMICAL", 13, 25], ["N-Boc-b-alanine dimethylamide 37", "SIMPLE_CHEMICAL", 67, 99], ["sulfonyl chloride", "SIMPLE_CHEMICAL", 142, 159], ["sulfonamides", "TREATMENT", 13, 25], ["alanine dimethylamide", "TREATMENT", 75, 96], ["the appropriate sulfonyl chloride", "TREATMENT", 126, 159]]], ["As expected, the condensation 36 with the bromoketone proceeds readily, and can be followed by hydrogenolysis to remove the Cbz group in quantitative yield and form the corresponding amino compounds 9 and 10.", [["bromoketone", "CHEMICAL", 42, 53], ["Cbz", "CHEMICAL", 124, 127], ["bromoketone", "CHEMICAL", 42, 53], ["Cbz", "CHEMICAL", 124, 127], ["amino", "CHEMICAL", 183, 188], ["bromoketone", "SIMPLE_CHEMICAL", 42, 53], ["Cbz", "SIMPLE_CHEMICAL", 124, 127], ["the corresponding amino compounds", "TEST", 165, 198]]], ["Studies on sequence recognition by HAV 3C proteinase using model peptides suggests that the P 4 residue should be a hydrophobic amino acid such as l-leucine, and that the P 2 and P 3 residues can be l-alanine.", [["amino acid", "CHEMICAL", 128, 138], ["l-leucine", "CHEMICAL", 147, 156], ["l-alanine", "CHEMICAL", 199, 208], ["amino acid", "CHEMICAL", 128, 138], ["l-leucine", "CHEMICAL", 147, 156], ["l-alanine", "CHEMICAL", 199, 208], ["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 35, 52], ["amino acid", "AMINO_ACID", 128, 138], ["l-leucine", "SIMPLE_CHEMICAL", 147, 156], ["l-alanine", "SIMPLE_CHEMICAL", 199, 208], ["HAV 3C proteinase", "PROTEIN", 35, 52], ["HAV 3C", "SPECIES", 35, 41], ["sequence recognition", "TEST", 11, 31], ["HAV 3C proteinase", "TEST", 35, 52], ["model peptides", "TREATMENT", 59, 73], ["the P 4 residue", "PROBLEM", 88, 103], ["a hydrophobic amino acid", "TREATMENT", 114, 138], ["the P 2 and P 3 residues", "TREATMENT", 167, 191]]], ["38 This idea is supported by Scheme 1. inhibition of the enzyme at nanomolar levels by aldehyde and\u00afuoromethylketone peptide analogues that have such sequences.", [["aldehyde and\u00afuoromethylketone", "CHEMICAL", 87, 116], ["aldehyde and\u00afuoromethylketone peptide", "CHEMICAL", 87, 124], ["aldehyde and\u00afuoromethylketone peptide analogues", "SIMPLE_CHEMICAL", 87, 134], ["the enzyme", "TEST", 53, 63], ["nanomolar levels", "TEST", 67, 83], ["aldehyde and\u00afuoromethylketone peptide analogues", "TREATMENT", 87, 134], ["such sequences", "TEST", 145, 159]]], ["13, 16 Thus coupling of 9 or 10 to Nacetyl-l-leucinyl-l-alanine proceeds readily with ethyl chloroformate to generate the target tetrapeptide azaglutamine sulfonamide derivatives 11 and 12.IntroductionAssay of the sulfonamides 7, 8, 11, and 12 for inhibition of HAV 3C proteinase employed a C24S mutant in which the non-essential surface cysteine was replaced with serine and which displays catalytic parameters indistinguishable from the wild-type enzyme.", [["surface", "ANATOMY", 330, 337], ["Nacetyl-l-leucinyl-l-alanine", "CHEMICAL", 35, 63], ["ethyl chloroformate", "CHEMICAL", 86, 105], ["azaglutamine sulfonamide", "CHEMICAL", 142, 166], ["sulfonamides 7, 8, 11, and 12", "CHEMICAL", 214, 243], ["cysteine", "CHEMICAL", 338, 346], ["serine", "CHEMICAL", 365, 371], ["Nacetyl-l-leucinyl-l-alanine", "CHEMICAL", 35, 63], ["ethyl chloroformate", "CHEMICAL", 86, 105], ["azaglutamine sulfonamide", "CHEMICAL", 142, 166], ["sulfonamides", "CHEMICAL", 214, 226], ["cysteine", "CHEMICAL", 338, 346], ["serine", "CHEMICAL", 365, 371], ["Nacetyl-l-leucinyl-l-alanine", "SIMPLE_CHEMICAL", 35, 63], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 86, 105], ["azaglutamine sulfonamide derivatives", "SIMPLE_CHEMICAL", 142, 178], ["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 262, 279], ["C24S mutant", "ORGANISM", 291, 302], ["surface", "CELLULAR_COMPONENT", 330, 337], ["cysteine", "AMINO_ACID", 338, 346], ["serine", "AMINO_ACID", 365, 371], ["HAV 3C proteinase", "PROTEIN", 262, 279], ["C24S mutant", "PROTEIN", 291, 302], ["wild-type enzyme", "PROTEIN", 439, 455], ["HAV", "SPECIES", 262, 265], ["Nacetyl", "TEST", 35, 42], ["leucinyl", "TREATMENT", 45, 53], ["alanine proceeds", "TREATMENT", 56, 72], ["ethyl chloroformate", "TREATMENT", 86, 105], ["the target tetrapeptide azaglutamine sulfonamide derivatives", "TREATMENT", 118, 178], ["the sulfonamides", "TREATMENT", 210, 226], ["HAV 3C proteinase", "TREATMENT", 262, 279], ["a C24S mutant", "TREATMENT", 289, 302], ["the non-essential surface cysteine", "TREATMENT", 312, 346], ["catalytic parameters", "TEST", 391, 411], ["surface cysteine", "OBSERVATION", 330, 346]]], ["16, 39 All of these compounds are weak competitive inhibitors, with 8 being the most potent with an IC 50 value of 75 mM.", [["weak competitive inhibitors", "PROBLEM", 34, 61], ["weak", "OBSERVATION_MODIFIER", 34, 38], ["competitive", "OBSERVATION", 39, 50]]], ["This is signi\u00aecantly lower than the K m for an ideal hexapeptide substrate (2.1 mM), but not potent enough to warrant extensive study in view of the nanomolar inhibition achieved with a peptide aldehyde 13 and \u0101 uoromethyl ketone.", [["aldehyde", "CHEMICAL", 194, 202], ["\u0101 uoromethyl ketone", "CHEMICAL", 210, 229], ["aldehyde", "CHEMICAL", 194, 202], ["\u0101 uoromethyl ketone", "CHEMICAL", 210, 229], ["K m", "GENE_OR_GENE_PRODUCT", 36, 39], ["aldehyde 13", "SIMPLE_CHEMICAL", 194, 205], ["\u0101 uoromethyl ketone", "SIMPLE_CHEMICAL", 210, 229], ["an ideal hexapeptide substrate", "TREATMENT", 44, 74], ["extensive study", "TEST", 118, 133], ["the nanomolar inhibition", "TREATMENT", 145, 169], ["a peptide aldehyde", "TEST", 184, 202], ["lower", "OBSERVATION_MODIFIER", 21, 26]]], ["16 The other sulfonamides had IC 50 values !100 mM.Synthesis and testing of sulfenamide azapeptides and haloacetyl azapeptidesFor the synthesis of potential inhibitors with the structural framework A, Michael addition of hydrazine to N,N-dimethylacrylamide followed by protection of the more nucleophilic secondary nitrogen with benzyl chloroformate generates 13 along with the corresponding bisacylated product 14 (Scheme 3).", [["sulfonamides", "CHEMICAL", 13, 25], ["sulfenamide", "CHEMICAL", 76, 87], ["haloacetyl azapeptides", "CHEMICAL", 104, 126], ["hydrazine", "CHEMICAL", 221, 230], ["N,N-dimethylacrylamide", "CHEMICAL", 234, 256], ["nitrogen", "CHEMICAL", 315, 323], ["benzyl chloroformate", "CHEMICAL", 329, 349], ["sulfonamides", "CHEMICAL", 13, 25], ["sulfenamide azapeptides", "CHEMICAL", 76, 99], ["haloacetyl azapeptides", "CHEMICAL", 104, 126], ["hydrazine", "CHEMICAL", 221, 230], ["N,N-dimethylacrylamide", "CHEMICAL", 234, 256], ["nitrogen", "CHEMICAL", 315, 323], ["benzyl chloroformate", "CHEMICAL", 329, 349], ["sulfonamides", "SIMPLE_CHEMICAL", 13, 25], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 76, 99], ["haloacetyl azapeptides", "SIMPLE_CHEMICAL", 104, 126], ["hydrazine", "SIMPLE_CHEMICAL", 221, 230], ["N,N-dimethylacrylamide", "SIMPLE_CHEMICAL", 234, 256], ["benzyl chloroformate", "SIMPLE_CHEMICAL", 329, 349], ["The other sulfonamides", "TREATMENT", 3, 25], ["Synthesis", "TREATMENT", 51, 60], ["sulfenamide azapeptides", "TREATMENT", 76, 99], ["haloacetyl azapeptides", "TREATMENT", 104, 126], ["potential inhibitors", "TREATMENT", 147, 167], ["hydrazine", "TREATMENT", 221, 230], ["dimethylacrylamide", "TREATMENT", 238, 256], ["benzyl chloroformate", "TREATMENT", 329, 349], ["the corresponding bisacylated product", "TREATMENT", 374, 411]]], ["Coupling of the free primary nitrogen with the tripeptide, N-acetyl-lleucinyl-l-alanyl-l-alanine proceeds smoothly to give 15.", [["nitrogen", "CHEMICAL", 29, 37], ["N-acetyl-lleucinyl-l-alanyl-l-alanine", "CHEMICAL", 59, 96], ["primary nitrogen", "CHEMICAL", 21, 37], ["tripeptide", "CHEMICAL", 47, 57], ["N-acetyl-lleucinyl-l-alanyl-l-alanine", "CHEMICAL", 59, 96], ["nitrogen", "SIMPLE_CHEMICAL", 29, 37], ["N-acetyl-lleucinyl-l-alanyl-l-alanine", "SIMPLE_CHEMICAL", 59, 96], ["the tripeptide", "TREATMENT", 43, 57], ["acetyl", "TREATMENT", 61, 67], ["lleucinyl", "TREATMENT", 68, 77], ["alanyl-l-alanine proceeds", "TREATMENT", 80, 105]]], ["Hydrogenolytic deprotection liberates the alkylated nitrogen, which then immediately reacts with o-nitrosulfenyl chloride to aord the target sulfenamide 16.", [["alkylated nitrogen", "CHEMICAL", 42, 60], ["o-nitrosulfenyl chloride", "CHEMICAL", 97, 121], ["sulfenamide", "CHEMICAL", 141, 152], ["nitrogen", "CHEMICAL", 52, 60], ["o-nitrosulfenyl chloride", "CHEMICAL", 97, 121], ["sulfenamide", "CHEMICAL", 141, 152], ["nitrogen", "SIMPLE_CHEMICAL", 52, 60], ["o-nitrosulfenyl chloride", "SIMPLE_CHEMICAL", 97, 121], ["aord", "SIMPLE_CHEMICAL", 125, 129], ["sulfenamide 16", "SIMPLE_CHEMICAL", 141, 155], ["Hydrogenolytic deprotection", "TREATMENT", 0, 27], ["the alkylated nitrogen", "TREATMENT", 38, 60], ["o-nitrosulfenyl chloride", "TREATMENT", 97, 121], ["the target sulfenamide", "TREATMENT", 130, 152], ["alkylated nitrogen", "OBSERVATION", 42, 60]]], ["During these transformations it became clear that in the azaglutamine series, compounds which have amide character at only one nitrogen are prone to facile decomposition and should be protected at the other basic nitrogen as quickly as possible.", [["azaglutamine", "CHEMICAL", 57, 69], ["azaglutamine", "CHEMICAL", 57, 69], ["amide", "CHEMICAL", 99, 104], ["nitrogen", "CHEMICAL", 127, 135], ["nitrogen", "CHEMICAL", 213, 221], ["azaglutamine", "SIMPLE_CHEMICAL", 57, 69], ["nitrogen", "SIMPLE_CHEMICAL", 127, 135], ["the azaglutamine series", "TEST", 53, 76], ["clear", "OBSERVATION", 39, 44]]], ["Disappointingly, 16 shows no signi\u00aecant inhibition (IC 50 >1 mM) of HAV 3C proteinase despite the presence of the P 4 -P 1 backbone.", [["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 68, 85], ["HAV 3C proteinase", "PROTEIN", 68, 85], ["P 4 -P 1 backbone", "DNA", 114, 131], ["HAV", "SPECIES", 68, 71], ["signi\u00aecant inhibition", "PROBLEM", 29, 50], ["IC", "TEST", 52, 54], ["HAV 3C proteinase", "PROBLEM", 68, 85]]], ["Not only is there no detectable reaction with the inhibitor, but the level of competitive binding at the active site is also very low.", [["detectable reaction", "PROBLEM", 21, 40], ["the inhibitor", "TREATMENT", 46, 59], ["competitive binding", "PROBLEM", 78, 97], ["detectable", "OBSERVATION_MODIFIER", 21, 31], ["reaction", "OBSERVATION", 32, 40], ["active site", "OBSERVATION", 105, 116]]], ["Presumably the aromatic sulfenamide moiety is too bulky to be easily accommodated in the enzyme site which binds the P 1 H substrate residue.", [["sulfenamide", "CHEMICAL", 24, 35], ["sulfenamide", "CHEMICAL", 24, 35], ["H", "CHEMICAL", 121, 122], ["sulfenamide", "SIMPLE_CHEMICAL", 24, 35], ["enzyme site", "PROTEIN", 89, 100], ["P 1 H substrate", "PROTEIN", 117, 132], ["the aromatic sulfenamide moiety", "TREATMENT", 11, 42], ["aromatic sulfenamide", "OBSERVATION", 15, 35]]], ["Other sulfenamides were prepared wherein the o-nitrophenyl group is replaced with methyl or tri\u00afuoroethyl, but these compounds display very poor stability, especially in water, and were not pursued further.Synthesis and testing of sulfenamide azapeptides and haloacetyl azapeptidesThe preparation of structural type B again begins with Michael addition of hydrazine to N,N-dimethylacrylamide, this time with protection of the central nitrogen with a tert-butoxycarbonyl group to generate 17 (Scheme 4).", [["sulfenamides", "CHEMICAL", 6, 18], ["o-nitrophenyl", "CHEMICAL", 45, 58], ["methyl", "CHEMICAL", 82, 88], ["tri\u00afuoroethyl", "CHEMICAL", 92, 105], ["sulfenamide", "CHEMICAL", 231, 242], ["haloacetyl azapeptides", "CHEMICAL", 259, 281], ["hydrazine", "CHEMICAL", 356, 365], ["N,N-dimethylacrylamide", "CHEMICAL", 369, 391], ["nitrogen", "CHEMICAL", 434, 442], ["tert-butoxycarbonyl", "CHEMICAL", 450, 469], ["sulfenamides", "CHEMICAL", 6, 18], ["o-nitrophenyl", "CHEMICAL", 45, 58], ["methyl", "CHEMICAL", 82, 88], ["tri\u00afuoroethyl", "CHEMICAL", 92, 105], ["sulfenamide azapeptides", "CHEMICAL", 231, 254], ["haloacetyl azapeptides", "CHEMICAL", 259, 281], ["hydrazine", "CHEMICAL", 356, 365], ["N,N-dimethylacrylamide", "CHEMICAL", 369, 391], ["nitrogen", "CHEMICAL", 434, 442], ["tert-butoxycarbonyl", "CHEMICAL", 450, 469], ["sulfenamides", "SIMPLE_CHEMICAL", 6, 18], ["o-nitrophenyl", "SIMPLE_CHEMICAL", 45, 58], ["methyl", "SIMPLE_CHEMICAL", 82, 88], ["tri\u00afuoroethyl", "SIMPLE_CHEMICAL", 92, 105], ["water", "SIMPLE_CHEMICAL", 170, 175], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 231, 254], ["haloacetyl azapeptides", "SIMPLE_CHEMICAL", 259, 281], ["hydrazine", "SIMPLE_CHEMICAL", 356, 365], ["N,N-dimethylacrylamide", "SIMPLE_CHEMICAL", 369, 391], ["tert-butoxycarbonyl", "SIMPLE_CHEMICAL", 450, 469], ["Other sulfenamides", "TREATMENT", 0, 18], ["methyl or tri\u00afuoroethyl", "TREATMENT", 82, 105], ["Synthesis", "TREATMENT", 206, 215], ["sulfenamide azapeptides", "TREATMENT", 231, 254], ["haloacetyl azapeptides", "TREATMENT", 259, 281], ["hydrazine", "TREATMENT", 356, 365], ["dimethylacrylamide", "TREATMENT", 373, 391], ["the central nitrogen", "TREATMENT", 422, 442], ["a tert-butoxycarbonyl group", "TREATMENT", 448, 475], ["very", "OBSERVATION_MODIFIER", 135, 139], ["poor", "OBSERVATION_MODIFIER", 140, 144], ["stability", "OBSERVATION", 145, 154]]], ["Reaction with benzyl chloroformate aords 18, which can then be deprotected with tri\u00afuoroacetic acid to liberate the secondary nitrogen and permit its acylation with a variety of protected amino acids and peptides.", [["benzyl chloroformate", "CHEMICAL", 14, 34], ["tri\u00afuoroacetic acid", "CHEMICAL", 80, 99], ["nitrogen", "CHEMICAL", 126, 134], ["amino acids", "CHEMICAL", 188, 199], ["benzyl chloroformate", "CHEMICAL", 14, 34], ["tri\u00afuoroacetic acid", "CHEMICAL", 80, 99], ["nitrogen", "CHEMICAL", 126, 134], ["amino acids", "CHEMICAL", 188, 199], ["benzyl chloroformate aords 18", "SIMPLE_CHEMICAL", 14, 43], ["tri\u00afuoroacetic acid", "SIMPLE_CHEMICAL", 80, 99], ["amino acids", "AMINO_ACID", 188, 199], ["benzyl chloroformate aords", "TREATMENT", 14, 40], ["tri\u00afuoroacetic acid", "TREATMENT", 80, 99], ["the secondary nitrogen", "TREATMENT", 112, 134], ["its acylation", "TREATMENT", 146, 159], ["protected amino acids", "TREATMENT", 178, 199]]], ["Such condensations aord azaglutamine derivatives 19\u00b122.", [["azaglutamine", "CHEMICAL", 24, 36], ["azaglutamine", "CHEMICAL", 24, 36], ["aord azaglutamine derivatives", "SIMPLE_CHEMICAL", 19, 48], ["azaglutamine derivatives", "TEST", 24, 48]]], ["Because of the relative instability of the intermediate having the free basic nitrogen and solubility Scheme 2. problems with the N-acetyl-l-leucinyl-l-alanyl-l-alanine tripeptide, it proved advantageous to form tetrapeptide analogues via a two stage coupling.", [["N-acetyl-l-leucinyl-l-alanyl-l-alanine", "CHEMICAL", 130, 168], ["nitrogen", "CHEMICAL", 78, 86], ["N-acetyl-l-leucinyl-l-alanyl-l-alanine tripeptide", "CHEMICAL", 130, 179], ["tetrapeptide", "CHEMICAL", 212, 224], ["N-acetyl-l-leucinyl-l-alanyl-l-alanine tripeptide", "SIMPLE_CHEMICAL", 130, 179], ["the free basic nitrogen and solubility Scheme", "TREATMENT", 63, 108], ["the N-acetyl", "TREATMENT", 126, 138], ["leucinyl", "TREATMENT", 141, 149], ["l-alanyl-l-alanine tripeptide", "TREATMENT", 150, 179], ["tetrapeptide analogues", "TREATMENT", 212, 234], ["a two stage coupling", "PROBLEM", 239, 259], ["instability", "OBSERVATION", 24, 35]]], ["Thus compounds 21 and 22 were deprotected and coupled to the dipeptide, N-acetyl-l-leucinyl-l-alanine, to give 23 and 24, respectively.", [["N-acetyl-l-leucinyl-l-alanine", "CHEMICAL", 72, 101], ["dipeptide", "CHEMICAL", 61, 70], ["N-acetyl-l-leucinyl-l-alanine", "CHEMICAL", 72, 101], ["N-acetyl-l-leucinyl-l-alanine", "SIMPLE_CHEMICAL", 72, 101], ["the dipeptide", "TEST", 57, 70], ["acetyl", "TREATMENT", 74, 80], ["leucinyl-l-alanine", "TREATMENT", 83, 101]]], ["Hydrogenolytic removal of the Cbz groups of 19, 20, 23, and 24 followed by immediate reaction with o-nitrosulfenyl chloride yields the corresponding azaglutamine sulfenamide derivatives 25\u00b128, respectively.", [["Cbz", "CHEMICAL", 30, 33], ["19, 20, 23, and 24", "CHEMICAL", 44, 62], ["o-nitrosulfenyl chloride", "CHEMICAL", 99, 123], ["azaglutamine", "CHEMICAL", 149, 161], ["Cbz", "CHEMICAL", 30, 33], ["o-nitrosulfenyl chloride", "CHEMICAL", 99, 123], ["azaglutamine sulfenamide", "CHEMICAL", 149, 173], ["o-nitrosulfenyl chloride", "SIMPLE_CHEMICAL", 99, 123], ["azaglutamine sulfenamide derivatives", "SIMPLE_CHEMICAL", 149, 185], ["Hydrogenolytic removal", "TREATMENT", 0, 22], ["the Cbz groups", "TEST", 26, 40], ["immediate reaction", "PROBLEM", 75, 93], ["o-nitrosulfenyl chloride", "TREATMENT", 99, 123], ["the corresponding azaglutamine sulfenamide derivatives", "TREATMENT", 131, 185]]], ["These compounds all have a hydrazo nitrogen at the nominal position of the substrate P 1 carbonyl and sulfur at the P 1 H nitrogen site.Synthesis and testing of sulfenamide azapeptides and haloacetyl azapeptidesAssay of the type B compounds (i.e. 25\u00b128) for inhibition of HAV 3C proteinase shows better binding than with the type A analogue 16, presumably because the frame shift on the peptide backbone allows the bulky o-nitrophenyl group to occupy a site further down the P H binding region in the enzyme active site.", [["hydrazo nitrogen", "CHEMICAL", 27, 43], ["P 1 carbonyl", "CHEMICAL", 85, 97], ["sulfur", "CHEMICAL", 102, 108], ["H nitrogen", "CHEMICAL", 120, 130], ["sulfenamide", "CHEMICAL", 161, 172], ["haloacetyl azapeptides", "CHEMICAL", 189, 211], ["o-nitrophenyl", "CHEMICAL", 421, 434], ["hydrazo nitrogen", "CHEMICAL", 27, 43], ["carbonyl", "CHEMICAL", 89, 97], ["sulfur", "CHEMICAL", 102, 108], ["H", "CHEMICAL", 120, 121], ["nitrogen", "CHEMICAL", 122, 130], ["sulfenamide azapeptides", "CHEMICAL", 161, 184], ["haloacetyl azapeptides", "CHEMICAL", 189, 211], ["o-nitrophenyl", "CHEMICAL", 421, 434], ["P H", "CHEMICAL", 475, 478], ["hydrazo", "SIMPLE_CHEMICAL", 27, 34], ["P 1 carbonyl", "SIMPLE_CHEMICAL", 85, 97], ["sulfur", "SIMPLE_CHEMICAL", 102, 108], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 161, 184], ["haloacetyl azapeptides", "SIMPLE_CHEMICAL", 189, 211], ["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 272, 289], ["P 1 H nitrogen site", "DNA", 116, 135], ["HAV 3C proteinase", "PROTEIN", 272, 289], ["P H binding region", "DNA", 475, 493], ["enzyme active site", "PROTEIN", 501, 519], ["HAV 3C", "SPECIES", 272, 278], ["a hydrazo nitrogen", "TREATMENT", 25, 43], ["the substrate P 1 carbonyl", "TREATMENT", 71, 97], ["sulfur", "TREATMENT", 102, 108], ["Synthesis", "TREATMENT", 136, 145], ["sulfenamide azapeptides", "TREATMENT", 161, 184], ["haloacetyl azapeptides", "TREATMENT", 189, 211], ["Assay", "TEST", 211, 216], ["the type B compounds", "PROBLEM", 220, 240], ["HAV 3C proteinase", "TEST", 272, 289], ["the peptide backbone", "TREATMENT", 383, 403], ["the bulky o-nitrophenyl group", "TREATMENT", 411, 440], ["a site", "PROBLEM", 451, 457], ["enzyme", "ANATOMY", 501, 507], ["active site", "OBSERVATION", 508, 519]]], ["However, these substances still give only modest levels of inhibition with IC 50 values of 0.4 to 0.5 mM, with the exception of the tetrapeptide analogue 27, which has an initial IC 50 of ca 100 mM.", [["tetrapeptide", "CHEMICAL", 132, 144], ["IC 50 values", "TEST", 75, 87], ["the tetrapeptide analogue", "TEST", 128, 153]]], ["Electrospray mass spectrometry of the C24S HAV 3C enzyme inhibited with 27 for a prolonged period (!3 h) does show formation of an enzyme-nitrophenyl disul\u00aede, with the protein molecular ion peak shifting to higher mass by 1541 units (\u00c0H+C 6 H 4 NO 2 S).", [["nitrophenyl disul\u00aede", "CHEMICAL", 138, 158], ["NO", "CHEMICAL", 246, 248], ["nitrophenyl disul\u00aede", "CHEMICAL", 138, 158], ["H 4 NO 2 S", "CHEMICAL", 242, 252], ["enzyme-nitrophenyl disul\u00aede", "SIMPLE_CHEMICAL", 131, 158], ["C24S HAV 3C enzyme", "PROTEIN", 38, 56], ["enzyme", "PROTEIN", 131, 137], ["C24S HAV", "SPECIES", 38, 46], ["Electrospray mass spectrometry", "TEST", 0, 30], ["the C24S HAV 3C enzyme", "TEST", 34, 56], ["an enzyme", "TEST", 128, 137], ["nitrophenyl disul\u00aede", "TREATMENT", 138, 158], ["higher mass", "PROBLEM", 208, 219]]], ["The relatively poor competition with substrate may again be due to unfavorable interactions of the aromatic portion of the inhibitor with the enzyme active site.", [["enzyme active site", "PROTEIN", 142, 160], ["the inhibitor", "TREATMENT", 119, 132], ["the enzyme active site", "PROBLEM", 138, 160]]], ["Although the sulfenamide azapeptides are not as potent inhibitors of HAV 3C proteinase as the peptidic aldehydes 13\u00b115 or\u00afuoromethyl ketone, 16 they represent new structural types that are reasonably accessible and stable, and may be useful for inhibition of other cysteine proteinases.", [["sulfenamide", "CHEMICAL", 13, 24], ["aldehydes 13\u00b115 or\u00afuoromethyl ketone", "CHEMICAL", 103, 139], ["sulfenamide azapeptides", "CHEMICAL", 13, 36], ["aldehydes", "CHEMICAL", 103, 112], ["or\u00afuoromethyl ketone", "CHEMICAL", 119, 139], ["cysteine", "CHEMICAL", 265, 273], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 13, 36], ["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 69, 86], ["or\u00afuoromethyl ketone", "SIMPLE_CHEMICAL", 119, 139], ["cysteine proteinases", "GENE_OR_GENE_PRODUCT", 265, 285], ["HAV 3C proteinase", "PROTEIN", 69, 86], ["cysteine proteinases", "PROTEIN", 265, 285], ["HAV", "SPECIES", 69, 72], ["the sulfenamide azapeptides", "TREATMENT", 9, 36], ["HAV 3C proteinase", "TREATMENT", 69, 86], ["the peptidic aldehydes", "TEST", 90, 112], ["or\u00afuoromethyl ketone", "TEST", 119, 139], ["other cysteine proteinases", "PROBLEM", 259, 285], ["new", "OBSERVATION_MODIFIER", 159, 162], ["structural types", "OBSERVATION", 163, 179], ["stable", "OBSERVATION_MODIFIER", 215, 221]]], ["Although additional thiols were not added to assay mixtures in the present study, and there is a possibility of non-speci\u00aec reaction of compounds B and C with free thiols in vivo, removal of o-nitrophenylsulfenyl groups by extraneous thiols generally requires harsh conditions that include strong acid (e.g. p-toluenesulfonic acid) with high concentrations of thiol.", [["thiols", "CHEMICAL", 20, 26], ["thiols", "CHEMICAL", 164, 170], ["o-nitrophenylsulfenyl", "CHEMICAL", 191, 212], ["thiols", "CHEMICAL", 234, 240], ["p-toluenesulfonic acid", "CHEMICAL", 308, 330], ["thiol", "CHEMICAL", 360, 365], ["thiols", "CHEMICAL", 20, 26], ["thiols", "CHEMICAL", 164, 170], ["o-nitrophenylsulfenyl", "CHEMICAL", 191, 212], ["thiols", "CHEMICAL", 234, 240], ["p-toluenesulfonic acid", "CHEMICAL", 308, 330], ["thiol", "CHEMICAL", 360, 365], ["thiols", "SIMPLE_CHEMICAL", 20, 26], ["B", "SIMPLE_CHEMICAL", 146, 147], ["C", "SIMPLE_CHEMICAL", 152, 153], ["free thiols", "SIMPLE_CHEMICAL", 159, 170], ["o-nitrophenylsulfenyl groups", "SIMPLE_CHEMICAL", 191, 219], ["extraneous thiols", "SIMPLE_CHEMICAL", 223, 240], ["p-toluenesulfonic acid", "SIMPLE_CHEMICAL", 308, 330], ["thiol", "SIMPLE_CHEMICAL", 360, 365], ["additional thiols", "TREATMENT", 9, 26], ["the present study", "TEST", 63, 80], ["non-speci\u00aec reaction", "PROBLEM", 112, 132], ["free thiols in vivo", "TREATMENT", 159, 178], ["removal of o-nitrophenylsulfenyl groups", "TREATMENT", 180, 219], ["harsh conditions", "TREATMENT", 260, 276], ["strong acid (e.g. p-toluenesulfonic acid", "TREATMENT", 290, 330], ["high concentrations of thiol", "TREATMENT", 337, 365]]], ["30\u00b132 Cell culture studies could help to determine whether such sulfenamide functionalities are likely to be benign and stable in vivo.Synthesis and testing of sulfenamide azapeptides and haloacetyl azapeptidesPeptidic halomethyl carbonyl compounds are potent inactivators of 3C proteinases, 16, 22, 23 and as mentioned above, the bromoacetyl azaglutamine derivative 1 has been reported as an irreversible inhibitor of the HRV 3C enzyme.", [["Cell", "ANATOMY", 6, 10], ["sulfenamide", "CHEMICAL", 64, 75], ["sulfenamide", "CHEMICAL", 160, 171], ["haloacetyl azapeptides", "CHEMICAL", 188, 210], ["halomethyl carbonyl", "CHEMICAL", 219, 238], ["bromoacetyl azaglutamine", "CHEMICAL", 331, 355], ["sulfenamide", "CHEMICAL", 64, 75], ["sulfenamide azapeptides", "CHEMICAL", 160, 183], ["haloacetyl azapeptides", "CHEMICAL", 188, 210], ["halomethyl carbonyl", "CHEMICAL", 219, 238], ["bromoacetyl azaglutamine", "CHEMICAL", 331, 355], ["Cell", "CELL", 6, 10], ["sulfenamide", "SIMPLE_CHEMICAL", 64, 75], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 160, 183], ["haloacetyl azapeptides", "SIMPLE_CHEMICAL", 188, 210], ["Peptidic halomethyl carbonyl compounds", "SIMPLE_CHEMICAL", 210, 248], ["bromoacetyl azaglutamine derivative 1", "SIMPLE_CHEMICAL", 331, 368], ["HRV 3C", "GENE_OR_GENE_PRODUCT", 423, 429], ["3C proteinases", "PROTEIN", 276, 290], ["HRV 3C enzyme", "PROTEIN", 423, 436], ["Cell culture studies", "TEST", 6, 26], ["such sulfenamide functionalities", "PROBLEM", 59, 91], ["Synthesis", "TREATMENT", 135, 144], ["sulfenamide azapeptides", "TREATMENT", 160, 183], ["haloacetyl azapeptides", "TREATMENT", 188, 210], ["Peptidic halomethyl carbonyl compounds", "TREATMENT", 210, 248], ["3C proteinases", "TEST", 276, 290], ["the bromoacetyl azaglutamine derivative", "TREATMENT", 327, 366], ["likely to be", "UNCERTAINTY", 96, 108], ["benign", "OBSERVATION", 109, 115], ["stable", "OBSERVATION_MODIFIER", 120, 126], ["carbonyl compounds", "OBSERVATION", 230, 248]]], ["22 The availability of precursors for aza analogues from our preceding work encouraged the construction of chloroacetyl and bromoacetyl azaglutamine derivatives 2 and 3, respectively (Scheme 5).Synthesis and testing of sulfenamide azapeptides and haloacetyl azapeptidesThus reductive deprotection of 15 as in Scheme 3, followed by immediate acylation with chloroacetyl chloride or bromoacetyl bromide aords the target compounds directly.", [["chloroacetyl", "CHEMICAL", 107, 119], ["bromoacetyl", "CHEMICAL", 124, 135], ["sulfenamide", "CHEMICAL", 219, 230], ["haloacetyl azapeptides", "CHEMICAL", 247, 269], ["chloroacetyl chloride", "CHEMICAL", 356, 377], ["bromoacetyl bromide", "CHEMICAL", 381, 400], ["aza", "CHEMICAL", 38, 41], ["chloroacetyl", "CHEMICAL", 107, 119], ["bromoacetyl azaglutamine", "CHEMICAL", 124, 148], ["sulfenamide azapeptides", "CHEMICAL", 219, 242], ["haloacetyl azapeptides", "CHEMICAL", 247, 269], ["chloroacetyl chloride", "CHEMICAL", 356, 377], ["bromoacetyl bromide", "CHEMICAL", 381, 400], ["aza analogues", "SIMPLE_CHEMICAL", 38, 51], ["chloroacetyl", "SIMPLE_CHEMICAL", 107, 119], ["bromoacetyl azaglutamine derivatives", "SIMPLE_CHEMICAL", 124, 160], ["sulfenamide azapeptides", "SIMPLE_CHEMICAL", 219, 242], ["haloacetyl azapeptides", "SIMPLE_CHEMICAL", 247, 269], ["chloroacetyl chloride", "SIMPLE_CHEMICAL", 356, 377], ["bromoacetyl bromide", "SIMPLE_CHEMICAL", 381, 400], ["aza analogues", "TREATMENT", 38, 51], ["chloroacetyl", "TREATMENT", 107, 119], ["bromoacetyl azaglutamine derivatives", "TREATMENT", 124, 160], ["Synthesis", "TREATMENT", 194, 203], ["sulfenamide azapeptides", "TREATMENT", 219, 242], ["haloacetyl azapeptides", "TREATMENT", 247, 269], ["reductive deprotection", "TREATMENT", 274, 296], ["immediate acylation", "TREATMENT", 331, 350], ["chloroacetyl chloride", "TREATMENT", 356, 377], ["bromoacetyl bromide", "TREATMENT", 381, 400], ["reductive", "OBSERVATION_MODIFIER", 274, 283], ["deprotection", "OBSERVATION", 284, 296]]], ["As expected, both 2 and 3 show potent time-dependent irreversible inhibition of HAV 3C proteinase with rate constants k obs /[I] of 680 M \u00c01 s \u00c01 and 870 M \u00c01 s \u00c01 , respectively.", [["HAV 3C proteinase", "GENE_OR_GENE_PRODUCT", 80, 97], ["HAV 3C proteinase", "PROTEIN", 80, 97], ["HAV", "SPECIES", 80, 83], ["dependent irreversible inhibition of HAV 3C proteinase", "PROBLEM", 43, 97], ["rate constants", "TEST", 103, 117], ["irreversible", "OBSERVATION_MODIFIER", 53, 65]]], ["Electrospray mass spectrometry of the enzyme-inhibitor complexes show addition of 470 mass units to the molecular ion and suggest that in each case there is displacement of halogen by the active site thiol of Cys-172.", [["thiol", "CHEMICAL", 200, 205], ["Cys-172", "CHEMICAL", 209, 216], ["halogen", "CHEMICAL", 173, 180], ["thiol", "CHEMICAL", 200, 205], ["Cys", "CHEMICAL", 209, 212], ["Cys-172", "AMINO_ACID", 209, 216], ["enzyme-inhibitor complexes", "PROTEIN", 38, 64], ["Electrospray mass spectrometry", "TEST", 0, 30], ["the enzyme-inhibitor complexes", "TEST", 34, 64], ["displacement of halogen", "PROBLEM", 157, 180], ["Cys", "TEST", 209, 212]]], ["This is in accord with the reaction of HAV 3C with a tetrapeptide\u00afuoromethyl ketone which has been studied by NMR spectrometry, 16 as well as with the displacement of halogen from iodoacetyl peptides by the active site thiol.", [["HAV 3C", "CHEMICAL", 39, 45], ["tetrapeptide\u00afuoromethyl ketone", "CHEMICAL", 53, 83], ["iodoacetyl", "CHEMICAL", 180, 190], ["thiol", "CHEMICAL", 219, 224], ["tetrapeptide\u00afuoromethyl ketone", "CHEMICAL", 53, 83], ["halogen", "CHEMICAL", 167, 174], ["iodoacetyl", "CHEMICAL", 180, 190], ["thiol", "CHEMICAL", 219, 224], ["tetrapeptide\u00afuoromethyl ketone", "SIMPLE_CHEMICAL", 53, 83], ["iodoacetyl peptides", "SIMPLE_CHEMICAL", 180, 199], ["HAV 3C", "TREATMENT", 39, 45], ["a tetrapeptide\u00afuoromethyl ketone", "TREATMENT", 51, 83], ["NMR spectrometry", "TEST", 110, 126], ["the displacement of halogen", "TREATMENT", 147, 174], ["iodoacetyl peptides", "TREATMENT", 180, 199], ["active", "OBSERVATION_MODIFIER", 207, 213], ["site thiol", "OBSERVATION", 214, 224]]], ["23, 40 Our compounds are somewhat less active against the HAV 3C enzyme than 1 is with the HRV 3C proteinase (k inact / K i value>2500 M \u00c01 s \u00c01 ).", [["HAV 3C", "ORGANISM", 58, 64], ["HAV 3C enzyme", "PROTEIN", 58, 71], ["HRV 3C proteinase", "PROTEIN", 91, 108], ["HAV 3C", "SPECIES", 58, 64], ["the HAV 3C enzyme", "TEST", 54, 71], ["the HRV", "TEST", 87, 94], ["proteinase", "TEST", 98, 108], ["k inact", "TEST", 110, 117], ["K i value", "TEST", 120, 129], ["somewhat less", "OBSERVATION_MODIFIER", 25, 38]]], ["22 The reasons for this are uncertain, but most likely re\u00afect dierences between the proximal subsite interactions (P 1 and P 2 ) between the two enzymes with their cognate inhibitors.", [["the proximal subsite interactions", "PROBLEM", 80, 113], ["the two enzymes", "TEST", 137, 152], ["their cognate inhibitors", "TREATMENT", 158, 182], ["proximal", "ANATOMY_MODIFIER", 84, 92]]], ["Possibly the presence of two methyl groups in the glutamine analogue side chain also has some eect.", [["methyl", "CHEMICAL", 29, 35], ["glutamine", "CHEMICAL", 50, 59], ["methyl", "CHEMICAL", 29, 35], ["glutamine", "CHEMICAL", 50, 59], ["methyl", "SIMPLE_CHEMICAL", 29, 35], ["glutamine", "AMINO_ACID", 50, 59], ["two methyl groups", "TREATMENT", 25, 42], ["the glutamine analogue side chain", "TREATMENT", 46, 79], ["methyl groups", "OBSERVATION", 29, 42], ["some", "OBSERVATION_MODIFIER", 89, 93], ["eect", "OBSERVATION", 94, 98]]], ["Moreover, it is clear that recognition of the peptide moiety in inhibitors 2 and 3 is crucial because the inherently more reactive compound, N-iodoacetamide, has a second order rate constant for inactivation of only about 3.1 M \u00c01 s \u00c01 .", [["N-iodoacetamide", "CHEMICAL", 141, 156], ["N-iodoacetamide", "CHEMICAL", 141, 156], ["N-iodoacetamide", "SIMPLE_CHEMICAL", 141, 156], ["the peptide moiety in inhibitors", "TREATMENT", 42, 74], ["iodoacetamide", "TREATMENT", 143, 156], ["clear", "OBSERVATION", 16, 21], ["reactive compound", "OBSERVATION", 122, 139]]], ["23 In conclusion, the present work provides synthetic access to four types of aza amino acid peptide analogues.", [["aza amino acid", "CHEMICAL", 78, 92], ["aza amino acid", "CHEMICAL", 78, 92], ["aza amino acid", "SIMPLE_CHEMICAL", 78, 92], ["aza amino acid peptide analogues", "TREATMENT", 78, 110]]], ["Although some show no binding (structural type A) or only weak initial inhibitory activity (structural types B and C) toward the hepatitis A virus 3C proteinase, the haloacetyl azaglutamine tetrapeptides 2 and 3 as well as the sulfenamide azaglutamine derivative 27 irreversibly react with the active site thiol (Cys-172).", [["hepatitis A", "DISEASE", 129, 140], ["haloacetyl azaglutamine", "CHEMICAL", 166, 189], ["azaglutamine", "CHEMICAL", 239, 251], ["thiol", "CHEMICAL", 306, 311], ["Cys-172", "CHEMICAL", 313, 320], ["haloacetyl azaglutamine tetrapeptides", "CHEMICAL", 166, 203], ["sulfenamide azaglutamine", "CHEMICAL", 227, 251], ["thiol", "CHEMICAL", 306, 311], ["Cys", "CHEMICAL", 313, 316], ["hepatitis A virus 3C", "ORGANISM", 129, 149], ["sulfenamide azaglutamine derivative 27", "SIMPLE_CHEMICAL", 227, 265], ["Cys-172", "SIMPLE_CHEMICAL", 313, 320], ["hepatitis A virus 3C proteinase", "PROTEIN", 129, 160], ["hepatitis A virus", "SPECIES", 129, 146], ["hepatitis A virus", "SPECIES", 129, 146], ["weak initial inhibitory activity", "PROBLEM", 58, 90], ["structural types B and C)", "PROBLEM", 92, 117], ["the hepatitis A virus 3C proteinase", "TREATMENT", 125, 160], ["the haloacetyl azaglutamine tetrapeptides", "TREATMENT", 162, 203], ["the sulfenamide azaglutamine derivative", "TREATMENT", 223, 262], ["Cys", "TEST", 313, 316], ["no", "UNCERTAINTY", 19, 21]]], ["It is not unreasonable to expect that such substrate analogues may be more potent and useful for other types of cysteine proteinases.", [["cysteine", "CHEMICAL", 112, 120], ["cysteine proteinases", "GENE_OR_GENE_PRODUCT", 112, 132], ["cysteine proteinases", "PROTEIN", 112, 132], ["such substrate analogues", "PROBLEM", 38, 62], ["cysteine proteinases", "PROBLEM", 112, 132], ["not unreasonable", "UNCERTAINTY", 6, 22]]], ["Current studies with other types of inhibitors of picornaviral proteinases will be reported shortly.General methods and enzyme assaysMost general procedures and instrumentation have been previously described.", [["picornaviral proteinases", "GENE_OR_GENE_PRODUCT", 50, 74], ["picornaviral proteinases", "PROTEIN", 50, 74], ["Current studies", "TEST", 0, 15], ["inhibitors", "TREATMENT", 36, 46], ["picornaviral proteinases", "PROBLEM", 50, 74], ["General methods", "TEST", 100, 115], ["enzyme assays", "TEST", 120, 133], ["general procedures", "TREATMENT", 138, 156], ["instrumentation", "TREATMENT", 161, 176], ["instrumentation", "OBSERVATION", 161, 176]]], ["41 Preparation, puri\u00aecation and assays of HAV 3C (C24S) protein with and without inhibitors were done as previously reported.", [["HAV 3C", "GENE_OR_GENE_PRODUCT", 42, 48], ["HAV 3C (C24S) protein", "PROTEIN", 42, 63], ["HAV 3C", "SPECIES", 42, 48], ["puri\u00aecation", "TEST", 16, 27], ["assays", "TEST", 32, 38], ["HAV 3C (C24S) protein", "TREATMENT", 42, 63], ["inhibitors", "TREATMENT", 81, 91]]], ["13, 16 Purity of the enzyme samples was greater than 90% as determined by SDS-PAGE analysis.", [["samples", "ANATOMY", 28, 35], ["the enzyme samples", "TEST", 17, 35], ["SDS", "TEST", 74, 77], ["PAGE analysis", "TEST", 78, 91]]], ["Proteinase concentrations were determined spectrophotometrically using e280=1.2 mg mL \u00c01 .", [["Proteinase", "GENE_OR_GENE_PRODUCT", 0, 10], ["Proteinase concentrations", "TEST", 0, 25]]], ["Enzyme activity was monitored using the trinitrobenzene sulfonate (TNBS) assay as previously described.", [["trinitrobenzene sulfonate", "CHEMICAL", 40, 65], ["TNBS", "CHEMICAL", 67, 71], ["trinitrobenzene sulfonate", "CHEMICAL", 40, 65], ["TNBS", "CHEMICAL", 67, 71], ["trinitrobenzene sulfonate", "SIMPLE_CHEMICAL", 40, 65], ["TNBS", "SIMPLE_CHEMICAL", 67, 71], ["Enzyme activity", "TEST", 0, 15], ["the trinitrobenzene sulfonate", "TREATMENT", 36, 65]]], ["13, 16, 38 Reaction mixtures were incubated in reaction buer at 20 C. Aliquots (10 mL) were removed from the reaction mixture at timed intervals and peptide hydrolysis was quenched with 50 mL of 0.25 M sodium borate, pH 10.", [["Aliquots", "ANATOMY", 70, 78], ["sodium borate", "CHEMICAL", 202, 215], ["sodium borate", "CHEMICAL", 202, 215], ["sodium borate", "SIMPLE_CHEMICAL", 202, 215], ["Reaction mixtures", "TEST", 11, 28], ["the reaction mixture", "TREATMENT", 105, 125], ["peptide hydrolysis", "TREATMENT", 149, 167], ["pH", "TEST", 217, 219]]], ["A solution (12.5 mL) of freshly prepared 0.14 M TNBS (Johnson\u00b1Matthey, Ward Hill,General methods and enzyme assaysMA) in 0.25 M sodium borate solution was added to the quenched reaction mixture and incubated for 10 min at 20 C. The color was stabilized by adding 200 mL of 3.5 mM Na 2 SO 3 , 0.2 M KH 2 PO 4 .", [["TNBS", "CHEMICAL", 48, 52], ["sodium borate", "CHEMICAL", 128, 141], ["Na", "CHEMICAL", 280, 282], ["TNBS", "CHEMICAL", 48, 52], ["sodium borate", "CHEMICAL", 128, 141], ["Na 2 SO 3", "CHEMICAL", 280, 289], ["KH 2 PO 4", "CHEMICAL", 298, 307], ["TNBS", "SIMPLE_CHEMICAL", 48, 52], ["sodium borate solution", "SIMPLE_CHEMICAL", 128, 150], ["A solution", "TREATMENT", 0, 10], ["General methods", "TREATMENT", 81, 96], ["enzyme assaysMA)", "TREATMENT", 101, 117], ["sodium borate solution", "TREATMENT", 128, 150], ["the quenched reaction mixture", "TREATMENT", 164, 193]]], ["The concentration of free amine generated during peptide hydrolysis was determined by measuring the absorbance at 405 nM using a microtitre plate reader (Biorad, Richmond, CA).", [["amine", "CHEMICAL", 26, 31], ["amine", "CHEMICAL", 26, 31], ["free amine", "SIMPLE_CHEMICAL", 21, 31], ["The concentration of free amine", "TREATMENT", 0, 31], ["peptide hydrolysis", "TREATMENT", 49, 67], ["a microtitre plate", "TREATMENT", 127, 145]]], ["Proteinase inactivation was quantitatively evaluated by progress curve analysis as previously described.", [["Proteinase", "GENE_OR_GENE_PRODUCT", 0, 10], ["Proteinase inactivation", "PROBLEM", 0, 23], ["curve analysis", "TEST", 65, 79]]], ["13 The extent of peptide proteolysis (release of a-amino groups) was monitored using the TNBS assay.", [["TNBS", "CHEMICAL", 89, 93], ["a-amino", "CHEMICAL", 49, 56], ["TNBS", "SIMPLE_CHEMICAL", 89, 93], ["peptide proteolysis", "PROBLEM", 17, 36], ["a-amino groups", "TREATMENT", 49, 63], ["the TNBS assay", "TEST", 85, 99], ["extent", "OBSERVATION_MODIFIER", 7, 13], ["peptide proteolysis", "OBSERVATION", 17, 36]]], ["The concentrations of potential inhibitors were varied from 0.5 to 500 mM; substrate (Ac-ELRTQSFS-amide) concentration was 2 mM and HAV-3C proteinase (C24S mutant) concentration was 0.07 mM.", [["Ac-ELRTQSFS-amide", "CHEMICAL", 86, 103], ["amide", "CHEMICAL", 98, 103], ["HAV-3C proteinase", "GENE_OR_GENE_PRODUCT", 132, 149], ["HAV-3C proteinase", "PROTEIN", 132, 149], ["potential inhibitors", "TREATMENT", 22, 42], ["substrate (Ac-ELRTQSFS-amide) concentration", "TREATMENT", 75, 118], ["HAV", "TEST", 132, 135], ["3C proteinase (C24S mutant) concentration", "TREATMENT", 136, 177]]], ["Enzyme was dialyzed against reaction buer to remove DTT immediately prior to use.", [["DTT", "CHEMICAL", 52, 55], ["DTT", "CHEMICAL", 52, 55], ["DTT", "SIMPLE_CHEMICAL", 52, 55], ["Enzyme", "TEST", 0, 6], ["DTT", "TREATMENT", 52, 55]]], ["Reactions were initiated with enzyme and absorbances were converted into mmoles of product using a glycine standard curve.", [["glycine", "CHEMICAL", 99, 106], ["glycine", "CHEMICAL", 99, 106], ["glycine", "SIMPLE_CHEMICAL", 99, 106], ["enzyme", "TEST", 30, 36], ["absorbances", "TEST", 41, 52], ["a glycine standard curve", "TREATMENT", 97, 121]]], ["All determinations were performed in triplicate with dierent enzyme and inhibitor preparations.", [["All determinations", "TEST", 0, 18], ["dierent enzyme", "TREATMENT", 53, 67], ["inhibitor preparations", "TREATMENT", 72, 94]]], ["Progress curves were \u00aetted using least squares non-linear regression analysis using Mac Curve Fit 1.0.7, (K. Raner):General methods and enzyme assayswhere n o is the initial velocity and k is the apparent \u00aerst order rate constant (k obs ) for the inactivation process.", [["non-linear regression analysis", "TEST", 47, 77], ["Mac Curve Fit", "TEST", 84, 97], ["the initial velocity", "TEST", 162, 182], ["the inactivation process", "PROBLEM", 243, 267]]], ["The weighted average of parameter estimates from a minimum of three individual experiments was used to calculate reported rate constants.General methods and enzyme assaysGeneral peptide synthesis and puri\u00aecation procedures have been described earlier, 16 and employed a Rainin PS-3 solid-phase peptide synthesizer using standard Fmoc chemistry on Wang Resin.", [["Rainin PS-3", "CHEMICAL", 270, 281], ["Fmoc", "CHEMICAL", 329, 333], ["General methods", "TEST", 137, 152], ["enzyme assays", "TEST", 157, 170], ["General peptide synthesis", "TREATMENT", 170, 195], ["puri\u00aecation procedures", "TREATMENT", 200, 222], ["a Rainin PS", "TREATMENT", 268, 279], ["solid-phase peptide synthesizer", "TREATMENT", 282, 313], ["Wang Resin", "TREATMENT", 347, 357]]], ["All peptides were puri\u00aeed by reverse-phase HPLC (C-18, 5\u00c225 cm, Vydac, 2%/min linear gradient of 0.1% TFA/water adding 0.1% TFA/acetonitrile).", [["TFA/acetonitrile", "CHEMICAL", 124, 140], ["TFA", "CHEMICAL", 102, 105], ["TFA", "CHEMICAL", 124, 127], ["acetonitrile", "CHEMICAL", 128, 140], ["puri\u00aeed", "SIMPLE_CHEMICAL", 18, 25], ["TFA", "SIMPLE_CHEMICAL", 124, 127], ["acetonitrile", "SIMPLE_CHEMICAL", 128, 140], ["All peptides", "TEST", 0, 12], ["HPLC", "TEST", 43, 47], ["C", "TEST", 49, 50], ["Vydac", "TEST", 64, 69], ["linear gradient", "TEST", 78, 93], ["acetonitrile", "TREATMENT", 128, 140]]], ["Peptide structures were veri\u00aeed by NMR and mass spectrometry.", [["Peptide structures", "PROBLEM", 0, 18], ["mass spectrometry", "PROBLEM", 43, 60], ["mass spectrometry", "OBSERVATION", 43, 60]]], ["In cases where restricted rotation around amide bonds generates conformers detectable by NMR spectrometry, high temperature studies were done to demonstrate equilibria and coalescence of resonances.", [["amide", "CHEMICAL", 42, 47], ["amide bonds", "SIMPLE_CHEMICAL", 42, 53], ["restricted rotation around amide bonds generates conformers", "PROBLEM", 15, 74], ["NMR spectrometry", "TEST", 89, 105], ["high temperature studies", "TEST", 107, 131], ["equilibria and coalescence of resonances", "PROBLEM", 157, 197]]], ["Mass spectrometry of enzyme-inhibitor complexes employed instrumentation and methodology speci\u00aeed in preceding publications.", [["enzyme-inhibitor complexes", "PROTEIN", 21, 47], ["Mass spectrometry of enzyme-inhibitor complexes", "PROBLEM", 0, 47], ["instrumentation", "TREATMENT", 57, 72]]], ["13,23 Triethylamine (0.90 mL, 6.00 mmol) was added dropwise to a stirred solution of this amine salt (1.15 g, 5.00 mmol) in dry CH 2 Cl 2 (20 mL) under argon at 0 C. The mixture was stirred at 0 C for 5 min, and then methanesulfonyl chloride (0.39 mL, 5.00 mmol) and triethylamine (0.90 mL, 6.00 mmol) were added dropwise.", [["13,23", "CHEMICAL", 0, 5], ["Triethylamine", "CHEMICAL", 6, 19], ["amine salt", "CHEMICAL", 90, 100], ["CH 2 Cl", "CHEMICAL", 128, 135], ["methanesulfonyl chloride", "CHEMICAL", 217, 241], ["triethylamine", "CHEMICAL", 267, 280], ["Triethylamine", "CHEMICAL", 6, 19], ["amine", "CHEMICAL", 90, 95], ["CH 2 Cl 2", "CHEMICAL", 128, 137], ["methanesulfonyl chloride", "CHEMICAL", 217, 241], ["triethylamine", "CHEMICAL", 267, 280], ["13,23", "SIMPLE_CHEMICAL", 0, 5], ["Triethylamine", "SIMPLE_CHEMICAL", 6, 19], ["amine salt", "SIMPLE_CHEMICAL", 90, 100], ["methanesulfonyl chloride", "SIMPLE_CHEMICAL", 217, 241], ["triethylamine", "SIMPLE_CHEMICAL", 267, 280], ["Triethylamine", "TREATMENT", 6, 19], ["a stirred solution of this amine salt", "TREATMENT", 63, 100], ["argon", "TREATMENT", 152, 157], ["methanesulfonyl chloride", "TREATMENT", 217, 241], ["triethylamine", "TREATMENT", 267, 280]]], ["The reaction mixture was stirred at 0 C for 2 h, and then concentrated in vacuo.", [["The reaction mixture", "TREATMENT", 0, 20], ["vacuo", "OBSERVATION", 74, 79]]], ["EtOAc (150 mL) was added to the residue, and the precipitate was removed by \u00aeltration.", [["EtOAc", "CHEMICAL", 0, 5], ["EtOAc", "CHEMICAL", 0, 5], ["EtOAc", "SIMPLE_CHEMICAL", 0, 5], ["EtOAc", "TREATMENT", 0, 5]]], ["The \u00aeltrate was washed with water (20 mL), saturated aq NaHCO 3 (20 mL) and brine (50 mL), and dried (Na 2 SO 4 ).", [["NaHCO", "CHEMICAL", 56, 61], ["Na", "CHEMICAL", 102, 104], ["NaHCO 3", "CHEMICAL", 56, 63], ["Na 2 SO 4", "CHEMICAL", 102, 111], ["\u00aeltrate", "SIMPLE_CHEMICAL", 4, 11], ["The \u00aeltrate", "TREATMENT", 0, 11], ["saturated aq NaHCO", "TREATMENT", 43, 61], ["brine", "TREATMENT", 76, 81]]], ["The solvent was removed in vacuo to give an oil.", [["oil", "ANATOMY", 44, 47], ["oil", "ORGANISM_SUBSTANCE", 44, 47], ["The solvent", "TREATMENT", 0, 11]]], ["Puri\u00aecation by\u00afash chromatography (ethyl acetate) gave the sulfonamide 5 (0.65 g, 67%) as an oil: IR (CH 23-(p-Methylphenylsulfonylamino)-N,N-(dimethyl)propanamide (6) .", [["Puri\u00aecation by\u00afash", "CHEMICAL", 0, 18], ["ethyl acetate", "CHEMICAL", 35, 48], ["sulfonamide", "CHEMICAL", 59, 70], ["CH 23-(p-Methylphenylsulfonylamino)-N,N-(dimethyl)propanamide", "CHEMICAL", 102, 163], ["ethyl acetate", "CHEMICAL", 35, 48], ["sulfonamide", "CHEMICAL", 59, 70], ["CH 23-(p-Methylphenylsulfonylamino)-N,N-(dimethyl)propanamide", "CHEMICAL", 102, 163], ["Puri\u00aecation by\u00afash", "SIMPLE_CHEMICAL", 0, 18], ["ethyl acetate", "SIMPLE_CHEMICAL", 35, 48], ["oil", "ORGANISM_SUBSTANCE", 93, 96], ["CH 23-(p-Methylphenylsulfonylamino)-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 102, 163], ["Puri\u00aecation by\u00afash chromatography (ethyl acetate", "TREATMENT", 0, 48], ["the sulfonamide", "TREATMENT", 55, 70], ["IR (CH", "TREATMENT", 98, 104], ["p-Methylphenylsulfonylamino)", "TREATMENT", 109, 137], ["N,N-(dimethyl)propanamide", "TREATMENT", 138, 163]]], ["The procedure for preparation of 5 was employed to react amine salt (1.15 g, 5.00 mmol) obtained by deprotection of Boc-b-alanine dimethylamide, 37 triethylamine (1.8 mL, 12.00 mmol) and ptoluenesulfonyl chloride (0.95 g, 5.00 mmol) to give the previously reported 43 (7).", [["amine salt", "CHEMICAL", 57, 67], ["Boc-b-alanine dimethylamide", "CHEMICAL", 116, 143], ["37 triethylamine", "CHEMICAL", 145, 161], ["ptoluenesulfonyl chloride", "CHEMICAL", 187, 212], ["amine", "CHEMICAL", 57, 62], ["Boc-b-alanine dimethylamide", "CHEMICAL", 116, 143], ["37 triethylamine", "CHEMICAL", 145, 161], ["ptoluenesulfonyl chloride", "CHEMICAL", 187, 212], ["amine salt", "SIMPLE_CHEMICAL", 57, 67], ["Boc-b-alanine dimethylamide", "SIMPLE_CHEMICAL", 116, 143], ["37 triethylamine", "SIMPLE_CHEMICAL", 145, 161], ["ptoluenesulfonyl chloride", "SIMPLE_CHEMICAL", 187, 212], ["The procedure", "TREATMENT", 0, 13], ["Boc-b-alanine dimethylamide", "TREATMENT", 116, 143], ["triethylamine", "TREATMENT", 148, 161], ["ptoluenesulfonyl chloride", "TREATMENT", 187, 212]]], ["To a stirred solution of sulfonamide 5 (0.82 g, 4.2 mmol) in anhydrous DMF (10 mL) under argon at 0 C, was added NaH (60% dispersion in mineral oil) (0.237 g, 5.9 mmol) in small portions, and the mixture was stirred at 0 C for an additional 30 min.", [["sulfonamide 5", "CHEMICAL", 25, 38], ["anhydrous DMF", "CHEMICAL", 61, 74], ["NaH", "CHEMICAL", 113, 116], ["sulfonamide", "CHEMICAL", 25, 36], ["anhydrous DMF", "CHEMICAL", 61, 74], ["NaH", "CHEMICAL", 113, 116], ["sulfonamide 5", "SIMPLE_CHEMICAL", 25, 38], ["anhydrous DMF", "SIMPLE_CHEMICAL", 61, 74], ["NaH", "SIMPLE_CHEMICAL", 113, 116], ["a stirred solution of sulfonamide", "TREATMENT", 3, 36], ["NaH (60% dispersion in mineral oil", "TREATMENT", 113, 147]]], ["The resulting yellow anion solution was added dropwise over a 30 min period to a stirred solution of bromo compound 4 34,35 (1.51 g, 5.0 mmol) in DMF (5 mL).", [["bromo compound 4 34,35", "CHEMICAL", 101, 123], ["DMF", "CHEMICAL", 146, 149], ["bromo", "CHEMICAL", 101, 106], ["DMF", "CHEMICAL", 146, 149], ["yellow anion", "SIMPLE_CHEMICAL", 14, 26], ["DMF", "SIMPLE_CHEMICAL", 146, 149], ["The resulting yellow anion solution", "TREATMENT", 0, 35], ["a stirred solution of bromo compound", "TREATMENT", 79, 115], ["yellow anion", "OBSERVATION", 14, 26]]], ["After 1 h at room temperature, the solvent was removed in vacuo, and the residue was dissolved in CH 2 Cl 2 , and washed with 1% aq HCl (10 mL), 5% aq NaHCO 3 (10 mL) and brine (10 mL).", [["CH 2 Cl", "CHEMICAL", 98, 105], ["aq HCl", "CHEMICAL", 129, 135], ["NaHCO", "CHEMICAL", 151, 156], ["CH 2 Cl 2", "CHEMICAL", 98, 107], ["HCl", "CHEMICAL", 132, 135], ["NaHCO 3", "CHEMICAL", 151, 158], ["aq HCl", "SIMPLE_CHEMICAL", 129, 135], ["the solvent", "TREATMENT", 31, 42], ["vacuo", "TREATMENT", 58, 63], ["the residue", "PROBLEM", 69, 80], ["5% aq NaHCO", "TREATMENT", 145, 156]]], ["The organic phase was dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil.", [["oil", "ANATOMY", 78, 81], ["Na 2 SO 4", "CHEMICAL", 29, 38], ["Na 2 SO 4", "CHEMICAL", 29, 38], ["oil", "ORGANISM_SUBSTANCE", 78, 81], ["The organic phase", "TEST", 0, 17], ["Na", "TEST", 29, 31], ["organic phase", "OBSERVATION_MODIFIER", 4, 17]]], ["The procedure used for the preparation of 7, was employed to condense sulfonamide 6 (1.00 g, 3.7 mmol) and bromomethyl ketone 4 34, 35 (10) .", [["sulfonamide", "CHEMICAL", 70, 81], ["bromomethyl ketone", "CHEMICAL", 107, 125], ["sulfonamide", "CHEMICAL", 70, 81], ["bromomethyl ketone", "CHEMICAL", 107, 125], ["sulfonamide 6", "SIMPLE_CHEMICAL", 70, 83], ["bromomethyl ketone 4", "SIMPLE_CHEMICAL", 107, 127], ["The procedure", "TREATMENT", 0, 13], ["sulfonamide", "TREATMENT", 70, 81], ["bromomethyl ketone", "TREATMENT", 107, 125]]], ["The procedure used for the preparation of 9, was adapted to convert N-Cbz sulfonamide 8 (0.500 g, 1.02 mmol) with 10% palladium on charcoal (50 mg (11) .", [["N-Cbz sulfonamide", "CHEMICAL", 68, 85], ["palladium", "CHEMICAL", 118, 127], ["charcoal", "CHEMICAL", 131, 139], ["N-Cbz sulfonamide", "CHEMICAL", 68, 85], ["palladium", "CHEMICAL", 118, 127], ["N-Cbz sulfonamide 8", "SIMPLE_CHEMICAL", 68, 87], ["palladium", "SIMPLE_CHEMICAL", 118, 127], ["charcoal", "SIMPLE_CHEMICAL", 131, 139], ["The procedure", "TREATMENT", 0, 13], ["N-Cbz sulfonamide", "TREATMENT", 68, 85], ["charcoal", "TREATMENT", 131, 139]]], ["A solution of the dipeptide Ac-Leu-Ala-OH (0.216 g, 0.89 mmol) in dry THF (10 mL) under argon at 0 C was treated with ethyl chloroformate (90 mL, 0.89 mmol) and triethylamine (0.13 mL, 0.91 mmol) and stirred for 20 min.", [["Ac-Leu-Ala-OH", "CHEMICAL", 28, 41], ["THF", "CHEMICAL", 70, 73], ["ethyl chloroformate", "CHEMICAL", 118, 137], ["triethylamine", "CHEMICAL", 161, 174], ["Ac-Leu-Ala-OH", "CHEMICAL", 28, 41], ["THF", "CHEMICAL", 70, 73], ["ethyl chloroformate", "CHEMICAL", 118, 137], ["triethylamine", "CHEMICAL", 161, 174], ["dipeptide Ac-Leu-Ala-OH", "SIMPLE_CHEMICAL", 18, 41], ["THF", "SIMPLE_CHEMICAL", 70, 73], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 118, 137], ["triethylamine", "SIMPLE_CHEMICAL", 161, 174], ["the dipeptide Ac", "TREATMENT", 14, 30], ["Leu-Ala-OH", "TREATMENT", 31, 41], ["dry THF", "TREATMENT", 66, 73], ["argon", "TREATMENT", 88, 93], ["ethyl chloroformate", "TREATMENT", 118, 137], ["triethylamine", "TREATMENT", 161, 174]]], ["A solution of sulfonamido amine hydrochloride 9 (0.280 g, 0.89 mmol) in THF (5 mL), and triethylamine (0.13 mL, 0.91 mmol) were added, and the reaction mixture was stirred for 30 min.", [["sulfonamido amine hydrochloride 9", "CHEMICAL", 14, 47], ["THF", "CHEMICAL", 72, 75], ["triethylamine", "CHEMICAL", 88, 101], ["sulfonamido amine hydrochloride", "CHEMICAL", 14, 45], ["THF", "CHEMICAL", 72, 75], ["triethylamine", "CHEMICAL", 88, 101], ["sulfonamido amine hydrochloride", "SIMPLE_CHEMICAL", 14, 45], ["THF", "SIMPLE_CHEMICAL", 72, 75], ["triethylamine", "SIMPLE_CHEMICAL", 88, 101], ["A solution of sulfonamido amine hydrochloride", "TREATMENT", 0, 45], ["triethylamine", "TREATMENT", 88, 101]]], ["To the mixture was added EtOAc (40 mL), and the organic phase was washed with saturated aq NaHCO 3 (20 mL) and brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give the crude product 11.", [["NaHCO 3", "CHEMICAL", 91, 98], ["Na 2 SO 4 )", "CHEMICAL", 133, 144], ["EtOAc", "CHEMICAL", 25, 30], ["NaHCO 3", "CHEMICAL", 91, 98], ["Na 2 SO 4", "CHEMICAL", 133, 142], ["EtOAc", "SIMPLE_CHEMICAL", 25, 30], ["EtOAc", "TREATMENT", 25, 30], ["saturated aq NaHCO", "TREATMENT", 78, 96], ["the crude product", "TREATMENT", 179, 196]]], ["Puri\u00aecation by HPLC (linear gradient elution over 25 20, 175.37, 175.32, 173.83, 173.28, 55.22, 54.12, 54.02, 50.65, 46.19, 40.14, 39.49, 38.86, 36.38, 34.12, 25.67, 22.80, 22.39, 21.97, 19.39, 15.76 ; MS (FAB) 506.3 (80) (MH + ).", [["Puri\u00aecation", "CHEMICAL", 0, 11], ["Puri\u00aecation", "SIMPLE_CHEMICAL", 0, 11], ["Puri\u00aecation", "TEST", 0, 11], ["HPLC", "TEST", 15, 19], ["linear gradient elution", "TEST", 21, 44], ["MS", "TEST", 202, 204], ["FAB", "TEST", 206, 209]]], ["The procedure used for the preparation of 11, was used to condense dipeptide Ac-Leu-Ala-OH (0.156 g, 0.64 mmol) and sulfonamido amine hydrochloride 10 (0.250 g, 0.64 mmol) in the presence of ethyl chloroformate (62 mL, 0.64 mmol) and triethylamine (0.178 mL, 1.28 mmol).", [["Ac-Leu-Ala-OH", "CHEMICAL", 77, 90], ["sulfonamido amine hydrochloride", "CHEMICAL", 116, 147], ["ethyl chloroformate", "CHEMICAL", 191, 210], ["triethylamine", "CHEMICAL", 234, 247], ["dipeptide Ac-Leu-Ala-OH", "CHEMICAL", 67, 90], ["sulfonamido amine hydrochloride", "CHEMICAL", 116, 147], ["ethyl chloroformate", "CHEMICAL", 191, 210], ["triethylamine", "CHEMICAL", 234, 247], ["dipeptide Ac-Leu-Ala-OH", "SIMPLE_CHEMICAL", 67, 90], ["sulfonamido amine hydrochloride 10", "SIMPLE_CHEMICAL", 116, 150], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 191, 210], ["triethylamine", "SIMPLE_CHEMICAL", 234, 247], ["The procedure", "TREATMENT", 0, 13], ["dipeptide Ac", "TREATMENT", 67, 79], ["Leu-Ala-OH", "TREATMENT", 80, 90], ["sulfonamido amine hydrochloride", "TREATMENT", 116, 147], ["ethyl chloroformate", "TREATMENT", 191, 210], ["triethylamine", "TREATMENT", 234, 247]]], ["Puri\u00aecation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 30% to 50%, t R 15.8 min) gave the title compound 12 (0.208 g, 56%) as a solid.", [["Puri\u00aecation", "CHEMICAL", 0, 11], ["acetonitrile", "CHEMICAL", 60, 72], ["acetonitrile", "CHEMICAL", 60, 72], ["Puri\u00aecation", "SIMPLE_CHEMICAL", 0, 11], ["acetonitrile", "SIMPLE_CHEMICAL", 60, 72], ["HPLC", "TEST", 15, 19], ["linear gradient elution", "TREATMENT", 21, 44], ["acetonitrile", "TREATMENT", 60, 72], ["water", "TREATMENT", 77, 82]]], ["Spectral characterization showed a mixture of conformers (13) .", [["Spectral characterization", "TEST", 0, 25]]], ["N,N-Dimethylacrylamide (4.96 g, 50 mmol) was added dropwise to a solution of hydrazine monohydrate (2.50 g, 50 mmol) in MeOH (30 mL).", [["N,N-Dimethylacrylamide", "CHEMICAL", 0, 22], ["hydrazine", "CHEMICAL", 77, 86], ["MeOH", "CHEMICAL", 120, 124], ["N,N-Dimethylacrylamide", "CHEMICAL", 0, 22], ["hydrazine monohydrate", "CHEMICAL", 77, 98], ["MeOH", "CHEMICAL", 120, 124], ["N-Dimethylacrylamide", "SIMPLE_CHEMICAL", 2, 22], ["hydrazine monohydrate", "SIMPLE_CHEMICAL", 77, 98], ["MeOH", "SIMPLE_CHEMICAL", 120, 124], ["Dimethylacrylamide", "TREATMENT", 4, 22], ["a solution of hydrazine monohydrate", "TREATMENT", 63, 98]]], ["The reaction mixture was stirred at room temperature for 2 h, diluted with MeOH (30 mL), dried (Na 2 SO 4 ), and then concentrated in vacua to give crude 3-hydrazino-N,N-(dimethyl)propanamide (6.5 g).", [["MeOH", "CHEMICAL", 75, 79], ["Na 2 SO 4", "CHEMICAL", 96, 105], ["3-hydrazino-N,N-(dimethyl)propanamide", "CHEMICAL", 154, 191], ["MeOH", "CHEMICAL", 75, 79], ["Na 2 SO 4", "CHEMICAL", 96, 105], ["3-hydrazino-N,N-(dimethyl)propanamide", "CHEMICAL", 154, 191], ["MeOH", "SIMPLE_CHEMICAL", 75, 79], ["Na 2 SO 4", "SIMPLE_CHEMICAL", 96, 105], ["vacua", "SIMPLE_CHEMICAL", 134, 139], ["3-hydrazino-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 154, 191], ["The reaction mixture", "PROBLEM", 0, 20], ["crude", "TREATMENT", 148, 153], ["hydrazino", "TREATMENT", 156, 165], ["N-(dimethyl)propanamide", "TREATMENT", 168, 191]]], ["A stirred solution of this compound (2.62 g, 20 mmol) in a mixture of diethyl ether (30 mL), water (15 mL) and 1 N NaOH (20 mL) was cooled in an ice-bath.", [["diethyl ether", "CHEMICAL", 70, 83], ["N NaOH", "CHEMICAL", 113, 119], ["diethyl ether", "CHEMICAL", 70, 83], ["NaOH", "CHEMICAL", 115, 119], ["diethyl ether", "SIMPLE_CHEMICAL", 70, 83], ["water", "SIMPLE_CHEMICAL", 93, 98], ["A stirred solution", "TREATMENT", 0, 18], ["this compound", "TREATMENT", 22, 35], ["a mixture of diethyl ether", "TREATMENT", 57, 83], ["an ice-bath", "TREATMENT", 142, 153]]], ["Benzyl chloroformate (2.8 mL, 20 mmol) was added and stirring was continued in the ice-bath for 1 h.", [["Benzyl chloroformate", "CHEMICAL", 0, 20], ["Benzyl chloroformate", "CHEMICAL", 0, 20], ["Benzyl chloroformate", "SIMPLE_CHEMICAL", 0, 20], ["Benzyl chloroformate", "TREATMENT", 0, 20]]], ["The precipitate was \u00aeltered, the \u00aeltrate was concentrated in vacuo to 20 mL, and then extracted with ethyl acetate (3\u00c280 mL).", [["ethyl acetate", "CHEMICAL", 101, 114], ["ethyl acetate", "CHEMICAL", 101, 114], ["\u00aeltrate", "SIMPLE_CHEMICAL", 33, 40], ["ethyl acetate", "SIMPLE_CHEMICAL", 101, 114], ["the \u00aeltrate", "TREATMENT", 29, 40], ["ethyl acetate", "TREATMENT", 101, 114]]], ["The combined organic extracts were washed with brine (20 mL), dried (Na 2 SO 4 ) and the solvent was concentrated in vacua to give an oil.", [["extracts", "ANATOMY", 21, 29], ["oil", "ANATOMY", 134, 137], ["Na 2 SO 4", "CHEMICAL", 69, 78], ["Na 2 SO 4", "CHEMICAL", 69, 78], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["vacua", "SIMPLE_CHEMICAL", 117, 122], ["oil", "ORGANISM_SUBSTANCE", 134, 137], ["The combined organic extracts", "TREATMENT", 0, 29], ["the solvent", "TREATMENT", 85, 96], ["organic extracts", "OBSERVATION", 13, 29]]], ["Puri\u00aecation by\u00afash chromatography (ethyl acetate:methanol, 95:5) gave the desired 13 (1.59 g, 30%) (15) .", [["Puri\u00aecation by\u00afash", "CHEMICAL", 0, 18], ["ethyl acetate", "CHEMICAL", 35, 48], ["ethyl acetate", "CHEMICAL", 35, 48], ["methanol", "CHEMICAL", 49, 57], ["Puri\u00aecation by\u00afash", "SIMPLE_CHEMICAL", 0, 18], ["ethyl acetate", "SIMPLE_CHEMICAL", 35, 48], ["methanol", "SIMPLE_CHEMICAL", 49, 57], ["methanol", "TREATMENT", 49, 57]]], ["To a solution of tripeptide Ac-Leu-Ala-Ala-OH (0.315 g, 1 mmol), Cbz hydrazino derivative 13 (0.265 g, 1 mmol) and benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa\u00afuorophosphate (BOP) (0.442 g, 1 mmol) in DMF (10 mL) was added triethylamine (0.139 mL, 1 mmol).", [["tripeptide Ac-Leu-Ala-Ala-OH", "CHEMICAL", 17, 45], ["Cbz hydrazino derivative 13", "CHEMICAL", 65, 92], ["benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa\u00afuorophosphate", "CHEMICAL", 115, 184], ["BOP", "CHEMICAL", 186, 189], ["DMF", "CHEMICAL", 212, 215], ["triethylamine", "CHEMICAL", 234, 247], ["Ac-Leu-Ala-Ala-OH", "CHEMICAL", 28, 45], ["Cbz hydrazino", "CHEMICAL", 65, 78], ["benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa\u00afuorophosphate", "CHEMICAL", 115, 184], ["BOP", "CHEMICAL", 186, 189], ["DMF", "CHEMICAL", 212, 215], ["triethylamine", "CHEMICAL", 234, 247], ["tripeptide Ac-Leu-Ala-Ala-OH", "SIMPLE_CHEMICAL", 17, 45], ["Cbz hydrazino derivative 13", "SIMPLE_CHEMICAL", 65, 92], ["benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa\u00afuorophosphate", "SIMPLE_CHEMICAL", 115, 184], ["BOP", "SIMPLE_CHEMICAL", 186, 189], ["DMF", "SIMPLE_CHEMICAL", 212, 215], ["triethylamine", "SIMPLE_CHEMICAL", 234, 247], ["a solution of tripeptide Ac", "TREATMENT", 3, 30], ["Leu-Ala-Ala-OH", "TREATMENT", 31, 45], ["Cbz hydrazino derivative", "TREATMENT", 65, 89], ["benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa\u00afuorophosphate (BOP)", "TREATMENT", 115, 190], ["triethylamine", "TREATMENT", 234, 247]]], ["The mixture was stirred at room temperature for 6 h, and then concentrated in vacuo to give an oil.", [["oil", "ANATOMY", 95, 98], ["oil", "ORGANISM_SUBSTANCE", 95, 98], ["an oil", "TREATMENT", 92, 98]]], ["To a solution of Cbz derivative 15 (56.2 mg, 0.10 mmol) in methanol (10 mL) under argon was added 10% palladium on charcoal catalyst (10 mg).", [["Cbz", "CHEMICAL", 17, 20], ["methanol", "CHEMICAL", 59, 67], ["palladium", "CHEMICAL", 102, 111], ["charcoal catalyst", "CHEMICAL", 115, 132], ["Cbz", "CHEMICAL", 17, 20], ["methanol", "CHEMICAL", 59, 67], ["palladium", "CHEMICAL", 102, 111], ["Cbz derivative 15", "SIMPLE_CHEMICAL", 17, 34], ["methanol", "SIMPLE_CHEMICAL", 59, 67], ["palladium", "SIMPLE_CHEMICAL", 102, 111], ["charcoal catalyst", "SIMPLE_CHEMICAL", 115, 132], ["a solution of Cbz derivative", "TREATMENT", 3, 31], ["methanol", "TREATMENT", 59, 67], ["charcoal catalyst", "TREATMENT", 115, 132]]], ["The mixture was stirred under an atmosphere of hydrogen until gas absorption ceased.", [["hydrogen", "CHEMICAL", 47, 55], ["hydrogen", "CHEMICAL", 47, 55], ["hydrogen", "SIMPLE_CHEMICAL", 47, 55], ["hydrogen", "TREATMENT", 47, 55], ["gas absorption", "PROBLEM", 62, 76]]], ["The catalyst was removed by \u00aeltration through a column of Celite, and the \u00aeltrate was concentrated in vacuo to give the unstable deprotected hydrazine (42.8 mg, quantitative).", [["Celite", "CHEMICAL", 58, 64], ["hydrazine", "CHEMICAL", 141, 150], ["hydrazine", "CHEMICAL", 141, 150], ["\u00aeltration", "SIMPLE_CHEMICAL", 28, 37], ["Celite", "SIMPLE_CHEMICAL", 58, 64], ["\u00aeltrate", "SIMPLE_CHEMICAL", 74, 81], ["hydrazine", "SIMPLE_CHEMICAL", 141, 150], ["The catalyst", "TREATMENT", 0, 12], ["a column of Celite", "TREATMENT", 46, 64], ["the \u00aeltrate", "TREATMENT", 70, 81], ["the unstable deprotected hydrazine", "TREATMENT", 116, 150]]], ["To a stirred solution of this crude material (42.8 mg, 0.10 mmol) and o-nitrophenylsulfenyl chloride (18.9 mg, 0.10 mmol) in DMF (1 mL) under argon, at \u00c010 C, was added triethylamine (14 mL, 0.10 mmol).", [["o-nitrophenylsulfenyl chloride", "CHEMICAL", 70, 100], ["DMF", "CHEMICAL", 125, 128], ["triethylamine", "CHEMICAL", 169, 182], ["o-nitrophenylsulfenyl chloride", "CHEMICAL", 70, 100], ["DMF", "CHEMICAL", 125, 128], ["triethylamine", "CHEMICAL", 169, 182], ["o-nitrophenylsulfenyl chloride", "SIMPLE_CHEMICAL", 70, 100], ["DMF", "SIMPLE_CHEMICAL", 125, 128], ["triethylamine", "SIMPLE_CHEMICAL", 169, 182], ["a stirred solution of this crude material", "TREATMENT", 3, 44], ["o-nitrophenylsulfenyl chloride", "TREATMENT", 70, 100], ["argon", "TREATMENT", 142, 147], ["triethylamine", "TREATMENT", 169, 182]]], ["After 30 min at \u00c010 C, the reaction mixture was allowed to warm to room temperature and was stirred for 1 h.", [["the reaction mixture", "PROBLEM", 23, 43]]], ["The solution was then concentrated in vacuo.", [["The solution", "TREATMENT", 0, 12]]], ["Puri\u00aecation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 25% to 40%, t R 10.6 min) gave the title compound 16 (37.8 mg, 65%) as a yellow powder.", [["Puri\u00aecation", "CHEMICAL", 0, 11], ["acetonitrile", "CHEMICAL", 60, 72], ["acetonitrile", "CHEMICAL", 60, 72], ["Puri\u00aecation", "SIMPLE_CHEMICAL", 0, 11], ["acetonitrile", "SIMPLE_CHEMICAL", 60, 72], ["linear gradient elution", "TREATMENT", 21, 44], ["acetonitrile", "TREATMENT", 60, 72], ["water", "TREATMENT", 77, 82], ["a yellow powder", "TREATMENT", 160, 175]]], ["Spectral characterization indicated a mixture of conformers (conformer A:conformer B, 5:(3S) -{N 3 -(Benzyloxycarbonyl) -N 1 -[3 H -(N,N -dimethylamino)-3 H -oxopropyl]-N 1 -(methylsulfonyl)}-1,3-diaminobutan-2-one(3S)-{N 1 -[3 H -(N,N-Dimethylamino)-3 H -oxopropyl]-N 1 -(p- methylphenylsulfonyl)}-1,3-diaminobutan-2-one hydrochlo- ride(3S)-{N 3 -(Acetyl-L-leucyl-L-alanyl)-N 1 -[3 H -(N,N-dimethylamino)-3 H -oxopropyl]-N 1 -(p-methylphenylsulfonyl)}-1,3diaminobutan-2-one3 -[N 1 -(Benzyloxycarbonyl)hydrazino] -N,N -(dimethyl) - propanamide3-[N 1 -(tert-Butyloxycarbonyl)hydrazino]-N,N-(dimethyl)-propanamide (17) .", [["5:(3S) -{N 3 -(Benzyloxycarbonyl) -N 1 -[3 H -(N,N -dimethylamino)-3 H -oxopropyl]-N 1 -(methylsulfonyl)}-1,3-diaminobutan-2-one(3S)-{N", "CHEMICAL", 86, 221], ["1 -[3 H -(N,N-Dimethylamino)-3 H -oxopropyl]-N 1 -(p- methylphenylsulfonyl)}-1,3-diaminobutan-2-one hydrochlo- ride", "CHEMICAL", 222, 337], ["3S)-{N 3 -(Acetyl-L-leucyl-L-alanyl)-N 1 -[3 H -(N,N-dimethylamino)-3 H -oxopropyl]-N 1 -(p-methylphenylsulfonyl)}-1,3diaminobutan-2-one3 -[N 1 -(Benzyloxycarbonyl)hydrazino] -N,N -(dimethyl) - propanamide3-[N 1 -(tert-Butyloxycarbonyl)hydrazino]-N,N-(dimethyl)-propanamide", "CHEMICAL", 338, 611], ["(3S) -{N 3 -(Benzyloxycarbonyl) -N 1 -[3 H -(N,N -dimethylamino)-3 H -oxopropyl]-N 1 -(methylsulfonyl)}-1,3-diaminobutan-2-one(3S)-{N", "CHEMICAL", 88, 221], ["1 -[3 H -(N,N-Dimethylamino)-3 H -oxopropyl]-N 1 -(p- methylphenylsulfonyl)}-1,3-diaminobutan-2-one hydrochlo- ride", "CHEMICAL", 222, 337], ["(3S)-{N 3 -(Acetyl-L-leucyl-L-alanyl)-N 1 -[3 H -(N,N-dimethylamino)-3 H -oxopropyl]-N 1 -(p-methylphenylsulfonyl)}-1,3diaminobutan-2-one3 -[N 1 -(Benzyloxycarbonyl)hydrazino] -N,N -(dimethyl) - propanamide3-[N 1 -(tert-Butyloxycarbonyl)hydrazino]-N,N-(dimethyl)-propanamide", "CHEMICAL", 337, 611], ["conformer A:conformer B", "SIMPLE_CHEMICAL", 61, 84], ["5:(3S) -{N 3 -(Benzyloxycarbonyl) -N 1 -[3 H -(N,N -dimethylamino)-3 H -oxopropyl]-N 1 -(methylsulfonyl)}-1,3-diaminobutan-2-one(3S)-{N", "SIMPLE_CHEMICAL", 86, 221], ["1 -[3 H -(N,N-Dimethylamino)-3 H -oxopropyl]-N 1 -(p- methylphenylsulfonyl)}-1,3-diaminobutan-2-one hydrochlo- ride(3S)-{N 3 -(Acetyl-L-leucyl-L-alanyl)-N 1 -[3 H -(N,N-dimethylamino)-3 H -oxopropyl]-N 1 -(p-methylphenylsulfonyl)}-1,3diaminobutan-2-one3 -[N 1 -(Benzyloxycarbonyl)hydrazino] -N,N -(dimethyl) - propanamide3-[N 1 -(tert-Butyloxycarbonyl)hydrazino]-N,N-(dimethyl)-propanamide", "SIMPLE_CHEMICAL", 222, 611], ["Spectral characterization", "TEST", 0, 25], ["Benzyloxycarbonyl)", "TREATMENT", 101, 119], ["N -dimethylamino)", "TREATMENT", 135, 152], ["-oxopropyl]-N", "TREATMENT", 157, 170], ["(N,N-Dimethylamino)", "TREATMENT", 231, 250], ["oxopropyl]", "TREATMENT", 256, 266], ["methylphenylsulfonyl", "TREATMENT", 276, 296], ["hydrochlo- ride(3S)", "TREATMENT", 322, 341], ["Acetyl-L-leucyl-L-alanyl)", "TREATMENT", 349, 374], ["(N,N-dimethylamino)", "TREATMENT", 386, 405], ["oxopropyl]-N", "TREATMENT", 411, 423], ["Benzyloxycarbonyl)hydrazino", "TREATMENT", 484, 511], ["(dimethyl)", "TREATMENT", 519, 529], ["propanamide3", "TREATMENT", 532, 544], ["tert-Butyloxycarbonyl)hydrazino", "TREATMENT", 552, 583], ["(dimethyl)-propanamide", "TREATMENT", 589, 611]]], ["A stirred solution of the crude 3hydrazino-N,N-(dimethyl)propanamide (2.62 g, 20 mmol), which was obtained as in the preparation of 13, in a mixture of dioxane (30 mL), water (15 mL) and 1 N NaOH (20 mL) was cooled in an ice-bath.", [["3hydrazino-N,N-(dimethyl)propanamide", "CHEMICAL", 32, 68], ["dioxane", "CHEMICAL", 152, 159], ["N NaOH", "CHEMICAL", 189, 195], ["3hydrazino-N,N-(dimethyl)propanamide", "CHEMICAL", 32, 68], ["dioxane", "CHEMICAL", 152, 159], ["NaOH", "CHEMICAL", 191, 195], ["3hydrazino-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 32, 68], ["dioxane", "SIMPLE_CHEMICAL", 152, 159], ["A stirred solution", "TREATMENT", 0, 18], ["the crude 3hydrazino", "TREATMENT", 22, 42], ["N-(dimethyl)propanamide", "TREATMENT", 45, 68], ["dioxane", "TREATMENT", 152, 159], ["an ice-bath", "TREATMENT", 218, 229]]], ["Di-tert-butyl pyrocarbonate (4.8 g, 22 mmol) was added and stirring was continued at room temperature for 1 h.", [["Di-tert-butyl pyrocarbonate", "CHEMICAL", 0, 27], ["Di-tert-butyl pyrocarbonate", "CHEMICAL", 0, 27], ["Di-tert-butyl pyrocarbonate", "SIMPLE_CHEMICAL", 0, 27], ["Di-tert-butyl pyrocarbonate", "TREATMENT", 0, 27]]], ["The precipitate was \u00aeltered, the \u00aeltrate was concentrated in vacuo to 25 mL, and then extracted with ethyl acetate (3\u00c280 mL).", [["ethyl acetate", "CHEMICAL", 101, 114], ["ethyl acetate", "CHEMICAL", 101, 114], ["\u00aeltrate", "SIMPLE_CHEMICAL", 33, 40], ["ethyl acetate", "SIMPLE_CHEMICAL", 101, 114], ["the \u00aeltrate", "TREATMENT", 29, 40], ["ethyl acetate", "TREATMENT", 101, 114]]], ["The combined organic extracts were washed with brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil.", [["extracts", "ANATOMY", 21, 29], ["oil", "ANATOMY", 118, 121], ["Na 2 SO 4 )", "CHEMICAL", 69, 80], ["Na 2 SO 4", "CHEMICAL", 69, 78], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["oil", "ORGANISM_SUBSTANCE", 118, 121], ["The combined organic extracts", "TREATMENT", 0, 29], ["organic extracts", "OBSERVATION", 13, 29]]], ["To a suspension of Boc-propanamide 17 (2.31 g, 10 mmol) and anhydrous potassium carbonate (6.91 g, 50 mmol) in dry THF (20 mL), was added benzyl chloroformate (1.88 g, 11 mmol) with vigorous stirring.", [["Boc-propanamide 17", "CHEMICAL", 19, 37], ["potassium carbonate", "CHEMICAL", 70, 89], ["THF", "CHEMICAL", 115, 118], ["benzyl chloroformate", "CHEMICAL", 138, 158], ["Boc-propanamide 17", "CHEMICAL", 19, 37], ["anhydrous potassium carbonate", "CHEMICAL", 60, 89], ["THF", "CHEMICAL", 115, 118], ["benzyl chloroformate", "CHEMICAL", 138, 158], ["Boc-propanamide 17", "SIMPLE_CHEMICAL", 19, 37], ["anhydrous potassium carbonate", "SIMPLE_CHEMICAL", 60, 89], ["THF", "SIMPLE_CHEMICAL", 115, 118], ["benzyl chloroformate", "SIMPLE_CHEMICAL", 138, 158], ["a suspension of Boc-propanamide", "TREATMENT", 3, 34], ["anhydrous potassium carbonate", "TREATMENT", 60, 89], ["benzyl chloroformate", "TREATMENT", 138, 158], ["vigorous stirring", "TREATMENT", 182, 199]]], ["The mixture was heated to 40\u00b150 C for 2 h.", [["The mixture", "TREATMENT", 0, 11]]], ["The precipitate of KHCO 3 and K 2 CO 3 was removed by \u00aeltration.", [["KHCO 3", "CHEMICAL", 19, 25], ["CO 3", "CHEMICAL", 34, 38], ["KHCO", "TEST", 19, 23], ["K 2 CO", "TREATMENT", 30, 36]]], ["The \u00aeltrate was concentrated in vacuo.", [["\u00aeltrate", "SIMPLE_CHEMICAL", 4, 11], ["The \u00aeltrate", "TREATMENT", 0, 11], ["vacuo", "OBSERVATION", 32, 37]]], ["The residue was dissolved in ethyl acetate (100 mL), washed with 1 N NaHCO 3 (20 mL), water (20 mL) and brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil.", [["oil", "ANATOMY", 175, 178], ["ethyl acetate", "CHEMICAL", 29, 42], ["Na 2 SO 4 )", "CHEMICAL", 126, 137], ["ethyl acetate", "CHEMICAL", 29, 42], ["NaHCO 3", "CHEMICAL", 69, 76], ["Na 2 SO 4", "CHEMICAL", 126, 135], ["ethyl acetate", "SIMPLE_CHEMICAL", 29, 42], ["oil", "ORGANISM_SUBSTANCE", 175, 178], ["The residue", "PROBLEM", 0, 11], ["ethyl acetate", "TREATMENT", 29, 42], ["1 N NaHCO", "TREATMENT", 65, 74]]], ["3-[N 1 -(Acetyl-D-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (19) .", [["3-[N 1 -(Acetyl-D-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 0, 86], ["3-[N 1 -(Acetyl-D-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 0, 86], ["3-[N 1 -(Acetyl-D-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 0, 86], ["Acetyl-D-alanyl)", "TREATMENT", 9, 25], ["benzyloxycarbonyl)hydrazino", "TREATMENT", 32, 59], ["(dimethyl)propanamide", "TREATMENT", 65, 86]]], ["To a stirred solution of Boc derivative 18 (1.10 g, 3 mmol) in dry CH 2 Cl 2 (10 mL) under argon, was added tri\u00afuoroacetic acid (10 mL).", [["Boc derivative 18", "CHEMICAL", 25, 42], ["CH 2 Cl", "CHEMICAL", 67, 74], ["tri\u00afuoroacetic acid", "CHEMICAL", 108, 127], ["Boc", "CHEMICAL", 25, 28], ["CH 2 Cl 2", "CHEMICAL", 67, 76], ["tri\u00afuoroacetic acid", "CHEMICAL", 108, 127], ["Boc derivative 18", "SIMPLE_CHEMICAL", 25, 42], ["tri\u00afuoroacetic acid", "SIMPLE_CHEMICAL", 108, 127], ["a stirred solution of Boc derivative", "TREATMENT", 3, 39], ["tri\u00afuoroacetic acid", "TREATMENT", 108, 127]]], ["The solution was stirred at room temperature for 2 h and was then concentrated in vacuo.", [["The solution", "TREATMENT", 0, 12], ["vacuo", "OBSERVATION", 82, 87]]], ["Toluene (10 mL) was added, and the mixture was concentrated in vacuo.", [["Toluene", "CHEMICAL", 0, 7], ["Toluene", "CHEMICAL", 0, 7], ["Toluene", "SIMPLE_CHEMICAL", 0, 7], ["vacuo", "OBSERVATION", 63, 68]]], ["The residue was dried in vacuo overnight to give the crude unstable hydrazino compound.", [["hydrazino", "CHEMICAL", 68, 77], ["hydrazino", "CHEMICAL", 68, 77], ["hydrazino compound", "SIMPLE_CHEMICAL", 68, 86], ["The residue", "PROBLEM", 0, 11], ["the crude unstable hydrazino compound", "PROBLEM", 49, 86]]], ["This was dissolved in dry THF (3 mL), and triethylamine (1.57 mL, 10.5 mmol) was added to form the amine solution A. A solution of N-acetyl-d-alanine (0.393 g, 3.0 mmol) in dry THF (10 mL) was cooled to \u00c05 C with stirring under argon.", [["dry THF", "CHEMICAL", 22, 29], ["triethylamine", "CHEMICAL", 42, 55], ["amine", "CHEMICAL", 99, 104], ["N-acetyl-d-alanine", "CHEMICAL", 131, 149], ["THF", "CHEMICAL", 177, 180], ["THF", "CHEMICAL", 26, 29], ["triethylamine", "CHEMICAL", 42, 55], ["amine", "CHEMICAL", 99, 104], ["N-acetyl-d-alanine", "CHEMICAL", 131, 149], ["THF", "CHEMICAL", 177, 180], ["triethylamine", "SIMPLE_CHEMICAL", 42, 55], ["amine", "SIMPLE_CHEMICAL", 99, 104], ["N-acetyl-d-alanine", "SIMPLE_CHEMICAL", 131, 149], ["THF", "SIMPLE_CHEMICAL", 177, 180], ["\u00c05 C", "SIMPLE_CHEMICAL", 203, 207], ["dry THF", "TREATMENT", 22, 29], ["triethylamine", "TREATMENT", 42, 55], ["N-acetyl-d-alanine", "TREATMENT", 131, 149]]], ["Triethylamine (0.45 mL, 3.0 mmol) and ethyl chloroformate (0.29 mL, 3.0 mmol) were added.", [["Triethylamine", "CHEMICAL", 0, 13], ["ethyl chloroformate", "CHEMICAL", 38, 57], ["Triethylamine", "CHEMICAL", 0, 13], ["ethyl chloroformate", "CHEMICAL", 38, 57], ["Triethylamine", "SIMPLE_CHEMICAL", 0, 13], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 38, 57], ["Triethylamine", "TREATMENT", 0, 13], ["ethyl chloroformate", "TREATMENT", 38, 57]]], ["The mixture was stirred for 20 min at \u00c05 C, then the amine solution A was added.", [["amine", "CHEMICAL", 53, 58], ["amine", "CHEMICAL", 53, 58], ["amine solution A", "SIMPLE_CHEMICAL", 53, 69], ["the amine solution A", "TREATMENT", 49, 69]]], ["After 30 min at \u00c05 C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h.", [["the reaction mixture", "PROBLEM", 22, 42]]], ["The precipitate was \u00aeltered and the \u00aeltrate was concentrated in vacuo.", [["\u00aeltrate", "SIMPLE_CHEMICAL", 36, 43], ["the \u00aeltrate", "TREATMENT", 32, 43]]], ["The residue was dissolved in ethyl acetate (100 mL), washed with said aq NH 4 Cl (15 mL), 1 N NaHCO 3 (15 mL) and brine (15 mL), dried (Na 2 SO 4 ) and concentrated in vacua to give an oil.", [["oil", "ANATOMY", 185, 188], ["ethyl acetate", "CHEMICAL", 29, 42], ["aq NH 4 Cl", "CHEMICAL", 70, 80], ["NaHCO", "CHEMICAL", 94, 99], ["Na 2 SO 4", "CHEMICAL", 136, 145], ["ethyl acetate", "CHEMICAL", 29, 42], ["NH 4 Cl", "CHEMICAL", 73, 80], ["NaHCO 3", "CHEMICAL", 94, 101], ["Na 2 SO 4", "CHEMICAL", 136, 145], ["ethyl acetate", "SIMPLE_CHEMICAL", 29, 42], ["vacua", "SIMPLE_CHEMICAL", 168, 173], ["oil", "ORGANISM_SUBSTANCE", 185, 188], ["The residue", "PROBLEM", 0, 11], ["ethyl acetate", "TREATMENT", 29, 42], ["1 N NaHCO", "TREATMENT", 90, 99]]], ["The procedure used for the preparation of 19 was adapted to prepare the tri\u00afuoroacetate salt (1.14 g, 3 mmol) and condense it with N-acetyl-l-alanine (0.393 g, 3 mmol) to give 20 (0.86 g, 76%) as a gum: IR (CH 2 3-[N 1 -(tert-Butyloxycarbonyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (21) .", [["tri\u00afuoroacetate", "CHEMICAL", 72, 87], ["N-acetyl-l-alanine", "CHEMICAL", 131, 149], ["IR", "CHEMICAL", 203, 205], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 207, 313], ["tri\u00afuoroacetate salt", "CHEMICAL", 72, 92], ["N-acetyl-l-alanine", "CHEMICAL", 131, 149], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 207, 313], ["tri\u00afuoroacetate salt", "SIMPLE_CHEMICAL", 72, 92], ["N-acetyl-l-alanine", "SIMPLE_CHEMICAL", 131, 149], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 207, 313], ["The procedure", "TREATMENT", 0, 13], ["the tri\u00afuoroacetate salt", "TREATMENT", 68, 92], ["acetyl", "TREATMENT", 133, 139], ["alanine", "TREATMENT", 142, 149], ["IR (CH", "TREATMENT", 203, 209], ["tert", "TREATMENT", 221, 225], ["Butyloxycarbonyl-L-alanyl)", "TREATMENT", 226, 252], ["benzyloxycarbonyl)hydrazino", "TREATMENT", 259, 286], ["N-(dimethyl)propanamide", "TREATMENT", 290, 313]]], ["The above procedure for the preparation of 19, was adapted to prepare and condense the tri\u00afuoroacetate salt (0.376 g, 1 mmol) and N-t-Boc-l-alanine (0.131 g, 1 mmol) to give 21 (0.350 g, 80%) as a colorless oil: IR (CH 2 3-[N 1 -(tert-Butyloxycarbonyl--alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (22) .", [["tri\u00afuoroacetate", "CHEMICAL", 87, 102], ["N-t-Boc-l-alanine", "CHEMICAL", 130, 147], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl--alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 216, 321], ["tri\u00afuoroacetate salt", "CHEMICAL", 87, 107], ["N-t-Boc-l-alanine", "CHEMICAL", 130, 147], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl--alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 216, 321], ["tri\u00afuoroacetate salt", "SIMPLE_CHEMICAL", 87, 107], ["N-t-Boc-l-alanine", "SIMPLE_CHEMICAL", 130, 147], ["CH 2 3-[N 1 -(tert-Butyloxycarbonyl--alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 216, 321], ["The above procedure", "TREATMENT", 0, 19], ["the tri\u00afuoroacetate salt", "TREATMENT", 83, 107], ["t-Boc-l-alanine", "TREATMENT", 132, 147], ["a colorless oil", "TREATMENT", 195, 210], ["IR (CH", "TREATMENT", 212, 218], ["tert-Butyloxycarbonyl--alanyl)", "TREATMENT", 230, 260], ["benzyloxycarbonyl)hydrazino", "TREATMENT", 267, 294], ["N-(dimethyl)propanamide", "TREATMENT", 298, 321]]], ["The procedure used for the preparation of 19, was adapted to prepare and convert the tri\u00afuoroacetate salt (2.93 g, 7.8 mmol) and N-t-Boc-b-alanine (1.47 g, 7.8 mmol) to 22 (2.14 g, 63%) as an oil: IR (CH 2 3-[N 1 -(Acetyl-L-leucyl-L-alanyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (23).", [["tri\u00afuoroacetate", "CHEMICAL", 85, 100], ["N-t-Boc-b-alanine", "CHEMICAL", 129, 146], ["CH 2 3-[N 1 -(Acetyl-L-leucyl-L-alanyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 201, 310], ["tri\u00afuoroacetate salt", "CHEMICAL", 85, 105], ["N-t-Boc-b-alanine", "CHEMICAL", 129, 146], ["CH 2 3-[N 1 -(Acetyl-L-leucyl-L-alanyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "CHEMICAL", 201, 310], ["tri\u00afuoroacetate salt", "SIMPLE_CHEMICAL", 85, 105], ["N-t-Boc-b-alanine", "SIMPLE_CHEMICAL", 129, 146], ["CH 2 3-[N 1 -(Acetyl-L-leucyl-L-alanyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide", "SIMPLE_CHEMICAL", 201, 310], ["The procedure", "TREATMENT", 0, 13], ["the tri\u00afuoroacetate salt", "TREATMENT", 81, 105], ["N-t-Boc-b-alanine", "TREATMENT", 129, 146], ["IR (CH", "TREATMENT", 197, 203], ["Acetyl", "TREATMENT", 215, 221], ["L-leucyl-L-alanyl-L-alanyl)", "TREATMENT", 222, 249], ["benzyloxycarbonyl)hydrazino", "TREATMENT", 256, 283], ["(dimethyl)propanamide", "TREATMENT", 289, 310]]], ["The above procedure for the preparation of 19, was adapted to convert 21 (0.130 g, 0.3 mmol) and Ac-Leu-Ala-OH (73.2 mg, 0.3 mmol) to the crude product.", [["Ac-Leu-Ala-OH", "CHEMICAL", 97, 110], ["Ac-Leu-Ala-OH", "CHEMICAL", 97, 110], ["Ac-Leu-Ala-OH", "SIMPLE_CHEMICAL", 97, 110], ["The above procedure", "TREATMENT", 0, 19], ["Ac-Leu-Ala-OH", "TREATMENT", 97, 110]]], ["This was puri\u00aeed by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 20% to 40%, t R 12.8 min) to give 23 (0.118 g, 70%) as a white solid: mp 183\u00b1184 C; IR (CH 2", [["acetonitrile", "CHEMICAL", 65, 77], ["acetonitrile", "CHEMICAL", 65, 77], ["acetonitrile", "SIMPLE_CHEMICAL", 65, 77], ["linear gradient elution", "TREATMENT", 26, 49], ["acetonitrile", "TREATMENT", 65, 77], ["water", "TREATMENT", 82, 87], ["IR", "TEST", 178, 180]]]], "PMC4519904": []}